Evaluation and improvement of nuclease cleavage specificity

Description

BACKGROUND OF THE INVENTION

Site-specific endonucleases theoretically allow for the targeted manipulation of a single site within a genome, and are useful in the context of gene targeting as well as for therapeutic applications. In a variety of organisms, including mammals, site-specific endonucleases, for example, zinc-finger nucleases (ZFNs), have been used for genome engineering by stimulating either non-homologous end joining or homologous recombination. In addition to providing powerful research tools, ZFNs also have potential as gene therapy agents, and two ZFNs have recently entered clinical trials: one, CCR5-2246, targeting a human CCR-5 allele as part of an anti-HIV therapeutic approach (NCT00842634, NCT01044654, NCT01252641), and the other one, VF24684, targeting the human VEGF-A promoter as part of an anti-cancer therapeutic approach (NCT01082926).

Precise targeting of the intended target site is crucial for minimizing undesired off-target effects of site-specific nucleases, particularly in therapeutic applications, as imperfect specificity of some engineered site-specific binding domains has been linked to cellular toxicity. However, the site preferences for engineered site-specific nucleases, including current ZFNs, which cleave their target site after dimerization, has previously only been evaluated in vitro or in silico using methods that are limited to calculating binding and cleavage specificity for monomeric proteins.

Therefore, improved systems for evaluating the off-target sites of nucleases and other nucleic acid cleaving agents are needed and would be useful in the design of nucleases with better specificity, especially for therapeutic applications.

SUMMARY OF THE INVENTION

This invention is at least partly based on the recognition that the reported toxicity of some engineered site-specific endonucleases is based on off-target DNA cleavage, rather than on off-target binding alone. Information about the specificity of site-specific nucleases to date has been based on the assumptions that (i) dimeric nucleases cleave DNA with the same sequence specificity with which isolated monomeric domains bind DNA; and that (ii) the binding of one domain does not influence the binding of the other domain in a given dimeric nuclease. No study to date has reported a method for determining the broad DNA cleavage specificity of active, dimeric site-specific nucleases. Such a method would not only be useful in determining the DNA cleavage specificity of nucleases but would also find use in evaluating the cleavage specificity of other DNA cleaving agents, such as small molecules that cleave DNA.

This invention addresses the shortcomings of previous attempts to evaluate and characterize the sequence specificity of site-specific nucleases, and in particular of nucleases that dimerize or multimerize in order to cleave their target sequence. Some aspects of this invention provide an in vitro selection method to broadly examine the cleavage specificity of active nucleases. In some aspects, the invention provide methods of identifying suitable nuclease target sites that are sufficiently different from any other site within a genome to achieve specific cleavage by a given nuclease without any or at least minimal off-target cleavage. The invention provide methods of evaluating, selecting, and/or designing site specific nucleases with enhanced specificity as compared to current nucleases. Methods for minimizing off-target cleavage by a given nuclease, for example, by enhancing nuclease specificity by designing variant nucleases with binding domains having decreased binding affinity, by lowering the final concentration of the nuclease, and by choosing target sites that differ by at least three base pairs from their closest sequence relatives in the genome are provided. Compositions and kits useful in the practice of the inventive methods are also provided. The provided methods, compositions and kits are also useful in the evaluation, design, and selection of other nucleic acid (e.g., DNA) cleaving agents as would be appreciated by one of skill in the art.

In another aspect, the invention provides nucleases and other nucleic acid cleaving agents designed or selected using the provided system. Isolated ZFNs and TALENs designed, evaluated, or selected according to methods provided herein and pharmaceutical compositions comprising such nucleases are also provided.

Some aspects of this invention provide a method for identifying a target site of a nuclease. In some embodiments, the method comprises (a) providing a nuclease that cuts a double-stranded nucleic acid target site and creates a 5′ overhang, wherein the target site comprises a [left-half site]-[spacer sequence]-[right-half site] (LSR) structure, and the nuclease cuts the target site within the spacer sequence. In some embodiments, the method comprises (b) contacting the nuclease with a library of candidate nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence, under conditions suitable for the nuclease to cut a candidate nucleic acid molecule comprising a target site of the nuclease. In some embodiments, the method comprises (c) filling in the 5′ overhangs of a nucleic acid molecule that has been cut twice by the nuclease and comprises a constant insert sequence flanked by a left half-site and cut spacer sequence on one side, and a right half-site and cut spacer sequence on the other side, thereby creating blunt ends. In some embodiments, the method comprises (d) identifying the nuclease target site cut by the nuclease by determining the sequence of the left-half site, the right-half-site, and/or the spacer sequence of the nucleic acid molecule of step (c). In some embodiments, determining the sequence of step (d) comprises ligating sequencing adapters to the blunt ends of the nucleic acid molecule of step (c) and amplifying and/or sequencing the nucleic acid molecule. In some embodiments, the method comprises amplifying the nucleic acid molecule after ligation of the sequencing adapters via PCR. In some embodiments, the method further comprises a step of enriching the nucleic acid molecules of step (c) or step (d) for molecules comprising a single constant insert sequence. In some embodiments, the step of enriching comprises a size fractionation. In some embodiments, the size fractionation is done by gel purification. In some embodiments, the method further comprises discarding any sequences determined in step (d) if the nucleic acid molecule did not comprise a complementary pair of filled-in 5′ overhangs. In some embodiments, the method further comprises compiling a plurality of nuclease target sites identified in step (d), thereby generating a nuclease target site profile. In some embodiments, the nuclease is a therapeutic nuclease which cuts a specific nuclease target site in a gene associated with a disease. In some embodiments, the method further comprises determining a maximum concentration of the therapeutic nuclease at which the therapeutic nuclease cuts the specific nuclease target site, and does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or no additional nuclease target sites. In some embodiments, the method further comprises administering the therapeutic nuclease to a subject in an amount effective to generate a final concentration equal or lower than the maximum concentration. In some embodiments, the nuclease comprises an unspecific nucleic acid cleavage domain. In some embodiments, the nuclease comprises a FokI cleavage domain. In some embodiments, the nuclease comprises a nucleic acid cleavage domain that cleaves a target sequence upon cleavage domain dimerization. In some embodiments, the nuclease comprises a binding domain that specifically binds a nucleic acid sequence. In some embodiments, the binding domain comprises a zinc finger. In some embodiments, the binding domain comprises at least 2, at least 3, at least 4, or at least 5 zinc fingers. In some embodiments, the nuclease is a Zinc Finger Nuclease. In some embodiments, the binding domain comprises a Transcriptional Activator-Like Element. In some embodiments, the nuclease is a Transcriptional Activator-Like Element Nuclease (TALEN). In some embodiments, the nuclease comprises an organic compound. In some embodiments, the nuclease comprises an enediyne. In some embodiments, the nuclease is an antibiotic. In some embodiments, the compound is dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof. In some embodiments, the nuclease is a homing endonuclease.

Some aspects of this invention provide libraries of nucleic acid molecule. In some embodiments, a library of nucleic acid molecules is provided that comprises a plurality of nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a candidate nuclease target site and a constant insert sequence spacer sequence. In some embodiments, the candidate nuclease target site comprises a [left-half site]-[spacer sequence]-[right-half site] (LSR) structure. In some embodiments, the left-half site and/or the right-half site is between 10-18 nucleotides long. In some embodiments, the library comprises candidate nuclease target sites that can be cleaved by a nuclease comprising a FokI cleavage domain. In some embodiments, the library comprises candidate nuclease target sites that can be cleaved by a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, and/or bleomycin. In some embodiments, the library comprises at least 10⁵, at least 10⁶, at least 10⁷, at least 10⁸, at least 10⁹, at least 10¹⁰, at least 10¹¹, or at least 10¹²different candidate nuclease target sites. In some embodiments, the library comprises nucleic acid molecules of a molecular weight of at least 5 kDa, at least 6 kDa, at least 7 kDa, at least 8 kDa, at least 9 kDa, at least 10 kDa, at least 12 kDa, or at least 15 kDa. In some embodiments, the candidate nuclease target sites comprise a partially randomized left-half site, a partially randomized right-half site, and/or a partially randomized spacer sequence. In some embodiments, the library is templated on a known target site of a nuclease of interest. In some embodiments, the nuclease of interest is a ZFN, a TALEN, a homing endonuclease, an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof. In some embodiments, partial randomized sites differ from the consensus site by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30% on average, distributed binomially. In some embodiments, partial randomized sites differ from the consensus site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially. In some embodiments, the candidate nuclease target sites comprise a randomized spacer sequence.

Some aspects of this invention provide methods of selecting a nuclease based on an evaluation of cleavage specificity. In some embodiments, a method of selecting a nuclease that specifically cuts a consensus target site from a plurality of nucleases is provided. In some embodiments, the method comprises (a) providing a plurality of candidate nucleases that cut the same consensus sequence; (b) for each of the candidate nucleases of step (a), identifying a nuclease target site cleaved by the candidate nuclease that differ from the consensus target site; and (c) selecting a nuclease based on the nuclease target site(s) identified in step (b). In some embodiments, the nuclease selected in step (c) is the nuclease that cleaves the consensus target site with the highest specificity. In some embodiments, the nuclease that cleaves the consensus target site with the highest specificity is the candidate nuclease that cleaves the lowest number of target sites that differ from the consensus site. In some embodiments, the candidate nuclease that cleaves the consensus target site with the highest specificity is the candidate nuclease that cleaves the lowest number of target sites that are different from the consensus site in the context of a target genome. In some embodiments, the candidate nuclease selected in step (c) is a nuclease that does not cleave any target site other than the consensus target site. In some embodiments, the candidate nuclease selected in step (c) is a nuclease that does not cleave any target site other than the consensus target site within the genome of a subject at a therapeutically effective concentration of the nuclease. In some embodiments, the method further comprises contacting a genome with the nuclease selected in step (c). In some embodiments, the genome is a vertebrate, mammalian, human, non-human primate, rodent, mouse rat, hamster, goat, sheep, cattle, dog, cat, reptile, amphibian, fish, nematode, insect, or fly genome. In some embodiments, the genome is within a living cell. In some embodiments, the genome is within a subject. In some embodiments, the consensus target site is within an allele that is associated with a disease or disorder. In some embodiments, cleavage of the consensus target site results in treatment or prevention of the disease or disorder. In some embodiments, cleavage of the consensus target site results in the alleviation of a symptom of the disease or disorder. In some embodiments, the disease is HIV/AIDS, or a proliferative disease. In some embodiments, the allele is a CCR5 or VEGFA allele.

Some aspects of this invention provide a method for selecting a nuclease target site within a genome. In some embodiments, the method comprises (a) identifying a candidate nuclease target site; and (b) using a general purpose computer, comparing the candidate nuclease target site to other sequences within the genome, wherein if the candidate nuclease target site differs from any other sequence within the genome by at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotides, selecting the candidate nuclease site. In some embodiments, the candidate nuclease target site comprises a [left-half site]-[spacer sequence]-[right-half site] (LSR) structure. In some embodiments, the left-half site and/or the right-half site is 10-18 nucleotides long. In some embodiments, the spacer is 10-24 nucleotides long. In some embodiments, the method further comprises designing and/or generating a nuclease targeting the candidate nuclease site selected in step (b). In some embodiments, designing and/or generating is done by recombinant technology. In some embodiments, designing and/or generating comprises designing a binding domain that specifically binds the selected candidate target site, or a half-site thereof. In some embodiments, designing and/or generating comprises conjugating the binding domain with a nucleic acid cleavage domain. In some embodiments, the nucleic acid cleavage domain is a non-specific cleavage domain and/or wherein the nucleic acid cleavage domain must dimerize or multimerize in order to cut a nucleic acid. In some embodiments, the nucleic acid cleavage domain comprises a FokI cleavage domain. In some embodiments, the method further comprises isolating the nuclease. In some embodiments, the nuclease is a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or is or comprises an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof. In some embodiments, the candidate target site is within a genomic sequence the cleavage of which is known to be associated with an alleviation of a symptom of a disease or disorder. In some embodiments, the disease is HIV/AIDS, or a proliferative disease. In some embodiments, the genomic sequence is a CCR5 or VEGFA sequence.

Some aspects of this invention provide isolated nucleases with enhanced specificity and nucleic acids encoding such nucleases. In some embodiments, an isolated nuclease is provided that has been engineered to cleave a target site within a genome, wherein the nuclease has been selected according to any of the selection methods described herein. In some embodiments, an isolated nuclease is provided that cuts a target site selected according to any of the methods described herein. In some embodiments, an isolated nuclease is provided that is designed or engineered according to any of the concepts or parameters described herein. In some embodiments, the nuclease is a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or is or comprises an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof.

Some aspects of this invention provide kits comprising nucleases and nuclease compositions. In some embodiments, a kit is provided that comprises an isolated nuclease described herein. In some embodiments, the kit further comprises a nucleic acid comprising a target site of the isolated nuclease. In some embodiments, the kit comprises an excipient and instructions for contacting the nuclease with the excipient to generate a composition suitable for contacting a nucleic acid with the nuclease. In some embodiments, the nucleic acid is a genome or part of a genome. In some embodiments, the genome is within a cell. In some embodiments, the genome is within a subject and the excipient is a pharmaceutically acceptable excipient.

Some aspects of this invention provide pharmaceutical compositions comprising a nuclease or a nucleic acid encoding a nuclease as described herein. In some embodiments, pharmaceutical composition for administration to a subject is provided. In some embodiments, the composition comprises an isolated nuclease described herein or a nucleic acid encoding such a nuclease and a pharmaceutically acceptable excipient.

Other advantages, features, and uses of the invention will be apparent from the detailed description of certain non-limiting embodiments; the drawings, which are schematic and not intended to be drawn to scale; and the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. In vitro selection for ZFN-mediated cleavage. Pre-selection library members are concatemers (represented by arrows) of identical ZFN target sites lacking 5′ phosphates. L=left half-site; R=right half-site, S=spacer; L′, S′, R′=complementary sequences to L, S, R. ZFN cleavage reveals a 5′ phosphate, which is required for sequencing adapter ligation. The only sequences that can be amplified by PCR using primers complementary to the adapters are sequences that have been cleaved twice and have adapters on both ends. DNA cleaved at adjacent sites are purified by gel electrophoresis and sequenced. A computational screening step after sequencing ensures that the filled-in spacer sequences (S and S′) are complementary and therefore from the same molecule.

FIGS. 2A-2B. DNA cleavage sequence specificity profiles for CCR5-224 and VF2468 ZFNs. The heat maps show specificity scores compiled from all sequences identified in selections for cleavage of 14 nM of DNA library with (FIG. 2A) 2 nM CCR5-224 or (FIG. 2B) 1 nM VF2468. The target DNA sequence is shown below each half-site. Black boxes indicate target base pairs. Specificity scores were calculated by dividing the change in frequency of each base pair at each position in the post-selection DNA pool compared to the pre-selection pool by the maximal possible change in frequency from pre-selection library to post-selection library of each base pair at each position. Blue boxes indicate enrichment for a base pair at a given position, white boxes indicate no enrichment, and red boxes indicate enrichment against a base pair at a given position. The darkest blue shown in the legend corresponds to absolute preference for a given base pair (specificity score=1.0), while the darkest red corresponds to an absolute preference against a given base pair (specificity score=−1.0). Sequences correspond, from top to bottom, to SEQ ID NOs: 1 and 2 (FIG. 2A) and SEQ ID NOs: 3 and 4 (FIG. 2B).

FIGS. 3A-3B. Evidence for a compensation model of ZFN target site recognition. The heat maps show the changes in specificity score upon mutation at the black-boxed positions in selections with (FIG. 3A) 2 nM CCR5-224 or (FIG. 3B) 1 nM VF2468. Each row corresponds to a different mutant position (explained graphically in FIGS. 12A-12B). Sites are listed in their genomic orientation; the (+) half-site of CCR5-224 and the (+) half-site of VF2468 are therefore listed as reverse complements of the sequences found in FIGS. 2A-2B. Shades of blue indicate increased specificity score (more stringency) when the black boxed position is mutated and shades of red indicate decreased specificity score (less stringency). Sequences in FIG. 3A correspond, from top to bottom, to SEQ ID NOs: 5-6.

FIGS. 4A-4B. ZFNs can cleave a large fraction of target sites with three or fewer mutations in vitro. The percentages of the sequences with one, two, or three mutations that are enriched for in vitro cleavage (enrichment factor >1) by the (FIG. 4A) CCR5-224 ZFN and r three mutations that are enriched for in vitro cleavage (enrichment factor >1) by the (FIG. 4B) VF2468 ZFN are shown. Enrichment factors are calculated for each sequence identified in the selection by dividing the observed frequency of that sequence in the post-selection sequenced library by the frequency of that sequence in the pre-selection library.

FIG. 5. In vitro synthesis of target site library. Library members consist of a partially randomized left-half site (L), a fully randomized 4-7 nucleotide spacer sequence (S), and a partially randomized right-half site (R). Library members present on DNA primers were incorporated into a linear ˜545 base pair double-stranded DNA by PCR. During PCR, a primer with a library member (L S R) can anneal to a DNA strand with a different library member (L*S*R*), resulting in a double-strand DNA with two different library members at one end. The 3′-5′ exonuclease and 5′-3′ polymerase activities of T4 DNA polymerase removed mismatched library members and replaced them with complementary, matched library members (L'S‘R’). After 5′ phosphorylation with T4 polynucleotide kinase, the library DNA was subjected to blunt-end ligation, resulting in a mixture of linear and circular monomeric and multimeric species. Circular monomers were purified by gel electrophoresis and concatenated through rolling-circle amplification with D29 DNA polymerase.

FIGS. 6A-6D. Expression and quantification of ZFNs. Western blots for CCR5-224 and VF2468 are shown (FIG. 6A) for the ZFN samples used in the in vitro selection, and (FIG. 6B) for quantification. (FIG. 6C) Known quantities of N-terminal FLAG-tagged bacterial alkaline phosphatase (FLAG-BAP) were used to generate a standard curve for ZFN quantification. Diamonds represent the intensities of FLAG-BAP standards from the Western blot shown in (FIG. 6B), plus signs represent the intensities of bands of ZFNs, and the line shows the best-fit curve of FLAG-BAP standards that was used to quantify ZFNs. (FIG. 6D) Gels are shown of activity assays of CCR5-224 and VF2468 on an 8 nM linear substrate containing one target cleavage site. The ZFNs were each incubated with their respective substrate for 4 hours at 37° C. DNA in the “+ lysate” lane was incubated with an amount of in vitro transcription/translation mixture equivalent to that used in the 2.5 nM ZFN reaction. ZFN-mediated cleavage results in two linear fragments approximately 700 bp and 300 bp in length. 2 nM CCR5-224 and 1 nM VF2468 were the amounts required for 50% cleavage of the linear substrate.

FIGS. 7A-7B. Library cleavage with ZFNs. Cleavage of 1 μg of concatemeric libraries of CCR5-224 (FIG. 7A) or VF2468 (FIG. 7B) target sites are shown with varying amounts CCR5-224 or VF2468, respectively. The lane labeled “+ lysate” refers to pre-selection concatemeric library incubated with the volume of in vitro transcription/translation mixture contained in the samples containing 4 nM CCR5-224 or 4 nM of VF2468. Uncut DNA, which would be observed in the “+ lysate” lane, is of length >12 kb and is lost upon purification due to its size and therefore is not present on the gel. The lane labeled “+ PvuI” is a digest of the pre-selection library at PvuI sites introduced adjacent to library members. The laddering on the gels results from cleavage of pre-selection DNA concatemers at more than one site. There is a dose dependent increase in the amount of the bottom band, which corresponds to cleavage at two adjacent library sites in the same pre-selection DNA molecule. This bottom band of DNA was enriched by PCR and gel purification before sequencing.

FIGS. 8A-8B. ZFN off-target cleavage is dependent on enzyme concentration. For both (FIG. 8A) CCR5-224 and (FIG. 8B) VF2468 the distribution of cleavable sites revealed by in vitro selection shifts to include sites that are less similar to the target site as the concentration of ZFN increases. Both CCR5-224 and VF2468 selections enrich for sites that have fewer mutations than the pre-selection library. For comparisons between preselection and post-selection library means for all combinations of selection stringencies, P-values are 0 with the exception of the comparison between 0.5 nM and 1 nM VF2468 selections, which has a P-value of 1.7×10⁻¹⁴.

FIGS. 9A-9B. Cleavage efficiency of individual sequences is related to selection stringency. In vitro DNA digests were performed on sequences identified in selections of varying stringencies (marked with ‘X’s). 2 nM CCR5-224 (SEQ ID NOs: 7-14) (FIG. 9A) or 1 nM VF2468 (SEQ ID NOs:15-24) (FIG. 9B) was incubated with 8 nM of linear substrate containing the sequence shown. The 1 kb linear substrate contained a single cleavage site with the spacer sequence found in the genomic target of CCR5-224 (“CTGAT”) or VF2468 (“TCGAA”) and the indicated (+) and (−) half-sites. Mutant base pairs are represented with lowercase letters. CCR5-224 sites and VF2468 sites that were identified in the highest stringency selections (0.5 nM ZFN) are cleaved most efficiently, while sites that were identified only in the lowest stringency selections (4 nM ZFN) are cleaved least efficiently. Sequences in FIG. 9A correspond, from top to bottom, to SEQ ID NOs: 7-14. Sequences in FIG. 9B correspond, from top to bottom, to SEQ ID NOs: 15-24.

FIGS. 10A-10D. Concentration-dependent sequence profiles for CCR5-224 and VF2468 ZFNs. The heat maps show specificity scores for the cleavage of 14 nM of total DNA library with varying amounts of (FIGS. 10A-10B) CCR5-224 or (FIGS. 10C-10D) VF2468. The target DNA sequence is shown below each half-site. Black boxes indicate target base pairs. Specificity scores were calculated by dividing the change in frequency of each base pair at each position in the post-selection DNA pool compared to the pre-selection pool by the maximal possible change in frequency of each base pair at each position. Blue boxes indicate specificity for a base pair at a given position, white boxes indicate no specificity, and red boxes indicate specificity against a base pair at a given position. The darkest blue shown in the legend corresponds to absolute preference for a given base pair (specificity score=1.0), while the darkest red corresponds to an absolute preference against a given base pair (specificity score=−1.0). Sequences in FIGS. 10A-10D correspond, from top to bottom, to SEQ ID NOs: 25-28.

FIG. 11. Stringency at the (+) half-site increases when CCR5-224 cleaves sites with mutations at highly specified base pairs in the (−) half-site. The heat maps show specificity scores for sequences identified in the in vitro selection with 2 nM CCR5-224. For (−)A3 and (−)G6, indicated by filled black boxes, both pre-selection library sequences and post-selection sequences were filtered to exclude any sequences that contained an A at position 3 in the (−) half-site or G at position 6 in the (−) half-site, respectively, before specificity scores were calculated. For sites with either (−) half-site mutation, there is an increase in specificity at the (+) half-site. Black boxes indicate target base pairs. Specificity scores were calculated by dividing the change in frequency of each base pair at each position in the post-selection DNA pool compared to the pre-selection pool by the maximal possible change in frequency of each base pair at each position. Blue boxes indicate specificity for a base pair at a given position, white boxes indicate no specificity, and red boxes indicate specificity against a base pair at a given position. The darkest blue shown in the legend corresponds to absolute preference for a given base pair (specificity score=1.0), while the darkest red corresponds to an absolute preference against a given base pair (specificity score=−1.0). Sequences on the left correspond to SEQ ID NO: 29. Sequences on the right correspond to SEQ ID NO: 30.

FIGS. 12A-12B. Data processing steps used to create mutation compensation difference maps. The steps to create each line of the difference map in FIGS. 3A-3B are shown for the example of a mutation at position (−)A3. (FIG. 12A) Heat maps of the type described in FIG. 11 are condensed into one line to show only the specificity scores for intended target site nucleotides (in black outlined boxes in FIG. 11). (FIG. 12B) The condensed heat maps are then compared to a condensed heat map corresponding to the unfiltered baseline profile from FIGS. 2A-2B, to create a condensed difference heat map that shows the relative effect of mutation at the position specified by the white box with black outline on the specificity score profile. Blue boxes indicate an increase in sequence stringency at positions in cleaved sites that contain mutations at the position indicated by the white box, while red boxes indicate a decrease in sequence stringency and white boxes, no change in sequence stringency. The (+) half-site difference map is reversed to match the orientation of the (+) half-site as it is found in the genome rather than as it is recognized by the zinc finger domain of the ZFN. Sequences in FIG. 12A correspond, from top left to bottom right, to SEQ ID NOs: 31-36. Sequences in FIG. 12B correspond to SEQ ID NOs: 37 and 38 (left) and SEQ ID NO: 39 (right).

FIG. 13. Stringency at both half-sites increases when VF2468 cleaves sites with mutations at the first base pair of both half-sites. The heat maps show specificity scores for sequences identified in the in vitro selection with 4 nM VF2468. For (+)G1, (−)G1, and (+)G1/(−)G1, indicated by filled black boxes, both pre-selection library sequences and post-selection sequences were filtered to exclude any sequences that contained an G at position 1 in the (+) half-site and/or G at position 1 in the (−) half-site, before specificity scores were calculated. For sites with either mutation, there is decrease in mutational tolerance at the opposite half-site and a very slight decrease in mutational tolerance at the same half-site. Sites with both mutations show a strong increase in stringency at both half-sites. Black boxes indicate on-target base pairs. Specificity scores were calculated by dividing the change in frequency of each base pair at each position in the post-selection DNA pool compared to the pre-selection pool by the maximal possible change in frequency of each base pair at each position. Blue boxes indicate specificity for a base pair at a given position, white boxes indicate no specificity, and red boxes indicate specificity against a base pair at a given position. The darkest blue shown in the legend corresponds to absolute preference for a given base pair (specificity score=1.0), while the darkest red corresponds to an absolute preference against a given base pair (specificity score=−1.0). Sequences correspond to SEQ ID NO:40 for VF2468(+) and SEQ ID NO: 41 for VF2468(−).

FIGS. 14A-14B. ZFN cleavage occurs at characteristic locations in the DNA target site. The plots show the locations of cleavage sites identified in the in vitro selections with (FIG. 14A) 4 nM CCR5-224 or (FIG. 14B) 4 nM VF2468. The cleavage site locations show similar patterns for both ZFNs except in the case of five-base pair spacers with four-base overhangs. The titles refer to the spacer length/overhang length combination that is plotted (e.g., a site with a six base-pair spacer and a four base overhang is referred to as “6/4”). The black bars indicate the relative number of sequences cleaved for each combination of spacer length and overhang length. ‘P’ refers to nucleotides in the (+) target half-site, ‘M’ refers to nucleotides in the (−) target half site, and ‘N’ refers to nucleotides in the spacer. There were no “7/7” sequences from the 4 nM VF2468 selection. Only sequences with overhangs of at least 4 bases were tabulated.

FIGS. 15A-15D. CCR5-224 preferentially cleaves five- and six-base pair spacers and cleaves five-base pair spacers to leave five-nucleotide overhangs. The heat maps show the percentage of all sequences surviving each of the four CCR5-224 in vitro selections FIGS. 15A-15D that have the spacer and overhang lengths shown.

FIGS. 16A-16D. VF2468 preferentially cleaves five- and six-base pair spacers, cleaves five-base pair spacers to leave five-nucleotide overhangs, and cleaves six-base pair spacers to leave four-nucleotide overhangs. The heat maps show the percentage of all sequences surviving each of the four VF2468 in vitro selections (FIGS. 16A-16D) that have the spacer and overhang lengths shown.

FIGS. 17A-17L. ZFNs show spacer length-dependent sequence preferences. Both CCR5-224 (FIGS. 17A-17H) and VF2468 (FIGS. 17I-17L) show increased specificity for half-sites flanking four- and seven-base pair spacers than for half-sites flanking five- and six-base pair spacers. For both ZFNs, one half-site has a greater change in mutational tolerance than the other, and the change in mutational tolerance is concentration dependent.

FIG. 18. Model for ZFN tolerance of off-target sequences. Our results suggest that some ZFNs recognize their intended target sites (top, black DNA strands with no Xs) with more binding energy than is required for cleavage under a given set of conditions (dotted line). Sequences with one or two mutations (one or two Xs) are generally tolerated since they do not decrease the ZFN:DNA binding energy below the threshold necessary for cleavage. Some sequences with additional mutations can still be cleaved if the additional mutations occur in regions of the zinc-finger binding interface that have already been disrupted (three Xs above the dotted line), as long as optimal interactions present at other locations in the ZFN:DNA binding interface maintain binding energies above threshold values. Additional mutations that disrupt key interactions at other locations in the ZFN:DNA interface, however, result in binding energies that fall short of the cleavage threshold.

FIG. 19. Profiling The Specificity of TAL Nucleases. Selection 1: +28 vs. +63 aa Linker Between TAL DNA Binding Domain and Fok1 Cleavage Domain (SEQ ID NOs: 42-45).

FIG. 20. Structure of TAL DNA binding domain and RVDs (SEQ ID NOs: 46 and 47).

FIG. 21. Mutations in target sites from TALN selection. The +28 linker enriched for cleaved sequences with less mutations suggesting the +28 linker is more specific. There are significantly less mutations in the post-selected sequences compared to the pre-selection library sequences indicating a successful selection.

FIG. 22. Enrichment of Mutations in Total Target Site Between Left and Right Half Sites of Previous TALN Selection. The relatively regular (log relationship) trend between number of half sites mutations and enrichment is consistent with a single repeat binding a base pair independent of other repeat binding.

FIG. 23. TALN Cleavage Dependence on DNA Spacer Length. There is a similar preference for cut site spacer lengths in our in vitro selection compared to previous studies. In vitro, TALN cleavage. Dependence on Linker Length & Spacer Length from Mussolino (2011).

FIG. 24. Specificity score at individual bases.

FIG. 25. Specificity score at individual bases. There is variable specificity at each individual position again with +28 linker demonstrating significantly better specificity (SEQ ID NOs: 48 and 49).

FIG. 26. Compensating Difference in Specificity of TALNs Analysis (SEQ ID NOs: 50-51).

FIG. 27. Compensating Difference in Specificity of L16 R16 TALN. A single mutation in the cleavage site does not alter the distribution of other mutations suggesting that the TAL repeat domains bind independently (SEQ ID NOs: 52-53).

FIG. 28. Profiling the Specificity of TALNs Selection II: Varying TALN Lengths (SEQ ID NOs: 54-61).

FIG. 29. Enrichment of Mutations in Common Target Site (SEQ ID NOs: 62-69).

FIG. 30. Distribution of Mutations in Total Targeted Site of TALN Digestion vs. Pre-Selection Library.

FIG. 31. Distribution of Mutations in Total Targeted Site of TALN Digestion vs. Pre-Selection Library.

FIG. 32. Enrichment of Mutations in Total Target Site Between Right and Left Half Sites of TALN Pairs.

FIG. 33. Enrichment of Mutations in Total Target Site Between Right and Left Half Sites of TALN Pairs.

FIG. 34. Enrichment of Mutations in Total Targeted Site of TALN Digestion vs. Pre-Selection Library for L10 R10 TALN Pair.

FIG. 35. DNA spacer profile. While the vast majority of sequences have a spacer preference, the highly mutant sequences have no significant spacer preference as might be expected from alternate frames changing the spacer length.

FIG. 36. Cleavage point profile. While the vast majority of sequences are cut in the spacer as expected, the R16 L16 highly mutant sequences are not predominately cut in spacer but the L10 R10 ones are cut in the spacer possibly indicative of a frame-shifted binding site leading to productive spacer cutting.

FIG. 37. Highly Mutant Half Sites in L10 R10 TALN Pair. Many potential binding sites in frames outside of the intended frame have sites more similar to the intended target (SEQ ID NOs:70-90).

FIG. 38. Enrichment of Mutations in Total Target Site Between Left and Right Half Sites of TALN Pairs Edited for Frame-shifted Binding Sites.

FIG. 39. Highly Mutant Half Sites in L16 R16 TALN Pair (SEQ ID NOs: 91-111).

FIG. 40. Highly Mutant Half Sites in L16 R16 TALN Pair. The highly mutant sequences from L16 R16 cannot be explained by a frame-shift (top figure), have no DNA Spacer preference and seem to be cutting more often outside of the DNA Spacer (bottom figure) indicating perhaps homodimer cleavage (even with heterodimer) or heterodimer cleavage independent of a TAL domain binding target site DNA (i.e. dimerization through the Fok1 cleavage domain).

FIG. 41. Heat Maps of TALN Pair Specificity Score (SEQ ID NOs: 112 and 113).

FIG. 42. Compensating Difference in Specificity of L16 R16 TALN. A single mutation in the cleavage site does not alter the distribution of other mutations suggesting that the TAL repeat domains bind independently (SEQ ID NOs: 114 and 115).

FIG. 43. Enrichment of Mutations in Full, Total Target Site of TALN Pairs. The enrichments seem to have similar log slopes in the low mutation range, the selections containing a TALN recognizing 16 bps seem to be the exceptions indicating R16 binding may be saturating for some very low mutation sites (aka R16 & L16 were near or above the Kd for the wild type site).

FIG. 44. TALN Off-Target Sites in the Human Genome.

FIG. 45. TALN Off-Target Sites Predicted Cleavage.

FIG. 46. TALN Off-Target Sites Predicted Cleavage For Very Mutant Target Sites below Detection Limit.

FIG. 47. TALN Off-Target Sites Predicted Cleavage For Very Mutant Target Sites below Detection Limit.

FIG. 48. TALN Off-Target Sites Predicted Cleavage For Sequences (Not just Number of Mutations). Combining the regular log decrease of cleavage efficiency (enrichment) as total target site mutations increase and the enrichment at each position we should be able to predict the off-target site cleavage of any sequence (SEQ ID NOs: 116-118).

FIG. 49. Comparing TALNs vs. ZFNs. For the most part, in the TALN selection the enrichment is dependent on the total mutations in both half sites and not on the distribution of mutations between half sites like for zinc finger nucleases (ZFN). This observation combined with the context dependent binding of ZFNs potentially make ZFN far less specific than their TAL equivalents.

DEFINITIONS

As used herein and in the claims, the singular forms “a,” “an,” and “the” include the singular and the plural reference unless the context clearly indicates otherwise. Thus, for example, a reference to “an agent” includes a single agent and a plurality of such agents.

The term “concatemer,” as used herein in the context of nucleic acid molecules, refers to a nucleic acid molecule that contains multiple copies of the same DNA sequences linked in a series. For example, a concatemer comprising ten copies of a specific sequence of nucleotides (e.g., [XYZ]₁₀), would comprise ten copies of the same specific sequence linked to each other in series, e.g., 5′-XYZXYZXYZXYZXYZXYZXYZXYZXYZXYZ-3′. A concatemer may comprise any number of copies of the repeat unit or sequence, e.g., at least 2 copies, at least 3 copies, at least 4 copies, at least 5 copies, at least 10 copies, at least 100 copies, at least 1000 copies, etc. An example of a concatemer of a nucleic acid sequence comprising a nuclease target site and a constant insert sequence would be [(target site)-(constant insert sequence)]₃₀₀. A concatemer may be a linear nucleic acid molecule, or may be circular.

The terms “conjugating,” “conjugated,” and “conjugation” refer to an association of two entities, for example, of two molecules such as two proteins, two domains (e.g., a binding domain and a cleavage domain), or a protein and an agent, e.g., a protein binding domain and a small molecule. The association can be, for example, via a direct or indirect (e.g., via a linker) covalent linkage or via non-covalent interactions. In some embodiments, the association is covalent. In some embodiments, two molecules are conjugated via a linker connecting both molecules. For example, in some embodiments where two proteins are conjugated to each other, e.g., a binding domain and a cleavage domain of an engineered nuclease, to form a protein fusion, the two proteins may be conjugated via a polypeptide linker, e.g., an amino acid sequence connecting the C-terminus of one protein to the N-terminus of the other protein.

The term “consensus sequence,” as used herein in the context of nucleic acid sequences, refers to a calculated sequence representing the most frequent nucleotide residues found at each position in a plurality of similar sequences. Typically, a consensus sequence is determined by sequence alignment in which similar sequences are compared to each other and similar sequence motifs are calculated. In the context of nuclease target site sequences, a consensus sequence of a nuclease target site may, in some embodiments, be the sequence most frequently bound, or bound with the highest affinity, by a given nuclease.

The term “effective amount,” as used herein, refers to an amount of a biologically active agent that is sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a nuclease may refer to the amount of the nuclease that is sufficient to induce cleavage of a target site specifically bound and cleaved by the nuclease. As will be appreciated by the skilled artisan, the effective amount of an agent, e.g., a nuclease, a hybrid protein, or a polynucleotide, may vary depending on various factors as, for example, on the desired biological response, the specific allele, genome, target site, cell, or tissue being targeted, and the agent being used.

The term “enediyne,” as used herein, refers to a class of bacterial natural products characterized by either nine- and ten-membered rings containing two triple bonds separated by a double bond (see, e.g., K. C. Nicolaou; A. L. Smith; E. W. Yue (1993). “Chemistry and biology of natural and designed enediynes”. PNAS 90 (13): 5881-5888; the entire contents of which are incorporated herein by reference). Some enediynes are capable of undergoing Bergman cyclization, and the resulting diradical, a 1,4-dehydrobenzene derivative, is capable of abstracting hydrogen atoms from the sugar backbone of DNA which results in DNA strand cleavage (see, e.g., S. Walker; R. Landovitz; W. D. Ding; G. A. Ellestad; D. Kahne (1992). “Cleavage behavior of calicheamicin gamma 1 and calicheamicin T”. Proc Natl Acad Sci U.S.A. 89 (10): 4608-12; the entire contents of which are incorporated herein by reference). Their reactivity with DNA confers an antibiotic character to many enediynes, and some enediynes are clinically investigated as anticancer antibiotics. Nonlimiting examples of enediynes are dynemicin, neocarzinostatin, calicheamicin, esperamicin (see, e.g., Adrian L. Smith and K. C. Bicolaou, “The Enediyne Antibiotics” J. Med. Chem., 1996, 39 (11), pp 2103-2117; and Donald Borders, “Enediyne antibiotics as antitumor agents,” Informa Healthcare; 1^stedition (Nov. 23, 1994, ISBN-10: 0824789385; the entire contents of which are incorporated herein by reference).

The term “homing endonuclease,” as used herein, refers to a type of restriction enzymes typically encoded by introns or inteins Edgell D R (February 2009). “Selfish DNA: homing endonucleases find a home”. Curr Biol 19 (3): R115-R117; Jasin M (June 1996). “Genetic manipulation of genomonth with rare-cutting endonucleases”. Trends Genet 12 (6): 224-8; Burt A, Koufopanou V (December 2004). “Homing endonuclease genes: the rise and fall and rise again of a selfish element”. Curr Opin Genet Dev 14 (6): 609-15; the entire contents of which are incorporated herein by reference. Homing endonuclease recognition sequences are long enough to occur randomly only with a very low probability (approximately once every 7×10¹⁰bp), and are normally found in only one instance per genome.

The term “library,” as used herein in the context of nucleic acids or proteins, refers to a population of two or more different nucleic acids or proteins, respectively. For example, a library of nuclease target sites comprises at least two nucleic acid molecules comprising different nuclease target sites. In some embodiments, a library comprises at least 10¹, at least 10², at least 10³, at least 10⁴, at least 10⁵, at least 10⁶, at least 10⁷, at least 10⁸, at least 10⁹, at least 10¹⁰, at least 10¹¹, at least 10¹², at least 10¹³, at least 10¹⁴, or at least 10¹⁵different nucleic acids or proteins. In some embodiments, the members of the library may comprise randomized sequences, for example, fully or partially randomized sequences. In some embodiments, the library comprises nucleic acid molecules that are unrelated to each other, e.g., nucleic acids comprising fully randomized sequences. In other embodiments, at least some members of the library may be related, for example, they may be variants or derivatives of a particular sequence, such as a consensus target site sequence.

The term “linker,” as used herein, refers to a chemical group or a molecule linking two adjacent molecules or moieties, e.g., a binding domain and a cleavage domain of a nuclease. Typically, the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two. In some embodiments, the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein). In some embodiments, the linker is an organic molecule, group, polymer, or chemical moiety.

The term “nuclease,” as used herein, refers to an agent, for example a protein or a small molecule, capable of cleaving a phosphodiester bond connecting nucleotide residues in a nucleic acid molecule. In some embodiments, a nuclease is a protein, e.g., an enzyme that can bind a nucleic acid molecule and cleave a phosphodiester bond connecting nucleotide residues within the nucleic acid molecule. A nuclease may be an endonuclease, cleaving a phosphodiester bonds within a polynucleotide chain, or an exonuclease, cleaving a phosphodiester bond at the end of the polynucleotide chain. In some embodiments, a nuclease is a site-specific nuclease, binding and/or cleaving a specific phosphodiester bond within a specific nucleotide sequence, which is also referred to herein as the “recognition sequence,” the “nuclease target site,” or the “target site.” In some embodiments, a nuclease recognizes a single stranded target site, while in other embodiments, a nuclease recognizes a double-stranded target site, for example a double-stranded DNA target site. The target sites of many naturally occurring nucleases, for example, many naturally occurring DNA restriction nucleases, are well known to those of skill in the art. In many cases, a DNA nuclease, such as EcoRI, HindIII, or BamHI, recognize a palindromic, double-stranded DNA target site of 4 to 10 base pairs in length, and cut each of the two DNA strands at a specific position within the target site. Some endonucleases cut a double-stranded nucleic acid target site symmetrically, i.e., cutting both strands at the same position so that the ends comprise base-paired nucleotides, also referred to herein as blunt ends. Other endonucleases cut a double-stranded nucleic acid target site asymmetrically, i.e., cutting each strand at a different position so that the ends comprise unpaired nucleotides. Unpaired nucleotides at the end of a double-stranded DNA molecule are also referred to as “overhangs,” e.g., as “5′-overhang” or as “3′-overhang,” depending on whether the unpaired nucleotide(s) form(s) the 5′ or the 5′ end of the respective DNA strand. Double-stranded DNA molecule ends ending with unpaired nucleotide(s) are also referred to as sticky ends, as they can “stick to” other double-stranded DNA molecule ends comprising complementary unpaired nucleotide(s). A nuclease protein typically comprises a “binding domain” that mediates the interaction of the protein with the nucleic acid substrate, and also, in some cases, specifically binds to a target site, and a “cleavage domain” that catalyzes the cleavage of the phosphodiester bond within the nucleic acid backbone. In some embodiments a nuclease protein can bind and cleave a nucleic acid molecule in a monomeric form, while, in other embodiments, a nuclease protein has to dimerize or multimerize in order to cleave a target nucleic acid molecule. Binding domains and cleavage domains of naturally occurring nucleases, as well as modular binding domains and cleavage domains that can be fused to create nucleases binding specific target sites, are well known to those of skill in the art. For example, zinc fingers or transcriptional activator like elements can be used as binding domains to specifically bind a desired target site, and fused or conjugated to a cleavage domain, for example, the cleavage domain of FokI, to create an engineered nuclease cleaving the target site.

The terms “nucleic acid” and “nucleic acid molecule,” as used herein, refers to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides. Typically, polymeric nucleic acids, e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage. In some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides). In some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising three or more individual nucleotide residues. As used herein, the terms “oligonucleotide” and “polynucleotide” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides). In some embodiments, “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA. Nucleic acids may be naturally occurring, for example, in the context of a genome, a transcript, an mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecule. On the other hand, a nucleic acid molecule may be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides. Furthermore, the terms “nucleic acid,” “DNA,” “RNA,” and/or similar terms include nucleic acid analogs, i.e. analogs having other than a phosphodiester backbone. Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications' A nucleic acid sequence is presented in the 5′ to 3′ direction unless otherwise indicated. In some embodiments, a nucleic acid is or comprises natural nucleosides (e.g. adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 0(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); intercalated bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and/or modified phosphate groups (e.g., phosphorothioates and 5′-N-phosphoramidite linkages).

The term “pharmaceutical composition,” as used herein, refers to a composition that can be administrated to a subject in the context of treatment of a disease or disorder. In some embodiments, a pharmaceutical composition comprises an active ingredient, e.g. a nuclease or a nucleic acid encoding a nuclease, and a pharmaceutically acceptable excipient.

The term “proliferative disease,” as used herein, refers to any disease in which cell or tissue homeostasis is disturbed in that a cell or cell population exhibits an abnormally elevated proliferation rate. Proliferative diseases include hyperproliferative diseases, such as pre-neoplastic hyperplastic conditions and neoplastic diseases. Neoplastic diseases are characterized by an abnormal proliferation of cells and include both benign and malignant neoplasias. Malignant neoplasia is also referred to a s cancer.

The terms “protein,” “peptide,” and “polypeptide” are used interchangeably herein, and refer to a polymer of amino acid residues linked together by peptide (amide) bonds. The terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long. A protein, peptide, or polypeptide may refer to an individual protein or a collection of proteins. One or more of the amino acids in a protein, peptide, or polypeptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. A protein, peptide, or polypeptide may also be a single molecule or may be a multi-molecular complex. A protein, peptide, or polypeptide may be just a fragment of a naturally occurring protein or peptide. A protein, peptide, or polypeptide may be naturally occurring, recombinant, or synthetic, or any combination thereof. A protein may comprise different domains, for example, a nucleic acid binding domain and a nucleic acid cleavage domain. In some embodiments, a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent.

The term “randomized,” as used herein in the context of nucleic acid sequences, refers to a sequence or residue within a sequence that has been synthesized to incorporate a mixture of free nucleotides, for example, a mixture of all four nucleotides A, T, G, and C. Randomized residues are typically represented by the letter N within a nucleotide sequence. In some embodiments, a randomized sequence or residue is fully randomized, in which case the randomized residues are synthesized by adding equal amounts of the nucleotides to be incorporated (e.g., 25% T, 25% A, 25% G, and 25% C) during the synthesis step of the respective sequence residue. In some embodiments, a randomized sequence or residue is partially randomized, in which case the randomized residues are synthesized by adding non-equal amounts of the nucleotides to be incorporated (e.g., 79% T, 7% A, 7% G, and 7% C) during the synthesis step of the respective sequence residue. Partial randomization allows for the generation of sequences that are templated on a given sequence, but have incorporated mutations at a desired frequency. E.g., if a known nuclease target site is used as a synthesis template, partial randomization in which at each step the nucleotide represented at the respective residue is added to the synthesis at 79%, and the other three nucleotides are added at 7% each, will result in a mixture of partially randomized target sites being synthesized, which still represent the consensus sequence of the original target site, but which differ from the original target site at each residue with a statistical frequency of 21% for each residue so synthesized (distributed binomially). In some embodiments, a partially randomized sequence differs from the consensus sequence by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30% on average, distributed binomially. In some embodiments, a partially randomized sequence differs from the consensus site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially.

The terms “small molecule” and “organic compound” are used interchangeably herein and refer to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. Typically, an organic compound contains carbon. An organic compound may contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyl, carbonyls, or heterocyclic rings). In some embodiments, organic compounds are monomeric and have a molecular weight of less than about 1500 g/mol. In certain embodiments, the molecular weight of the small molecule is less than about 1000 g/mol or less than about 500 g/mol. In certain embodiments, the small molecule is a drug, for example, a drug that has already been deemed safe and effective for use in humans or animals by the appropriate governmental agency or regulatory body. In certain embodiments, the organic molecule is known to bind and/or cleave a nucleic acid. In some embodiments, the organic compound is an enediyne. In some embodiments, the organic compound is an antibiotic drug, for example, an anticancer antibiotic such as dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof.

The term “subject,” as used herein, refers to an individual organism, for example, an individual mammal. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human mammal. In some embodiments, the subject is a non-human primate. In some embodiments, the subject is a rodent. In some embodiments, the subject is a sheep, a goat, a cattle, a cat, or a dog. In some embodiments, the subject is a vertebrate, an amphibian, a reptile, a fish, an insect, a fly, or a nematode.

The terms “target nucleic acid,” and “target genome,” as used herein in the context of nucleases, refer to a nucleic acid molecule or a genome, respectively, that comprises at least one target site of a given nuclease.

The term “target site,” used herein interchangeably with the term “nuclease target site,” refers to a sequence within a nucleic acid molecule that is bound and cleaved by a nuclease. A target site may be single-stranded or double-stranded. In the context of nucleases that dimerize, for example, nucleases comprising a FokI DNA cleavage domain, a target sites typically comprises a left-half site (bound by one monomer of the nuclease), a right-half site (bound by the second monomer of the nuclease), and a spacer sequence between the half sites in which the cut is made. This structure ([left-half site]-[spacer sequence]-[right-half site]) is referred to herein as an LSR structure. In some embodiments, the left-half site and/or the right-half site is between 10-18 nucleotides long. In some embodiments, either or both half-sites are shorter or longer. In some embodiments, the left and right half sites comprise different nucleic acid sequences.

The term “Transcriptional Activator-Like Effector,” (TALE) as used herein, refers to bacterial proteins comprising a DNA binding domain, which contains a highly conserved 33-34 amino acid sequence comprising a highly variable two-amino acid motif (Repeat Variable Diresidue, RVD). The RVD motif determines binding specificity to a nucleic acid sequence, and can be engineered according to methods well known to those of skill in the art to specifically bind a desired DNA sequence (see, e.g., Miller, Jeffrey; et. al. (February 2011). “A TALE nuclease architecture for efficient genome editing”. Nature Biotechnology 29 (2): 143-8; Zhang, Feng; et. al. (February 2011). “Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription”. Nature Biotechnology 29 (2): 149-53; Geiβler, R.; Scholze, H.; Hahn, S.; Streubel, J.; Bonas, U.; Behrens, S. E.; Boch, J. (2011), Shiu, Shin-Han. ed. “Transcriptional Activators of Human Genes with Programmable DNA-Specificity”. PLoS ONE 6 (5): e19509; Boch, Jens (February 2011). “TALEs of genome targeting”. Nature Biotechnology 29 (2): 135-6; Boch, Jens; et. al. (December 2009). “Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors”. Science 326 (5959): 1509-12; and Moscou, Matthew J.; Adam J. Bogdanove (December 2009). “A Simple Cipher Governs DNA Recognition by TAL Effectors”. Science 326 (5959): 1501; the entire contents of each of which are incorporated herein by reference). The simple relationship between amino acid sequence and DNA recognition has allowed for the engineering of specific DNA binding domains by selecting a combination of repeat segments containing the appropriate RVDs.

The term “Transcriptional Activator-Like Element Nuclease,” (TALEN) as used herein, refers to an artificial nuclease comprising a transcriptional activator like effector DNA binding domain to a DNA cleavage domain, for example, a FokI domain. A number of modular assembly schemes for generating engineered TALE constructs have been reported (Zhang, Feng; et. al. (February 2011). “Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription”. Nature Biotechnology 29 (2): 149-53; Geiβler, R.; Scholze, H.; Hahn, S.; Streubel, J.; Bonas, U.; Behrens, S. E.; Boch, J. (2011), Shiu, Shin-Han. ed. “Transcriptional Activators of Human Genes with Programmable DNA-Specificity”. PLoS ONE 6 (5): e19509; Cermak, T.; Doyle, E. L.; Christian, M.; Wang, L.; Zhang, Y.; Schmidt, C.; Baller, J. A.; Somia, N. V. et al. (2011). “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting”. Nucleic Acids Research; Morbitzer, R.; Elsaesser, J.; Hausner, J.; Lahaye, T. (2011). “Assembly of custom TALE-type DNA binding domains by modular cloning”. Nucleic Acids Research; Li, T.; Huang, S.; Zhao, X.; Wright, D. A.; Carpenter, S.; Spalding, M. H.; Weeks, D. P.; Yang, B. (2011). “Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes”. Nucleic Acids Research.; Weber, E.; Gruetzner, R.; Werner, S.; Engler, C.; Marillonnet, S. (2011). Bendahmane, Mohammed. ed. “Assembly of Designer TAL Effectors by Golden Gate Cloning”. PLoS ONE 6 (5): e19722; the entire contents of each of which are incorporated herein by reference).

The terms “treatment,” “treat,” and “treating,” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. As used herein, the terms “treatment,” “treat,” and “treating” refer to a clinical intervention aimed to reverse, alleviate, delay the onset of, or inhibit the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed and/or after a disease has been diagnosed. In other embodiments, treatment may be administered in the absence of symptoms, e.g., to prevent or delay onset of a symptom or inhibit onset or progression of a disease. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

The term “zinc finger,” as used herein, refers to a small nucleic acid-binding protein structural motif characterized by a fold and the coordination of one or more zinc ions that stabilize the fold. Zinc fingers encompass a wide variety of differing protein structures (see, e.g., Klug A, Rhodes D (1987). “Zinc fingers: a novel protein fold for nucleic acid recognition”. Cold Spring Harb. Symp. Quant. Biol. 52: 473-82, the entire contents of which are incorporated herein by reference). Zinc fingers can be designed to bind a specific sequence of nucleotides, and zinc finger arrays comprising fusions of a series of zinc fingers, can be designed to bind virtually any desired target sequence. Such zinc finger arrays can form a binding domain of a protein, for example, of a nuclease, e.g., if conjugated to a nucleic acid cleavage domain. Different type of zinc finger motifs are known to those of skill in the art, including, but not limited to, Cys₂His₂, Gag knuckle, Treble clef, Zinc ribbon, Zn₂/Cys₆, and TAZ2 domain-like motifs (see, e.g., Krishna S S, Majumdar I, Grishin N V (January 2003). “Structural classification of zinc fingers: survey and summary”. Nucleic Acids Res. 31 (2): 532-50). Typically, a single zinc finger motif binds 3 or 4 nucleotides of a nucleic acid molecule. Accordingly, a zinc finger domain comprising 2 zinc finger motifs may bind 6-8 nucleotides, a zinc finger domain comprising 3 zinc finger motifs may bind 9-12 nucleotides, a zinc finger domain comprising 4 zinc finger motifs may bind 12-16 nucleotides, and so forth. Any suitable protein engineering technique can be employed to alter the DNA-binding specificity of zinc fingers and/or design novel zinc finger fusions to bind virtually any desired target sequence from 3-30 nucleotides in length (see, e.g., Pabo C O, Peisach E, Grant R A (2001). “Design and selection of novel cys2His2 Zinc finger proteins”. Annual Review of Biochemistry 70: 313-340; Jamieson A C, Miller J C, Pabo C O (2003). “Drug discovery with engineered zinc-finger proteins”. Nature Reviews Drug Discovery 2 (5): 361-368; and Liu Q, Segal D J, Ghiara J B, Barbas C F (May 1997). “Design of polydactyl zinc-finger proteins for unique addressing within complex genomes”. Proc. Natl. Acad. Sci. U.S.A. 94 (11); the entire contents of each of which are incorporated herein by reference). Fusions between engineered zinc finger arrays and protein domains that cleave a nucleic acid can be used to generate a “zinc finger nuclease.” A zinc finger nuclease typically comprises a zinc finger domain that binds a specific target site within a nucleic acid molecule, and a nucleic acid cleavage domain that cuts the nucleic acid molecule within or in proximity to the target site bound by the binding domain. Typical engineered zinc finger nucleases comprise a binding domain having between 3 and 6 individual zinc finger motifs and binding target sites ranging from 9 base pairs to 18 base pairs in length. Longer target sites are particularly attractive in situations where it is desired to bind and cleave a target site that is unique in a given genome.

The term “zinc finger nuclease,” as used herein, refers to a nuclease comprising a nucleic acid cleavage domain conjugated to a binding domain that comprises a zinc finger array. In some embodiments, the cleavage domain is the cleavage domain of the type II restriction endonuclease FokI. Zinc finger nucleases can be designed to target virtually any desired sequence in a given nucleic acid molecule for cleavage, and the possibility to the design zinc finger binding domains to bind unique sites in the context of complex genomes allows for targeted cleavage of a single genomic site in living cells, for example, to achieve a targeted genomic alteration of therapeutic value. Targeting a double-strand break to a desired genomic locus can be used to introduce frame-shift mutations into the coding sequence of a gene due to the error-prone nature of the non-homologous DNA repair pathway. Zinc finger nucleases can be generated to target a site of interest by methods well known to those of skill in the art. For example, zinc finger binding domains with a desired specificity can be designed by combining individual zinc finger motifs of known specificity. The structure of the zinc finger protein Zif268 bound to DNA has informed much of the work in this field and the concept of obtaining zinc fingers for each of the 64 possible base pair triplets and then mixing and matching these modular zinc fingers to design proteins with any desired sequence specificity has been described (Pavletich N P, Pabo C O (May 1991). “Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A”. Science 252 (5007): 809-17, the entire contents of which are incorporated herein). In some embodiments, separate zinc fingers that each recognize a 3 base pair DNA sequence are combined to generate 3-, 4-, 5-, or 6-finger arrays that recognize target sites ranging from 9 base pairs to 18 base pairs in length. In some embodiments, longer arrays are contemplated. In other embodiments, 2-finger modules recognizing 6-8 nucleotides are combined to generate 4-, 6-, or 8-zinc finger arrays. In some embodiments, bacterial or phage display is employed to develop a zinc finger domain that recognizes a desired nucleic acid sequence, for example, a desired nuclease target site of 3-30 bp in length. Zinc finger nucleases, in some embodiments, comprise a zinc finger binding domain and a cleavage domain fused or otherwise conjugated to each other via a linker, for example, a polypeptide linker. The length of the linker determines the distance of the cut from the nucleic acid sequence bound by the zinc finger domain. If a shorter linker is used, the cleavage domain will cut the nucleic acid closer to the bound nucleic acid sequence, while a longer linker will result in a greater distance between the cut and the bound nucleic acid sequence. In some embodiments, the cleavage domain of a zinc finger nuclease has to dimerize in order to cut a bound nucleic acid. In some such embodiments, the dimer is a heterodimer of two monomers, each of which comprise a different zinc finger binding domain. For example, in some embodiments, the dimer may comprise one monomer comprising zinc finger domain A conjugated to a FokI cleavage domain, and one monomer comprising zinc finger domain B conjugated to a FokI cleavage domain. In this nonlimiting example, zinc finger domain A binds a nucleic acid sequence on one side of the target site, zinc finger domain B binds a nucleic acid sequence on the other side of the target site, and the dimerize FokI domain cuts the nucleic acid in between the zinc finger domain binding sites.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

Introduction

Site-specific nucleases are powerful tools for the targeted modification of a genome. Some site specific nucleases can theoretically achieve a level of specificity for a target cleavage site that would allow to target a single unique site in a genome for cleaveage without affecting any other genomic site. It has been reported that nuclease cleavage in living cells triggers a DNA repair mechanism that frequently results in a modification of the cleaved, repaired genomic sequence, for example, via homologous recombination. Accordingly, the targeted cleavage of a specific unique sequence within a genome opens up new avenues for gene targeting and gene modification in living cells, including cells that are hard to manipulate with conventional gene targeting methods, such as many human somatic or embryonic stem cells. Nuclease-mediated modification of disease-related sequences, e.g., the CCR-5 allele in HIV/AIDS patients, or of genes necessary for tumor neovascularization, can be used in the clinical context, and two site specific nucleases are currently in clinical trials.

One important aspect in the field of site-specific nuclease-mediated modification are off-target nuclease effects, e.g., the cleavage of genomic sequences that differ from the intended target sequence by one or more nucleotides. Undesired side effects of off-target cleavage ranges from insertion into unwanted loci during a gene targeting event to severe complications in a clinical scenario. Off target cleavage of sequences encoding essential gene functions or tumor suppressor genes by an andonuclease administered to a subject may result in disease or even death of the subject. Accordingly, it is desirable to characterize the cleavage preferences of a nuclease before using it in the laboratory or the clinic in order to determine its efficacy and safety. Further, the characterization of nuclease cleavage properties allows for the selection of the nuclease best suited for a specific task from a group of candidate nucleases, or for the selection of evolution products obtained from existing nucleases. Such a characterization of nuclease cleavage properties may also inform the de-novo design of nucleases with enhanced properties, such as enhanced specificity or efficiency.

In many scenarios where a nuclease is employed for the targeted manipulation of a nucleic acid, cleavage specificity is a crucial feature. The imperfect specificity of some engineered nuclease binding domains can lead to off-target cleavage and undesired effects both in vitro and in vivo. Current methods of evaluating site-specific nuclease specificity, including ELISA assays, microarrays, one-hybrid systems, SELEX and its variants, and Rosetta-based computational predictions, are all premised on the assumption that the binding specificity of nuclease molecules is equvalent or proportionate to their cleavage specificity.

However, the work presented here is based on the discovery that prediction of nuclease off-target binding effects constitutes an imperfect approximation of a nuclease's off-target cleavage effects that may result in undesired biological effects. This finding is consistent with the notion that the reported toxicity of some site specific DNA nucleases results from off-target DNA cleavage, rather than off-target binding alone.

The methods and reagents provided herein allow for an accurate evaluation of a given nuclease's target site specificity and provide strategies for the selection of suitable unique target sites and the design of highly specific nucleases for the targeted cleavage of a single site in the context of a complex genome. Further, methods, reagents, and strategies provided herein allow those of skill to enhance the specificity and minimize the off-target effects of any given site-specific nuclease. While of particular relevance to DNA and DNA-cleaving nucleases, the inventive concepts, methods, strategies, and reagents provided herein are not limited in this respect, but can be applied to any nucleic acid:nuclease pair.

Identifying Nuclease Target Sites Cleaved by a Site-Specific Nuclease

Some aspects of this invention provide methods and reagents to determine the nucleic acid target sites cleaved by any site-specific nuclease. In general, such methods comprise contacting a given nuclease with a library of target sites under conditions suitable for the nuclease to bind and cut a target site, and determining which target sites the nuclease actually cuts. A determination of a nuclease's target site profile based on actual cutting has the advantage over methods that rely on binding that it measures a parameter more relevant for mediating undesired off-target effects of site-specific nucleases.

In some embodiments, a method for identifying a target site of a nuclease is provided. In some embodiments, the method comprises (a) providing a nuclease that cuts a double-stranded nucleic acid target site and creates a 5′ overhang, wherein the target site comprises a [left-half site]-[spacer sequence]-[right-half site] (LSR) structure, and the nuclease cuts the target site within the spacer sequence. In some embodiments, the method comprises (b) contacting the nuclease with a library of candidate nucleic acid molecules, wherein each nucleic acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence, under conditions suitable for the nuclease to cut a candidate nucleic acid molecule comprising a target site of the nuclease. In some embodiments, the method comprises (c) filling in the 5′ overhangs of a nucleic acid molecule that has been cut twice by the nuclease and comprises a constant insert sequence flanked by a left half-site and cut spacer sequence on one side, and a right half-site and cut spacer sequence on the other side, thereby creating blunt ends. In some embodiments, the method comprises (d) identifying the nuclease target site cut by the nuclease by determining the sequence of the left-half site, the right-half-site, and/or the spacer sequence of the nucleic acid molecule of step (c). In some embodiments, the method comprises providing a nuclease and contacting the nuclease with a library of candidate nucleic acid molecules comprising candidate target sites. In some embodiments, the candidate nucleic acid molecules are double-stranded nucleic acid molecules. In some embodiments, the candidate nucleic acid molecules are DNA molecules. In some embodiments, the nuclease dimerizes at the target site, and the target site comprises an LSR structure ([left-half site]-[spacer sequence]-[right-half site]). In some embodiments, the nuclease cuts the target site within the spacer sequence. In some embodiments, the nuclease is a nuclease that cuts a double-stranded nucleic acid target site and creates a 5′ overhang. In some embodiments, each nucleic acid molecule in the library comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence.

For example, in some embodiments, the candidate nucleic acid molecules of the library comprise the structure R₁-[(LSR)-(constant region)]x-R₂, wherein R1 and R2 are, independently, nucleic acid sequences that may comprise a fragment of the [(LSR)-(constant region)] repeat unit, and X is an integer between 2 and y. In some embodiments, y is at least 10¹, at least 10², at least 10³, at least 10⁴, at least 10⁵, at least 10⁶, at least 10⁷, at least 10⁸, at least 10⁹, at least 10¹⁰, at least 10¹¹, at least 10¹², at least 10¹³, at least 10¹⁴, or at least 10¹⁵. In some embodiments, y is less than 10², less than 10³, less than 10⁴, less than 10⁵, less than 10⁶, less than 10⁷, less than 10⁸, less than 10⁹, less than 10¹⁰, less than 10¹¹, less than 10¹², less than 10¹³, less than 10¹⁴, or less than 10¹⁵. The constant region, in some embodiments, is of a length that allows for efficient self ligation of a single repeat unit. Suitable lengths will be apparent to those of skill in the art. For example, in some embodiments, the constant region is between 100 and 1000 base pairs long, for example, about 100 base pairs, about 200 base pairs, about 300 base pairs, about 400 base pairs, about 450 base pairs, about 500 base pairs, about 600 base pairs, about 700 base pairs, about 800 base pairs, about 900 base pairs, or about 1000 base pairs long in some embodiments, the constant region is shorter than about 100 base pairs or longer than about 1000 base pairs.

Incubation of the nuclease with the library nucleic acids will result in cleavage of those concatemers in the library that comprise target sites that can be bound and cleaved by the nuclease. If a given nuclease cleaves a specific target site with high efficiency, a concatemer comprising target sites will be cut multiple times, resulting in the generation of fragments comprising a single repeat unit. The repeat unit released from the concatemer by nuclease cleavage will be of the structure S₂R-(constant region)-LS₁, wherein S₁and S₂represent complementary spacer region fragments after being cut by the nuclease. Any repeat units released from library candidate molecules can then be isolated and/or the sequence of the LSR cleaved by the nuclease identified by sequencing the S₂R and LS₁regions of released repeat units.

Any method suitable for isolation and sequencing of the repeat units can be employed to elucidate the LSR sequence cleaved by the nuclease. For example, since the length of the constant region is known, individual released repeat units can be separated based on their size from the larger uncut library nucleic acid molecules as well as from fragments of library nucleic acid molecules that comprise multiple repeat units (indicating non-efficient targeted cleavage by the nuclease). Suitable methods for separating and/or isolating nucleic acid molecules based on their size a well-known to those of skill in the art and include, for example, size fractionation methods, such as gel electrophoresis, density gradient centrifugation, and dialysis over a semi-permeable membrane with a suitable molecular cutoff value. The separated/isolated nucleic acid molecules can then be further characterized, for example, by ligating PCR and/or sequencing adapters to the cut ends and amplifying and/or sequencing the respective nucleic acids. Further, if the length of the constant region is selected to favor self-ligation of individual released repeat units, such individual released repeat units may be enriched by contacting the nuclease treated library molecules with a ligase and subsequent amplification and/or sequencing based on the circularized nature of the self-ligated individual repeat units.

In some embodiments, where a nuclease is used that generates 5′ overhangs as a result of cutting a target nucleic acid, the 5′ overhangs of the cut nucleic acid molecules are filled in. Methods for filling in 5′ overhangs are well known to those of skill in the art and include, for example, methods using DNA polymerase I Klenow fragment lacking exonuclease activity (Klenow (3′->5′ exo-)). Filling in 5′ overhangs results in the overhang-templated extension of the recessed strand, which, in turn, results in blunt ends. In the case of single repeat units released from library concatemers, the resulting structure is a blunt-ended S₂′R-(constant region)-LS₁′, with S₁′ and S₂′ comprising blunt ends. PCR and/or sequencing adapters can then be added to the ends by blunt end ligation and the respective repeat units (including S₂′R and LS₁′ regions) can be sequenced. From the sequence data, the original LSR region can be deducted. Blunting of the overhangs created during the nuclease cleavage process also allows for distinguishing between target sites that were properly cut by the respective nuclease and target sites that were non-specifically cut e.g., based on non-nuclease effects such as physical shearing. Correctly cleaved nuclease target sites can be recognized by the existence of complementary S₂′R and LS₁′ regions, which comprise a duplication of the overhang nucleotides as a result of the overhang fill in, while target sites that were not cleaved by the respective nuclease are unlikely to comprise overhang nucleotide duplications. In some embodiments, the method comprises identifying the nuclease target site cut by the nuclease by determining the sequence of the left-half site, the right-half-site, and/or the spacer sequence of a released individual repeat unit. Any suitable method for amplifying and/or sequencing can be used to identify the LSR sequence of the target site cleaved by the respective nuclease. Methods for amplifying and/or sequencing nucleic acid molecules are well known to those of skill in the art and the invention is not limited in this respect.

Some of the methods and strategies provided herein allow for the simultaneous assessment of a plurality of candidate target sites as possible cleavage targets for any given nuclease. Accordingly, the data obtained from such methods can be used to compile a list of target sites cleaved by a given nuclease, which is also referred to herein as a target site profile. If they sequencing method is used that allows for the generation of quantitative sequencing data, it is also possible to record the relative abundance of any nuclease target site detected to be cleaved by the respective nuclease. Target sites that are cleaved more efficiently by the nuclease will be detected more frequently in the sequencing step, while target sites that are not cleaved efficiently will only rarely release an individual repeat unit from a candidate concatemer, and thus, will only generate few, if any sequencing reads. Such quantitative sequencing data can be integrated into a target site profile to generate a ranked list of highly preferred and less preferred nuclease target sites.

The methods and strategies of nuclease target site profiling provided herein can be applied to any site-specific nuclease, including, for example, ZFNs, TALENs, and homing endonucleases. As described in more detail herein, nuclease specificity typically decreases with increasing nuclease concentration, and the methods described herein can be used to determine a concentration at which a given nuclease efficiently cuts its intended target site, but does not efficiently cut any off target sequences. In some embodiments, a maximum concentration of a therapeutic nuclease is determined at which the therapeutic nuclease cuts its intended nuclease target site, but does not cut more than 10, more than 5, more than 4, more than 3, more than 2, more than 1, or any additional nuclease target sites. In some embodiments, a therapeutic nuclease is administered to a subject in an amount effective to generate a final concentration equal or lower to the maximum concentration determined as described above.

Nuclease Target Site Libraries

Some embodiments of this invention provide libraries of nucleic acid molecules for nuclease target site profiling. In some embodiments such a library comprises a plurality of nucleic acid molecules, each comprising a concatemer of a candidate nuclease target site and a constant insert sequence spacer sequence. For example, in some embodiments, the candidate nucleic acid molecules of the library comprise the structure R1-[(LSR)-(constant region)]x-R₂, wherein R1 and R2 are, independently, nucleic acid sequences that may comprise a fragment of the [(LSR)-(constant region)] repeat unit, and X is an integer between 2 and y. In some embodiments, y is at least 10¹, at least 10², at least 10³, at least 10⁴, at least 10⁵, at least 10⁶, at least 10⁷, at least 10⁸, at least 10⁹, at least 10¹⁰, at least 10¹¹, at least 10¹², at least 10¹³, at least 10¹⁴, or at least 10¹⁵. In some embodiments, y is less than 10², less than 10³, less than 10⁴, less than 10⁵, less than 10⁶, less than 10⁷, less than 10⁸, less than 10⁹, less than 10¹⁰, less than 10¹¹, less than 10¹², less than 10¹³, less than 10¹⁴, or less than 10¹⁵. The constant region, in some embodiments, is of a length that allows for efficient self ligation of a single repeat unit. In some embodiments, the constant region is of a length that allows for efficient separation of single repeat units from fragments comprising two or more repeat units. In some embodiments, the concentration is over length allows for efficient sequencing of a complete repeat unit in one sequencing read. Suitable lengths will be apparent to those of skill in the art. For example, in some embodiments, the constant region is between 100 and 1000 base pairs long, for example, about 100 base pairs, about 200 base pairs, about 300 base pairs, about 400 base pairs, about 450 base pairs, about 500 base pairs, about 600 base pairs, about 700 base pairs, about 800 base pairs, about 900 base pairs, or about 1000 base pairs long in some embodiments, the constant region is shorter than about 100 base pairs or longer than about 1000 base pairs.

An LSR site typically comprises a [left-half site]-[spacer sequence]-[right-half site] structure. The lengths of the half-size and the spacer sequence will depend on the specific nuclease to be evaluated. In general, the half-sites will be 6-30 nucleotides long, and preferably 10-18 nucleotides long. For example, each half site individually may be 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides long. In some embodiments, an LSR site may be longer than 30 nucleotides. In some embodiments, the left half site and the right half site of an LSR are of the same length. In some embodiments, the left half site and the right half site of an LSR are of different lengths. In some embodiments, the left half site and the right half site of an LSR are of different sequences. In some embodiments, a library is provided that comprises candidate nucleic acids which comprise LSRs that can be cleaved by a FokI cleavage domain, a Zinc Finger Nuclease (ZFN), a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, and/or bleomycin.

In some embodiments, a library of candidate nucleic acid molecules is provided that comprises at least 10⁵, at least 10⁶, at least 10⁷, at least 10⁸, at least 10⁹, at least 10¹⁰, at least 10¹¹, or at least 10¹²different candidate nuclease target sites. In some embodiments, the candidate nucleic acid molecules of the library are concatemers produced from a secularized templates by rolling cycle amplification. In some embodiments, the library comprises nucleic acid molecules, e.g., concatemers, of a molecular weight of at least 5 kDa, at least 6 kDa, at least 7 kDa, at least 8 kDa, at least 9 kDa, at least 10 kDa, at least 12 kDa, or at least 15 kDa. in some embodiments, the molecular weight of the nucleic acid molecules within the library may be larger than 15 kDa. In some embodiments, the library comprises nucleic acid molecules within a specific size range, for example, within a range of 5-7 kDa, 5-10 kDa, 8-12 kDa, 10-15 kDa, or 12-15 kDa, or 5-10 kDa or any possible subrange. While some methods suitable for generating nucleic acid concatemers according to some aspects of this invention result in the generation of nucleic acid molecules of greatly different molecular weights, such mixtures of nucleic acid molecules may be size fractionated to obtain a desired size distribution. Suitable methods for enriching nucleic acid molecules of a desired size or excluding nucleic acid molecules of a desired size are well known to those of skill in the art and the invention is not limited in this respect.

In some embodiments, a library is provided comprising candidate nucleic acid molecules that comprise target sites with a partially randomized left-half site, a partially randomized right-half site, and/or a partially randomized spacer sequence.

In some embodiments, the library is provided comprising candidate nucleic acid molecules that comprise target sites with a partially randomized left half site, a fully randomized spacer sequence, and a partially randomized right half site. In some embodiments, partially randomized sites differ from the consensus site by more than 5%, more than 10%, more than 15%, more than 20%, more than 25%, or more than 30% on average, distributed binomially. In some embodiments, partially randomized sites differ from the consensus site by no more than 10%, no more than 15%, no more than 20%, no more than 25%, nor more than 30%, no more than 40%, or no more than 50% on average, distributed binomially. For example, in some embodiments partially randomized sites differ from the consensus site by more than 5%, but by no more than 10%; by more than 10%, but by no more than 20%; by more than 20%, but by no more than 25%; by more than 5%, but by no more than 20%, and so on. Using partially randomized nuclease target sites in the library is useful to increase the concentration of library members comprising target sites that are closely related to the consensus site, for example, that differ from the consensus sites in only one, only two, only three, only four, or only five residues. The rationale behind this is that a given nuclease, for example a given ZFN, is likely to cut its intended target site and any closely related target sites, but unlikely to cut a target sites that is vastly different from or completely unrelated to the intended target site. Accordingly, using a library comprising partially randomized target sites can be more efficient than using libraries comprising fully randomized target sites without compromising the sensitivity in detecting any off target cleavage events for any given nuclease. Thus, the use of partially randomized libraries significantly reduces the cost and effort required to produce a library having a high likelihood of covering virtually all off target sites of a given nuclease. In some embodiments however it may be desirable to use a fully randomized library of target sites, for example, in embodiments, where the specificity of a given nuclease is to be evaluated in the context of any possible site in a given genome.

Selection and Design of Site-Specific Nucleases

Some aspects of this invention provide methods and strategies for selecting and designing site-specific nucleases that allow the targeted cleavage of a single, unique sites in the context of a complex genome. In some embodiments, a method is provided that comprises providing a plurality of candidate nucleases that are designed or known to cut the same consensus sequence; profiling the target sites actually cleaved by each candidate nuclease, thus detecting any cleaved off-target sites (target sites that differ from the consensus target site); and selecting a candidate nuclease based on the off-target site(s) so identified. In some embodiments, this method is used to select the most specific nuclease from a group of candidate nucleases, for example, the nuclease that cleaves the consensus target site with the highest specificity, the nuclease that cleaves the lowest number of off-target sites, the nuclease that cleaves the lowest number of off-target sites in the context of a target genome, or a nuclease that does not cleave any target site other than the consensus target site. In some embodiments, this method is used to select a nuclease that does not cleave any off-target site in the context of the genome of a subject at concentration that is equal to or higher than a therapeutically effective concentration of the nuclease.

The methods and reagents provided herein can be used, for example, to evaluate a plurality of different nucleases targeting the same intended targets site, for example, a plurality of variations of a given site-specific nuclease, for example a given zinc finger nuclease. Accordingly, such methods may be used as the selection step in evolving or designing a novel site-specific nucleases with improved specificity.

Identifying Unique Nuclease Target Sites within a Genome

Some embodiments of this invention provide a method for selecting a nuclease target site within a genome. As described in more detail elsewhere herein, it was surprisingly discovered that off target sites cleaved by a given nuclease are typically highly similar to the consensus target site, e.g., differing from the consensus target site in only one, only two, only three, only four, or only five nucleotide residues. Based on this discovery, a nuclease target sites within the genome can be selected to increase the likelihood of a nuclease targeting this site not cleaving any off target sites within the genome. For example, in some embodiments, a method is provided that comprises identifying a candidate nuclease target site; and comparing the candidate nuclease target site to other sequences within the genome. Methods for comparing candidate nuclease target sites to other sequences within the genome are well known to those of skill in the art and include for example sequence alignment methods, for example, using a sequence alignment software or algorithm such as BLAST on a general purpose computer. A suitable unique nuclease target site can then be selected based on the results of the sequence comparison. In some embodiments, if the candidate nuclease target site differs from any other sequence within the genome by at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotides, the nuclease target site is selected as a unique site within the genome, whereas if the site does not fulfill this criteria, the site may be discarded. In some embodiments, once a site is selected based on the sequence comparison, as outlined above, a site-specific nuclease targeting the selected site is designed. For example, a zinc finger nuclease may be designed to target any selected nuclease target site by constructing a zinc finger array binding the target site, and conjugating the zinc finger array to a DNA cleavage domain. In embodiments where the DNA cleavage domain needs to dimerize in order to cleave DNA, to zinc finger arrays will be designed, each binding a half site of the nuclease target site, and each conjugated to a cleavage domain. In some embodiments, nuclease designing and/or generating is done by recombinant technology. Suitable recombinant technologies are well known to those of skill in the art, and the invention is not limited in this respect.

In some embodiments, a site-specific nuclease designed or generated according to aspects of this invention is isolated and/or purified. The methods and strategies for designing site-specific nucleases according to aspects of this invention can be applied to design or generate any site-specific nuclease, including, but not limited to Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases (TALENs), homing endonucleases, organic compound nucleases, enediyne nucleases, antibiotic nucleases, and dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof variants or derivatives.

Site-Specific Nucleases

Some aspects of this invention provide isolated site-specific nucleases with enhanced specificity that are designed using the methods and strategies described herein. Some embodiments, of this invention provide nucleic acids encoding such nucleases. Some embodiments of this invention provide expression constructs comprising such encoding nucleic acids. For example, in some embodiments an isolated nuclease is provided that has been engineered to cleave a desired target site within a genome, and has been evaluated according to a method provided herein to cut less than 1, less than 2, less than 3, less than 4, less than 5, less than 6, less than 7, less than 8, less than 9 or less than 10 off-target sites at a concentration effective for the nuclease to cut its intended target site. In some embodiments an isolated nuclease is provided that has been engineered to cleave a desired unique target site that has been selected to differ from any other site within a genome by at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 nucleotide residues. In some embodiments, the isolated nuclease is a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like Effector Nuclease (TALEN), a homing endonuclease, or is or comprises an organic compound nuclease, an enediyne, an antibiotic nuclease, dynemicin, neocarzinostatin, calicheamicin, esperamicin, bleomycin, or a derivative thereof. In some embodiments, the isolated nuclease cleaves a consensus target site within an allele that is associated with a disease or disorder. In some embodiments, the isolated nuclease cleaves a consensus target site the cleavage of which results in treatment or prevention of a disease or disorder. In some embodiments, the disease is HIV/AIDS, or a proliferative disease. In some embodiments, the allele is a CCR5 (for treating HIV/AIDS) or a VEGFA allele (for treating a proliferative disease).

In some embodiments, the isolated nuclease is provided as part of a pharmaceutical composition. For example, some embodiments provide pharmaceutical compositions comprising a nuclease as provided herein, or a nucleic acid encoding such a nuclease, and a pharmaceutically acceptable excipient. Pharmaceutical compositions may optionally comprise one or more additional therapeutically active substances.

In some embodiments, compositions provided herein are administered to a subject, for example, to a human subject, in order to effect a targeted genomic modification within the subject. In some embodiments, cells are obtained from the subject and contacted with a nuclease or a nuclease-encoding nucleic acid ex vivo, and re-administered to the subject after the desired genomic modification has been effected or detected in the cells. Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to animals of all sorts. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, and/or rats; and/or birds, including commercially relevant birds such as chickens, ducks, geese, and/or turkeys.

Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if necessary and/or desirable, shaping and/or packaging the product into a desired single- or multi-dose unit.

Pharmaceutical formulations may additionally comprise a pharmaceutically acceptable excipient, which, as used herein, includes any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's The Science and Practice of Pharmacy, 21^stEdition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, M D, 2006; incorporated herein by reference) discloses various excipients used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Except insofar as any conventional excipient medium is incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition, its use is contemplated to be within the scope of this invention.

The function and advantage of these and other embodiments of the present invention will be more fully understood from the Examples below. The following Examples are intended to illustrate the benefits of the present invention and to describe particular embodiments, but are not intended to exemplify the full scope of the invention. Accordingly, it will be understood that the Examples are not meant to limit the scope of the invention.

EXAMPLES
Example 1 Zinc Finger Nucleases
Introduction

Zinc finger nucleases (ZFNs) are enzymes engineered to recognize and cleave desired target DNA sequences. A ZFN monomer consists of a zinc finger DNA-binding domain fused with a non-specific FokI restriction endonuclease cleavage domain¹. Since the FokI nuclease domain must dimerize and bridge two DNA half-sites to cleave DNA², ZFNs are designed to recognize two unique sequences flanking a spacer sequence of variable length and to cleave only when bound as a dimer to DNA. ZFNs have been used for genome engineering in a variety of organisms including mammals^3-9by stimulating either non-homologous end joining or homologous recombination. In addition to providing powerful research tools, ZFNs also have potential as gene therapy agents. Indeed, two ZFNs have recently entered clinical trials: one as part of an anti-HIV therapeutic approach (NCT00842634, NCT01044654, NCT01252641) and the other to modify cells used as anti-cancer therapeutics (NCT01082926).

DNA cleavage specificity is a crucial feature of ZFNs. The imperfect specificity of some engineered zinc fingers domains has been linked to cellular toxicity¹⁰and therefore determining the specificities of ZFNs is of significant interest. ELISA assays¹¹, microarrays¹², a bacterial one-hybrid system¹³, SELEX and its variants^14-16, and Rosetta-based computational predictions¹⁷have all been used to characterize the DNA-binding specificity of monomeric zinc finger domains in isolation. However, the toxicity of ZFNs is believed to result from DNA cleavage, rather than binding alone^18,19. As a result, information about the specificity of zinc finger nucleases to date has been based on the unproven assumptions that (i) dimeric zinc finger nucleases cleave DNA with the same sequence specificity with which isolated monomeric zinc finger domains bind DNA; and (ii) the binding of one zinc finger domain does not influence the binding of the other zinc finger domain in a given ZFN. The DNA-binding specificities of monomeric zinc finger domains have been used to predict potential off-target cleavage sites of dimeric ZFNs in genomes^6,20, but to our knowledge no study to date has reported a method for determining the broad DNA cleavage specificity of active, dimeric zinc finger nucleases.

In this work we present an in vitro selection method to broadly examine the DNA cleavage specificity of active ZFNs. Our selection was coupled with high-throughput DNA sequencing technology to evaluate two obligate heterodimeric ZFNs, CCR5-224⁶, currently in clinical trials (NCT00842634, NCT01044654, NCT01252641), and VF2468⁴, that targets the human VEGF-A promoter, for their abilities to cleave each of 10¹¹potential target sites. We identified 37 sites present in the human genome that can be cleaved in vitro by CCR5-224, 2,652 sites in the human genome that can be cleaved in vitro by VF2468, and hundreds of thousands of in vitro cleavable sites for both ZFNs that are not present in the human genome. To demonstrate that sites identified by our in vitro selection can also be cleaved by ZFNs in cells, we examined 34 or 90 sites for evidence of ZFN-induced mutagenesis in cultured human K562 cells expressing the CCR5-224 or VF2468 ZFNs, respectively. Ten of the CCR5-224 sites and 32 of the VF2468 sites we tested show DNA sequence changes consistent with ZFN-mediated cleavage in human cells, although we anticipate that cleavage is likely to be dependent on cell type and ZFN concentration. One CCR5-224 off-target site lies in a promoter of the malignancy-associated BTBD10 gene.

Our results, which could not have been obtained by determining binding specificities of monomeric zinc finger domains alone, indicate that excess DNA-binding energy results in increased off-target ZFN cleavage activity and suggest that ZFN specificity can be enhanced by designing ZFNs with decreased binding affinity, by lowering ZFN expression levels, and by choosing target sites that differ by at least three base pairs from their closest sequence relatives in the genome.

Results

In Vitro Selection for ZFN-Mediated DNA Cleavage

Libraries of potential cleavage sites were prepared as double-stranded DNA using synthetic primers and PCR (FIG. 5). Each partially randomized position in the primer was synthesized by incorporating a mixture containing 79% wild-type phosphoramidite and 21% of an equimolar mixture of all three other phosphoramidites. Library sequences therefore differed from canonical ZFN cleavage sites by 21% on average, distributed binomially. We used a blunt ligation strategy to create a 10¹²-member minicircle library. Using rolling-circle amplification, >10¹¹members of this library were both amplified and concatenated into high molecular weight (>12 kb) DNA molecules. In theory, this library covers with at least 10-fold excess all DNA sequences that are seven or fewer mutations from the wild-type target sequences.

We incubated the CCR5-224 or VF2468 DNA cleavage site library at a total cleavage site concentration of 14 nM with two-fold dilutions, ranging from 0.5 nM to 4 nM, of crude in vitro-translated CCR5-224 or VF2468, respectively (FIGS. 6A-6D). Following digestion, we subjected the resulting DNA molecules (FIGS. 7A-7B) to in vitro selection for DNA cleavage and subsequent paired-end high-throughput DNA sequencing. Briefly, three selection steps (FIG. 1) enabled the separation of sequences that were cleaved from those that were not. First, only sites that had been cleaved contained 5′ phosphates, which are necessary for the ligation of adapters required for sequencing. Second, after PCR, a gel purification step enriched the smaller, cleaved library members. Finally, a computational filter applied after sequencing only counted sequences that have filled-in, complementary 5′ overhangs on both ends, the hallmark for cleavage of a target site concatemer (Table 2 and Protocols 1-9). We prepared pre-selection library sequences for sequencing by cleaving the library at a PvuI restriction endonuclease recognition site adjacent to the library sequence and subjecting the digestion products to the same protocol as the ZFN-digested library sequences. High-throughput sequencing confirmed that the rolling-circle-amplified, pre-selection library contained the expected distribution of mutations (FIGS. 8A-8B).

Design of an In Vitro Selection for ZFN-Mediated DNA Cleavage.

To characterize comprehensively the DNA cleavage specificity of active ZFNs, we first generated a large library of potential DNA substrates that can be selected for DNA cleavage in one step without requiring iterative enrichment steps that could amplify noise and introduce bias. We designed the substrate library such that each molecule in the library is a concatemer of one of >10¹¹potential substrate sequences (FIG. 5). Incubation with ZFN results in some molecules that are uncut, some that have been cut once, and some that have been cut at least twice. Those molecules that have been cleaved at least twice have ends consisting of each half of the cleaved DNA sequence (FIG. 1). Cut library members are enriched relative to uncut library members in three ways (FIG. 1). First, sequences that have been cleaved twice have two complementary 5′ overhangs, which can be identified computationally following DNA sequencing as hallmarks of bona fide cleavage products. Second, since ZFN-mediated cleavage reveals 5′ phosphates that are not present in the pre-selection library, only DNA that has undergone cleavage is amenable to sequencing adapter ligation. Third, after PCR using primers complementary to the sequencing adapters, a gel purification step ensures that all sequenced material is of a length consistent with library members that have been cleaved at two adjacent sites. This gel-purified material is subjected to high-throughput DNA sequencing using the Illumina method (Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53-9 (2008)). Ideally, the library used in a ZFN cleavage selection would consist of every possible DNA sequence of the length recognized by the ZFN. Only one out of every 105 members of such a library, however, would contain a sequence that was within seven mutations of a 24-base pair recognition sequence. Since off-target recognition sequences most likely resemble target recognition sites, we used instead a biased library that ensures >10-fold coverage of all half-site sequences that differ from the wild-type recognition sequences by up to seven mutations. Library members consist of a fully randomized base pair adjacent to the 5′ end of the recognition site, two partially randomized half sites flanking a 4-, 5-, 6-, or 7-bp fully randomized spacer, and another fully randomized base pair adjacent to the 3′ end of the recognition site. A fully randomized five-base pair tag follows each library member. This tag, along with the randomized flanking base pairs and the randomized spacer sequence, was used as a unique identifier “key” for each library member. If this unique key was associated with more than one sequence read containing identical library members, these duplicate sequencing reads likely arose during PCR amplification and were therefore treated as one data point.

Analysis of CCR5-224 and VF2468 ZFNs Using the DNA Cleavage Selection.

Each member of a sequence pair consisted of a fragment of the spacer, an entire half-site, an adjacent nucleotide, and constant sequence. One end of the spacer was generally found in one sequence and the other end in its corresponding paired sequence, with the overhang sequence present in both paired sequence reads because overhangs were blunted by extension prior to ligation of adapters. The spacer sequences were reconstructed by first identifying the shared overhang sequence and then any nucleotides present between the overhang sequence and the half-site sequence. Only sequences containing no ambiguous nucleotides and overhangs of at least 4 nucleotides were analyzed. Overall, this computational screen for unique sequences that originated from two cleavage events on identical library members yielded 2.0 million total reads of cleaved library members (Table 2). There are far fewer analyzed sequences for the 0.5 nM, 1 nM, and 2 nM CCR5-224 and VF2468 selections compared to the 4 nM selections due to the presence of a large number of sequence repeats, identified through the use of the unique identifier key described above. The high abundance of repeated sequences in the 0.5 nM, 1 nM, and 2 nM selections indicate that the number of sequencing reads obtained in those selections, before repeat sequences were removed, was larger than the number of individual DNA sequences that survived all experimental selection steps. We estimated the error rate of sequencing to be 0.086% per nucleotide by analysis of a constant nucleotide in all paired reads. Using this error rate, we estimate that 98% of the post-selection ZFN target site sequences contain no errors.

Off-Target Cleavage is Dependent on ZFN Concentration

As expected, only a subset of library members was cleaved by each enzyme. The pre-selection libraries for CCR5-224 and VF2468 contained means of 4.56 and 3.45 mutations per complete target site (two half-sites), respectively, while post-selection libraries exposed to the highest concentrations of ZFN used (4 nM CCR5-224 and 4 nM VF2468) had means of 2.79 and 1.53 mutations per target site, respectively (FIGS. 8A-8B). As ZFN concentration decreased, both ZFNs exhibited less tolerance for off-target sequences. At the lowest concentrations (0.5 nM CCR5-224 and 0.5 nM VF2468), cleaved sites contained an average of 1.84 and 1.10 mutations, respectively. We placed a small subset of the identified sites in a new DNA context and incubated in vitro with 2 nM CCR5-224 or 1 nM VF2468 for 4 hours at 37° C. (FIGS. 9A-9B). We observed cleavage for all tested sites and those sites emerging from the more stringent (low ZFN concentration) selections were cleaved more efficiently than those from the less stringent selections. Notably, all of the tested sequences contain several mutations, yet some were cleaved in vitro more efficiently than the designed target.

The DNA-cleavage specificity profile of the dimeric CCR5-224 ZFN (FIG. 2A and FIGS. 10A-10B) was notably different than the DNA-binding specificity profiles of the CCR5-224 monomers previously determined by SELEX⁶. For example, some positions, such as (+)A5 and (+)T9, exhibited tolerance for off-target base pairs in our cleavage selection that were not predicted by the SELEX study. VF2468, which had not been previously characterized with respect to either DNA-binding or DNA-cleavage specificity, revealed two positions, (−)C5 and (+)A9, that exhibited limited sequence preference, suggesting that they were poorly recognized by the ZFNs (FIG. 2B and FIGS. 10C-10D).

Compensation Between Half-Sites Affects DNA Recognition

Our results reveal that ZFN substrates with mutations in one half-site are more likely to have additional mutations in nearby positions in the same half-site compared to the pre-selection library and less likely to have additional mutations in the other half-site. While this effect was found to be largest when the most strongly recognized base pairs were mutated (FIG. 11), we observed this compensatory phenomenon for all specified half-site positions for both the CCR5 and VEGF-targeting ZFNs (FIGS. 3A-3B and FIGS. 12A-12B). For a minority of nucleotides in cleaved sites, such as VF2468 target site positions (+)G1, (−)G1, (−)A2, and (−)C3, mutation led to decreased tolerance of mutations in base pairs in the other half-site and also a slight decrease, rather than an increase, in mutational tolerance in the same half-site. When two of these mutations, (+)G1 and (−)G1, were enforced at the same time, mutational tolerance at all other positions decreased (FIG. 13). Collectively, these results show that tolerance of mutations at one half-site is influenced by DNA recognition at the other half-site.

This compensation model for ZFN site recognition applies not only to non-ideal half-sites, but also to spacers with non-ideal lengths. In general, the ZFNs cleaved at characteristic locations within the spacers (FIGS. 14A-14B), and five- and six-base pair spacers were preferred over four- and seven-base pair spacers (FIGS. 15A-15D and FIGS. 16A-16D). However, cleaved sites with five- or six-base pair spacers showed greater sequence tolerance at the flanking half-sites than sites with four- or seven-base pair spacers (FIG. 17A-17L). Therefore, spacer imperfections, similar to half-site mutations, lead to more stringent in vitro recognition of other regions of the DNA substrate.

ZFNs can Cleave Many Sequences with Up to Three Mutations

We calculated enrichment factors for all sequences containing three or fewer mutations by dividing each sequence's frequency of occurrence in the post-selection libraries by its frequency of occurrence in the pre-selection libraries. Among sequences enriched by cleavage (enrichment factor >1), CCR5-224 was capable of cleaving all unique single-mutant sequences, 93% of all unique double-mutant sequences, and half of all possible triple-mutant sequences (FIG. 4A and Table 3a) at the highest enzyme concentration used. VF2468 was capable of cleaving 98% of all unique single-mutant sequences, half of all unique double-mutant sequences, and 17% of all triple-mutant sequences (FIG. 4B and Table 3b).

Since our approach assays active ZFN dimers, it reveals the complete sequences of ZFN sites that can be cleaved. Ignoring the sequence of the spacer, the selection revealed 37 sites in the human genome with five- or six-base pair spacers that can be cleaved in vitro by CCR5-224 (Table 1 and Table 4), and 2,652 sites in the human genome that can be cleaved by VF2468 (VF2468 Data). Among the genomic sites that were cleaved in vitro by VF2468, 1,428 sites had three or fewer mutations relative to the canonical target site (excluding the spacer sequence). Despite greater discrimination against single-, double-, and triple-mutant sequences by VF2468 compared to CCR5-224 (FIGS. 4A-4B and Table 3), the larger number of in vitro-cleavable VF2468 sites reflects the difference in the number of sites in the human genome that are three or fewer mutations away from the VF2468 target site (3,450 sites) versus those that are three or fewer mutations away from the CCR5-224 target site (eight sites) (Table 5).

Identified Sites are Cleaved by ZFNs in Human Cells

We tested whether CCR5-224 could cleave at sites identified by our selections in human cells by expressing CCR5-224 in K562 cells and examining 34 potential target sites within the human genome for evidence of ZFN-induced mutations using PCR and high-throughput DNA sequencing. We defined sites with evidence of ZFN-mediated cleavage as those with insertion or deletion mutations (indels) characteristic of non-homologous end joining (NHEJ) repair (Table 6) that were significantly enriched (P<0.05) in cells expressing active CCR5-224 compared to control cells containing an empty vector. We obtained approximately 100,000 sequences or more for each site analyzed, which enabled the detection of sites that were significantly modified at frequencies of approximately 1 in 10,000. Our analysis identified ten such sites: the intended target sequence in CCR5, a previously identified sequence in CCR2, and eight other off-target sequences (Tables 1, 4, and 6), one of which lies within the promoter of the BTBD10 gene. The eight newly identified off-target sites are modified at frequencies ranging from 1 in 300 to 1 in 5,300. We also expressed VF2468 in cultured K562 cells and performed the above analysis for 90 of the most highly cleaved sites identified by in vitro selection. Out of the 90 VF2468 sites analyzed, 32 showed indels consistent with ZFN-mediated targeting in K562 cells (Table 7). We were unable to obtain site-specific PCR amplification products for three CCR5-224 sites and seven VF2468 sites and therefore could not analyze the occurrence of NHEJ at those loci. Taken together, these observations indicate that off-target sequences identified through the in vitro selection method include many DNA sequences that can be cleaved by ZFNs in human cells.

Discussion

The method presented here identified hundreds of thousands of sequences that can be cleaved by two active, dimeric ZFNs, including many that are present and can be cut in the genome of human cells. One newly identified cleavage site for the CCR5-224 ZFN is within the promoter of the BTBD10 gene. When downregulated, BTBD10 has been associated with malignancy²¹and with pancreatic beta cell apoptosis²². When upregulated, BTBD10 has been shown to enhance neuronal cell growth²³and pancreatic beta cell proliferation through phosphorylation of Akt family proteins^22,23. This potentially important off-target cleavage site as well as seven others we observed in cells were not identified in a recent study⁶that used in vitro monomer-binding data to predict potential CCR5-224 substrates.

We have previously shown that ZFNs that can cleave at sites in one cell line may not necessarily function in a different cell line⁴, most likely due to local differences in chromatin structure. Therefore, it is likely that a different subset of the in vitro-cleavable off-target sites would be modified by CCR5-224 or VF2468 when expressed in different cell lines. Purely cellular studies of endonuclease specificity, such as a recent study of homing endonuclease off-target cleavage²⁴, may likewise be influenced by cell line choice. While our in vitro method does not account for some features of cellular DNA, it provides general, cell type-independent information about endonuclease specificity and off-target sites that can inform subsequent studies performed in cell types of interest. In addition, while our pre-selection library oversamples with at least 10-fold coverage all sequences within seven mutations of the intended ZFN target sites, the number of sequence reads obtained per selection (approximately one million) is likely insufficient to cover all cleaved sequences present in the post-selection libraries. It is therefore possible that additional off-target cleavage sites for CCR5-224 and VF2468 could be identified in the human genome as sequencing capabilities continue to improve.

Although both ZFNs we analyzed were engineered to a unique sequence in the human genome, both cleave a significant number of off-target sites in cells. This finding is particularly surprising for the four-finger CCR5-224 pair given that its theoretical specificity is 4,096-fold better than that of the three-finger VF2468 pair (CCR5-224 should recognize a 24-base pair site that is six base pairs longer than the 18-base pair VF2468 site). Examination of the CCR5-224 and VF2468 cleavage profiles (FIGS. 2A-2B) and mutational tolerances of sequences with three or fewer mutations (FIGS. 4A-4B) suggests different strategies may be required to engineer variants of these ZFNs with reduced off-target cleavage activities. The four-finger CCR5-224 ZFN showed a more diffuse range of positions with relaxed specificity and a higher tolerance of mutant sequences with three or fewer mutations than the three-finger VF2468 ZFN. For VF2468, re-optimization of only a subset of fingers may enable a substantial reduction in undesired cleavage events. For CCR5-224, in contrast, a more extensive re-optimization of many or all fingers may be required to eliminate off-target cleavage events.

We note that not all four- and three-finger ZFNs will necessarily be as specific as the two ZFNs tested in this study. Both CCR5-224 and VF2468 were engineered using methods designed to optimize the binding activity of the ZFNs. Previous work has shown that for both three-finger and four-finger ZFNs, the specific methodology used to engineer the ZFN pair can have a tremendous impact on the quality and specificity of nucleases^7,13,25,26.

Our findings have significant implications for the design and application of ZFNs with increased specificity. Half or more of all potential substrates with one or two site mutations could be cleaved by ZFNs, suggesting that binding affinity between ZFN and DNA substrate is sufficiently high for cleavage to occur even with suboptimal molecular interactions at mutant positions. We also observed that ZFNs presented with sites that have mutations in one half-site exhibited higher mutational tolerance at other positions within the mutated half-site and lower tolerance at positions in the other half-site. These results collectively suggest that in order to meet a minimum affinity threshold for cleavage, a shortage of binding energy from a half-site harboring an off-target base pair must be energetically compensated by excess zinc finger:DNA binding energy in the other half-site, which demands increased sequence recognition stringency at the non-mutated half-site (FIG. 18). Conversely, the relaxed stringency at other positions in mutated half-sites can be explained by the decreased contribution of that mutant half-site to overall ZFN binding energy. This hypothesis is supported by a recent study showing that reducing the number of zinc fingers in a ZFN can actually increase, rather than decrease, activity²⁷.

This model also explains our observation that sites with suboptimal spacer lengths, which presumably were bound less favorably by ZFNs, were recognized with higher stringency than sites with optimal spacer lengths. In vitro spacer preferences do not necessarily reflect spacer preferences in cells;^28,29however, our results suggest that the dimeric FokI cleavage domain can influence ZFN target-site recognition. Consistent with this model, Wolfe and co-workers recently observed differences in the frequency of off-target events in zebrafish of two ZFNs with identical zinc-finger domains but different FokI domain variants.²⁰

Collectively, our findings suggest that (i) ZFN specificity can be increased by avoiding the design of ZFNs with excess DNA binding energy; (ii) off-target cleavage can be minimized by designing ZFNs to target sites that do not have relatives in the genome within three mutations; and (iii) ZFNs should be used at the lowest concentrations necessary to cleave the target sequence to the desired extent. While this study focused on ZFNs, our method should be applicable to all sequence-specific endonucleases that cleave DNA in vitro, including engineered homing endonucleases and engineered transcription activator-like effector (TALE) nucleases. This approach can provide important information when choosing target sites in genomes for sequence-specific endonucleases, and when engineering these enzymes, especially for therapeutic applications.

Methods

Oligonucleotides and Sequences. All oligonucleotides were purchased from Integrated DNA Technologies or Invitrogen and are listed in Table 8. Primers with degenerate positions were synthesized by Integrated DNA Technologies using hand-mixed phosphoramidites containing 79% of the indicated base and 7% of each of the other standard DNA bases.

Sequences of ZFNs used in this study. DNA and protein sequences are shown for the ZFNs used in this study. The T7 promoter is underlined, and the start codon is in bold.

CCR5-224 (+) DNA sequence (SEQ ID NO: 119):

TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCCACCATGGACTACAAAGACCATGACGGTGATTATAAA

GATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACGGG

GTACCCGCCGCTATGGCTGAGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTGATCGCTCTAACCTG

AGTCGGCACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAGTTTGCCATCTCC

TCCAACCTGAACTCCCATACCAAGATACACACGGGATCTCAGAAGCCCTTCCAGTGTCGAATCTGCATGCGTAAC

TTCAGTCGCTCCGACAACCTGGCCCGCCACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGACATTTGT

GGGAGGAAATTTGCCACCTCCGGCAACCTGACCCGCCATACCAAGATACACCTGCGGGGATCCCAACTAGTCAAA

AGTGAACTGGAGGAGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATT

GAAATTGCCAGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGA

TATAGAGGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTAC

GGTGTGATCGTGGATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGCAACGA

TATGTCAAAGAAAATCAAACACGAAACAAACATATCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTA

ACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCAT

AAGACTAATTGTAATGGAGCTGTTCTTAGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACA

TTAACCTTAGAGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTTTAA

CCR5-224 (+) protein sequence (SEQ ID NO: 120):

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAAMAERPFQCRICMRNFSDRSNLSRHIRTHTGEKPFA

CDICGRKFAISSNLNSHTKIHTGSQKPFQCRICMRNFSRSDNLARHIRTHTGEKPFACDICGRKFATSGNLTRHT

KIHLRGSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDG

AIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKG

NYKAQLTRLNHKTNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF

CCR5-224 (−) DNA sequence (SEQ ID NO: 121):

TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCCACCATGGACTACAAAGACCATGACGGTGATTATAAA

GATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACGGG

GTACCTGCCGCTATGGCTGAGAGGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTCAGTCGCTCCGACAACCTG

TCCGTGCACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGGAGGAAGTTTGCCCAGAAG

ATCAACCTGCAGGTGCATACCAAGATACACACCGGCGAGAAGCCCTTCCAGTGTCGAATCTGCATGCGTAACTTC

AGTCGCTCCGACGTGCTGTCCGAGCACATCCGCACCCACACAGGCGAGAAGCCTTTTGCCTGTGACATTTGTGGG

AGGAAATTTGCCCAGCGCAACCACCGCACCACCCATACCAAGATACACCTGCGGGGATCCCAACTAGTCAAAAGT

GAACTGGAGGAGAAGAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATTGAA

ATTGCCAGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGATAT

AGAGGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCCTATTGATTACGGT

GTGATCGTGGATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCAAGCAGATGAAATGGAGCGATAT

GTCGAAGAAAATCAAACACGAAACAAACATCTCAACCCTAATGAATGGTGGAAAGTCTATCCATCTTCTGTAACG

GAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAAAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATC

ACTAATTGTAATGGAGCTGTTCTTAGTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTA

ACCTTAGAGGAAGTGAGACGGAAATTTAATAACGGCGAGATAAACTTTTAA

CCR5-224 (−) protein sequence (SEQ ID NO: 122):

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPAAMAERPFQCRICMRNFSRSDNLSVHIR

THTGEKPFACDICGRKFAQKINLQVHTKIHTGEKPFQCRICMRNFSRSDVLSEHIRTHTGEKPFACDICG

RKFAQRNHRTTHTKIHLRGSQLVKSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFF

MKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMERYVEENQTRNKHL

NPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRENHITNCNGAVLSVEELLIGGEMIKAGTLTLEE

VRRKFNNGEINF

VF2468 (+) DNA sequence (SEQ ID NO: 123):

TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCCACCATGGACTACAAAGACCATGACGG

TGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGA

GGAAGGTGGGCATTCACGGGGTGCCGTCTAGACCCGGGGAGCGCCCCTTCCAGTGTCGCATTTGC

ATGCGGAACTTTTCGCGCCAGGACAGGCTTGACAGGCATACCCGTACTCATACCGGTGAAAAACC

GTTTCAGTGTCGGATCTGTATGCGAAATTTCTCCCAGAAGGAGCACTTGGCGGGGCATCTACGTAC

GCACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTCGCCGCGACAACC

TGAACCGGCACCTAAAAACCCACCTGAGGGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGAA

GAAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATTGAAATTGC

CAGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGG

ATATAGAGGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTC

CTATTGATTACGGTGTGATCGTGGATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCC

AAGCAGATGAAATGCAACGATATGTCAAAGAAAATCAAACACGAAACAAACATATCAACCCTAAT

GAATGGTGGAAAGTCTATCCATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTA

AAGGAAACTACAAAGCTCAGCTTACACGATTAAATCATAAGACTAATTGTAATGGAGCTGTTCTTA

GTGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAGAGGAAGTG

AGACGGAAATTTAATAACGGCGAGATAAACTTTTAA

VF2468 (+) protein sequence (SEQ ID NO: 124):

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPSRPGERPFQCRICMRNFSRQDRLDRHTR

THTGEKPFQCRICMRNFSQKEHLAGHLRTHTGEKPFQCRICMRNFSRRDNLNRHLKTHLRGSQLVKSE

LEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGS

PIDYGVIVDTKAYSGGYNLPIGQADEMQRYVKENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKG

NYKAQLTRLNHKTNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF

VF2468 (−) DNA sequence (SEQ ID NO: 125):

TAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGCCACCATGGACTACAAAGACCATGACGG

TGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGATGGCCCCCAAGAAGAAGA

GGAAGGTGGGCATTCACGGGGTGCCGTCTAGACCCGGGGAGCGCCCCTTCCAGTGTCGCATTTGC

ATGCGGAACTTTTCGACCGGCCAGATCCTTGACCGCCATACCCGTACTCATACCGGTGAAAAACCG

TTTCAGTGTCGGATCTGTATGCGAAATTTCTCCGTGGCGCACAGCTTGAAGAGGCATCTACGTACG

CACACCGGCGAGAAGCCATTCCAATGCCGAATATGCATGCGCAACTTCAGTGACCCCAGCAACCT

GCGGCGCCACCTAAAAACCCACCTGAGGGGATCCCAACTAGTCAAAAGTGAACTGGAGGAGAAG

AAATCTGAACTTCGTCATAAATTGAAATATGTGCCTCATGAATATATTGAATTAATTGAAATTGCC

AGAAATTCCACTCAGGATAGAATTCTTGAAATGAAGGTAATGGAATTTTTTATGAAAGTTTATGGA

TATAGAGGTAAACATTTGGGTGGATCAAGGAAACCGGACGGAGCAATTTATACTGTCGGATCTCC

TATTGATTACGGTGTGATCGTGGATACTAAAGCTTATAGCGGAGGTTATAATCTGCCAATTGGCCA

AGCAGATGAAATGGAGCGATATGTCGAAGAAAATCAAACACGAAACAAACATCTCAACCCTAATG

AATGGTGGAAAGTCTATCCATCTTCTGTAACGGAATTTAAGTTTTTATTTGTGAGTGGTCACTTTAA

AGGAAACTACAAAGCTCAGCTTACACGATTAAATCATATCACTAATTGTAATGGAGCTGTTCTTAG

TGTAGAAGAGCTTTTAATTGGTGGAGAAATGATTAAAGCCGGCACATTAACCTTAGAGGAAGTGA

GACGGAAATTTAATAACGGCGAGATAAACTTTTAA

VF2468 (−) protein sequence (SEQ ID NO: 126):

MDYKDHDGDYKDHDIDYKDDDDKMAPKKKRKVGIHGVPSRPGERPFQCRICMRNFSTGQILDRHTRT

HTGEKPFQCRICMRNFSVAHSLKRHLRTHTGEKPFQCRICMRNFSDPSNLRRHLKTHLRGSQLVKSELE

EKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPI

DYGVIVDTKAYSGGYNLPIGQADEMERYVEENQTRNKHLNPNEWWKVYPSSVTEFKFLFVSGHFKGN

YKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINF

Library Construction. Libraries of target sites were incorporated into double-stranded DNA by PCR with Taq DNA Polymerase (NEB) on a pUC19 starting template with primers “N5-PvuI” and “CCR5-224-N4,” “CCR5-224-N5,” “CCR5-224-N6,” “CCR5-224-N7,” “VF2468-N4,” “VF2468-N5,” “VF2468-N6,” or “VF2468-N7,” yielding an approximately 545-bp product with a PvuI restriction site adjacent to the library sequence, and purified with the Qiagen PCR Purification Kit.

Library-encoding oligonucleotides were of the form 5′ backbone-PvuI site-NNNNNN-partially randomized half-site-N_4-7-partially randomized half site-N-backbone 3′. The purified oligonucleotide mixture (approximately 10 μg) was blunted and phosphorylated with a mixture of 50 units of T4 Polynucleotide Kinase and 15 units of T4 DNA polymerase (NEBNext End Repair Enzyme Mix, NEB) in 1×NEBNext End Repair Reaction Buffer (50 mM Tris-HCl, 10 mM MgCl₂, 10 mM dithiothreitol, 1 mM ATP, 0.4 mM dATP, 0.4 mM dCTP, 0.4 mM dGTP, 0.4 mM dTTP, pH 7.5) for 1.5 hours at room temperature. The blunt-ended and phosphorylated DNA was purified with the Qiagen PCR Purification Kit according to the manufacturer's protocol, diluted to 10 ng/μL in NEB T4 DNA Ligase Buffer (50 mM Tris-HCl, 10 mM MgCl₂, 10 mM dithiothreitol, 1 mM ATP, pH 7.5) and circularized by ligation with 200 units of T4 DNA ligase (NEB) for 15.5 hours at room temperature. Circular monomers were gel purified on 1% TAE-Agarose gels. 70 ng of circular monomer was used as a substrate for rolling-circle amplification at 30° C. for 20 hours in a 100 μL reaction using the Illustra TempliPhi 100 Amplification Kit (GE Healthcare). Reactions were stopped by incubation at 65° C. for 10 minutes. Target site libraries were quantified with the Quant-iT PicoGreen dsDNA Reagent (Invitrogen). Libraries with N₄, N₅, N₆, and N₇spacer sequences between partially randomized half-sites were pooled in equimolar concentrations for both CCR5-224 and VF2468.

Zincfinger Nuclease Expression and Characterization. 3×FLAG-tagged zinc finger proteins for CCR5-224 and VF2468 were expressed as fusions to FokI obligate heterodimers³⁰in mammalian expression vectors⁴derived from pMLM290 and pMLM292. DNA and protein sequences are provided elsewhere herein. Complete vector sequences are available upon request. 2 μg of ZFN-encoding vector was transcribed and translated in vitro using the TNT Quick Coupled rabbit reticulocyte system (Promega). Zinc chloride (Sigma-Aldrich) was added at 500 μM and the transcription/translation reaction was performed for 2 hours at 30° C. Glycerol was added to a 50% final concentration. Western blots were used to visualize protein using the anti-FLAG M2 monoclonal antibody (Sigma-Aldrich). ZFN concentrations were determined by Western blot and comparison with a standard curve of N-terminal FLAG-tagged bacterial alkaline phosphatase (Sigma-Aldrich).

Test substrates for CCR5-224 and VF2468 were constructed by cloning into the HindIII/XbaI sites of pUC19. PCR with primers “test fwd” and “test rev” and Taq DNA polymerase yielded a linear 1 kb DNA that could be cleaved by the appropriate ZFN into two fragments of sizes ˜300 bp and ˜700 bp. Activity profiles for the zinc finger nucleases were obtained by modifying the in vitro cleavage protocols used by Miller et al.³⁰and Cradick et al.³¹. 1 μg of linear 1 kb DNA was digested with varying amounts of ZFN in 1×NEBuffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 7.9) for 4 hours at 37° C. 100 μg of RNase A (Qiagen) was added to the reaction for 10 minutes at room temperature to remove RNA from the in vitro transcription/translation mixture that could interfere with purification and gel analysis. Reactions were purified with the Qiagen PCR Purification Kit and analyzed on 1% TAE-agarose gels.

In Vitro Selection. ZFNs of varying concentrations, an amount of TNT reaction mixture without any protein-encoding DNA template equivalent to the greatest amount of ZFN used (“lysate”), or 50 units PvuI (NEB) were incubated with 1 μg of rolling-circle amplified library for 4 hours at 37° C. in 1×NEBuffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol, pH 7.9). 100 μg of RNase A (Qiagen) was added to the reaction for 10 minutes at room temperature to remove RNA from the in vitro transcription/translation mixture that could interfere with purification and gel analysis. Reactions were purified with the Qiagen PCR Purification Kit. 1/10 of the reaction mixture was visualized by gel electrophoresis on a 1% TAE-agarose gel and staining with SYBR Gold Nucleic Acid Gel Stain (Invitrogen).

The purified DNA was blunted with 5 units DNA Polymerase I, Large (Klenow) Fragment (NEB) in 1×NEBuffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 7.9) with 500 μM dNTP mix (Bio-Rad) for 30 minutes at room temperature. The reaction mixture was purified with the Qiagen PCR Purification Kit and incubated with 5 units of Klenow Fragment (3′ exo) (NEB) for 30 minutes at 37° C. in 1×NEBuffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl₂, 1 mM dithiothreitol, pH 7.9) with 240 μM dATP (Promega) in a 50 μL final volume. 10 mM Tris-HCl, pH 8.5 was added to a volume of 90 μL and the reaction was incubated for 20 minutes at 75° C. to inactivate the enzyme before cooling to 12° C. 300 fmol of “adapter1/2”, barcoded according to enzyme concentration, or 6 pmol of “adapter1/2” for the PvuI digest, were added to the reaction mixture, along with 10 ul 10×NEB T4 DNA Ligase Reaction Buffer (500 mM Tris-HCl, 100 mM MgCl₂, 100 mM dithiothreitol, 10 mM ATP). Adapters were ligated onto the blunt DNA ends with 400 units of T4 DNA ligase at room temperature for 17.5 hours and ligated DNA was purified away from unligated adapters with Illustra Microspin S-400 HR sephacryl columns (GE Healthcare). DNA with ligated adapters were amplified by PCR with 2 units of Phusion Hot Start II DNA Polymerase (NEB) and 10 pmol each of primers “PE1” and “PE2” in 1×Phusion GC Buffer supplemented with 3% DMSO and 1.7 mM MgCl₂. PCR conditions were 98° C. for 3 min, followed by cycles of 98° C. for 15 s, 60° C. for 15 s, and 72° C. for 15 s, and a final 5 min extension at 72° C. The PCR was run for enough cycles (typically 20-30) to see a visible product on gel. The reactions were pooled in equimolar amounts and purified with the Qiagen PCR Purification Kit. The purified DNA was gel purified on a 1% TAE-agarose gel, and submitted to the Harvard Medical School Biopolymers Facility for Illumina 36-base paired-end sequencing.

Data Analysis. Illumina sequencing reads were analyzed using programs written in C++. Algorithms are described elsewhere herein (e.g., Protocols 1-9), and the source code is available on request. Sequences containing the same barcode on both paired sequences and no positions with a quality score of ‘B’ were binned by barcode. Half-site sequence, overhang and spacer sequences, and adjacent randomized positions were determined by positional relationship to constant sequences and searching for sequences similar to the designed CCR5-224 and VF2468 recognition sequences. These sequences were subjected to a computational selection step for complementary, filled-in overhang ends of at least 4 base pairs, corresponding to rolling-circle concatemers that had been cleaved at two adjacent and identical sites. Specificity scores were calculated with the formulae: positive specificity score=(frequency of base pair at position [post-selection]−frequency of base pair at position [pre-selection])/(1−frequency of base pair at position [pre-selection]) and negative specificity score=(frequency of base pair at position [post-selection]−frequency of base pair at position[pre-selection])/(frequency of base pair at position[pre-selection]).

Positive specificity scores reflect base pairs that appear with greater frequency in the post-selection library than in the starting library at a given position; negative specificity scores reflect base pairs that are less frequent in the post-selection library than in the starting library at a given position. A score of +1 indicates an absolute preference, a score of −1 indicates an absolute intolerance, and a score of 0 indicates no preference.

Assay of Genome Modification at Cleavage Sites in Human Cells. CCR5-224 ZFNs were cloned into a CMV-driven mammalian expression vector in which both ZFN monomers were translated from the same mRNA transcript in stoichiometric quantities using a self-cleaving T2A peptide sequence similar to a previously described vector³². This vector also expresses enhanced green fluorescent protein (eGFP) from a PGK promoter downstream of the ZFN expression cassette. An empty vector expressing only eGFP was used as a negative control.

To deliver ZFN expression plasmids into cells, 15 μg of either active CCR5-224 ZFN DNA or empty vector DNA were used to Nucleofect 2×10⁶K562 cells in duplicate reactions following the manufacturer's instructions for Cell Line Nucleofector Kit V (Lonza). GFP-positive cells were isolated by FACS 24 hours post-transfection, expanded, and harvested five days post-transfection with the QIAamp DNA Blood Mini Kit (Qiagen). PCR for 37 potential CCR5-224 substrates and 97 potential VF2468 substrates was performed with Phusion DNA Polymerase (NEB) and primers “[ZFN] [#] fwd” and “[ZFN] [#] rev” (Table 9) in 1× Phusion HF Buffer supplemented with 3% DMSO. Primers were designed using Primer3³³. The amplified DNA was purified with the Qiagen PCR Purification Kit, eluted with 10 mM Tris-HCl, pH 8.5, and quantified by 1K Chip on a LabChip GX instrument (Caliper Life Sciences) and combined into separate equimolar pools for the catalytically active and empty vector control samples. PCR products were not obtained for 3 CCR5 sites and 7 VF2468 sites, which excluded these samples from further analysis. Multiplexed Illumina library preparation was performed according to the manufacturer's specifications, except that AMPure XP beads (Agencourt) were used for purification following adapter ligation and PCR enrichment steps. Illumina indices 11 (“GGCTAC”) and 12 (“CTTGTA”) were used for ZFN-treated libraries while indices 4 (“TGACCA”) and 6 (“GCCAAT”) were used for the empty vector controls. Library concentrations were quantified by KAPA Library Quantification Kit for Illumina Genome Analyzer Platform (Kapa Biosystems). Equal amounts of the barcoded libraries derived from active- and empty vector-treated cells were diluted to 10 nM and subjected to single read sequencing on an Illumina HiSeq 2000 at the Harvard University FAS Center for Systems Biology Core facility. Sequences were analyzed using Protocol 9 for active ZFN samples and empty vector controls.

Statistical Analysis. In FIGS. 8A-8B, P-values were calculated for a one-sided test of the difference in the means of the number of target site mutations in all possible pairwise comparisons among pre-selection, 0.5 nM post-selection, 1 nM post-selection, 2 nM post-selection, and 4 nM post-selection libraries for CCR5-224 or VF2468. The t-statistic was calculated as t (x_bar₁−x_bar₂)/sqrt(1× p_hat₁×(1-p_hat₁)/n₁+1×p_hat₂×(1−p_hat₂)/n₂), where x_bar₁and x_bar₂are the means of the distributions being compared, 1 is the target site length (24 for CCR5-224; 18 for VF2468), p_hat₁and p_hat₂are the calculated probabilities of mutation (x_bar/1) for each library, and n₁and n₂are the total number of sequences analyzed for each selection (Table 2). All pre- and post-selection libraries were assumed to be binomially distributed.

In Tables 4 and 7, P-values were calculated for a one-sided test of the difference in the proportions of sequences with insertions or deletions from the active ZFN sample and the empty vector control samples. The t-statistic was calculated as t (p_hat₁−p_hat₂)/sqrt((p_hat₁×(1−p_hat₁)/n₁)+(p_hat₂×(1−p_hat₂)/n₂)), where p_hat₁and n₁are the proportion and total number, respectively, of sequences from the active sample and p_hat₂and n₂are the proportion and total number, respectively, of sequences from the empty vector control sample.

Plots. All heat maps were generated in the R software package with the following command: image([variable], zlim=c(−1,1), col=colorRampPalette(c(“red”,“white”,“blue”),space=“Lab”)(2500)

Protocol 1: Quality Score Filtering and Sequence Binning.

- 1) search each position of both pairs of sequencing read for quality score, reject if any position has quality score=‘B’
- 2) output to separate files all sequence reads where the first sequence in the pair start with barcodes (“AAT”, “ATA”, “TAA”, “CAC”, “TCG”) and count the number of sequences corresponding to each barcode

Protocol 2: Filtering by ZFN (“AAT”, “ATA”, “TAA”, “CAC”)

For each binned file,

- 1) accept only sequence pairs where both sequences in the pair start with the same barcode
- 2) identify orientation of sequence read by searching for constant regions
  - orientation 1 is identified by the constant region “CGATCGTTGG” (SEQ ID NO:127)
  - orientation 2 is identified by the constant region “CAGTGGAACG” (SEQ ID NO:128)
- 3) search sequences from position 4 (after the barcode) up to the first position in the constant region for the subsequence that has the fewest mutations compared to the CCR5-224 and VF2468 half site that corresponds to the identified constant region
  - search sequences with orientation 1 for “GATGAGGATGAC” (SEQ ID NO:129) (CCR5-224(+)) and “GACGCTGCT” (SEQ ID NO:130) (VF2468(−))
  - search sequences with orientation 2 for “AAACTGCAAAAG” (SEQ ID NO:131) (CCR5-224(−)) and “GAGTGAGGA” (SEQ ID NO:132) (VF2468(+))
- 4) bin sequences as CCR5-224 or VF2468 by testing for the fewest mutations across both half-sites
- 5) the positions of the half-sites and constant sequences are used to determine the overhang/spacer sequences, the flanking nucleotide sequences, and the tag sequences
  - the subsequence between the half-site of orientation 1 and the constant region is the tag sequence
  - if there is no tag sequence, the tag sequence is denoted by ‘X’
  - the overhang sequence is determined by searching for the longest reverse-complementary subsequences between the subsequences of orientation 1 and orientation 2 that start after the barcodes
  - the spacer sequence is determined by concatenating the reverse complement of the subsequence in orientation 1 that is between the overhang and the half-site (if any), the overhang, and the subsequence in orientation 2 that is between the overhang and the halfsite
  - if there is overlap between the overhang and half-site, only the non-overlapping subsequence present in the overhang is counted as part of the spacer
- 6) to remove duplicate sequences, sort each sequence pair into a tree
  - each level of the tree corresponds to a position in the sequence
  - each node at each level corresponds to a particular base (A, C, G, T, or X=not(A, C, G, or T)) and points to the base of the next position (A,C,G,T,X)
  - the sequence pairs are encoded in the nodes and a subsequence consisting of the concatenation of the spacer sequence, flanking nucleotide sequence, and tag sequence is sorted in the tree
  - at the terminal nodes of the tree, each newly entered sequence is compared to all other sequences in the node to avoid duplication
- 7) the contents of the tree are recursively outputted into separate files based on barcode and ZFN

Protocol 3: Library Filtering (“TCG”)

- 1) accept only sequence pairs where both sequences in the pair start with the same barcode
- 2) analyze the sequence pair that does not contain the sequence “TCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGAC” (SEQ ID NO:133) (the other pair contains the library sequence)
- 3) search sequences for ZFN half-sites and bin by the ZFN site that has fewer mutations
  - search for “GTCATCCTCATC” (SEQ ID NO:134) and “AAACTGCAAAAG” (SEQ ID NO:135) (CCR5-224) and “AGCAGCGTC” (SEQ ID NO:136) and “GAGTGAGGA” (SEQ ID NO:137) (VF2468)
- 4) identify the spacer, flanking nucleotide, and nucleotide tag sequences based on the locations of the half-sites
- 5) use the tree algorithm in step 6 under Filtering by ZFN to eliminate duplicate sequences

Protocol 4: Sequence Profiles

- 1) analyze only sequences that contain no ‘N’ positions and have spacer lengths between 4 and 7
- 2) tabulate the total number of mutations, the spacer length, the overhang length, the nucleotide frequencies for the (+) and (−) half-sites, the nucleotide frequencies for spacers that are 4-bp, 5-bp, 6-bp, and 7-bp long, and the nucleotide frequencies for the flanking nucleotide and the tag sequence
- 3) repeat steps 1 and 2 for library sequences
- 4) calculate specificity scores at each position using positive specificity score=(frequency of base pair at position [post-selection]-frequency of base pair at position[pre-selection])/(1-frequency of base pair at position[pre-selection]) negative specificity score=(frequency of base pair at position [post-selection]-frequency of base pair at position[pre-selection])/(frequency of base pair at position [pre-selection])

Protocol 5: Genomic Matches

- 1) the human genome sequence was searched with 24 and 25 base windows (CCR5-224) and 18 and 19 base windows (VF2468) for all sites within nine mutations (CCR5-224) or six mutations (VF2468) of the canonical target site with all spacer sequences of five or six bases being accepted
- 2) each post-selection sequence was compared to the set of genomic sequences within nine and six mutations of CCR5-224 and VF2468, respectively

Protocol 6: Enrichment Factors for Sequences with 0, 1, 2, or 3 Mutations

- 1) for each sequence, divide the frequency of occurrence in the post-selection library by the frequency of occurrence in the pre-selection library

Protocol 7: Filtered Sequence Profiles

- 1) use the algorithm described above in Sequence profiles, except in addition, only analyze sequences with off-target bases at given positions for both pre- and post-selection data

Protocol 8: Compensation Difference Map

- 1) use Filtered sequence profiles algorithm for mutation at every position in both half-sites
- 2) calculate A(specificity score)=filtered specificity score—non-filtered specificity score

Protocol 9: NHEJ Search

- 1) identify the site by searching for exact flanking sequences
- 2) count the number of inserted or deleted bases by comparing the length of the calculated site to the length of the expected site and by searching for similarity to the unmodified target site (sequences with 5 or fewer mutations compared to the intended site were counted as unmodified)
- 3) inspect all sites other than CCR5, CCR2, and VEGF-A promoter by hand to identify true insertions or deletions

REFERENCES

1. Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci USA 93, 1156-60 (1996).

2. Vanamee, E. S., Santagata, S. & Aggarwal, A. K. FokI requires two specific DNA sites for cleavage. J Mol Biol 309, 69-78 (2001).

3. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27, 851-7 (2009).

4. Maeder, M. L. et al. Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31, 294-301 (2008).

5. Zou, J. et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5, 97-110 (2009).

6. Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26, 808-16 (2008).

7. Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-51 (2005).

8. Santiago, Y. et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA 105, 5809-14 (2008).

9. Cui, X. et al. Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol 29, 64-7 (2011).

10. Cornu, T. I. et al. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther 16, 352-8 (2008).

11. Segal, D. J., Dreier, B., Beerli, R. R. & Barbas, C. F., 3rd. Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences. Proc Natl Acad Sci USA 96, 2758-63 (1999).

12. Bulyk, M. L., Huang, X., Choo, Y. & Church, G. M. Exploring the DNA-binding specificities of zinc fingers with DNA microarrays. Proc Natl Acad Sci USA 98, 7158-63 (2001).

13. Meng, X., Thibodeau-Beganny, S., Jiang, T., Joung, J. K. & Wolfe, S. A. Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method. Nucleic Acids Res 35, e81 (2007).

14. Wolfe, S. A., Greisman, H. A., Ramm, E. I. & Pabo, C. O. Analysis of zinc fingers optimized via phage display: evaluating the utility of a recognition code. J Mol Biol 285, 1917-34 (1999).

15. Segal, D. J. et al. Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry 42, 2137-48 (2003).

16. Zykovich, A., Korf, I. & Segal, D. J. Bind-n-Seq: high-throughput analysis of in vitro protein-DNA interactions using massively parallel sequencing. Nucleic Acids Res 37, e151 (2009).

17. Yanover, C. & Bradley, P. Extensive protein and DNA backbone sampling improves structure-based specificity prediction for C2H2 zinc fingers. Nucleic Acids Res (2011).

18. Beumer, K., Bhattacharyya, G., Bibikova, M., Trautman, J. K. & Carroll, D. Efficient gene targeting in Drosophila with zinc-finger nucleases. Genetics 172, 2391-403 (2006).

19. Bibikova, M., Golic, M., Golic, K. G. & Carroll, D. Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics 161, 1169-75 (2002).

20. Gupta, A., Meng, X., Zhu, L. J., Lawson, N. D. & Wolfe, S. A. Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res 39, 381-92 (2011).

21. Chen, J. et al. Molecular cloning and characterization of a novel human BTB domain-containing gene, BTBD10, which is down-regulated in glioma. Gene 340, 61-9 (2004).

22. Wang, X. et al. Glucose metabolism-related protein 1 (GMRP1) regulates pancreatic beta cell proliferation and apoptosis via activation of Akt signalling pathway in rats and mice. Diabetologia 54, 852-63 (2011).

23. Nawa, M., Kanekura, K., Hashimoto, Y., Aiso, S. & Matsuoka, M. A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt/PKB. Cell Signal 20, 493-505 (2008).

24. Petek, L. M., Russell, D. W. & Miller, D. G. Frequent endonuclease cleavage at off-target locations in vivo. Mol Ther 18, 983-6 (2010).

25. Hurt, J. A., Thibodeau, S. A., Hirsh, A. S., Pabo, C. O. & Joung, J. K. Highly specific zinc finger proteins obtained by directed domain shuffling and cell-based selection. Proc Natl Acad Sci USA 100, 12271-6 (2003).

26. Ramirez, C. L. et al. Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods 5, 374-5 (2008).

27. Shimizu, Y. et al. Adding Fingers to an Engineered Zinc Finger Nuclease Can Reduce Activity. Biochemistry 50, 5033-41 (2011).

28. Bibikova, M. et al. Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol 21, 289-97 (2001).

29. Handel, E. M., Alwin, S. & Cathomen, T. Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity. Mol Ther 17, 104-11 (2009).

30. Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-85 (2007).

31. Cradick, T. J., Keck, K., Bradshaw, S., Jamieson, A. C. & McCaffrey, A. P. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18, 947-54 (2010).

32. Doyon, Y. et al. Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol 26, 702-8 (2008).

33. Rozen, S. & Skaletsky, H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365-86 (2000).

All publications, patents and sequence database entries mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Example 2—TALENs

The site preferences of different TALENs were profiled in analogy to the work done for ZFN profiling described above. The experiments and results are described in FIGS. 19-49. Selection 1 included a comparison between TALENs having a +28 vs. a +63 linker. Selection 2 included a comparison of TALENs of different TAL domain length.

TAL DNA binding domains are the basis of a transformative technology to specifically modulate target DNA both in vitro and in cells. The designable TAL DNA binding domains have advantages in targetable sequence space and ease of construction compared to other DNA binding domains, for example, zinc fingers. These TAL DNA binding domains are comprised of repeats of a 34 amino acid domain with a highly variable di-amino acid (RVD) coding for recognition of a single base pair in the target DNA sequence (FIG. 20). Based on the robustness of this RVD code and the crystal structure of a TAL bound to its DNA target, it is likely that binding of a single repeat to a base pair is relatively independent of adjacent repeat binding. The TAL DNA binding domain (an array of repeats) can be linked to the monomer of a heterodimeric nuclease domain to form a TAL nuclease. Thus, two distinct TAL nucleases can bind adjacent target half sites to cleave a specific sequence resulting in genome modifications in vivo (FIGS. 19 and 20). While a number of studies have investigated the specificity of TAL DNA binding, to our knowledge no studies have profiled the specificity of TAL nucleases on a large scale. We applied the concept of high-throughput, in vitro selection for nuclease specificity outlined for ZFNs in Example 1 to TAL nucleases to both confirm the modular, independent binding of TAL repeats expected from their easy design-ability and also identify genomic off-target sequences cut by therapeutically relevant TAL nucleases.

The selection scheme for profiling the specificity of TAL nucleases via in vitro library screening was in analogy to the selection scheme described for ZFNs in Example. Detailed protocols are provided below:

Preparation of Library of Partly Randomized Target Sites

- 2 ul of 10 pmol TALNCCR5 Library Oligo (separate reactions for each oligo)
- 2 ul 10×CircLigase II 10× Reaction Buffer
- 1 ul 50 mM MnCl2
- 1 ul CircLigase II ssDNA Ligase (100 U) [Epicentre]
- X ul water to 20 uL total volume
  
  Incubate 16 hrs at 60° C. Incubate 10 min at 85° C. to inactivate.
  
  Add 2.5 ul of each Circligase II reaction (without purification)
  
  Add 25 ul TempliPhi™ [GE Healthcare] 100 sample buffer.
  
  Incubate 3 min at 95° C. Slow cool to 4° C.
  
  Add 25 ul TempliPhi™ reaction buffer/1 ul enzyme mix.
  
  Incubate 16 hrs at 30° C. Heat inactive 10 min at 55° C.
  
  Quantify amount of dsDNA using Quant-iT™ PicoGreen® dsDNA [Invitrogen]
  
  Combine equal moles of TempliPhi™ reactions to final 2 uM with respect to number of cut sites.

TALN Expression

- 16 ul TnT® Quick Coupled [Promega]
- 0.4 ul 1 mM methionine
- 2 uL of 0.8 ug TALN vector expression plasmid or water for empty lysate
- 1.6 uL of water
  
  Incubate at 30 for 1.5 hours and then store at 4° C. overnight.
  
  Quantify amount of TALN in lysate via Western Blot.

TALN Digestion

- 25 uL of 10×NEB Buffer 3 [New England Biolabs]
- 10 uL of 2 uM TempliPh Library DNA
- 165 uL water
  
  Add left TALN lysate to 20 nM total left TALN
  
  Add right TALN lysate to 20 nM total right TALN
  
  Add empty lysate to total of 50 uL lysate
  
  Incubate 2 hrs at 37° C. Add 5 ul (50 ug) RNaseA (Qiagen). Incubate 10 min at RT. Purify with Qiagen PCR Purification Kit. Elute in 50 uL of 1 mM Tris, pH 8.0.

Adapter Ligation, PCR and Gel Purification of TALN Digestion

- 50 ul digested DNA
- 3 ul dNTP mix
- 6 ul NEB 2
- 1 ul Klenow [New England Biolabs]
  
  Incubate 30 min at RT. Purify with Qiagen PCR Purification Kit.
- 50 ul eluted DNA
- 5.9 ul T4 DNA Ligase Buffer (NEB)
- 2 ul (20 pmol) heat/cooled adapter (different adapter for each selection)
- 1 ul T4 DNA ligase (NEB, 400 units)
  
  Incubate at RT for 20 hrs. Purify with Qiagen PCR Purification Kit.
- 6 uL of TALN digested DNA
- 30 uL of 5× Buffer HF
- 1.5 uL 100 uM Illumina_fwd Primer
- 1.5 uL 100 uM PE_TALN_rev1 Primer
- 3 uL 10 mM dNTP
- 1.5 uL Phusion Hot Start II
- 106.5 uL of water
  
  98° C. for 3 min, do 15 cycles of 98° C. for 15 s, 60° C. for 15 s, 72° C. for 1 min. Purify with QiagenPCR Purification Kit
  
  Gel Purify on 2% Agarose gel loading lug of eluted DNA in 40 uL of 10% glycerol. Run on gel at 135V for 35 min. Gel purify bands of the length corresponding to a cut half site+full half site+adapter with filter paper. Remove filter paper and collect supernatant. Purify with Qiagen PCR Purification Kit.
- 6 uL of TALN digested DNA (5-26-12)
- 30 uL of 5× Buffer HF
- 1.5 uL 100 uM Illumina_fwd Primer
- 1.5 uL 100 uM PE_TALN_rev2 Primer
- 3 uL 10 mM dNTP
- 1.5 uL Phusion Hot Start II
- 106.5 uL of water
  
  98° C. for 3 min, do 6 cycles of 98° C. for 15 s, 60° C. for 15 s, 72° C. for 1 min. Purify with Qiagen PCR Purification Kit.

Preparation of Pre-Selection Library

- 25 uL of 10×NEB Buffer 4
- 10 uL of 2 uM TempliPhi Library DNA
- 165 uL water
- 5 uL of Appropriate Restriction Enzyme [New England Biolabs]
- 210 uL of water
  
  Incubate 1 hrs at 37° C. Purify with Qiagen PCR Purification Kit.
- 50 ul eluted DNA
- 5.9 ul T4 DNA Ligase Buffer (NEB)
- 2 ul (20 pmol) heat/cooled adapter (pool of 4 adapter sequences)
- 1 ul T4 DNA ligase (NEB, 400 units)
  
  Incubate at RT for 20 hrs. Purify with Qiagen PCR Purification Kit.
- 6 uL of Restriction Enzyme Digested DNA (5-26-12)
- 30 uL of 5× Buffer HF
- 1.5 uL 100 uM Illumina_rev Primer
- 1.5 uL 100 uM TALNLibPCR Primer
- 3 uL 10 mM dNTP
- 1.5 uL Phusion Hot Start II
- 106.5 uL of water
  
  98° C. for 3 min, 12 cycles of 98° C. for 15 s, 60° C. for 15 s, 72° C. for 1 min. Purify with Qiagen PCR Purification Kit

High-throughput Sequencing

- Quantify via RT-qPCR
  - 12.5 uL of IQ SYBR Green Supermix
  - 1 uL of 10 uM Illumina_rev
  - 1 uL of 10 uM Illumina_fwd
  - 9.5 uL of water
  - 1 uL of DNA template (both Pre-Selection Library and TALN Digestion) 95° C. for 5 min, do 30 cycles of 95° C. for 30 s, 65° C. for 30 s, 72° C. for 40 s.
- Dilute DNA to 2 nM (compared to sequencing standard)
  - 5 uL of TALN Digestion 2 nM DNA
  - 2.5 uL of Pre-Selection Library 2 nM DNA
  - 10 uL of 0.1N NaOH
- Incubate at room temp for 5 min
- Sequence via Illumina Mi-Seq

Computational Filtering

- For TALN Digested sequences, find two appropriately spaced constant oligo sequences
- For Pre-selection Library sequences, find appropriately spaced constant oligo sequence and library adapter sequence
- Parse sequence into cut overhang, left half site, spacer, right half site
- Remove sequences with poor Illumina base scores in half sites (<B=rejected)

Primer sequences

Primer
Sequence

J61TALCCR5B_10
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNN(N2)(N3)

(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)NCCTCGGG

ACT (SEQ ID NOs: 138 and 139; full sequence: SEQ ID NO: 8767)

J63TALCCR5B_12
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNN(N2)

(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)NCCTC

GGGACT (SEQ ID NOs: 140 and 141; full sequence: SEQ ID NO: 8768)

J65TALCCR5B_14
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNN

(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)NCC

TCGGGACT (SEQ ID NOs: 142 and 143; full sequence: SEQ ID

NO: 8769)

J66TALCCR5B_15
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)NC

CTCGGGACT (SEQ ID NOs: 144 and 145; full sequence: SEQ ID

NO: 8770)

J67TALCCR5B_16
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

N(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)N

CCTCGGGACT (SEQ ID NOs: 146 and 147; full sequence: SEQ ID

NO: 8771)

J68TALCCR5B_17
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

NN(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)

NCCTCGGGACT (SEQ ID NOs: 148 and 149; full sequence: SEQ ID

NO: 8772)

J69TALCCR5B_18
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

NNN(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)(N3)

NCCTCGGGACT (SEQ ID NOs: 150 and 151; full sequence: SEQ ID

NO: 8773)

J71TALCCR5B_20
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

NNNNN(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)(N2)

(N3)NCCTCGGGACT (SEQ ID NOs: 152 and 153; full sequence: SEQ ID

NO: 8774)

J73TALCCR5B_22
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

NNNNNNN(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)(N1)

(N2)(N3)NCCTCGGGACT (SEQ ID NOs: 154 and 155; full sequence:

SEQ ID NO: 8775)

J75TALCCR5B_24
CCACGCTN(N1: 07070779)(N2: 07790707)(N1)(N1)(N2)(N3: 79070707)(N1)

(N1)(N3)(N2)(N3)(N2)(N2)(N1)(N4: 07077907)(N2)NNNNNNNNNNNNNNN

NNNNNNNNN(N2)(N3)(N1)(N3)(N2)(N3)(N4)(N1)(N2)(N3)(N4)(N1)(N3)

(N1)(N2)(N3)NCCTCGGGACT (SEQ ID NOs: 156 and 157; full sequence:

SEQ ID NO: 8776)

CGTAAadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTCGTAA (SEQ ID NO: 158)

CGTAAadapterREV
TTACGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 159)

GTACTadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTGTACT (SEQ ID NO: 160)

GTACTadapterREV
AGTACAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 161)

TACGAadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTTACGA (SEQ ID NO: 162)

TACGAadapterREV
TCGTAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 163)

ATGCTadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTATGCT (SEQ ID NO: 164)

ATGCTadapterREV
AGCATAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 165)

TGCAAadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTTGCAA (SEQ ID NO: 166)

TGCAAadapterREV
TTGCAAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 167)

GCATTadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTGCATT (SEQ ID NO: 168)

GCATTadapterREV
AATGCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 169)

GACTAadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTGACTA (SEQ ID NO: 170)

GACTAadapterREV
TAGTCAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 171)

ACTGTadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTACTGT (SEQ ID NO: 172)

ACTGTadapterREV
ACAGTAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 173)

CTGAAadapterfwd
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTCTGAA (SEQ ID NO: 174)

CTGAAadapterREV
TTCAGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCG

GTGG (SEQ ID NO: 175)

PE_TALCCR5B_rev1
CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTCAGA

CGTGTGCTCTTCCG (SEQ ID NO: 176)

PE_TALCCR5B_rev2
CAGACGTGTGCTCTTCCGATCNNNNAGCGTGGAGTCCCGAGG (SEQ

ID NO: 177)

PE_TALCCR5B_rev
CAAGCAGAAGACGGCATACGAGATACAGTCGTGACTGGAGTTCAGA

CGTGTGCTCTTCCGATCNNNNAGCGTGGAGTCCCGAGG (SEQ ID

NO: 178)

PE_TALCCR5Blib
TCGGGAACGTGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGT

adapter1
CTAATCTCGTATGCCGTCTTCTGCTTG (SEQ ID NO: 179)

PE_TALCCR5Blib
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCACGTT (SEQ ID

adapterrev1
NO: 180)

PE_TALCCR5Blib
TCGGGACGTAGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGT

adapter2
CTAATCTCGTATGCCGTCTTCTGCTTG (SEQ ID NO: 181)

PE_TALCCR5Blib
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACGT (SEQ ID

adapterrev2
NO: 182)

PE_TALCCR5Blib
TCGGGAGTACGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGT

adapter3
CTAATCTCGTATGCCGTCTTCTGCTTG (SEQ ID NO: 183)

PE_TALCCR5Blib
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCGTACT (SEQ ID

adapterrev3
NO: 184)

PE_TALCCR5Blib
TCGGGATACGGATCGGAAGAGCACACGTCTGAACTCCAGTCACCGT

adapter4
CTAATCTCGTATGCCGTCTTCTGCTTG (SEQ ID NO: 185)

PE_TALCCR5Blib
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCCGTAT (SEQ ID

adapterrev4
NO: 186)

TALCCR5BlibPCR
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACG

CTCTTCCGATCTNNNNCCTCGGGACTCCACGCT (SEQ ID NO: 187)

IlluminaFwd
AATGATACGGCGACCAC (SEQ ID NO: 188)

IlluminaRev
CAAGCAGAAGACGGCATACGA (SEQ ID NO: 189)

CONCLUSIONS

The relatively regular (log relationship) trend between number of half sites mutations and enrichment is consistent with a single TAL repeat binding a base pair independent of other repeat binding. A single mutation in the cleavage site does not significantly alter the distribution of other mutations in the compensation difference analysis suggesting that the TAL repeat domains bind independently. The +28 linker is more specific than the +63 linker TALN constructs. While TALNs recognizing larger target sites are less specific in that they can tolerate more mutations, the abundance of the mutant larger sequences is less than the increase in enrichment, thus the in vitro selection data and abundance of off-target sites indicates off-target cleavage to be significantly less likely in longer TALN pairs. Combining the regular decrease of cleavage efficiency (enrichment) as total target site mutations increase and the enrichment at each position it is possible to predict the off-target site cleavage of any sequence. For the most part, in the TALN selection the enrichment was dependent on the total mutations in both half sites and not on the distribution of mutations between half sites as was observed for zinc finger nucleases (ZFN). This observation combined with the context dependent binding of ZFNs indicated that TALENs may readily be engineered to a specificity as high or higher than their ZFN equivalents.

Equivalents and Scope

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the present invention is not intended to be limited to the above description, but rather is as set forth in the appended claims.

In the claims articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process.

Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the claims or from relevant portions of the description is introduced into another claim. For example, any claim that is dependent on another claim can be modified to include one or more limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of using the composition for any of the purposes disclosed herein are included, and methods of making the composition according to any of the methods of making disclosed herein or other methods known in the art are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

Where elements are presented as lists, e.g., in Markush group format, it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, steps, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, steps, etc. For purposes of simplicity those embodiments have not been specifically set forth in haec verba herein. Thus for each embodiment of the invention that comprises one or more elements, features, steps, etc., the invention also provides embodiments that consist or consist essentially of those elements, features, steps, etc.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein.

TABLE 1

CCR5-224 off-target sites in the genome of human K562 cells.

(+) half-site

(−) half-site
in vitro selection
K562

mutations

(SEQ ID NOs:

(SEQ ID
stringency (nM)
modification

T
(+)
(−)
gene
190-226)
spacer
NOs: 227-263)
4
2
1
0.5
frequency

0
0
0
CCR5 (coding)
GTCATCCTCATC
CTGAT
AAACTGCAAAAG
X
X
X
X
1 : 2.3

2
1
1
CCR2 (coding)
GTCgTCCTCATC
TTAAT
AAACTGCAAAAa
X
X
X
X
1 : 10

3
2
1
BTBD10
GTttTCCTCATC
AAAGC
AAACTGCAAAAt
X
X

1 : 1,400

(promoter)

4
0
4

GTCATCCTCATC
AGAGA
AAACTGgctAAt
X
X

n.d.

4
3
1
SLC4A8
taaATCCTCATC
TCTATA
AAAaTGCAAAAG
X
X

n.d.

3
2
1
Z83955 RNA
GTCATCCcaATC
GAAGAA
AAACTGaAAAAG
X

X
n.d.

3
1
2
DGKK
cTCATCCTCATC
CATGC
AcAaTGCAAAAG
X

n.d.

3
1
2
GALNT13
GTCATCCTCAgC
ATGGG
AAACaGCAgAAG
X

n.d.

3
1
2

GTCATCtTCATC
AAAAG
gAACTGCAAAAc
X

1 : 2,800

4
0
4

GTCATCCTCATC
CAATA
AAAgaaCAAAgG
X

n.d.

4
1
3
TACR3
GTCATCtTCATC
AGCAT
AAACTGtAAAgt
X

1 : 300

4
1
3
PIWIL2
GTCATCCTCATa
CATAA
AAACTGCcttAG
X

4
1
3

aTCATCCTCATC
CATCC
AAtgTtCAAAAG
X

n.d.

4
3
1

GTCcTgCTCAgC
AAAAG
AAACTGaAAAAG
X

1 : 4,000

4
3
1
KCNB2
aTgtTCCTCATC
TCCCG
AAACTGCAAAtG
X

1 : 1,400

4
3
1

GTCtTCCTgATg
CTACC
AAACTGgAAAAG
X

1 : 5,300

4
3
1

aaCATCCaCATC
ATGAA
AAACTGCAAAAa
X

n.d.

6
3
3

aTCtTCCTCATt
ACAGG
AAAaTGtAAtAG
X

n.d.

6
4
2
CUBN
GgCtTCCTgAcC
CACGG
AAACTGtAAAtG
X

6
5
1
NID1
GTttTgCaCATt
TCAAT
tAACTGCAAAAG
X

n.d.

3
2
1

GTCAaCCTCAaC
ACCTAC
AgACTGCAAAAG
X

1 : 1,700

4
1
3
WWOX
GTCATCCTCcTC
CAACTC
cAAtTGCtAAAG
X

n.d.

4
2
2
AMBRA1
GTCtTCCTCcTC
TGCACA
tcACTGCAAAAG
X

n.d.

4
2
2

GTgATaCTCATC
ATCAGC
AAtCTGCAtAAG
X

n.d.

4
2
2
WBSCR17
GTtATCCTCAgC
AAACTA
AAACTGgAAcAG
X

1 : 860

4
2
2
ITSN
cTCATgCTCATC
ATTTGT
tAACTGCAAAAt
X

n.d.

4
4
0

GcCAgtCTCAgC
ATGGTG
AAACTGCAAAAG
X

n.d.

4
4
0

cTCATtCTgtTC
ATGAAA
AAACTGCAAAAG
X

n.d.

5
3
2

GaagTCCTCATC
CCGAAG
AAACTGaAAgAG
X

n.d.

5
3
2
ZNF462
GTCtTCCTCtTt
CACATA
AAACcGCAAAtG
X

n.d.

5
4
1

aTaATCCTttTC
TGTTTA
AAACaGCAAAAG
X

n.d.

5
4
1

GaCATCCaaATt
ACATGG
AAACTGaAAAAG
X

n.d.

5
5
0
SDK1
GTCtTgCTgtTg
CACCTC
AAACTGCAAAAG
X

n.d.

4
1
3
SPTB(coding)
GTCATCCgCATC
GCCCTG
gAACTGgAAAAa

X

n.d.

4
2
2

aTCATCCTCAaC
AAACTA
AAACaGgAAAAG

X

4
4
0
KIAA1680
GgaATgCcCATC
ACCACA
AAACTGCAAAAG

X

n.d.

5
5
0

GTttTgCTCcTg
TACTTC
AAACTGCAAAAG

X

n.d.

Lower case letters indicate mutations compared to the target site. Sites marked with an ‘X’ were found in the corresponding in vitro selection dataset. ‘T’ refers to the total number of mutations in the site, and ‘(+)’ and ‘(−)’ to the number of mutations in the (+) and (−) half-sites, respectively. The sequences of the sites are listed as 5′ (+) half-site/spacer/(−) half-site 3′, therefore the (+) half-site is listed in the reverse sense as it is in the sequence profiles. K562 modification frequency is the frequency of observed sequences showing significant evidence of non-homologous end joining repair (see Methods) in cells expressing active ZFN compared to cells expressing empty vector. Sites that did not show statistically significant evidence of modifications are listed as not detected (n.d.), and K562 modification frequency is left blank for the three sites that were not analyzed due to non-specific PCR amplification from the genome. Table 4 shows the sequence counts and P-values for the tested sites used to determine K562 modification frequency, and Table 6 shows the modified sequences obtained for each site.

TABLE 2

Sequencing statistics.

Rejected Sequences

Uncalled

Total
Analyzed
Incompatible
Repeated
Bases in

Sequences
Sequences
Overhangs
Sequences
Half-Sites

CCR5-224 Pre-
1,426,442
1,392,576
0
33,660
206

Selection

CCR5-224 0.5 nM
649,348
52,552
209,442
387,299
55

CCR5-224 1 nM
488,798
55,618
89,672
343,442
66

CCR5-224 2 nM
1,184,523
303,462
170,700
710,212
149

CCR5-224 4 nM
1,339,631
815,634
352,888
170,700
159

Total
5,088,742
2,619,842
822,702
1,645,563
635

VF2468 Pre-
1,431,372
1,393,153
0
38,128
91

Selection

VF2468 0.5 nM
297,650
25,851
79,113
192,671
15

VF2468 1 nM
148,556
24,735
19,276
104,541
4

VF2468 2 nM
1,362,058
339,076
217,475
805,433
74

VF2468 4 nM
1,055,972
397,573
376,364
281,991
44

Total
4,295,608
2,180,388
692,228
1,422,764
228

The total number of interpretable sequences (“total sequences”) and the number of analyzed sequences for each in vitro selection condition are shown. Analyzed sequences are non-repeated sequences containing no ambiguous nucleotides that, for post-selection sequences, contained reverse complementary overhang sequences of at least four bases, a signature used in this study as a hallmark of ZFN-mediated cleavage. “Incompatible overhangs” refer to sequences that did not contain reverse complementary overhang sequences of at least four bases. The high abundance of repeated sequences in the 0.5 nM, 1 nM, and 2 nM selections indicate that the number of sequencing reads obtained in those selections, before repeat sequences were removed, was larger than the number of individual DNA sequences that survived all experimental selection steps.

TABLE 3

Both ZFNs tested have the ability to cleave a large fraction of target sites with three or fewer mutations.

a

4 nM (wt EF = 5.48)
2 nM (wt EF = 8.11)
1 nM (wt EF = 16.6)
0.5 nM (wt EF = 24.9)

CCR5-224
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts

EF > 0
100%
99.96%
76%
100%
99%
49%
100%
83%
14%
100%
75%
11%

EF > 1
100%
93%
55%
100%
84%
42%
100%
68%
14%
100%
58%
11%

EF > 2
100%
78%
37%
100%
70%
31%
99%
55%
14%
96%
46%
11%

EF >
100%
63%
28%
93%
40%
17%
51%
15%
8%
31%
8%
4%

(.5 × wt EF)

EF > wt EF
14%
9%
10%
8%
6%
6%
3%
2%
3%
6%
1%
2%

b

4nM (wt EF = 16.7)
2 nM (wt EF = 22.5)
1 nM (wt EF = 30.2)
0.5 nM (wt EF = 33.1)

VF2468
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts
1 mut
2 muts
3 muts

EF > 0
100%
95%
38%
100%
92%
26%
100%
47%
5%
100%
44%
4%

EF > 1
98%
49%
17%
93%
34%
11%
83%
24%
5%
80%
21%
4%

EF > 2
89%
31%
10%
83%
23%
7%
74%
17%
5%
61%
14%
4%

EF >
57%
15%
4%
30%
10%
2%
11%
6%
1%
9%
5%
1%

(.5 × wt EF)

EF > wt EF
7%
1%
1%
7%
1%
0.4%
7%
1%
0.4%
7%
1%
0.3%

The percentage of the set of sequences with 1, 2, or 3 mutations (muts) that can be cleaved by (a) the CCR5-224 ZFN and (b) the VF2468 ZFN is shown. Enrichment factors (EFs) were calculated for each sequence identified in the selection by dividing the observed frequency of that sequence in the post-selection sequenced library by the observed frequency of that sequence in the preselection library. The enrichment factors for the wild-type sequence (wt EFs) calculated for each in vitro selection stringency are shown in the first row of the table.

TABLE 4

Continued below; (+) half-sites SEQ ID NOs: 190-226 descending; (−) half sites

SEQ ID NOs: 227-263 descending; full sequence with spacer descending SEQ ID NOs: 264-

300.

mutations

T
(+)
(−)
gene
build 36 coordinates
(+) half-site
spacer
(−) half-site

CCR5-224 1
0
0
0
CCR5 (coding)
chr3: 46389548-46389576
GTCATCCTCATC
CTGAT
AAACTGCAAAAG

CCR5-224 2
2
1
1
CCR2 (coding)
chr3: 46374209-46374237
GTCgTCCTCATC
TTAAT
AAACTGCAAAAa

CCR5-224 3
3
2
1
BTBD10 (promoter)
chr11: 13441738-13441766
GTttTCCTCATC
AAAGC
AAACTGCAAAAt

CCR5-224 4
4
0
4

chr10: 29604352-29604380
GTCATCCTCATC
AGAGA
AAACTGgctAAt

CCR5-224 5
4
3
1
SLC4A8
chr12: 50186653-50186682
taaATCCTCATC
TCTATA
AAAaTGCAAAAG

CCR5-224 6
3
2
1
Z83955 RNA
chr12: 33484433-33484462
GTCATCCcaATC
GAAGAA
AAACTGaAAAAG

CCR5-224 7
3
1
2
DGKK
chrX: 50149961-50149989
cTCATCCTCATC
CATGC
AcAaTGCAAAAG

CCR5-224 8
3
1
2
GALNT13
chr2: 154567664-154567692
GTCATCCTCAgC
ATGGG
AAACaGCAgAAG

CCR5-224 9
3
1
2

chr17: 61624429-61624457
GTCATCtTCATC
AAAAG
gAACTGCAAAAc

CCR5-224 10
4
0
4

chrX: 145275453-145275481
GTCATCCTCATC
CAATA
AAAgaaCAAAgG

CCR5-224 11
4
1
3
TACR3
chr4: 104775175-104775203
GTCATCtTCATC
AGCAT
AAACTGtAAAgt

CCR5-224 12
4
1
3
PIWIL2
chr8: 22191670-22191698
GTCATCCTCATa
CATAA
AAACTGCcttAG

CCR5-224 13
4
1
3

chr9: 76194351-76194379
aTCATCCTCATC
CATCC
AAtgTtCAAAAG

CCR5-224 14
4
3
1

chr6: 52114315-52114343
GTCcTgCTCAgC
AAAAG
AAACTGaAAAAG

CCR5-224 15
4
3
1
KCNB2
chr8: 73899370-73899398
aTgtTCCTCATC
TCCCG
AAACTGCAAAtG

CCR5-224 16
4
3
1

chr8: 4865886-4865914
GTCtTCCTgATg
CTACC
AAACTGgAAAAG

CCR5-224 17
4
3
1

chr9: 14931072-14931100
aaCATCCaCATC
ATGAA
AAACTGCAAAAa

CCR5-224 18
6
3
3

chr13: 65537258-65537286
aTCtTCCTCATt
ACAGG
AAAaTGtAAtAG

CCR5-224 19
6
4
2
CUBN
chr10: 17044849-17044877
GgCtTCCTgAcC
CACGG
AAACTGtAAAtG

CCR5-224 20
6
5
1
NID1
chr1: 234244827-234244855
GTttTgCaCATt
TCAAT
tAACTGCAAAAG

CCR5-224 21
3
2
1

chr9: 80584200-80584229
GTCAaCCTCAaC
ACCTAC
AgACTGCAAAAG

CCR5-224 22
4
1
3
WWOX
chr16: 77185306-77185335
GTCATCCTCcTC
CAACTC
cAAtTGCtAAAG

CCR5-224 23
4
2
2
AMBRA1
chr11: 46422800-46422829
GTCtTCCTCcTC
TGCACA
tcACTGCAAAAG

CCR5-224 24
4
2
2

chr1: 99456616-99456645
GTgATaCTCATC
ATCAGC
AAtCTGCAtAAG

CCR5-224 25
4
2
2
WBSCR17
chr7: 70557254-70557283
GTtATCCTCAgC
AAACTA
AAACTGgAAcAG

CCR5-224 26
4
2
2
ITSN
chr21: 34098210-34098239
cTCATgCTCATC
ATTTGT
tAACTGCAAAAt

CCR5-224 27
4
4
0

chr9: 106457399-106457428
GcCAgtCTCAgC
ATGGTG
AAACTGCAAAAG

CCR5-224 28
4
4
0

chr17: 49929141-49929170
cTCATtCTgtTC
ATGAAA
AAACTGCAAAAG

CCR5-224 29
5
3
2

chr15: 96714952-96714981
GaagTCCTCATC
CCGAAG
AAACTGaAAgAG

CCR5-224 30
5
3
2
ZNF462
chr9: 108684858-108684887
GTCtTCCTCtTt
CACATA
AAACcGCAAAtG

CCR5-224 31
5
4
1

chr5: 101113644-101113673
aTaATCCTttTC
TGTTTA
AAACaGCAAAAG

CCR5-224 32
5
4
1

chr17: 43908810-43908839
GaCATCCaaATt
ACATGG
AAACTGaAAAAG

CCR5-224 33
5
5
0
SDK1
chr7: 3446932-3446961
GTCtTgCTgtTg
CACCTC
AAACTGCAAAAG

CCR5-224 34
4
1
3
SPTB (coding)
chr14: 64329872-64329901
GTCATCCgCATC
GCCCTG
gAACTGgAAAAa

CCR5-224 35
4
2
2

chr10: 54268729-54268758
aTCATCCTCAaC
AAACTA
AAACaGgAAAAG

CCR5-224 36
4
4
0
KIAA1680
chr4: 92322851-92322880
GgaATgCcCATC
ACCACA
AAACTGCAAAAG

CCR5-224 37
5
5
0

chr5: 114708142-114708171
GTttTgCTCcTG
TACTTC
AAACTGCAAAAG

TABLE 5

Potential CCR5-224 genomic off-target sites.

in vitro selection stingency
empty vector
active CCR5-224

4 nM
2 nM
1 nM
0.5 nM
indels
total
mutation frequency
indels
total
mutation frequency
p-value

X

X

X

X

1

226676

0.00044%

105639

240966

44%

0

X

X

X

X

0

114904

12856

130496

10%

0

X

X

1

283015

0.00035%

155

224000

0.070%

0

X
X

2
297084
0.00067%
3
245078
0.0012%
0.26

X
X

0
147246

0
138979

X

X
0
147157

1
146283
0.00068%
0.16

X

0
316468

0
313981

X

0
136684

0
94657

X

0

178692

52

146525

0.035%

2.7E−13

X

0
296730

0
276961

X

0

273436

1045

308726

0.34%

0

X

X

0
168244

1
171618
0.00058%
0.16

X

0

66317

35

138728

0.025%

1.6E−09

X

1

427161

0.00023%

280

393899

0.071%

0

X

0

190993

32

171160

0.019%

7.7E−09

X

0
163704

0
146176

X

0
109939

0
100948

X

X

0
114743

0
120169

X

0

188149

127

213248

0.060%

0

X

0
366156

0
354878

X

0
237240

0
227568

X

0
129468

0
144274

X

0

172543

486

417198

0.12%

0

X

0
267772

0
308093

X

0
350592

0
335281

X

0
105012

0
99968

X

0
355674

0
338910

X

0
173646

1
152744
0.00065%
0.16

X

1
245650
0.00041%
0
185572

0.84

X

0
482635

2
413317
0.00048%
0.079

X

0
237791

0
200398

X

0
180783

0
167885

X

X

0
165657

2
153995
0.0013%
0.079

X

0
152083

0
183305

The human genome was searched for DNA sequences surviving in vitro selection for CCR5-224 cleavage. Sites marked with an ‘X’ were found in the in vitro selection dataset. ‘T’ refers to the total number of mutations in the site, and ‘(+)’ and ‘(−)’ to the number of mutations in the (+) and (−) half-sites, respectively. Chromosomal coordinates from build 36 of the human genome are listed. Mutation frequency for each site is the percentage of sequences with insertions or deletions (indels) in the sequenced DNA from cultured K562 cells expressing active CCR5-224. Bolded red sites have significantly enriched indel percentages in the active nuclease sample compared to cells containing empty vector. The sequences of the sites are listed as 5′ (+) halfsite/spacer/(−) half-site 3′, therefore the (+) half-site is listed in the reverse sense as it is in the sequence profiles. Three sites were not tested since they did not yield site-specific PCR amplification products. Indels and totals are not shown for those sites that were not tested. P-values shown are for the one-sided alternative hypothesis that the indel frequency is greater for active ZFN treated cells than for cells not expressing ZFN.

TABLE 6

There are many more potential genomic VF2468

target sites than CCR5-224 target sites.

CCR5-224

VF2468

# of
# of sites in
# of
# of sites in

mutations
genome
mutations
genome

0
1
0
1

1
0
1
3

2
1
2
245

3
6
3
3,201

4
99
4
35,995

5
964
5
316,213

6
9,671
6
2,025,878

7
65,449

8
372,801

9
1,854,317

The human genome was computationally searched for sites up to nine mutations away from the canonical CCR5-224 target site and up to six mutations away from the canonical VF2468 target site. The number of occurrences of sites containing five or six base pair spacers in the genome, including repeated sequences, is listed in the table.

TABLE 7

Sequences of CCR5-224-mediated genomic DNA modifi-

cations identified in cultured human K562 cells

(SEQ ID NOs: 301-365, descending, then left to

right).

# of

sequences

BTBD10 (promoter)

ATTTTGCAGTTT GCTTT GATGAGGAAAAC

ATTTTGCAGTTT GCTTT GATGAGGAAAAC
63

ATTTTGCAGTTT GCTTTGCTTT GATGAGGAAAAC
86

ATTTTGCAGTTT GgTTTGCTTT GATGAGGAAAAC
1

ATTTTGCAGTTT GCTTTGCTTT GgTGAGGAAAAC
1

gTTTTGCAGTTT GCTTTGCTTT GATGAGGAAAAC
1

cTTTTGCAGgTT GCTTTGCTTT GATGAGGAAAAC
1

ATTTTGCAGTTT GCTTTGCTTT GATGtGGAAAC
1

ATTTTGCAGTTT GCTTT GATGAGGAAAAC
1

chr17: 61624429-61624457

GTTTTGCAGTTC CTTTT GATGAAGATGAC

GTTTTGCAGTTC CTTTT GATGAAGATGAC
51

GTTTTGCAGgTC CTTTT GATGAAGATGAC
1

TACR3

ACTTTACAGTTT ATGCT GATGAAGATGAC

ACTTTACAGTTT ATGCT GATGAAGATGAC
5

ACTTTACAGTTT ATGCT GATGAAGATGAC
169

gCTTTACAGTTT ATGCT GATGAAGATGAC
1

ACTTTACAGTTT ATGCT GATGAAGAatAC
1

ACTTTACAGTTT ATGCT GATGAAGATGtt
1

ACTTTACAGTTT ATGCT GATGAAGATGAC
34

ACTTTACgGTTT ATGCT GATGAAGATGAC
1

ACTTTACAGTTT ATGCT GATGAAGATGAC
180

ACTTTACAGTTT ATGCT GATGAAGATGcC
1

ACTTTACAGTTT ATGCTATGCT GATGAAGATGAC
507

gCTTTACAGTTT ATGCTATGCT GATGAAGATGAC
1

ACTTTACgGTTT ATGCTATGCT GATGAAGATGAC
1

ACTTTACAGTTT ATGCTATGCT GATGAtGATGAC
1

ACgTTACAGTTT ATGCTATGCT GATGAAGATGAC
1

ACTTTACAGTTT ATGCT GATGAAGATGAC
140

ACTTTACAGTTT ATGCT GATGAAGATGtC
1

WBSCR17

GTTATCCTCAGC AAACTA AAACTGGAACAG

GTTATCCTCAGC AAACTAACTA AAACTGGAACAG
128

GTTATCCTCAGC AAACTA AAACTGGAACAG
118

GTTATCCTCAGC AAACTA AAACTGGgACAG
1

GTTATCCTCAGC AAACTA AAACTGGAcCAG
1

GTTATaCTCAGC AAACTA AAACTGGAACAG
1

GTTATCCTCAGC AAACTA AAACTGGAACAG
116

aTTATCCTCAGC AAACTA AAACTGGAACAG
1

GTTATCCTtAGC AAACTA AAACTGGAACAG
1

GTTATCCTCAGC AAACTA AAACTGGAACAG
118

GaTATCCTCAGC AAACTA AAACTGGAACAG
1

chr6: 52114315-52114343

CTTTTTCAGTTT CTTTT GCTGAGCAGGAC

CTTTTTCAGTTT CTTTT GCTGAGCAGGAC
35

KCNB2

CATTTGCAGTTT CGGGA GATGAGGAACAT

CATTTGCAGTTT CGGGAGA GATGAGGAACAT
158

CATTTGCAGTTa CGGGAGA GATGAGGAACAT
1

CATTTGCAGTTT CGGGAGA GATGAGGgACAT
1

CATTTGacGcTT CGGGAGA GgTGAGGgACAT
1

CATTTGCAGTTT CGGGCGGGA GATGAGGAACAT
109

CATTTGCAGTTT CGGGCGGGA GATGcGGAACAT
1

CATTTGCAGTTT CGGGCGGGc GATGAGGAACAT
1

CATTTGCAGTTT CGGGCGGGA GgTGAGGAACAT
1

CgTTTGCAGTTT CGGGCGGGA GATGAGGAACAT
2

CATTTGCtGTTT CGGGCGGGA GATGAGGAACAT
1

CATTTGCAGTTT CGGGCGGGA GATGAGGAcCAT
1

CATTTGCAGTTT CGGGCGGGA GgTGAGGAACAT
1

CcTTTGCAGTTT CGGGCGGGA GATGAGGAACAT
1

CATTTGCAGTTg CGGGCGGGA GATGAGGAACAT
1

chr8: 4865886-4865914

GTCTTCCTGATG CTACC AAACTGGAAAAG

GTCTTCCTGATG CTACC AAACTGGAAAAG
30

GTCTTCCTGATG CTACC AAACTtGAAAAG
1

GTCTTCaTGATG CTACC AAACTGGAAAAG
1

chr9: 80584200-80584229

CTTTTGCAGTCT GTAGGT GTTGAGGTTGAC

CTTTTGCAGTCT GTAGGT GTTGAGGTTGAC
125

CTTTTGCAGTCT GTAGGT GTTGAGGTTGAC
1

CTTTTGCAGTCT GTAGGT GTTGAGGTTGAC
1

Sequences with insertions (blue) and deletions (red) identified after sequencing potential CCR5-224 off-target sites from cultured K562 cells expressing CCR5-224 are shown. The numbers of occurrences are shown to the right of each sequence. Other mutations are indicated with lowercase letters and likely reflect mutations that arose during PCR or sequencing. The unmodified site is listed under the gene name or coordinates (build 36), and the spacer sequence is underlined.

TABLE 8

Potential VF2468 genomic off-target sites. DNA for 90 out of 97 potential VF2468

genomic target sites were amplified by PCR from cultured K562 cells expressing active

VF2468 ZFN or from cells containing empty expression vector (SEQ ID NOs: 366-653).

in vitro

muta-

selection

tions

(+)

(−)
4
2
1
0.5

T
(+)
(−)
gene
build 36 coordinates
half-site
spacer
half-site
nM
nM
nM
nM

VF2468 1
0
0
0
VEGF-A
chr6: 43,846,383-43,846,416
AGCAGCGTC
TTCGA
GAGTGAGGA
X
X
X
X

(promoter)

VF2468 2
1
0
1

chr1: 168,832,650-168,832,672
AGCAGCGTC
AATAC
GAGTGAaGA
X
X
X
X

VF2468 3
1
1
0

chr1: 242,574,122-252,574,144
AGCAGCcTC
TGCTT
GAGTGAGGA
X
X
X
X

VF2468 4
1
1
0
ZNF683
chr1: 26,569,668-26,569,690
AGCAGCGTt
GGGAG
GAGTGAGGA
X
X
X
X

VF2468 5
2
0
2
GSG1L
chr16: 27,853,984-27,854,006
AGCAGCGTC
AAAAA
cAGTGAGcA
X
X
X
X

VF2468 6
2
0
2
C9orf96
chr9: 134,536,934-134,536,956
AGCAGCGTC
GTGTG
GtGTGAGGt
X
X
X
X

VF2468 7
2
0
2
EFHD1
chr2: 233,205,384-233,205,407
AGCAGCGTC
GTTCTC
aAGTGgGGA
X
X
X
X

VF2468 8
2
0
2

chr20: 30,234,845-30,234,868
AGCAGCGTC
TAGGCA
GAGgGAaGA
X
X
X
X

VF2468 9
2
0
2
KIAA0841
chr18: 40,800,787-40,800,820
AGCAGCGTC
TAGGGG
GACgGAGGg
X
X
X
X

(exon-

intron)

VF2468 10
2
0
2
CE87
chr16: 54,501,919-54,501,941
AGCAGCGTC
TCAAAA
GAGTGtGcA
X
X
X
X

VF2468 11
2
0
2
PTK28
chr8: 27,339,866-27,320,878
AGCAGCGTC
TCCCTT
GAGTGAtGg
X
X
X
X

VF2468 12
2
0
2

chr9: 137,315,490-137,316,621
AGCAGCGTC
TGAAA
GAGTGAaaA
X
X
X
X

VF2468 13
2
1
1

chr20: 7,985,471-7,985,493
AGaAGCGTC
AGCGA
GAGTGAGGt
X
X
X
X

VF2468 14
2
1
1

chrY: 8,461,018-8,461,041
AGCAaCGTC
AGATAG
GgGTGAGGA
X
X
X
X

VF2468 15
2
1
1

chr1: 63,720,668-63,720,690
AGCAaCGTC
ATATT
cAGTGAGGA
X
X
X
X

VF2468 16
2
1
1

chrX: 122,132,519-122,132,541
AGCAaCGTC
GTAGT
GAtTGAGGA
X
X
X
X

VF2468 17
2
1
1
F4HA1
chr10: 74,506,346-74,506,368
AGCAcCGTC
TTTTC
tAGTGAGGA
X
X
X
X

VF2468 18
2
1
1
DFKZp888-
chrX: 58,830,910-58,830,933
AGCAGaGTC
AGACTT
GAGTGAGGt
X
X
X
X

L07201

VF2468 19
2
1
1
TTC4
chr1: 64,881,895-54,881,917
AGCAGaGTC
TCTGA
GAGTGAGGc
X
X
X
X

VF2468 20
2
1
1

chr1: 175,647,668-175,647,690
AGCAGCaTC
AGTGA
GAGTGAGGc
X
X
X
X

VF2468 21
2
1
1

chr1: 50,490,333-50,490,356
AGCAGCcTC
TCCAAA
GAGTGAGGc
X
X
X
X

VF2468 22
2
1
1

chr4: 128,244,847-128,244,870
AGCAGCcTC
TGCATC
GAGTGAGGt
X
X
X
X

VF2468 23
2
1
1

chr13: 27,384,187-27,390,210
AGCAGCGaC
GCCTGG
GAGTGAGGt
X
X
X
X

VF2468 24
2
1
1

chr16: 82,803,303-82,803,238
AGCAGCGTa
TCACAT
GAGTGAGGg
X
X
X
X

VF2468 25
2
1
1

chr11: 69,063,501-69,063,523
AGCAGCGTg
CCCAA
GAGTGAGGc
X
X
X
X

VF2468 26
2
1
1
THR
chr1: 173,885,442-173,885,465
AGCAGCtTC
AGGGGA
GtGTGAGGA
X
X
X
X

VF2468 27
2
1
1
PTPRM
chr18: 8,320,310-8,320-332
AGCAGCtTC
CTTTT
GAGTGAGaA
X
X
X
X

VF2468 28
2
1
1

chr12: 26,724,682-26,724,689
AGCAGCtTC
TCCTGG
GAGTGAGGg
X
X
X
X

VF2468 29
2
1
1

chr13: 82,033,140-82,033,183
AGCAGgGTC
AGGGCT
GAGTGAGGc
X
X
X
X

VF2468 30
2
1
1

chr3: 131,302,806-131,301,818
AGCAGtGTC
AGGCTG
GtGTGAGGA
X
X
X
X

VF2468 31
2
1
1

chr3: 76,708,287-76,708,410
AGCAGtGTC
AGGCTG
GtGTGAGGA
X
X
X
X

VF2468 32
2
1
1

chr11: 3,650,200-3,650,322
AGCAGtGTC
AGGCTG
GtGTGAGGA
X
X
X
X

VF2468 33
2
1
1

chr3: 128,870,762,128,870,785
AGCAGtGTC
AGGCTG
GtGTGAGGA
X
X
X
X

VF2468 34
2
1
1

chr11: 71,030,894-71,030,907
AGCAGtGTC
AGGCTG
GtGTGAGGA
X
X
X
X

VF2468 35
2
1
1
8BF2/
chr11: 8,884,211-8,884,224
AGCAGtGTC
CTAAGG
GgGTGAGGA
X
X
X
X

U80709

VF2468 36
2
1
1
KRI1 -
chr19: 10,534,492-10,534,515
AGCAtCGTC
ATCAGA
cAGTGAGGA
X
X
X
X

(coding)

VF2468 37
2
1
1

chr8: 112,421,478,112,421,480
AGCAtCGTC
TGAAGT
GAGTGAGGc
X
X
X
X

VF2468 38
2
1
1
MHCAL3/
chr22: 10,718,914-10,718,937
AGCAtCGTC
TTCTGT
GAGTGAGtA
X
X
X
X

KIAA1384

VF2468 39
2
1
1
MUC16
chr19: 8,894,218-8,894,241
AGgAGCGTC
TCACCT
GAGTGAGGc
X
X
X
X

(exon-

intron)

VF2468 40
2
2
0

chr8: 6,638,000-6,638,023
AaCAGCtTC
ATCTCG
GAGTGAGGA
X
X
X
X

VF2468 41
2
2
0
PREX1
chr20: 46,733,644-46,733,667
AaCAGCtTC
TCGGGA
GAGTGAGGA
X
X
X
X

VF2468 42
2
2
0
CDH20
chr18: 57,303,454-57,303,477
AaCAGCtTC
TCTGAG
GAGTGAGGA
X
X
X
X

VF2468 43
2
2
0

chr20: 6,213,500-6,213,522
AGCAaaGTC
AAACA
GAGTGAGGA
X
X
X
X

VF2468 44
2
2
0

chr5: 85,841,308-85,841,331
AGCAaCtTC
TGGAAA
GAGTGAGGA
X
X
X
X

VF2468 45
2
2
0

chr8: 20,481,270-20,481,292
AGCAcCtTC
AATTG
GAGTGAGGA
X
X
X
X

VF2468 46
2
2
0

chr5: 95,417,045-95,417,068
AGCAGCaTa
ATAGCA
GAGTGAGGA
X
X
X
X

VF2468 47
2
2
0
RORA
chr15: 59,165,302-59,165,325
AGCAGCaTa
GATATG
GAGTGAGGA
X
X
X
X

VF2468 48
2
2
0

chr6: 24,504,489-24,504,511
AGCAGCaTa
TCAGG
GAGTGAGGA
X
X
X
X

VF2468 49
2
2
0

chr3: 31,085,287-31,085,309
AGCAGCGag
AAAGA
GAGTGAGGA
X
X
X
X

VF2468 50
2
2
0

chr6: 27,579,690-27,579,712
AGCAGCGgt
CTTAG
GAGTGAGGA
X
X
X
X

VF2468 51
2
2
0

chr12: 113,410,592-113,410,615
AGCAGgGTt
CTTCAA
GAGTGAGGA
X
X
X
X

VF2468 52
2
2
0

chr1: 11,399,534-11,399,556
AGCtGaGTC
CTAAA
GAGTGAGGA
X
X
X
X

VF2468 53
2
2
0
MCTP1
chr5: 94,590,016-94,590,038
AGCtGaGTC
TTAAG
GAGTGAGGA
X
X
X
X

VF2468 54
2
2
0

chr1: 13,394,902-13,394,924
AGCtGgGTC
ATGAG
GAGTGAGGA
X
X
X
X

VF2468 55
2
2
0
PRAMEF20
chr1: 13,615,741-13,615,763
AGCtGgGTC
ATGAG
GAGTGAGGA
X
X
X
X

VF2468 56
2
2
0

chr20: 59,154,784-59,154,806
AGCtGtGTC
CACAG
GAGTGAGGA
X
X
X
X

VF2468 57
2
2
0

chr14: 100,903,675-100,903,697
AGCtGtGTC
TTGCA
GAGTGAGGA
X
X
X
X

VF2468 58
2
2
0

chrX: 141,701,170-141,701,192
AGtAGCGgC
AAATT
GAGTGAGGA
X
X
X
X

VF2468 59
2
2
0
GTF3C1
chr16: 27,452,953-27,452,975
AGtgGCGTC
CCAGT
GAGTGAGGA
X
X
X
X

VF2468 60
2
2
0
DNMBP/
chr10: 101,688,961-101,688,983
gCCAGaGTC
CTAGA
GAGTGAGGA
X
X
X
X

AKD89111

VF2468 61
2
2
0

chr6: 137,852,455-137,852,478
tcCAGCGTC
CTCCCA
GAGTGAGGA
X
X
X
X

VF2468 62
2
2
0
8ARDH
chr9: 136,682,253-136,682,476
tGCAGCGgC
GTAGGG
GAGTGAGGA
X
X
X
X

VF2468 63
2
2
0

chr7: 19,683,400-19,683,423
tGCAGCGTt
AAAATA
GAGTGAGGA
X
X
X
X

VF2468 64
2
2
0
ZNF628
chr19: 60,683,246-60,683,269
tGCAGgGTC
GGGCAG
GAGTGAGGA
X
X
X
X

VF2468 65
2
2
0

chr3: 130,430,426-130,430,448
tGCAGtGTC
CACAA
GAGTGAGGA
X
X
X
X

VF2468 66
3
1
2
GBF1
chr10: 104,073,868-104,074,012
AGCAaCGTC
CATAGT
GtGTGAGaA
X
X
X
X

VF2468 67
3
1
2

chr14: 96,461,728-96,561,751
AGCAaCGTC
TAACCC
GAGTGttGA
X
X
X
X

VF2468 68
3
1
2
PDE8A
chr21: 42,032,081-42,082,106
AGCAcCGTC
CCCCT
cAGTGAGGc
X
X
X
X

VF2468 69
3
1
2
MTX2
chr2: 178,842,448-178,842,479
AGCAGCGgC
GGCTG
cAGTGAGGc
X
X
X
X

VF2468 70
3
1
2

chr6: 104,071,041-104,071,063
AGCAGCGgC
TTAAGG
GgGTGAGGt
X
X
X
X

VF2468 71
3
1
2

chr3: 32,220,862-32,220-885
AGCAGtGTC
TAAAAG
GAGTGAGat
X
X
X
X

VF2468 72
3
2
1

chr2: 11,420,195-11,420,218
AGaAaCGTC
GTGGAG
GAGTGAGGg
X
X
X
X

VF2468 73
3
2
1
PH6
chr8: 47,891,416-47,891,438
ACCAaaGTC
TGTACT
GAGTGAGGg
X
X
X
X

VF2468 74
3
2
1

chr2: 195,362,417-195,362,439
AGCAaCaTC
ATCTT
GAGTGAGGg
X
X
X
X

VF2468 75
3
2
1
MPOL1
chr14: 36,952,701-36,952,724
AGCAaCaTC
TGGTTG
GAGTGAGGg
X
X
X
X

VF2468 76
3
2
1

chr4: 138,603,959-138,603,981
AGCAaCtTC
ATCTT
GAGTGAGGg
X
X
X
X

VF2468 77
3
2
1
LRCH1
chr13: 46,079,921-46,079,943
AGCAaCtTC
CTGGC
GAGTGAGGg
X
X
X
X

VF2468 78
3
2
1
KIAAC888
chr11: 116,202,384-115,202,406
AGCAatGTC
AAAAA
GAGTGAGGc
X
X
X
X

VF2468 79
3
2
1

chr12: 13,363,829-13,363,861
AGCAcCGTg
GCTTC
GAGTGAGGc
X
X
X
X

VF2468 80
3
2
1
PLXMA4
chr7: 131,603,708-131,603,730
AGCAcgGTC
ATGAT
GAGTGAGGc
X
X
X
X

(coding)

VF2468 81
3
2
1
TSPEAR
chr21: 44,817,259-44,817,282
AGCAGCagC
CCACAG
GAGTGAGGg
X
X
X
X

VF2468 82
3
2
1

chr18: 74,634,790-74,634,812
AGCAGCagC
TAGGG
GAGTGAGGg
X
X
X
X

VF2468 83
3
2
1

chr10: 33,904,306-33,904,328
AGCAGCtcC
TCTCC
GAGTGAGGt
X
X
X
X

VF2468 84
3
2
1

chr6: 170,226,156-170,226,178
AGCAGgGTg
GCGTG
GAGTGAGGc
X
X
X
X

VF2468 85
3
2
1

chr3: 118,694,878-118,694,891
AGCAtaGTC
TAGGCC
GAGTGAGGc
X
X
X
X

VF2468 86
3
2
1
HRASLS
chr3: 184,462,126-184,462,147
AGCAtgGTC
CCAAG
GAGTGAGGg
X
X
X
X

VF2468 87
3
2
1

chr17: 18,434,508-18,434,531
AGCAttGTC
TCATGT
GAGTGAGGt
X
X
X
X

VF2468 88
3
2
1

chr8: 125,882,670-125,882,801
AGCAttGTC
TCCTG
GAGTGAGGg
X
X
X
X

VF2468 89
3
2
1
UHRF1BP1L
chr12: 99,011,715-99,011,737
AGtAGCGTt
TTTAG
GAGTGAGGt
X
X
X
X

VF2468 90
3
2
1

chr1: 14,762,405-14,762,427
AtCAGaGTC
TCTGG
GAGTGAGGc
X
X
X
X

VF2468 91
3
2
1
LAM83
chr1: 207,894,359-207,894,382
AtCAGtGTC
CCTCAG
GAGTGAGGc
X
X
X
X

(promoter)

VF2468 92
3
2
1
BRUNCL4
chr18: 33,160,009-33,160,032
gCCAGaGTC
AGGGCT
GAGTGAGGc
X
X
X
X

VF2468 93
3
2
1

chr16: 64,004,297-64,004,320
gGCAGCGgC
CGCTGT
GAGTGAGGt
X
X
X
X

VF2468 94
3
2
1
DFKZp386-
chr22: 48,558,064-48,558,086
tGCAGCtTC
ATGGT
GAGTGAGGc
X
X
X
X

E1619/BRD1

VF2468 95
3
3
0

chr7: 22,054,784-22,054,807
AGCAtaGTt
ACCTGG
GAGTGAGGA
X
X
X
X

VF2468 96
3
3
0

chr14: 25,876,126-25,876,149
AGtAaaGTC
TAAGTA
GAGTGAGGA
X
X
X
X

VF2468 97
4
3
1
CNNM2
chr10: 104,716,593-104,716,615
tGCAGtcTC
CTTGG
GAGTGAGGt
X
X
X
X

empty vector
active VF2468

mutation

mutation
p-

indels
total
frequency
indels
total
frequency
value

VF2468 1
125
147187
0.036%
27057
188786
14%
0

VF2468 2
0
57855

1
62195
0.0016%
0.16

VF2468 3
0
167447

0
147340

VF2468 4
0
111340

0
109365

VF2468 5
0
80047

0
69080

VF2468 6

VF2468 7
0
202694

0
204809

VF2468 8
0
160769

1
158835
0.00063%
0.16

VF2468 9
1
81104
0.0012%
446
79136
0.50%
0

VF2468 10
1
168501
0.00059%
0
144701

0.84

VF2468 11
0
178602

60
138848
0.040%
3.0E−14

VF2468 12
0
286630

186
254714
0.005%
0

VF2468 13
0
166514

0
148547

VF2468 14

VF2468 15
0
228680

146
200780
0.060%
0

VF2468 16
0
157651

0
136373

VF2468 17

VF2468 18
0
18000

13
12386
0.10%
0.00016

VF2468 19
0
176808

163
191327
0.086%
0

VF2468 20
1
286818
0.00035%
3
343497
0.00067%
0.20

VF2468 21
0
168032

0
183289

VF2468 22
0
86347

0
87663

VF2468 23
0
23188

394
34455
1.1%
0

VF2468 24
0
67001

283
62841
0.44%
0

VF2468 25
0
181022

0
221949

VF2468 26
0
132693

0
139071

VF2468 27
0
73084

0
100349

VF2468 28
0
323231

1116
363441
0.32%
0

VF2468 29
0
168241

439
108937
0.20%
0

VF2468 30
0
77427

1060
82701
2.1%
0

VF2468 31
0
34408

114
33870
0.34%
0

VF2468 32
0
19630

19
17490
0.11%
0.6E−04

VF2468 33
0
89679

2670

32.5%
0

VF2468 34
0
112460

231
160276
0.15%
0

VF2468 35
0
418063

836
632105
0.13%
0

VF2468 36
0
141739

0
139368

VF2468 37
0
163897

1174
178660
0.19%
0

VF2468 38
0
287706

176
283704
0.082%
0

VF2468 39
0
212038

0
219913

VF2468 40
0
132803

0
147070

VF2468 41
0
204408

0
227091

VF2468 42
1
313747
0.00032%
1
403382
0.00025%
0.57

VF2468 43
1
154154
0.00065%
0
183644

VF2468 44

VF2468 45
0
250890

0
297104

VF2468 46
0
274402

1
319493
0.00031%
0.16

VF2468 47
0
270263

1
3587041
0.00028%
0.16

VF2468 48
0
103878

0
176333

VF2468 49
0
542052

0
708517

VF2468 50
0
177732

1
212250
0.00047%
0.16

VF2468 51
0
294783

0
302167

VF2468 52
0
482765

1
402831
0.00025%
0.16

VF2468 53
0
183510

1
202083
0.00049%
0.16

VF2468 54
0
88944

0
105879

VF2468 55

VF2468 56
0
360710

0
351215

VF2468 57
0
140671

0
157922

VF2468 58
0
196624

0
209781

VF2468 59
0
223714

0
246196

VF2468 60
0
302495

0
383303

VF2468 61
0
84153

0
113996

VF2468 62
0
101187

138
212046
0.085%
0

VF2468 63
1
372808
0.00027%
2
438355
0.00046%
0.33

VF2468 64
0
167551

0
185442

VF2468 65

VF2468 66
4
645643
0.00073%
8768
687383
0.64%
0

VF2468 67
0
171147

0
203860

VF2468 68
0
80078

391
137236
0.28%
0

VF2468 69
0
88242

1163
60278
0.30%
0

VF2468 70
0
252020

0
277262

VF2468 71
0
178243

0
225921

VF2468 72
0
188844

84
221676
0.042%
0

VF2468 73
0
182606

2808
212728
1.3%
0

VF2468 74
0
103739

1
130505
0.00077%
0.16

VF2468 75
1
300572
0.00033%
0
355283

0.84

VF2468 76
0
185773

0
185094

VF2468 77
1
131239
0.00076%
0
133319

0.84

VF2468 78
0
212883

243
167414
0.15%
0

VF2468 79
0
112164

34
110005
0.029%
2.7E−00

VF2468 80
0
106677

77
188316
0.041%
0

VF2468 81
1
151845
0.00066%
0
144107

0.84

VF2468 82

VF2468 83
0
240952

1
233954
0.00043%
0.16

VF2468 84
0
191106

0
167663

VF2468 85
0
406443

209
356007
0.068%
0

VF2468 86
0
212842

383
247078
0.10%
0

VF2468 87
0
4171

18
3024
0.60%
1.0E−06

VF2468 88
0
116007

69
116268
0.061%
7.8E−16

VF2468 89
1
1718773
0.00058%
0
207336

0.84

VF2468 90
2
193447
0.0010%
1
196665
0.00051%
0.72

VF2468 91
0
107549

0
109933

VF2468 92
0
71298

0
77229

VF2468 93
0
99279

0
121284

VF2468 94
0
152251

0
206428

VF2468 95
0
91338

0
134004

VF2468 96
0
245402

0
345728

VF2468 97
0
76762

0
92742

Mutation frequency for each site is the percentage of sequences with insertions or deletions (indels) in the sequenced DNA from cultured K562 cells expressing active VF2468. Bolded red sites have significantly enriched indel percentages in the active nuclease sample compared to cells not expressing nuclease. The sequences of the sites are listed as 5′ (+) halfsite (SEQ ID NOs: 366-461)/spacer/(−) half-site 3′ (SEQ ID NOs:462-557) (Full sequences are SEQ ID NOs: 558-653), therefore the (+) half-site is listed in the reverse sense as it is in the sequence profiles. Seven sites were not tested since they did not yield site-specific PCR amplification products. Indels and totals are not shown for those sites that were not tested. P-values shown are for the one-sided alternative hypothesis that the indel frequency is greater for active ZFN treated cells than for cells not expressing ZFN.

TABLE 9

Oligonucleotides used in this study.

oligonucleotide

name
oligonucleotide sequence (5′→3′)

N5-Pvul
NNNNNCGATCGTTGGGAACCGGA

CCR5-224-N4
NG*T*C*A*T*C*C*T*C*A*T*C*NNNNA*A*A*C*T*G*C*A*A*A*A*G*NCAGTGGAACGAA

CCR5-224-N5
NG*T*C*A*T*C*C*T*C*A*T*C*NNNNNA*A*A*C*T*G*C*A*A*A*A*G*NCAGTGGAACGAAAACTCACG

CCR5-224-N6
NG*T*C*A*T*C*C*T*C*A*T*C*NNNNNNA*A*A*C*T*G*C*A*A*A*A*G*NCAGTGGAACGAAAACTCACG

CCR5-224-N7
NG*T*C*A*T*C*C*T*C*A*T*C*NNNNNNNA*A*A*C*T*G*C*A*A*A*A*G*NCAGTGGAACGAAAACTCACG

VF2468-N4
NA*G*C*A*G*C*G*T*C*NNNNG*A*G*T*G*A*G*G*A*NCAGTGGAACGAAAACTCACG

VF2468-N5
NA*G*C*A*G*C*G*T*C*NNNNNG*A*G*T*G*A*G*G*A*NCAGTGGAACGAAAACTCACG

VF2468-N6
NA*G*C*A*G*C*G*T*C*NNNNNNG*A*G*T*G*A*G*G*A*NCAGTGGAACGAAAACTCACG

VR2468-N7
NA*G*C*A*G*C*G*T*C*NNNNNNNG*A*G*T*G*A*G*G*A*NCAGTGGAACGAAAACTCACG

test fwd
GCGACACGGAAATGTTGAATACTCAT

test rev
CAGCGAGTCAGTGAGCGA

adapter1
ACACTCTTTCCCTACACGACGCTCTTCCGATCTT

adapter1(AAT)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATT

adapter1(ATA)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTATAT

adapter1(TAA)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTTAAT

adapter1(CAC)
ACACTCTTTCCCTACACGACGCTCTTCCGATCTCACT

adapter2
/5Phos/AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG

adapter2(AAT)
/Phos/ATTAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG

adapter2(ATA)
/5Phos/TATAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG

adapter2(TAA)
/5Phos/TTAAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG

adapter2(CAC)
/5Phos/GTGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG

PE1
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC

PE2
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATC

CCR5-224 1 fwd
ATACATCGGAGCCCTGCCAA
CCR5-224 1 rev
GGAAAAACAGGTCAGAGATGGC

CCR5-224 2 fwd
TCCTGCCTCCGCTCTACTCG
CCR5-224 2 rev
ACCCCAAAGGTGACCGTCCT

CCR5-224 3 fwd
TCCCACGTTTTCCCCTTGAC
CCR5-224 3 rev
GTCCCTCACGACGACCGACT

CCR5-224 4 fwd
GCACTGCCCCAGAAATATTGGTT
CCR5-224 4 rev
TGGTTTGTTGGGGGATCAGG

CCR5-224 5 fwd
ATGCCACCCCTGCCAGATAA
CCR5-224 5 rev
GCCTACCTCAATGCAGGCAAA

CCR5-224 6 fwd
TCTGCTTCTGCCCTTCTGGA
CCR5-224 6 rev
GGAGGATCGCCAAGACCTGA

CCR5-224 7 fwd
CCCCAGTGCTTAACATAGTTCTTGG
CCR5-224 7 rev
ACTCCCAGACAAACCCCGCT

CCR5-224 8 fwd
GGCACCAGAACTTACTCACTGCC
CCR5-224 8 rev
TGTGAAGGCCCAAAACCCTG

CCR5-224 9 fwd
GTTTTGGGGGTCATGGCAAA
CCR5-224 9 rev
TGGGCAGCCCTAGGTCCTTT

CCR5-224 10 fwd
TTTCCCTGGTGATGCACTCCT
CCR5-224 10 rev
TGATGAGTAACTTGGGCGAAAA

CCR5-224 11 fwd
TTGGGGGAATGAGATTGGGA
CCR5-224 11 rev
GGAAAATCCAGCAAGGTGAAA

CCR5-224 13 fwd
TCCTCCCGTTGAGGAAGCAC
CCR5-224 13 rev
CAACTCTCTAACAGCAAAGTGGCA

CCR5-224 14 fwd
CAGACCGCTGCTGCTGAGAC
CCR5-224 14 rev
GCCTCAAAAGCATAAACAGCA

CCR5-224 15 fwd
TGGGTTCCTCGGGTTCTCTG
CCR5-224 15 rev
AGGGCGGACTCATTGCTTTG

CCR5-224 16 fwd
AGGCATAAGCCACTGCACCC
CCR5-224 16 rev
GAAACCAGAAGTTCACAACAATGCTT

CCR5-224 17 fwd
GAGGATATTTTATTGCTGGCTCTTGC
CCR5-224 17 rev
TGGCAATGCCTAATCAGACCA

CCR5-224 18 fwd
GCTGAGGCCCACCTTTCCTT
CCR5-224 18 rev
GAGTTTGGGGAAAAGCCACTT

CCR5-224 20 fwd
TGTTTTGGGTGCATGTGGGT
CCR5-224 20 rev
TGCTCTGCCAACTGTGAGGG

CCR5-224 21 fwd
CTGGGTCAGCTGGGCCATAC
CCR5-224 21 rev
TCCAGGGAGTGAGGTGAAGACA

CCR5-224 22 fwd
CCAGCCTTGGAAAAATGGACA
CCR5-224 22 rev
TCACATCTCCGCCTCACGAT

CCR5-224 23 fwd
CATGGATGTAATGGGTTGTATCTGC
CCR5-224 23 rev
CTGACACAGTGGCCAGCAGC

CCR5-224 24 fwd
AGGATGCATTGTCCCCCAGA
CCR5-224 24 rev
GAGGGCAGAAGGGGGTGAGT

CCR5-224 25 fwd
CGTTGGCTTGCAGAAGGGAC
CCR5-224 25 rev
TGGAGTGACATGTATGAAGCCA

CCR5-224 26 fwd
TGACCCAACTAAGTCTGTGACCC
CCR5-224 26 rev
TGAACCCCGGATTTTTCAACC

CCR5-224 27 fwd
TGGGTTGTGTTTTGACTGACAGA
CCR5-224 27 rev
TTGGGAAAGCTTTGATGCTGG

CCR5-224 28 fwd
CACCCCCATGCAGGAAAATG
CCR5-224 28 rev
CCCTAGGGGTCACTGGAGCA

CCR5-224 29 fwd
GGCCATTGGTTCTGGAGGAA
CCR5-224 29 rev
TTGGCTGCTGGCATTTGGTA

CCR5-224 30 fwd
AGTCAGCAATGCCCCAGAGC
CCR5-224 30 rev
TCCGTTGCTTCATCCTTCCAA

CCR5-224 31 fwd
CCTGGGAGGGTGACTAGTTGGA
CCR5-224 31 rev
TGGAGAGGGTTTACTTTCCCAGA

CCR5-224 32 fwd
TGGCAATTAGGATGTGCCAG
CCR5-224 32 rev
GCTCAGGGCCTGGCTTACAG

CCR5-224 33 fwd
TGCCCCACATCTTCACCAGA
CCR5-224 33 rev
TCCACTCACAAATTTACCTTTCCAC

CCR5-224 34 fwd
GTTGCATCTGCGGTCTTCCA
CCR5-224 34 rev
CCGCATAAAGGAGGTGTCGG

CCR5-224 36 fwd
TAGTGGCCCCAACATGCAAA
CCR5-224 36 rev
GGAGAGTCTTCCGCCTGTGTT

CCR5-224 37 fwd
CCTTTCCAAAGCCCATTCCC
CCR5-224 37 rev
GCACATATCATGCACTGTGACTGTAA

VF2468 1 fwd
CCTTTCCAAAGCCCATTCCC
VF2468 1 rev
CAACCCCACACGCACACAC

VF2468 2 fwd
TTCACTGCCTTCAGGCCTCC
VF2468 2 rev
AATGGCCAGAAAATTCCCAAA

VF2468 3 fwd
CACAGGGACCCAGGACTGCT
VF2468 3 rev
TGACTGGAACCGTGCAGCAT

VF2468 4 fwd
GCACCAGGCTTCTCTGCCAT
VF2468 4 rev
TCGGGGGTCCATGGTATTTG

VF2468 5 fwd
CCAAGGCGAGGACATTGAGG
VF2468 5 rev
CCCCAAGTCAGACCCTGCAT

VF2468 7 fwd
ACCATAGTCCAGCGGGGTCA
VF2468 7 rev
TTCTCCCCAAGGAAGGCTGA

VF2468 8 fwd
AGAAAGGGTGGTCGGGGAAG
VF2468 8 rev
GCCACCATGCCCAGTCTACA

VF2468 9 fwd
TTCCCATGGGGTCTCAGCTC
VF2468 9 rev
ATGGCCTTCCCCAACTGTGA

VF2468 10 fwd
CAGCAAGGATGCCCTTCACC
VF2468 10 rev
CGTTGTGATTGAGGAGACGAGG

VF2468 11 fwd
GGCTTGAGCTGGAAGGACCA
VF2468 11 rev
TGGAGCAACTGAACATCTTGGG

VF2468 12 fwd
AACCGAGTTTGCACCGTCGT
VF2468 12 rev
CATAACCACCAGGACATCCGC

VF2468 13 fwd
TATCCTCCCCTTTCCCCTGA
VF2468 13 rev
TGTTGCCAGAAGTATCAGGTCCC

VF2468 15 fwd
AGAACCCGGAATCCCTTTGC
VF2468 15 rev
GCAGAGAAGGCAGCAGCACA

VF2468 16 fwd
GGTCTCTGCCATGCCCAACT
VF2468 16 rev
TGGAGGAAGCAGGAAAGGCAT

VF2468 18 fwd
CCCCTTGGGATCCTTGTCCT
VF2468 18 rev
TCAACAGGCAGCTACAGGGC

VF2468 19 fwd
CTAGGCCTGTGGGCTGAGGA
VF2468 19 rev
CAAATGTTGGGGTGTGGGTG

VF2468 20 fwd
TACCTGAAACCCCTGGCCCT
VF2468 20 rev
CAAGCTGGATGTGGATGCAGAG

VF2468 21 fwd
CGGGGGCCTGACATTAGTGA
VF2468 21 rev
GCCTGAAGATGCATTTGCCC

VF2468 22 fwd
TGCATTGGCTCAAGAATTGGG
VF2468 22 rev
TCACACAGTGGTAATGGACAGGAA

VF2468 23 fwd
GCGCTCCCTGTGTTCAGTACC
VF2468 23 rev
GCGCAAGTTCCCCTTTCTGA

VF2468 24 fwd
TGTTTGGGTTATGGGGGCAG
VF2468 24 rev
TCCAGCATCTGCTCCTGGTG

VF2468 25 fwd
AAGGAGACTTCTCAGGCCCCA
VF2468 25 rev
TGAAGGGAAGCCACAGCTCC

VF2468 26 fwd
CTTGGGGGCAGACAGCATCT
VF2468 26 rev
GCCATGGGATGGCAGTTAGG

VF2468 27 fwd
TGGCCTCAAGCAATCCTCCT
VF2468 27 rev
TTCCATGGCAGTGAAGGGTG

VF2468 28 fwd
CCAAAGAGCCTGGAGGAGCA
VF2468 28 rev
CAGAGGGTGTGGTGGTGTCG

VF2468 29 fwd
CCAGCCTGTGAAGCTGGAAGTAA
VF2468 29 rev
CCAGTGGGCTGAGTGGATGA

VF2468 30 fwd
CATCTGAATGCCCATGCTGC
VF2468 30 rev
CCGCCACACCCATTCCTC

VF2468 31 fwd
CCTCAAAGAAACGGCTGCTGA
VF2468 31 rev
GCCGCTCGAAAAGAGGGAAT

VF2468 32 fwd
CGGGCTCTCCTCCTCAAAGA
VF2468 32 rev
GGCCCCTTGAAAAGAGGGAA

VF2468 33 fwd
GGAATCGCATGACCTGAGGC
VF2468 33 rev
CGGGCTCTCCTCCTCAAAGA

VF2468 34 fwd
CCCGCCAGACACATTCCTCT
VF2468 34 rev
CATCTGAATGCCCATGCTGC

VF2468 35 fwd
CCGCACCTTTTTCCTATGTGGT
VF2468 35 rev
TCAGATGTGCTAGGACACAGATGAC

VF2468 36 fwd
GGTACATGGGCCGCACTTTC
VF2468 36 rev
GGACAGCTGGGAATTGGTGG

VF2468 37 fwd
TTACACCTGCTGGCAGGCAA
VF2468 37 rev
GCTGGTGTGAGCAAGAGGCA

VF2468 38 fwd
TGGCCAAGCCTGCCTAACTC
VF2468 38 rev
TGATCAGTTAGCCCTGGGGG

VF2468 39 fwd
CCCCTTCTGCTCCTGCTTCA
VF2468 39 rev
CCTTCCTTGCAGCTCAAACCC

VF2468 40 fwd
TGATTTTCAGCGTGGAGGGC
VF2468 40 rev
ACGGCAAAGCCAGAGCAAAG

VF2468 41 fwd
AAGCTGGCAGCCACTCTTCA
VF2468 41 rev
TCTCAGGGCTTCTGTGTGCG

VF2468 42 fwd
TCGATTCTCCATACACCATCAAT
VF2468 42 rev
GCAACCAACTCCCAACAGGG

VF2468 43 fwd
AGGTCCTGGCATTGTCTGGG
VF2468 43 rev
TGGTTGCCTGTTTCACACCC

VF2468 45 fwd
CTGGGAGGCAGCCAGTCAAG
VF2468 45 rev
GCCCTGTAAGCTGAAGCTGGA

VF2468 46 fwd
CAGGTGTGCATTTTGTTGCCA
VF2468 46 rev
GCCTGCCAGGTATTTCCTGTGT

VF2468 47 fwd
TGGCCCTGGTCATGTGAAAA
VF2468 47 rev
AACTGCAAGTGGCCTCCCAG

VF2468 48 fwd
TTGATAAGGGCGGTGCCACT
VF2468 48 rev
TAGAGGGAGGTGCTTGCCCA

VF2468 49 fwd
CATCCCCTTGACCAACAGGC
VF2468 49 rev
GCTTGGGCACTGATCCTGCT

VF2468 50 fwd
ACTGCCAATGGACCCTCTCG
VF2468 50 rev
GAGTTGCCCAGGTCAGCCAT

VF2468 51 fwd
GGGGAGCTAGAATGGTGGGC
VF2468 51 rev
CAAGGTACACAGCTGCCCAGG

VF2468 52 fwd
CCCATGCTGGTCCTGCTGTT
VF2468 52 rev
GGAGGCTCAGCGGAGAGGAT

VF2468 53 fwd
GGGGTCACCAGGGAAGGTTT
VF2468 53 rev
AGTTGCGGGGAGGTGCTACA

VF2468 54 fwd
TGCCCAGAGACCTTCCAAGC
VF2468 54 rev
TGGCCAAGGCCTCTCTAAGC

VF2468 56 fwd
GCCAATGTGCAATCGAGACG
VF2468 56 rev
TGCATGCCTCTGACTGATGCT

VF2468 57 fwd
TGACTTGAACTGGGTCCCCC
VF2468 57 rev
CTGGGGCTACAGCCCTCCTT

VF2468 58 fwd
CCCAATCCAGACACCACACG
VF2468 58 rev
TGCAGATTTTAGGGGTTGCCA

VF2468 59 fwd
GGTGAGGAAGGATGGGGGTT
VF2468 59 rev
GTAGGCTCTGCCACGCCAGT

VF2468 60 fwd
TGCCCATGTTGTTGCTCCAC
VF2468 60 rev
GACAAGTTAGACCATCCTAGCCCTCA

VF2468 61 fwd
TCACAGCTCCCCTTTCTCGG
VF2468 61 rev
TGTGCCTCCACTGACGCATT

VF2468 62 fwd
CCTAGGCACAGTGGGGGATG
VF2468 62 rev
GGGCTGACACACTGAGGGCT

VF2468 63 fwd
CCATGAGCACAATTGCCAAAA
VF2468 63 rev
TGAGTTATTTCGAAAGAGGAAACAGTG

VF2468 64 fwd
CTGCCAAGAACAGGAGGGGA
VF2468 64 rev
AGCCCATCTACCATCCAGCG

VF2468 65 fwd
ATCGGGGCAGGGCTAGAGTC
VF2468 65 rev
CCCCTGGCATTCCCTACACA

VF2468 67 fwd
GCCGTTAGTGCATTTGCCTG
VF2468 67 rev
TCCCTTTCAACCCCTGTAGTGC

VF2468 68 fwd
GTTCCTCCCAGAGTGGGGCT
VF2468 68 rev
ACTGAGGGAGGCAGCACTGG

VF2468 69 fwd
AGGCCTGGCGGTAACCTTG
VF2468 69 rev
AAGCTCCAGCCCTGTACCCC

VF2468 70 fwd
GGGATCCTACAGGATGGGACAA
VF2468 70 rev
CAGCCCAGGACAAGGGTAGC

VF2468 71 fwd
GCCACCAAATGTCCACTGGTT
VF2468 71 rev
TTCCCCAAGCAGTCCAGCTC

VF2468 72 fwd
GCACCAGCCTCTTCGATGGT
VF2468 72 rev
CCTTTGGCAGACTGTGGCCT

VF2468 73 fwd
AATGGGGCAAAAGGCAAGAAA
VF2468 73 rev
CAGACCTCGTGGTGCATGTG

VF2468 74 fwd
TGGCGAGATAGGCTCTGCTACA
VF2468 74 rev
TGGACAGGGATTACTCAGACCAG

VF2468 75 fwd
TGTGGGCATGAGACCACAGG
VF2468 75 rev
TTGACTCCCCCGCATTGTT

VF2468 76 fwd
TCCTATTTTCAGATGCACTCGAACC
VF2468 76 rev
GTGCTCACTGAAGCCCACCA

VF2468 77 fwd
GGACCTTCTTGCCCTCATGATTC
VF2468 77 rev
GGGAACTGTGCCTTTGCGTC

VF2468 78 fwd
CCTTGCAAAGGCTTGCCTAAA
VF2468 78 rev
GGCAGGCACCTGTAGTCCCA

VF2468 79 fwd
TGGCTTGCAGAGGAGGTGAG
VF2468 79 rev
CAGGGAAGGGTGTTGGCTTG

VF2468 80 fwd
GCTTCAGCACATCAGTGGCG
VF2468 80 rev
TTCGCCCAGCTCATCAACAA

VF2468 81 fwd
GGTGAGGCCACTGTAAGCCAA
VF2468 81 rev
TGGGCTGCCATGACAAACAG

VF2468 83 fwd
GAGTTGAGCTGTCAGCGGGG
VF2468 83 rev
GAAGCCAACTGCCTTGTGAGC

VF2468 84 fwd
TGTTTTCTGCAGTTTTGCAGGG
VF2468 84 rev
GGCTCAGGGAGTTTGAGCCA

VF2468 85 fwd
GCTCTGGCACCAGGCACACT
VF2468 85 rev
GGGAGAGAACCATGAATTTCCCA

VF2468 86 fwd
GCCAAACCCTTTCCAGGGAG
VF2468 86 rev
CCCACCCTATGCACAGAGCC

VF2468 87 fwd
CCTCAGCCAGTTGGAATCGG
VF2468 87 rev
CAACGGTTTAGTTTAGTTCCGGTTT

VF2468 88 fwd
TGGGTGGTGAAAATGGGGTT
VF2468 88 rev
GGTGGGGTATGCACTGGTCA

VF2468 89 fwd
GGAATGTGTGGAACTCAATTTCTTT
VF2468 89 rev
TTGCTTGCAGGGTGTGGAAA

VF2468 90 fwd
CCACAAGGGTCATCTGGGGA
VF2468 90 rev
CGGAGGCATCATCCACTGAG

VF2468 91 fwd
CCTGGAGTGGTTTGGCTTCG
VF2468 91 rev
TGGAGCCCTGGAGTTCTTGG

VF2468 92 fwd
GGCTCCTGGGGTCATTTTCC
VF2468 92 rev
TGTGCTCCATCCTCCTCCCT

VF2468 93 fwd
GTGTGTTTCCGCACACCCTG
VF2468 93 rev
GCTCTTGGCTTCCCAACCCT

VF2468 94 fwd
CCATCGCCGTGTCTGAGTGT
VF2468 94 rev
CAGCAGGAACATCATCCCCC

VF2468 95 fwd
AGGCAATGGCACCAAAATGG
VF2468 95 rev
GCAGCCTTCACCATACCTGTGA

VF2468 96 fwd
TTTTGACTTTGAGAACCCCCTGA
VF2468 96 rev
CCTTGTCCTTTCTCAGTTAGACACA

VF2468 97 fwd
GCTGAGTGCAAAGCTCAGGGA
VF2468 97 rev
GGCAACACAGCAAGACCCCT

Oligonucleotides “VFN1 fwd/rev” were ordered from Invitrogen. All other oligonucleotides were ordered from Integrated DNA Technologies. ‘N’ refers to machine mixed incorporation of ‘A’,′C′,′G′, or ‘T.’ An asterisk indicates that the preceding nucleotide was incorporated as a mixture containing 79 mol % of that nucleotide and 7 mol % each of the other canonical nucleotides. “/5Phos/” denotes a 5′ phosphate group installed during synthesis. Sequences correspond, from top left to bottom right, to SEQ ID NOs: 654-924.

VF2468 Data

Potential VF2468 genomic off-target sites. The human genome was searched for DNA sequences surviving in vitro selection for VF2468 cleavage. Sites marked with an ‘X’ were found in the in vitro selection dataset. ‘T’ refers to the total number of mutations in the site, and ‘(+)’ and ‘(−)’ to the number of mutations in the (+) and (−) half-sites, respectively. The sequences of the sites are listed as they appear in the genome, therefore the (−) half-site is listed in the reverse sense as it is in the sequence profiles. Sequence (+) half-sites correspond, from top to bottom, to SEQ ID NOs: 925-3538; sequence (−) half-sites correspond, from top to bottom, to SEQ ID NOs: 3539-6152; full sequences with spacers correspond, from top to bottom, to SEQ ID NOs: 6153-8766.

# of

VF2468

muta-

concentration

tions

4
2
1
0.5

T
(−)
(+)
(−) site
spacer
(+) site
nM
nM
nM
nM

2
1
1
AGCAGCTTC
CTTTT
GAGTGAGAA
X
X
X
X

2
1
1
AGCATCGTC
ATCAGA
CAGTGAGGA
X
X
X
X

2
1
1
AGCAACGTC
GTAGT
GATTGAGGA
X
X
X
X

2
2
0
AGCTGGGTC
ATGAG
GAGTGAGGA
X
X
X
X

2
2
0
AGCTGGGTC
ATGAG
GAGTGAGGA
X
X
X
X

2
2
0
AGCAACTTC
TGGAAA
GAGTGAGGA
X
X
X
X

2
2
0
AGCTGAGTC
TTAAG
GAGTGAGGA
X
X
X
X

2
2
0
TCCAGCGTC
CTCCCA
GAGTGAGGA
X
X
X
X

2
2
0
TGCAGCGTT
AAAATA
GAGTGAGGA
X
X
X
X

2
2
0
AGCACCTTC
AATTG
GAGTGAGGA
X
X
X
X

2
2
0
TGCAGCGGC
GTAGGG
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGGGTT
CTTCAA
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGCATA
GATATG
GAGTGAGGA
X
X
X
X

2
2
0
AACAGCTTC
TCTGAG
GAGTGAGGA
X
X
X
X

2
2
0
TGCAGGGTC
GGGCAG
GAGTGAGGA
X
X
X
X

2
2
0
AGCAAAGTC
AAACA
GAGTGAGGA
X
X
X
X

2
2
0
AACAGCTTC
TCGGGA
GAGTGAGGA
X
X
X
X

2
2
0
AGTAGCGGC
AAATT
GAGTGAGGA
X
X
X
X

2
2
0
AGCTGAGTC
CTAAA
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGCGAG
AAAGA
GAGTGAGGA
X
X
X
X

2
2
0
TGCAGTGTC
CACAA
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGCATA
ATAGCA
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGCATA
TCAGG
GAGTGAGGA
X
X
X
X

2
2
0
AGCAGCGGT
CTTAG
GAGTGAGGA
X
X
X
X

2
2
0
AACAGCTTC
ATCTCG
GAGTGAGGA
X
X
X
X

2
2
0
GGCAGAGTC
CTAGA
GAGTGAGGA
X
X
X
X

2
2
0
AGCTGTGTC
TTGGA
GAGTGAGGA
X
X
X
X

2
2
0
AGTGGCGTC
CCAGT
GAGTGAGGA
X
X
X
X

2
2
0
AGCTGTGTC
CACAG
GAGTGAGGA
X
X
X
X

3
1
2
AGCAGCGGC
TTAAGG
GGGTGAGGT
X
X
X
X

3
1
2
AGCAACGTC
TAACCC
GAGTGTTGA
X
X
X
X

3
1
2
AGCACCGTC
CCCCT
CAGTGAGGC
X
X
X
X

3
1
2
AGCAGCGGC
GGCTG
CAGTGAGGC
X
X
X
X

3
1
2
AGCAGTGTC
TAAAAG
GAGTGAGAT
X
X
X
X

3
1
2
AGCAACGTC
CATAGT
GTGTGAGAA
X
X
X
X

3
2
1
AGAAACGTC
GTGGAG
GAGTGAGGG
X
X
X
X

3
2
1
AGCATAGTC
TAGGCC
GAGTGAGGC
X
X
X
X

3
2
1
AGCAACTTC
ATCTT
GAGTGAGGG
X
X
X
X

3
2
1
AGCAGGGTG
GCGTG
GAGTGAGGC
X
X
X
X

3
2
1
AGCACGGTC
ATGAT
GAGTGAGGC
X
X
X
X

3
2
1
AGCATTGTC
TCCTG
GAGTGAGGG
X
X
X
X

3
2
1
AGCACCGTG
GCTTC
GAGTGAGGC
X
X
X
X

3
2
1
AGCAACTTC
CTGGC
GAGTGAGGG
X
X
X
X

3
2
1
AGCAACATC
TGGTTG
GAGTGAGGG
X
X
X
X

3
2
1
GGCAGCGGC
CGCTGT
GAGTGAGGT
X
X
X
X

3
2
1
AGCATTGTC
TCATGT
GAGTGAGGT
X
X
X
X

3
2
1
AGCAGCAGC
TAGGG
GAGTGAGGG
X
X
X
X

3
2
1
AGCAGCAGC
CCACAG
GAGTGAGGG
X
X
X
X

3
2
1
ATCAGAGTC
TCTGG
GAGTGAGGC
X
X
X
X

3
2
1
ATCAGTGTC
CCTCAG
GAGTGAGGC
X
X
X
X

3
2
1
AGCAACATC
ATCTT
GAGTGAGGG
X
X
X
X

3
2
1
AGCATGGTC
CCAAG
GAGTGAGGG
X
X
X
X

3
2
1
AGCAAAGTC
TGTACT
GAGTGAGGG
X
X
X
X

3
2
1
AGCAGCTCC
TCTCC
GAGTGAGGT
X
X
X
X

3
2
1
AGCAATGTC
AAAAA
GAGTGAGGC
X
X
X
X

3
2
1
AGTAGCGTT
TTTAG
GAGTGAGGT
X
X
X
X

3
2
1
GGCAGAGTC
AGGGCT
GAGTGAGGC
X
X
X
X

3
2
1
TGCAGCTTC
ATGGT
GAGTGAGGC
X
X
X
X

3
3
0
AGCATAGTT
ACCTGG
GAGTGAGGA
X
X
X
X

3
3
0
AGTAAAGTC
TAAGTA
GAGTGAGGA
X
X
X
X

3
3
0
AGCATTGTT
CTGCG
GAGTGAGGA
X
X
X
X

4
3
1
TGCAGTCTC
CTTGG
GAGTGAGGT
X
X
X
X

2
0
2
AGCAGCGTC
CACTTC
CAGAGAGGA
X
X
X

2
1
1
AGCAGCGTG
GACCCA
GAGTGAGCA
X
X
X

2
1
1
AGCAGCGCC
AATCC
GAGTGAGAA
X
X
X

2
1
1
AGCAGCGGC
AGGCT
GAGAGAGGA
X
X
X

2
1
1
AGCAGCTTC
TGCCTT
GAGTGAGTA
X
X
X

2
1
1
AGCAGCTTC
ACTGT
CAGTGAGGA
X
X
X

2
1
1
ATCAGCGTC
TTCAG
AAGTGAGGA
X
X
X

2
1
1
AGCAGCGTG
GACCCA
GAGTGAGCA
X
X
X

2
1
1
AGCAGGGTC
AAGAAA
GAGTGAGTA
X
X
X

2
1
1
AGCAGCGTT
ACACA
GAGTGGGGA
X
X
X

2
1
1
AGCAGCGGC
AAGAGA
GAATGAGGA
X
X
X

2
1
1
AGCAGAGTC
CAGGC
AAGTGAGGA
X
X
X

2
1
1
AGCAGAGTC
CAGGC
AAGTGAGGA
X
X
X

2
1
1
AGCAGGGTC
TGGGTA
GAGTGATGA
X
X
X

2
1
1
AGCAGCGTG
GACCCA
GAGTGAGCA
X
X
X

2
2
0
AGCAGCAGC
TAGCTA
GAGTGAGGA
X
X
X

2
2
0
AGGAGCTTC
ACTAA
GAGTGAGGA
X
X
X

2
2
0
AGCAGCCTG
CAATA
GAGTGAGGA
X
X
X

2
2
0
ACCAGTGTC
TGAGCT
GAGTGAGGA
X
X
X

2
2
0
AACAGAGTC
CCCAT
GAGTGAGGA
X
X
X

2
2
0
AGCAGCCTG
GCCAGG
GAGTGAGGA
X
X
X

2
2
0
AGCAGCAGC
AGTGA
GAGTGAGGA
X
X
X

2
2
0
ATCAGAGTC
TTAGG
GAGTGAGGA
X
X
X

2
2
0
AGCGGGGTC
TAGGGG
GAGTGAGGA
X
X
X

2
2
0
AGCAGCGGA
CAAGT
GAGTGAGGA
X
X
X

3
0
3
AGCAGCGTC
CCTGCC
TAGGGAGGG
X
X
X

3
0
3
AGCAGCGTC
TTTTCT
ATGTGAGGC
X
X
X

3
0
3
AGCAGCGTC
ACCTCT
GTGTGGGGC
X
X
X

3
0
3
AGCAGCGTC
TAAGG
GAGGGGGGT
X
X
X

3
0
3
AGCAGCGTC
TTGGG
GTGTGGGGC
X
X
X

3
0
3
AGCAGCGTC
TAGAG
TAGAGAGGT
X
X
X

3
1
2
AGCAGGGTC
TCCCAG
GAGTGTGAA
X
X
X

3
1
2
AGCAGTGTC
TATTT
CAGTGAGGG
X
X
X

3
1
2
AGCAGGGTC
AGCCCA
GAGTGGGGG
X
X
X

3
1
2
AGCAGGGTC
AGGCA
CAGTGAGGC
X
X
X

3
1
2
AGCAGGGTC
CTCTG
GAGTGGGGG
X
X
X

3
1
2
GGCAGCGTC
CGGAG
GAGTGAAGG
X
X
X

3
1
2
GGCAGCGTC
ACTCCA
GAGTTAGGT
X
X
X

3
1
2
AGCAGGGTC
ATTCAT
CAGTGAGGC
X
X
X

3
1
2
AGCAGAGTC
CTGTCA
GAGGGAGGC
X
X
X

3
1
2
AGCAGCATC
TTCTG
GAGTGAGAC
X
X
X

3
1
2
AGCATCGTC
TTTCT
GTGTGAGGC
X
X
X

3
1
2
AGCAGTGTC
TCACAG
GAGGGAGGG
X
X
X

3
1
2
GGCAGCGTC
CAGGA
GAGAGAGGT
X
X
X

3
1
2
AGCAGCGGC
CCCGG
GAGTTAGGT
X
X
X

3
1
2
AGCAGCGGC
GGGTGG
GAGTGGGGG
X
X
X

3
1
2
AGCAGTGTC
CAGAC
GAGGGAGGT
X
X
X

3
1
2
AGCAGTGTC
TATGA
GAGGGAGGG
X
X
X

3
1
2
AGCAGTGTC
AGCCAT
GAGGGAGGG
X
X
X

3
1
2
AGCAGTGTC
CCTGTG
GAGGGAGGT
X
X
X

3
1
2
AGCACCGTC
TGCCA
GAGTGGGCA
X
X
X

3
2
1
AGCCACGTC
CACAC
TAGTGAGGA
X
X
X

3
2
1
AGTAGCGCC
AAAAG
GAGTGAGGT
X
X
X

3
2
1
AACAGGGTC
TTTGAC
GAGTGAGGC
X
X
X

3
2
1
GGCAGGGTC
TCAAT
GAGTGAGGG
X
X
X

3
2
1
AACAGGGTC
CCTGA
GAGTGAGGG
X
X
X

3
2
1
AGGAGAGTC
CAGGT
GAGTGAGGG
X
X
X

3
2
1
AGCAGCCGC
CAACA
GAGTGAGGG
X
X
X

3
2
1
GGCAGAGTC
AGTGTT
GAGTGAGGG
X
X
X

3
2
1
AGCAGTGTG
TGAGCT
GAGTGAGGC
X
X
X

3
2
1
AGCATCTTC
CAGTG
GAGTGAGGG
X
X
X

3
2
1
AGCAGAGTG
GTTGA
GAGTGAGGT
X
X
X

3
2
1
ATCAGTGTC
CCAGA
GAGTGAGGG
X
X
X

3
2
1
TTCAGCGTC
CAAGAA
GAGTGAGGT
X
X
X

3
2
1
AGCAACTTC
CGGACA
GAGTAAGGA
X
X
X

3
2
1
AGCAGCGGG
AGATG
GAGTGAGGC
X
X
X

3
2
1
AGTAGCGTG
GAGAG
GAGTGAGGT
X
X
X

3
2
1
AGCTGCATC
TTTGG
GAGTGAGGT
X
X
X

3
2
1
ATCAGAGTC
AAAGAA
GAGTGAGGT
X
X
X

3
2
1
AGCAGGATC
TGAAAT
GAGTGAGGT
X
X
X

3
2
1
AGCCACGTC
CAGTTT
TAGTGAGGA
X
X
X

3
2
1
AGCAATGTC
TCAAAT
CAGTGAGGA
X
X
X

3
2
1
AGCAATGTC
TGAAA
CAGTGAGGA
X
X
X

3
2
1
GGCTGCGTC
ATCGG
GAGTGAGGT
X
X
X

3
2
1
GGCAGAGTC
AAAAT
GAGTGAGGT
X
X
X

3
2
1
AGCAGTGTG
CATGT
GAGTGAGGT
X
X
X

3
3
0
GGCAACATC
AAACAG
GAGTGAGGA
X
X
X

3
3
0
CCCAGCGGC
TGGCAG
GAGTGAGGA
X
X
X

3
3
0
AGCCTGGTC
GGAGAG
GAGTGAGGA
X
X
X

3
3
0
TGCAGTCTC
TATGG
GAGTGAGGA
X
X
X

3
3
0
AGCATTGTA
GAGGC
GAGTGAGGA
X
X
X

3
3
0
AGCCTGGTC
TCACA
GAGTGAGGA
X
X
X

3
3
0
AGCATAGTG
AATAT
GAGTGAGGA
X
X
X

3
3
0
AGCAAAGGC
ACCAG
GAGTGAGGA
X
X
X

3
3
0
AACATGGTC
CACGT
GAGTGAGGA
X
X
X

3
3
0
AGCTTTGTC
AACCTA
GAGTGAGGA
X
X
X

3
3
0
AGCAAAGGC
AAAAA
GAGTGAGGA
X
X
X

3
3
0
ATCAAGGTC
TTTTG
GAGTGAGGA
X
X
X

3
3
0
GCCAGTGTC
TCGTCT
GAGTGAGGA
X
X
X

3
3
0
TGCAAAGTC
AGATCT
GAGTGAGGA
X
X
X

4
1
3
AGCAACGTC
TACAG
GAGGAAGGT
X
X
X

4
1
3
AGCAACGTC
CCAGGA
AAGTGAAGG
X
X
X

4
2
2
GGCAGTGTC
CAGTAG
GAGTGAGAT
X
X
X

4
2
2
AGCAAAGTC
TCACA
AAGTGAGGT
X
X
X

4
3
1
TGCTGTGTC
AAACCC
GAGTGAGGT
X
X
X

4
3
1
GGCAAGGTC
TCTGTG
GAGTGAGGG
X
X
X

4
3
1
ATCAACGTG
TCTCA
GAGTGAGGC
X
X
X

2
0
2
AGCAGCGTC
TGAGGC
GGGTGAGAA
X
X

X

2
0
2
AGCAGCGTC
TGCATG
GTGTGGGGA
X
X

X

2
1
1
AGCAGAGTC
AGGCA
GAGTGAGAA
X
X

X

2
1
1
AGCAGCTTC
ATTTAT
GAGTGAGCA
X
X

X

2
1
1
GGCAGCGTC
CTTCT
GAGTGAGCA
X
X

X

2
1
1
AGCAGTGTC
GTGAA
GAGTCAGGA
X
X

X

2
1
1
AGCAGCTTC
CGGGGA
GAGAGAGGA
X
X

X

2
2
0
AGCAGCTGC
GGACC
GAGTGAGGA
X
X

X

2
2
0
AGCAGTGGC
ATTAA
GAGTGAGGA
X
X

X

2
2
0
AGCAGCATG
CACAT
GAGTGAGGA
X
X

X

2
2
0
AGCAGCATG
ACCAA
GAGTGAGGA
X
X

X

2
2
0
ACCAGGGTC
TGTGGG
GAGTGAGGA
X
X

X

2
2
0
AGCAGCATG
AAAAGG
GAGTGAGGA
X
X

X

2
2
0
AGCAGGGTG
ATGGA
GAGTGAGGA
X
X

X

2
2
0
AGCAGTGAC
CGAAG
GAGTGAGGA
X
X

X

2
2
0
AGCAGATTC
CTCAG
GAGTGAGGA
X
X

X

2
2
0
ATCAGCGTG
GCCAT
GAGTGAGGA
X
X

X

2
2
0
AGCAGGGGC
AAGAGA
GAGTGAGGA
X
X

X

2
2
0
AGCGCCGTC
CACAGG
GAGTGAGGA
X
X

X

3
0
3
AGCAGCGTC
CCCTG
GAGTGGCCA
X
X

X

3
0
3
AGCAGCGTC
CAGTGG
GAGTGGGCC
X
X

X

3
0
3
AGCAGCGTC
CTTCCT
CAGTGAGAC
X
X

X

3
1
2
AGCAGCGGC
GGCGGG
GAGGGAGGC
X
X

X

3
1
2
AGCAGAGTC
TGTTGA
GAGTGAGAC
X
X

X

3
1
2
TGCAGCGTC
AGAAG
GTGTGAGGC
X
X

X

3
1
2
AGCAGCGTG
CCTCT
GGGTGAGGC
X
X

X

3
1
2
AGCAGCTTC
CATCTG
GAGTGAGTC
X
X

X

3
1
2
AGCAGCATC
TGCTCT
TAGTGAGGC
X
X

X

3
1
2
AGCAACGTC
CTGCA
GAGGGAGAA
X
X

X

3
1
2
AGCAGCGGC
CCGCA
GAGGGAGGC
X
X

X

3
1
2
AGCAACGTC
AGCAA
CAGTGAGAA
X
X

X

3
1
2
AGTAGCGTC
TCGAA
GAGAGAGGC
X
X

X

3
1
2
AGCAGCGTT
TTCAG
GAGGGAGGG
X
X

X

3
1
2
AGCAGCGGC
ACCCT
GGGTGAGGC
X
X

X

3
2
1
AGCAAGGTC
AACTCA
GAGTGAGAA
X
X

X

3
2
1
AGCATGGTC
AGTTTC
TAGTGAGGA
X
X

X

3
2
1
AGTAGGGTC
ACGCCA
GAGTGAGGC
X
X

X

3
2
1
ATCAGGGTC
CTGTT
GAGTGAGGG
X
X

X

3
2
1
AGCATGGTC
TTTTTC
TAGTGAGGA
X
X

X

3
2
1
AGCAGGGTA
AGAGGG
GAGTGAGGG
X
X

X

3
2
1
GGCAACGTC
AACTCA
GAGTGAGAA
X
X

X

3
2
1
GCCAGCGTC
TTGGGT
GAGTGAGGT
X
X

X

3
2
1
AGCAGCTTT
CTGCT
GAGTGAGGC
X
X

X

3
2
1
AGCAGTGGC
TGCGG
GAGTGAGGC
X
X

X

3
2
1
GGCAGCATC
TGGGC
GAGTGAGGC
X
X

X

3
2
1
GGCAGCATC
TGAAT
GAGTGAGGC
X
X

X

3
2
1
AGCAGTGTA
TGTGG
GAGTGAGGT
X
X

X

3
2
1
AGGAGAGTC
CCTGG
GAGTGAGGC
X
X

X

3
2
1
AGCATGGTC
AGATTC
TAGTGAGGA
X
X

X

3
2
1
ATCAGGGTC
TTGAGG
GAGTGAGGT
X
X

X

3
2
1
AACAGCGTG
CTGTA
GAGTGAGGT
X
X

X

3
2
1
AGTAGCTTC
TGTGG
GAGTGAGGC
X
X

X

3
2
1
AGCAACTTC
TTGAT
GAGTGAGAA
X
X

X

3
2
1
AGCATGGTC
AGGTTC
TAGTGAGGA
X
X

X

3
2
1
AGAAGTGTC
AGAGTA
GAGTGAGGC
X
X

X

3
2
1
AACAGCGGC
ATGGG
GAGTGAGGC
X
X

X

3
2
1
AGCAGTGGC
ATCTAG
GAGTGAGGC
X
X

X

3
3
0
AAAAGTGTC
ATATAG
GAGTGAGGA
X
X

X

3
3
0
AGCAATGGC
TGGAT
GAGTGAGGA
X
X

X

3
3
0
GCCACCGTC
GGTGAG
GAGTGAGGA
X
X

X

3
3
0
AAAAGTGTC
AGTAGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGG
GAGTGAGGA
X
X

X

3
3
0
AACATTGTC
TAGTGA
GAGTGAGGA
X
X

X

3
3
0
ATCAACTTC
TTCAGG
GAGTGAGGA
X
X

X

3
3
0
AGCATGGTG
ATTAA
GAGTGAGGA
X
X

X

4
3
1
AGTAGTCTC
TGGCT
GAGTGAGGT
X
X

X

4
3
1
AGCATTGTT
TCTCA
GAGTGAGGT
X
X

X

4
3
1
AGCAAGGTT
AGGCT
GAGTGAGGG
X
X

X

4
3
1
AGCAGTCTT
CCACCA
GAGTGAGGC
X
X

X

4
3
1
AGCATTGTT
TGAGT
GAGTGAGGT
X
X

X

2
0
2
AGCAGCGTC
CGCAGC
AAGTTAGGA
X
X

2
0
2
AGCAGCGTC
ACTACA
GAGGCAGGA
X
X

2
1
1
GGCAGCGTC
TCTCTG
GGGTGAGGA
X
X

2
1
1
AGCAGAGTC
TTGAA
GAGTGAGTA
X
X

2
1
1
AGCAGCATC
TATGC
CAGTGAGGA
X
X

2
1
1
AGCAGAGTC
TGGCA
GAGAGAGGA
X
X

2
1
1
AGCAGTGTC
CCTCA
GAGTGTGGA
X
X

2
1
1
AGCAGCATC
TTGGA
GTGTGAGGA
X
X

2
1
1
AGCTGCGTC
TTCTG
GAGGGAGGA
X
X

2
1
1
AGCAGCTTC
AGAAGA
GAATGAGGA
X
X

2
1
1
AGCAGGGTC
GAGGG
GAGGGAGGA
X
X

2
1
1
AGCAGGGTC
TGGTG
CAGTGAGGA
X
X

2
1
1
AGCAGCATC
CATGT
CAGTGAGGA
X
X

2
1
1
AGCAGAGTC
CCAAG
GGGTGAGGA
X
X

2
1
1
AGCAGCCTC
TGAAC
AAGTGAGGA
X
X

2
1
1
AGCAGCCTC
TAGGT
AAGTGAGGA
X
X

2
1
1
AGCAGCTTC
AGATTT
GAGTTAGGA
X
X

2
1
1
AGCAGCCTC
ACAGG
CAGTGAGGA
X
X

2
1
1
AGCAGCATC
AACAC
CAGTGAGGA
X
X

2
1
1
AGCAGCGTG
TCAGCT
GTGTGAGGA
X
X

2
1
1
AGCAGCATC
TATGC
CAGTGAGGA
X
X

2
1
1
AGCAGCATC
AATAAT
AAGTGAGGA
X
X

2
1
1
AGCAGAGTC
ACCCA
GTGTGAGGA
X
X

2
1
1
GGCAGCGTC
TGGGAG
GAGTTAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCTGCGTC
GTGAG
AAGTGAGGA
X
X

2
1
1
AGCAGGGTC
ACACA
GGGTGAGGA
X
X

2
1
1
AGCAGAGTC
AGAGAG
GAGAGAGGA
X
X

2
1
1
AGCAGAGTC
ACTGAC
CAGTGAGGA
X
X

2
1
1
AGCAGTGTC
TCCCA
GAGTGTGGA
X
X

2
1
1
AGCAGTGTC
TGAGTA
GAGTGTGGA
X
X

2
1
1
AGCAGCATC
CCGGG
GAGTGAAGA
X
X

2
1
1
AACAGCGTC
AAGGCA
GAGTGAAGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCGCC
ATCTT
GAGCGAGGA
X
X

2
1
1
AGCAGCATC
CATGT
CAGTGAGGA
X
X

2
1
1
AGCAGAGTC
AGGGAG
GAGTGAAGA
X
X

2
1
1
AGCAGCCTC
ATGGTC
AAGTGAGGA
X
X

2
1
1
AGCAGCATC
GTGAGT
GAGTGTGGA
X
X

2
1
1
AGCAGTGTC
TAGCAC
GAATGAGGA
X
X

2
1
1
AGCAGAGTC
ACAGAA
GAGAGAGGA
X
X

2
1
1
AGCAGCGTG
GTTAA
GAGTCAGGA
X
X

2
1
1
ACCAGCGTC
TGGTGA
GAGTGGGGA
X
X

2
1
1
AGCAGTGTC
TTGCT
GAGAGAGGA
X
X

2
1
1
AGCAGCGAC
CTGGGC
GAGTGAGAA
X
X

2
1
1
AGCAGTGTC
TGCCGT
GAGTGGGGA
X
X

2
1
1
AGCAGCGTA
ATACA
CAGTGAGGA
X
X

2
1
1
AGCAGCCTC
TAGAGA
AAGTGAGGA
X
X

2
1
1
AGCAGAGTC
ACGGGT
GTGTGAGGA
X
X

2
1
1
TGCAGCGTC
ATCAA
GAGTGTGGA
X
X

2
2
0
AGCAGGGAC
CAGGTG
GAGTGAGGA
X
X

2
2
0
AGCAGGCTC
TAAAAT
GAGTGAGGA
X
X

2
2
0
AGCAGCCTA
GGAAT
GAGTGAGGA
X
X

2
2
0
AGCATCCTC
CAGGAG
GAGTGAGGA
X
X

2
2
0
AGCAGAGTA
CTCAGT
GAGTGAGGA
X
X

2
2
0
AGCAGGGTA
GAAGA
GAGTGAGGA
X
X

2
2
0
AGCAGAGAC
CTGAGG
GAGTGAGGA
X
X

2
2
0
AGCAGAGTG
GGCAA
GAGTGAGGA
X
X

2
2
0
AGCTGCCTC
GGTGGG
GAGTGAGGA
X
X

2
2
0
AGGAGGGTC
CTGGAT
GAGTGAGGA
X
X

2
2
0
AGCAGACTC
CTTGAT
GAGTGAGGA
X
X

2
2
0
AGCAGAGTA
TTTGG
GAGTGAGGA
X
X

2
2
0
AGCAGAGTT
GCCAG
GAGTGAGGA
X
X

2
2
0
AGCAGCACC
AAAATG
GAGTGAGGA
X
X

2
2
0
AGCAGGATC
AGGTTA
GAGTGAGGA
X
X

2
2
0
TGCAGCATC
CTTCAG
GAGTGAGGA
X
X

2
2
0
AGCAGAGTG
TGGTG
GAGTGAGGA
X
X

2
2
0
AGCAGTGCC
TACCA
GAGTGAGGA
X
X

2
2
0
AGCAGAGTA
CCCAT
GAGTGAGGA
X
X

2
2
0
AGCAGAGTG
AAAGGA
GAGTGAGGA
X
X

2
2
0
AGCAGGATC
AAGAAA
GAGTGAGGA
X
X

2
2
0
AGCAGCTTG
TGTCAT
GAGTGAGGA
X
X

2
2
0
AGCAGAGTA
GGTTGT
GAGTGAGGA
X
X

3
0
3
AGCAGCGTC
TGCAGT
TTGTGGGGA
X
X

3
0
3
AGCAGCGTC
AGGGGA
TTGTGGGGA
X
X

3
0
3
AGCAGCGTC
CAAGA
GAGTTACAA
X
X

3
0
3
AGCAGCGTC
AAAGT
TTGAGAGGA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
TTTTT
GAGAGAAGG
X
X

3
0
3
AGCAGCGTC
GGGGA
GAGTTGGGG
X
X

3
0
3
AGCAGCGTC
TCCAG
GAACGTGGA
X
X

3
0
3
AGCAGCGTC
CTTGGG
GAGTTTGGG
X
X

3
0
3
AGCAGCGTC
GTCAC
AGGGGAGGA
X
X

3
0
3
AGCAGCGTC
CAAAA
GGCTGAGGG
X
X

3
0
3
AGCAGCGTC
CGTCG
CAGTGGGGC
X
X

3
0
3
AGCAGCGTC
CGCACT
GAGGGGGCA
X
X

3
0
3
AGCAGCGTC
TCTGC
GGGAGAGGC
X
X

3
0
3
AGCAGCGTC
ATCTT
GAGTGGAGC
X
X

3
0
3
AGCAGCGTC
AGCGA
CAGAGAGGC
X
X

3
0
3
AGCAGCGTC
TGTAT
GTGTCAGAA
X
X

3
0
3
AGCAGCGTC
ATTAGG
GCATGAGCA
X
X

3
0
3
AGCAGCGTC
GATGGA
AAGGGAAGA
X
X

3
0
3
AGCAGCGTC
AGGAA
GAGTTGTGA
X
X

3
0
3
AGCAGCGTC
TACCGT
GAGTGCTCA
X
X

3
0
3
AGCAGCGTC
AGGGT
TTGAGAGGA
X
X

3
0
3
AGCAGCGTC
ATGAGT
GTGTAATGA
X
X

3
0
3
AGCAGCGTC
TCTTTA
GAGTGGGTT
X
X

3
0
3
AGCAGCGTC
CTGTG
GAGGCAGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGCTT
CAGTGTGAA
X
X

3
0
3
AGCAGCGTC
AGGGT
TTGAGAGGA
X
X

3
0
3
AGCAGCGTC
ACACTC
TACTGAGGT
X
X

3
0
3
AGCAGCGTC
ACATGC
CAGCGAGGT
X
X

3
0
3
AGCAGCGTC
CATGGT
GACAGAGGT
X
X

3
0
3
AGCAGCGTC
TTCCCT
GAGAGAGCT
X
X

3
0
3
AGCAGCGTC
CAGGA
GAGGAAGGC
X
X

3
0
3
AGCAGCGTC
ATACA
GGCTGAGGT
X
X

3
0
3
AGCAGCGTC
TGCAT
GAAGGAGGT
X
X

3
0
3
AGCAGCGTC
CCAGT
GAGCGATGG
X
X

3
0
3
AGCAGCGTC
TTGCA
AAGGGAGAA
X
X

3
0
3
AGCAGCGTC
AGGGT
TTGAGAGGA
X
X

3
0
3
AGCAGCGTC
CACGT
GTGTGCGGT
X
X

3
0
3
AGCAGCGTC
AGCCTC
TAGAGGGGA
X
X

3
0
3
AGCAGCGTC
CGCAG
GAGGTAGGG
X
X

3
0
3
AGCAGCGTC
CAAGA
GTGTTACGA
X
X

3
0
3
AGCAGCGTC
CTAGC
CTGTGAGGG
X
X

3
0
3
AGCAGCGTC
CTCCTG
GAGGGAGAG
X
X

3
0
3
AGCAGCGTC
AGGGAG
GAGGGGAGA
X
X

3
0
3
AGCAGCGTC
CCCCCG
CAGTGATGG
X
X

3
0
3
AGCAGCGTC
TCCTGA
GAGAGAAGG
X
X

3
0
3
AGCAGCGTC
TGTCCT
GAGTCCAGA
X
X

3
0
3
AGCAGCGTC
AAGGAT
TAGAGAGTA
X
X

3
0
3
AGCAGCGTC
TCCTGA
GAGAGAAGG
X
X

3
1
2
AGTAGCGTC
CTAAT
GAGTGTGAA
X
X

3
1
2
AGCAGCTTC
TCCATG
GAGTGAGAC
X
X

3
1
2
AGCAGGGTC
GGGGA
GAGGGAGGG
X
X

3
1
2
AGCAGCATC
CAGACT
CAGTGAGGT
X
X

3
1
2
AGCAGGGTC
AGCTAA
GAGGGAGGC
X
X

3
1
2
AGCAGCGGC
AGCGA
GAGTGATGT
X
X

3
1
2
GGCAGCGTC
TGACG
GAGTGAGTG
X
X

3
1
2
AGCAGTGTC
AGGTAG
GAGAGAGGC
X
X

3
1
2
AGCAGGGTC
TGAGTG
GAGTAAGGT
X
X

3
1
2
AGCAGTGTC
AGCTGG
TAGTGAGAA
X
X

3
1
2
AGCACCGTC
TGGGG
GAGGGAAGA
X
X

3
1
2
AGCAGCATC
AGCATG
GAGGGAGGC
X
X

3
1
2
AGCAGCCTC
GGTCAA
GAGTGAGAG
X
X

3
1
2
GGCAGCGTC
AATAA
AAGTGAGGG
X
X

3
1
2
AGCAACGTC
GGCAG
CAGTGGGGA
X
X

3
1
2
AGCAACGTC
AGCAAA
GTCTGAGGA
X
X

3
1
2
AGCAGGGTC
AGTGTC
TAGTGAGAA
X
X

3
1
2
AGCAGGGTC
AGGATG
GAGTGGGGT
X
X

3
1
2
AGCAGTGTC
AGTGAA
CAGTGAGGT
X
X

3
1
2
AGCAGGGTC
AGTGCC
TAGTGAGGG
X
X

3
1
2
AGCAGCGTA
CGGACT
GAGTGAGCC
X
X

3
1
2
AGCAGCTTC
CCCAGT
AAGTGAGAA
X
X

3
1
2
AGCAGCGGC
ACCTC
GAGAGAGAA
X
X

3
1
2
AGCAGTGTC
CTCAC
CAGTAAGGA
X
X

3
1
2
AGCAGGGTC
TGTTA
GAGTGAGTG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCACCGTC
ATCTAA
GGGTGAGGC
X
X

3
1
2
AGCATCGTC
CTGTG
GAGCGAGGG
X
X

3
1
2
AGCAGGGTC
CTTACT
CAGTGAGGT
X
X

3
1
2
AGCAGAGTC
TGAGA
GTGTGAGGT
X
X

3
1
2
AGCAGCGTG
CAGTGA
CAGTGAGGC
X
X

3
1
2
AGCACCGTC
ATTGGA
GAGGGAGAA
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGAGTC
GCTGCA
GAGTGAGCC
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGAGTC
CTTGG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCGTA
TGCATA
CAGTGAGGG
X
X

3
1
2
AGCAGTGTC
AGGCTG
GTGTGAGAA
X
X

3
1
2
AGCAGAGTC
GGCGTC
TAGTGAGGG
X
X

3
1
2
AGCAGCGTG
GGCCGG
GAGGGAGGT
X
X

3
1
2
GGCAGCGTC
CGATT
CAGTGAGGG
X
X

3
1
2
AGCAGCTTC
ACTGAA
GAGGGAGGC
X
X

3
1
2
ATCAGCGTC
TCTGG
GAGTGGGGC
X
X

3
1
2
AGCAGCGGC
AGGCGA
GAGTGACAA
X
X

3
1
2
AGCAGCTTC
AACGT
GAGTGATGT
X
X

3
1
2
AGCAGCTTC
CTGGG
GAGTGAGTT
X
X

3
1
2
AGCAGCATC
TCGTG
GAGGGAGGC
X
X

3
1
2
AGCAGAGTC
TTCAG
GAGAGAGGC
X
X

3
1
2
AGCAGGGTC
AAGTTC
CAGTGAGGG
X
X

3
1
2
AGCAGAGTC
AGTCTT
GAGTGAGTT
X
X

3
1
2
AGCAGAGTC
AGACTT
GAGTGAGTT
X
X

3
1
2
TGCAGCGTC
CAGAT
GAGGGAGGT
X
X

3
1
2
AGCATCGTC
AGAAT
GGGTGAGGG
X
X

3
1
2
AGCAGTGTC
CAGCTC
CAGTGAGGC
X
X

3
1
2
AGCAGCTTC
TAAAAG
GAGAGAGGT
X
X

3
1
2
AGCAGGGTC
CATGAG
GAGTGAGCC
X
X

3
1
2
AGCAGTGTC
ACCACA
GAGTGAAGG
X
X

3
1
2
AGCAGGGTC
AGGTTT
TAGTGAGGG
X
X

3
1
2
AGCAGCATC
AATGTC
TAGTGAGGG
X
X

3
1
2
AGCAGTGTC
CCGCAC
GAGGAAGGA
X
X

3
1
2
AGCAGCTTC
TTGTGA
GAGAGAGGT
X
X

3
1
2
AGCAGAGTC
CTAAGC
GGGTGAGGG
X
X

3
1
2
AGCAGTGTC
AAGTA
GAGTGAAGG
X
X

3
1
2
AGCATCGTC
AAGTTC
TGGTGAGGA
X
X

3
1
2
AGCAGGGTC
CCTGCT
GAGAGAGGG
X
X

3
1
2
AGCAGAGTC
AAGTCA
GAGAGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGAGTC
CAGTGG
GTGTGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
AGCCGA
GAGAGAGGG
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
AGCAGCGGC
AGCCGA
GAGAGAGGG
X
X

3
1
2
AGCAGCGGC
TGATG
GACTGAGGC
X
X

3
1
2
TGCAGCGTC
TTGTT
TAGTGAGGC
X
X

3
1
2
AGCAGTGTC
AGGCTG
GTGTGAGAA
X
X

3
1
2
AGCAGCGTA
GAGTGG
GAATGAGGG
X
X

3
1
2
AGCATCGTC
ACAGGA
GGGTGAGGT
X
X

3
1
2
AGCAGCGGC
ACCCA
GAATGAGGG
X
X

3
1
2
AGCAGCGTT
ATTTCA
GAGTGTGGT
X
X

3
1
2
AGCAGAGTC
GCTCCA
GAGTGAGCC
X
X

3
1
2
AGCAGTGTC
ATCTTT
GAGTGGGAA
X
X

3
1
2
AGCAGCATC
TCCTAG
CAGTGAGGG
X
X

3
1
2
AGCAACGTC
AGTGG
GACTGAGGG
X
X

3
1
2
AGCACCGTC
ATCTT
GAGTGAGCT
X
X

3
1
2
AGCAGGGTC
CTGAG
GGGAGAGGA
X
X

3
1
2
GGCAGCGTC
AGGAGA
GAGTGATGT
X
X

3
1
2
AGCATCGTC
GGGGAG
GAGTGGGAA
X
X

3
1
2
AGCAGTGTC
TGTGCT
CAGTGAGGT
X
X

3
1
2
AGCAGTGTC
AGTCCT
GAGAGAGCA
X
X

3
1
2
AGCAGCGTT
GCTTTC
TAGTGAGGT
X
X

3
1
2
AGCAGCGGC
GACAGG
GAGAGAGGG
X
X

3
1
2
AGCACCGTC
CTGAAA
CAGTGAGTA
X
X

3
1
2
AGCAGTGTC
TGCTGG
GAGGGTGGA
X
X

3
1
2
AGCAGCGCC
CTGTGG
GAGGGAGGT
X
X

3
1
2
AGCAGAGTC
AGAAA
GAGTAAGGC
X
X

3
1
2
AGCAGCTTC
TCTAAG
GAGTGGGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ATCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGCTTC
CTGCTC
CAGTGAGGG
X
X

3
1
2
AGCAGCTTC
ACCTG
GAGGGAGGG
X
X

3
1
2
AGCAGAGTC
AAGAGG
GTGTGAGGG
X
X

3
1
2
AGCAGGGTC
CTGAAG
GAGGGAGGG
X
X

3
1
2
AGCAGGGTC
AGCCCA
GAGGGAGGC
X
X

3
1
2
GGCAGCGTC
ATTTT
GAGTGGGGG
X
X

3
1
2
AGCAGCGTG
TGGCA
GAGAGAGGG
X
X

3
1
2
AGCACCGTC
CCCGAG
GTGGGAGGA
X
X

3
1
2
AGCAGCTTC
CCATC
GGGTGAGGG
X
X

3
1
2
AGCAGCATC
TGTGGA
CAGTGAGGT
X
X

3
1
2
AGCAGCGTG
CTGGAT
GAGTGTGGT
X
X

3
1
2
AGCAGCGGC
AGGCAC
CAGTGAGGG
X
X

3
1
2
AGCAGGGTC
AGGGGT
GAGTGGGGT
X
X

3
1
2
AGCAGCGGC
GAACA
GAGCGGGGA
X
X

3
1
2
AGCTGCGTC
TCTGGG
AAGTGAGGG
X
X

3
1
2
AGCAGGGTC
ATGACA
GAGAGAGGG
X
X

3
1
2
AGCAGCATC
TGGCA
GAGTAAGGG
X
X

3
1
2
AGCAGTGTC
CACCT
GAGTTAGGT
X
X

3
1
2
AGCAGCGAC
GGCGG
GTGTGAGGC
X
X

3
1
2
AGCAGGGTC
ACACTA
AAGTGAGGC
X
X

3
2
1
AGCTGTGTC
ATGAC
AAGTGAGGA
X
X

3
2
1
AGCTGGGTC
ATGTG
AAGTGAGGA
X
X

3
2
1
AGCTGGGTC
ATGTG
AAGTGAGGA
X
X

3
2
1
GGCAGCGGC
CGGAAA
AAGTGAGGA
X
X

3
2
1
AGCATGGTC
AATGA
CAGTGAGGA
X
X

3
2
1
ATCAGCCTC
TTGTAG
GAGTGAGGG
X
X

3
2
1
AGCATGGTC
ATGAA
CAGTGAGGA
X
X

3
2
1
AGCAGGGGC
ATGAGA
GAGTGAGGT
X
X

3
2
1
AACAGCGTG
GCGGA
GAGTGAGGG
X
X

3
2
1
AACAGAGTC
CAGGAA
GAGTGAGGT
X
X

3
2
1
AACAGCATC
AGCTCT
GAGTGAGGC
X
X

3
2
1
ATCAGTGTC
AGTGAG
CAGTGAGGA
X
X

3
2
1
AGCAGCTGC
ATGAT
GAGTGAGGT
X
X

3
2
1
AGCAGGGTT
GATCA
GAGGGAGGA
X
X

3
2
1
AGCATAGTC
CAGAT
TAGTGAGGA
X
X

3
2
1
AGCAGCAAC
CTTAA
GAGTGAGGG
X
X

3
2
1
AGCTACGTC
TAAGG
GAGAGAGGA
X
X

3
2
1
AGCAGCATT
GGTCCT
GAGTGAGGT
X
X

3
2
1
AGCATTGTC
ATGAA
GAGGGAGGA
X
X

3
2
1
AGCAGCACC
TGGCCT
GAGTGAGGG
X
X

3
2
1
AGCAGGGTT
GGGCA
GAGGGAGGA
X
X

3
2
1
AGTAGAGTC
TGACTA
AAGTGAGGA
X
X

3
2
1
AGCAACGTG
AGTGT
GAGCGAGGA
X
X

3
2
1
AGCAAGGTC
CCACT
CAGTGAGGA
X
X

3
2
1
AGCAGCCAC
AAGGT
GAGTGAGGG
X
X

3
2
1
AGCAATGTC
AGGGA
AAGTGAGGA
X
X

3
2
1
AGCAGCTAC
TCCAGA
GAGTGAGGT
X
X

3
2
1
AGCAGCTGC
AGCAG
GGGTGAGGA
X
X

3
2
1
AGCAGGGGC
AGCAT
GAGTGAGGT
X
X

3
2
1
AGCAACGTG
ACCTAC
TAGTGAGGA
X
X

3
2
1
AACAGCGTA
AGTAC
AAGTGAGGA
X
X

3
2
1
TGCACCGTC
AGTAA
CAGTGAGGA
X
X

3
2
1
AGCAGTGTG
TCCCAA
GAGTGAGGG
X
X

3
2
1
AGCAGCTGC
AATTAT
GAGAGAGGA
X
X

3
2
1
AGCACCTTC
TAGCTA
GAGTGAGCA
X
X

3
2
1
AGCAAGGTC
AGAAG
GAGTAAGGA
X
X

3
2
1
AGCTGCGTG
GGAGCA
GAGTGAGGC
X
X

3
2
1
AGCAAGGTC
CTAGT
GAGTGAAGA
X
X

3
2
1
AGCAGATTC
AGAAG
GAGTGAGGG
X
X

3
2
1
AGCAAAGTC
ATTAGA
GAGTAAGGA
X
X

3
2
1
TGCAGGGTC
TTCCC
GAGTGAGGG
X
X

3
2
1
AGCAGAATC
TTCTGG
GAGTGAGGT
X
X

3
2
1
AGCTGAGTC
CCTAGA
GAGGGAGGA
X
X

3
2
1
AGCATTGTC
CAGAAA
CAGTGAGGA
X
X

3
2
1
TGCAGGGTC
CCAGC
GAGTGAGGG
X
X

3
2
1
AGCAACTTC
ATGTAT
GAGTGTGGA
X
X

3
2
1
AGCAGCTGC
CTGCTG
GAGTGAGGG
X
X

3
2
1
AGCAGGGTT
GGGGA
GAGGGAGGA
X
X

3
2
1
AGCAAGGTC
ACTGA
GAGTAAGGA
X
X

3
2
1
AGCTGTGTC
AAAGG
AAGTGAGGA
X
X

3
2
1
AACAGCATC
TTAGGG
GAGTGAGGG
X
X

3
2
1
AGAAGCTTC
TAGGCT
GAGTGAGGC
X
X

3
2
1
AGCAGAGTT
TGGGGT
GAGTGAGAA
X
X

3
2
1
AGCAGAGTT
TGCTTT
GAGTGAGTA
X
X

3
2
1
AGGAGGGTC
TGAAGA
GAGTGAGGG
X
X

3
2
1
AGCAACTTC
AGCAAA
GTGTGAGGA
X
X

3
2
1
AGCAGCTCC
CTGGA
GAGTGAGGG
X
X

3
2
1
AGCAAAGTC
TGGGAG
AAGTGAGGA
X
X

3
2
1
AGCAACGTG
ACCCCT
GAGTGGGGA
X
X

3
2
1
AGCAGGGTG
TATAA
GAGTGAGGG
X
X

3
2
1
AGCAGGTTC
TTGGGA
GAGTGAGGT
X
X

3
2
1
AGCAGCTTG
TTTCT
GAGTGAGGG
X
X

3
2
1
AGCAGTGTT
GCATTA
AAGTGAGGA
X
X

3
2
1
AGAGGCGTC
TGAGCA
GAGTGAGGG
X
X

3
2
1
AGCAGTGAC
TTAGGA
AAGTGAGGA
X
X

3
2
1
AGCACCTTC
CGAGT
GAGTGAGCA
X
X

3
2
1
ATCAGTGTC
TCCTC
CAGTGAGGA
X
X

3
2
1
AGCAGCAGC
AGGAA
GAGTGAGGC
X
X

3
2
1
AGCAGTGAC
ACCTG
AAGTGAGGA
X
X

3
2
1
AGCAGGGTT
CACAGG
GAGGGAGGA
X
X

3
2
1
AGCTGCGGC
AGGCCC
GAGTGAGGC
X
X

3
2
1
AGCAACATC
TGCTA
CAGTGAGGA
X
X

3
2
1
AGCAACGTA
TAATC
TAGTGAGGA
X
X

3
2
1
AGCAGGATC
GCCTGT
GAGTGAGGG
X
X

3
2
1
AGCAGCAAC
ATGGGA
GAGTGAGGT
X
X

3
2
1
AGTAGCGGC
TTCACA
GAGTGAGAA
X
X

3
2
1
AGCAGCCCC
ATCCT
GAGTGAGGG
X
X

3
2
1
AGCAGCTGC
CAGAA
GAGAGAGGA
X
X

3
2
1
AGCACCGTT
GTTAG
AAGTGAGGA
X
X

3
2
1
AGCAGGGTG
GTTAA
GAGTGAGGG
X
X

3
2
1
AGCTGGGTC
TTGGGA
AAGTGAGGA
X
X

3
2
1
ACCACCGTC
GCGGA
AAGTGAGGA
X
X

3
2
1
AGAAGCTTC
AGTTG
GAGTGAGGT
X
X

3
2
1
AGCAGAGGC
ACCTTT
GAGTGAGGT
X
X

3
2
1
AGCATCGTT
GAGCT
CAGTGAGGA
X
X

3
2
1
AGAAGCGTG
TGCTG
GAGTGAGGC
X
X

3
2
1
GACAGCGTC
TGGGAG
GTGTGAGGA
X
X

3
2
1
AGCAGAGAC
CTGCAT
GAGTGAGGG
X
X

3
2
1
AGCAAAGTC
CTAAGG
AAGTGAGGA
X
X

3
2
1
AGCATTGTC
TCTAGA
GAATGAGGA
X
X

3
2
1
AGCAAAGTC
TTGAGA
GAGCGAGGA
X
X

3
2
1
AGCACAGTC
CCCGTT
GAGAGAGGA
X
X

3
2
1
AGCAGCAGC
ACTGA
GAGTGAGGC
X
X

3
2
1
AGCAGGGTG
GGGTGT
GAGTGAGGT
X
X

3
2
1
AGGAGCATC
GCGCAG
GAGTGAGGC
X
X

3
2
1
AGCTGGGTC
ATGTG
AAGTGAGGA
X
X

3
2
1
AGCTGTGTC
ATGAC
AAGTGAGGA
X
X

3
2
1
AGCTGTGTC
ATGAC
AAGTGAGGA
X
X

3
2
1
AGGAGCGTA
TCTTCT
GAGTGAGGC
X
X

3
2
1
AGCAGCCAC
AGCCA
GAGTGAGGG
X
X

3
2
1
AGCAGCATG
TGCAGG
GAGTGAGGC
X
X

3
2
1
AGCATTGTC
TTTTGA
GAGTGAGAA
X
X

3
2
1
AGCAGCCTG
GACGT
GAGTGAGGT
X
X

3
2
1
AGCAGCTCC
AGCGA
GAGTGAGGG
X
X

3
2
1
AGCAGCAGC
TAGGGA
GAGTGAGGC
X
X

3
2
1
AGCAACTTC
AATCAG
GAGTGTGGA
X
X

3
2
1
AGCAGAGTA
GCTTT
GAGTGAGGG
X
X

3
2
1
AGCAGCCTT
GTGTG
GAGTGAGGT
X
X

3
2
1
AGCAGTGTT
TCTGA
AAGTGAGGA
X
X

3
2
1
AGAAGCATC
TGTAT
GAGTGAGGC
X
X

3
2
1
AGCAGGGTA
AACAAA
GAGTGAGGT
X
X

3
2
1
AGCAGAGTT
AGGAGA
GAGTGAGGG
X
X

3
2
1
AGCAGAGGC
TGGGGA
GAGTGAGGG
X
X

3
2
1
AGCAACATC
TTATA
GAGTGAGCA
X
X

3
2
1
AGCAGAGTA
TGTCA
GAGTGAGGT
X
X

3
2
1
AGCATCGTT
GAGCT
GAGTGAAGA
X
X

3
2
1
AGAAGCTTC
CAGAAT
GAGTGAGGC
X
X

3
2
1
ATCAGCGGC
AGATGG
CAGTGAGGA
X
X

3
2
1
AGCAGAATC
TCTGG
GAGTGAGGC
X
X

3
2
1
AGCTACGTC
ACCTT
GAGGGAGGA
X
X

3
2
1
AGCAATGTC
AACAA
GAGTGAGAA
X
X

3
2
1
AGCATTGTC
ATGGTG
GAGGGAGGA
X
X

3
2
1
AGCACCGCC
GGGAA
AAGTGAGGA
X
X

3
2
1
AGCACGGTC
GGGTAC
TAGTGAGGA
X
X

3
2
1
AGCAACATC
TATAT
GAGTGAGCA
X
X

3
2
1
AGCAGGGTT
GGAGT
GAGGGAGGA
X
X

3
2
1
AGCAGCTGC
AGCACC
GAGTGAGGG
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AACAGAGTC
TGGTT
GAGTGAGGC
X
X

3
2
1
GGCAGTGTC
TGGCA
AAGTGAGGA
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAAGGTC
CAGACA
AAGTGAGGA
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAGTGTG
TGGGAG
GAGTGAGGG
X
X

3
2
1
AGCAGCATG
AGAGG
GAGTGAGGG
X
X

3
2
1
AGCACTGTC
ATTAT
AAGTGAGGA
X
X

3
2
1
GGCAGTGTC
TGGAAA
AAGTGAGGA
X
X

3
2
1
CACAGCGTC
ACCCTG
GAGTGAGAA
X
X

3
2
1
AGCACCTTC
CTGGCT
GAGTGAGGG
X
X

3
2
1
AGCACAGTC
CCAAAT
GAGTGAGAA
X
X

3
2
1
AGCAGATTC
TGGTA
GAGTGAGGG
X
X

3
2
1
AGGAGGGTC
AGCCT
GAGTGAGGG
X
X

3
2
1
AGCAACGTG
GCGGG
AAGTGAGGA
X
X

3
2
1
AGCGGCGTT
GAGCTT
GAGTGAGGC
X
X

3
2
1
AGGAGTGTC
TGGGT
GAGTGAGGT
X
X

3
2
1
AGCTGCTTC
ACTGAT
GAGTGAGGC
X
X

3
2
1
AGCAACATC
CACTG
CAGTGAGGA
X
X

3
2
1
AGCATAGTC
GGACAA
TAGTGAGGA
X
X

3
2
1
AGCAACATC
AAACCT
GAGAGAGGA
X
X

3
2
1
GGCAGCGCC
CATCT
GAGTGAGGG
X
X

3
2
1
AGCAGAGTG
TCCAA
GAGTGAGGG
X
X

3
2
1
AGCAAAGTC
CTAGAT
GAGGGAGGA
X
X

3
2
1
GACAGCGTC
ACACA
CAGTGAGGA
X
X

3
2
1
AGCGGCGGC
TGGAT
GAGTGAGGG
X
X

3
2
1
AGCCGCATC
ATCAA
GAGTGAGGC
X
X

3
2
1
AGCAAAGTC
CCCAG
GAGGGAGGA
X
X

3
2
1
AGCAGGTTC
TAAGA
GAGTGAGGT
X
X

3
2
1
AGCTGGGTC
ACACG
AAGTGAGGA
X
X

3
2
1
AGCAGAGAC
TGAATG
GAGTGAGGG
X
X

3
2
1
AGCAGAGGC
TTAAAG
GAGTGAGGG
X
X

3
2
1
AGCTGAGTC
TAGCCA
AAGTGAGGA
X
X

3
2
1
AGTAGAGTC
TTCCA
GAGTGAGAA
X
X

3
2
1
TGCAGCGAC
AACAG
GAGTGAGGT
X
X

3
2
1
AGCAGCTGC
CTCCG
GAGAGAGGA
X
X

3
2
1
AGCAGCATG
GCCCT
GAGTGAGGG
X
X

3
2
1
AGCTGAGTC
CCAAA
GAGTGAGAA
X
X

3
2
1
AGCAACATC
TGCTA
CAGTGAGGA
X
X

3
2
1
AGCAACATC
TGCTA
CAGTGAGGA
X
X

3
2
1
ACCAGCTTC
CTGCT
GAGTGAGGT
X
X

3
2
1
AGCAGCATT
ATTCT
GAGTGAGGG
X
X

3
2
1
AGGAGTGTC
GACAAG
GAGTGAGGG
X
X

3
2
1
AGAAGCGGC
TGCAG
GAGTGAGGG
X
X

3
2
1
AGCAGCCAC
AGACTA
GAGTGAGGC
X
X

3
2
1
AGCAGCAGC
AGCAG
GAGTGAGGC
X
X

3
2
1
AGCACAGTC
CGCAGG
GAGGGAGGA
X
X

3
2
1
AGCTGCGGC
GAATGA
GAGTGAGGG
X
X

3
2
1
AGCAAGGTC
TTATA
GGGTGAGGA
X
X

3
2
1
AGCACCTTC
TCCAT
GAGTGGGGA
X
X

3
2
1
AGCAGCATG
ATCCTG
GAGTGAGGC
X
X

3
2
1
AGCAAGGTC
AAGAGA
GAGTGAGCA
X
X

3
2
1
AGCATGGTC
AAAGCT
GAGTGAGAA
X
X

3
2
1
AGCAGCATG
ATCTTG
GAGTGAGGC
X
X

3
2
1
AGCAGGGTG
GGGTGT
GAGTGAGGT
X
X

3
3
0
AGAGGTGTC
GCCAT
GAGTGAGGA
X
X

3
3
0
GTCAGGGTC
ATCAG
GAGTGAGGA
X
X

3
3
0
TGCACTGTC
TCTCCC
GAGTGAGGA
X
X

3
3
0
TGCGGAGTC
GAGGGT
GAGTGAGGA
X
X

3
3
0
AGAAACGTT
CTTGCT
GAGTGAGGA
X
X

3
3
0
AGGAGCAAC
ATGCT
GAGTGAGGA
X
X

3
3
0
CGCTGTGTC
CCCGGG
GAGTGAGGA
X
X

3
3
0
AGCGTGGTC
ACTAGG
GAGTGAGGA
X
X

3
3
0
AGCAGGTCC
TTGAA
GAGTGAGGA
X
X

3
3
0
GGCTGTGTC
ATTCAG
GAGTGAGGA
X
X

3
3
0
TGCAGAGTT
AGAGGT
GAGTGAGGA
X
X

3
3
0
ATCATGGTC
AGAAAA
GAGTGAGGA
X
X

3
3
0
AGCAACGCG
GTGAGG
GAGTGAGGA
X
X

3
3
0
TGAAGTGTC
AGCTC
GAGTGAGGA
X
X

3
3
0
AGCAACTCC
GTCTT
GAGTGAGGA
X
X

3
3
0
AGAAATGTC
TTCCAG
GAGTGAGGA
X
X

3
3
0
GGCAGGGTA
TCACAG
GAGTGAGGA
X
X

3
3
0
AGCAACATG
GAGTT
GAGTGAGGA
X
X

3
3
0
GACAGCGTG
GCCAGT
GAGTGAGGA
X
X

3
3
0
GGCTGAGTC
ACTCT
GAGTGAGGA
X
X

3
3
0
TGCAGAGTT
TTGTG
GAGTGAGGA
X
X

3
3
0
AGCTGAGTG
CTGGAT
GAGTGAGGA
X
X

3
3
0
AACTGAGTC
TCTGA
GAGTGAGGA
X
X

3
3
0
AACATAGTC
TGTACA
GAGTGAGGA
X
X

3
3
0
AGCTGGGTG
ACAGT
GAGTGAGGA
X
X

3
3
0
AGCACCATA
TGGCT
GAGTGAGGA
X
X

3
3
0
ATCAGGTTC
CTTCT
GAGTGAGGA
X
X

3
3
0
ACCACGGTC
AGGTCT
GAGTGAGGA
X
X

3
3
0
ACCACGGTC
AGGTCT
GAGTGAGGA
X
X

3
3
0
ACCACGGTC
AGGTCT
GAGTGAGGA
X
X

3
3
0
ACCACGGTC
AGGTCT
GAGTGAGGA
X
X

3
3
0
ACCATGGTC
AAGTCT
GAGTGAGGA
X
X

3
3
0
AGAAACTTC
CTCTC
GAGTGAGGA
X
X

3
3
0
CACAGCTTC
TCACAG
GAGTGAGGA
X
X

3
3
0
ATCATGGTC
TTAGA
GAGTGAGGA
X
X

3
3
0
AGCAGTGAT
TGAGG
GAGTGAGGA
X
X

3
3
0
ACCAAGGTC
ACACT
GAGTGAGGA
X
X

3
3
0
AGCCCCTTC
CTAGAG
GAGTGAGGA
X
X

3
3
0
CTCAGTGTC
TAAGCA
GAGTGAGGA
X
X

3
3
0
AGTTGCTTC
CTGAG
GAGTGAGGA
X
X

3
3
0
AAGAGAGTC
TGAAA
GAGTGAGGA
X
X

3
3
0
GGCAGTGTG
GTCACC
GAGTGAGGA
X
X

3
3
0
TGCAGAGTT
GGGTCA
GAGTGAGGA
X
X

3
3
0
AGCCTCGTT
GCCAGA
GAGTGAGGA
X
X

3
3
0
ATCATCTTC
AAGTAA
GAGTGAGGA
X
X

3
3
0
AGTAGTGTG
TGAAGG
GAGTGAGGA
X
X

3
3
0
AGCCTCGTG
TCCTCA
GAGTGAGGA
X
X

3
3
0
AAAAGCGTT
TGGGAA
GAGTGAGGA
X
X

3
3
0
ACTAGAGTC
CCCCAA
GAGTGAGGA
X
X

3
3
0
GGCGGCGGC
GAAGG
GAGTGAGGA
X
X

3
3
0
ATGAGAGTC
CTGGG
GAGTGAGGA
X
X

3
3
0
AGCACAGTG
GCCTGA
GAGTGAGGA
X
X

3
3
0
TACAGGGTC
CTCGGT
GAGTGAGGA
X
X

3
3
0
AGCAGAGGT
GCTGA
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
CAGGG
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
CAGGG
GAGTGAGGA
X
X

3
3
0
AGTGGGGTC
TGTTGG
GAGTGAGGA
X
X

3
3
0
ATGAGGGTC
ACTGAG
GAGTGAGGA
X
X

3
3
0
GTCAGAGTC
CTAGG
GAGTGAGGA
X
X

3
3
0
GCCAGGGTC
TGGGAG
GAGTGAGGA
X
X

3
3
0
AGCAACTCC
ATCTT
GAGTGAGGA
X
X

3
3
0
AGGGGAGTC
GACAG
GAGTGAGGA
X
X

3
3
0
GTCAGGGTC
ATCAG
GAGTGAGGA
X
X

3
3
0
GTCAGGGTC
ATCAG
GAGTGAGGA
X
X

3
3
0
AGCATAGTA
GTTAA
GAGTGAGGA
X
X

3
3
0
GTCAGAGTC
CAAAA
GAGTGAGGA
X
X

3
3
0
GGCAGTGTT
ACAAA
GAGTGAGGA
X
X

3
3
0
GCCATCGTC
ACCCA
GAGTGAGGA
X
X

3
3
0
CTCAGTGTC
GAGAGA
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
AAGGGA
GAGTGAGGA
X
X

3
3
0
AGCAACTCC
AGAAGA
GAGTGAGGA
X
X

3
3
0
AGCCTCGGC
GGCCCT
GAGTGAGGA
X
X

3
3
0
GACAGGGTC
ACTTTA
GAGTGAGGA
X
X

3
3
0
AGAATAGTC
CTGGG
GAGTGAGGA
X
X

3
3
0
AGTAGAGTA
GTAAAG
GAGTGAGGA
X
X

3
3
0
GGGAGGGTC
GGTCAG
GAGTGAGGA
X
X

3
3
0
AACAGGGTT
ATCCA
GAGTGAGGA
X
X

3
3
0
GCCAGGGTC
ACCCA
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
TTACCT
GAGTGAGGA
X
X

3
3
0
AGTGGAGTC
ACCGTA
GAGTGAGGA
X
X

3
3
0
GCCAGAGTC
ACCCTT
GAGTGAGGA
X
X

3
3
0
GGCAGTGTA
ACTTAA
GAGTGAGGA
X
X

3
3
0
CTCAGTGTC
GTTGT
GAGTGAGGA
X
X

3
3
0
AGATGGGTC
TACAGA
GAGTGAGGA
X
X

3
3
0
GCCAGAGTC
TGAGTG
GAGTGAGGA
X
X

3
3
0
AGTAGGGTT
TGAAT
GAGTGAGGA
X
X

3
3
0
CACTGCGTC
CTTGGT
GAGTGAGGA
X
X

3
3
0
AACTGGGTC
CCTGAG
GAGTGAGGA
X
X

3
3
0
AGTAACATC
AGTAGT
GAGTGAGGA
X
X

3
3
0
GACAGAGTC
CACAGA
GAGTGAGGA
X
X

3
3
0
ATCAGGTTC
CAATA
GAGTGAGGA
X
X

3
3
0
AGCATGGTA
GTGGG
GAGTGAGGA
X
X

3
3
0
AGCAACTGC
CCTTCT
GAGTGAGGA
X
X

3
3
0
GGCTGAGTC
TTGCAG
GAGTGAGGA
X
X

3
3
0
AGCAGCCCA
GGGGGT
GAGTGAGGA
X
X

3
3
0
AGCAAAGTG
TCAAT
GAGTGAGGA
X
X

3
3
0
AGAAAAGTC
CACAGG
GAGTGAGGA
X
X

3
3
0
AACAACTTC
TCCTG
GAGTGAGGA
X
X

3
3
0
TGCGGAGTC
CCTGGG
GAGTGAGGA
X
X

3
3
0
AGAATGGTC
TCTGAT
GAGTGAGGA
X
X

3
3
0
AGCAGCAGA
ACAACT
GAGTGAGGA
X
X

3
3
0
AGCAGCAGA
TATTG
GAGTGAGGA
X
X

3
3
0
AGTTGCTTC
TTCTAA
GAGTGAGGA
X
X

3
3
0
GACAGGGTC
CTGGA
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
CGGGG
GAGTGAGGA
X
X

3
3
0
GGAAGAGTC
CAAAG
GAGTGAGGA
X
X

3
3
0
AGGGGGGTC
AAGAGT
GAGTGAGGA
X
X

3
3
0
AACAACTTC
CATGT
GAGTGAGGA
X
X

3
3
0
ACCAAGGTC
AGCAGG
GAGTGAGGA
X
X

3
3
0
GGCCACGTC
GCACAG
GAGTGAGGA
X
X

3
3
0
AGCAAGGTT
AGGAAG
GAGTGAGGA
X
X

3
3
0
AGTAGGGTT
GGAGGG
GAGTGAGGA
X
X

4
0
4
AGCAGCGTC
ACAAAA
TAGCAAGGT
X
X

4
0
4
AGCAGCGTC
AAGGG
GAGACAAGT
X
X

4
0
4
AGCAGCGTC
CGTCCC
GAGAGGCGC
X
X

4
1
3
AGCAGCGGC
CTAGC
GGGTGAGTC
X
X

4
1
3
AGCAGCGTT
GCTAT
GAGAAAGGT
X
X

4
1
3
AGCAACGTC
ATGTGC
TGGGGAGGA
X
X

4
1
3
AGCAGCGGC
CGGAG
AAGTGTGGG
X
X

4
1
3
AGCAACGTC
TGTTT
GTGTAAGGC
X
X

4
1
3
AGCAACGTC
ACCTG
GAGTCACGC
X
X

4
1
3
AGCAGTGTC
ATGATG
GTGTGTGAA
X
X

4
1
3
AGCAGCGGC
CACATA
GTGTGTGAA
X
X

4
1
3
AGCAACGTC
CAGTCC
AAGTGTGGC
X
X

4
1
3
AGCAACGTC
GGATGC
AGGTGAGCA
X
X

4
1
3
ATCAGCGTC
CAGATG
GTGTGAGTC
X
X

4
1
3
AGCAACGTC
CTTAC
TAGTGAATA
X
X

4
1
3
AGCAACGTC
GTGAC
GTGCGATGA
X
X

4
1
3
AGCAGTGTC
TGTCTG
GAGTGTTGC
X
X

4
1
3
AGCAGCGTT
GTTTTG
ATGTGAGGC
X
X

4
1
3
AGCAACGTC
TGTGT
GAGTGACAG
X
X

4
1
3
AGCACCGTC
TGCCG
GTGTGCGGT
X
X

4
1
3
AGCAACGTC
CAGTCC
AAGTGTGGC
X
X

4
2
2
AGCATTGTC
TTGTGG
GAGTAAGGC
X
X

4
2
2
AGCAGCGAT
GGGGTT
GAGTGAGAC
X
X

4
2
2
AGCTGTGTC
ATCCAT
GAGTGAGTC
X
X

4
2
2
AGCATGGTC
AAGTTC
TAGTGAGGG
X
X

4
2
2
AGCATGGTC
AAGTTC
TAGTGAGGG
X
X

4
2
2
AGCATCTTC
ATATG
GAGTGAGAG
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCATAGTC
AAGGG
GAGTGAGAG
X
X

4
2
2
AGCATGGTC
TCTTTC
TAGTGAGGG
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCATAGTC
TTTATT
GAGTGAGAG
X
X

4
2
2
AGCAAAGTC
CTGAAG
GAGTGAGAG
X
X

4
2
2
AGCAGCGCA
AAGCAC
GTGTGAGGC
X
X

4
2
2
ATCAACGTC
TGGAC
TAGTGAGGG
X
X

4
2
2
AGTAGTGTC
CACAG
AAGTGAGGG
X
X

4
2
2
AGCAAAGTC
CCTTG
GAGTGAGTG
X
X

4
2
2
AGCCACGTC
TATGCT
TTGTGAGGA
X
X

4
2
2
AGCATGGTC
GGGTTC
TAGTGAGGG
X
X

4
2
2
AGCAGAGTT
GGGAAA
AAGTGAGGG
X
X

4
2
2
AGCATTGTC
ACTGT
GAGTGAGAG
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCATGGTC
TAGCA
GAGTGAGTC
X
X

4
2
2
AGCTGTGTC
ATCCAT
GAGTGAGTC
X
X

4
2
2
AGTAGAGTC
TGGGTG
GAGTGAGAC
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCTGTGTC
CAGGAG
GAGTGAGTC
X
X

4
2
2
AGCAACTTC
TGATC
TAGTGAGGT
X
X

4
2
2
AGCTGAGTC
AACCT
GAGTAAGGG
X
X

4
2
2
AGTAGGGTC
ATCAG
AAGTGAGGT
X
X

4
2
2
AGCTGTGTC
ACCTT
GAGTGAGTC
X
X

4
2
2
AGCAACATC
TGGAA
GAGTGAGAG
X
X

4
2
2
AGCATCGTG
TTTGA
AAGTGAGGC
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCAACTTC
AGGGG
AAGTGAGGG
X
X

4
2
2
AGCATGGTC
AGATTA
TAGTGAGGG
X
X

4
2
2
AGCATGGTC
CGTGTC
TAGTGAGGG
X
X

4
2
2
AGCAAGGTC
ACCTGA
GAGTGAGAG
X
X

4
2
2
AGCATGGTC
AAGTTC
TAGTGAGGG
X
X

4
2
2
AGCAGGGTA
TAGGG
GAGTGAGAT
X
X

4
2
2
GGCAGAGTC
CAAGCA
GAGTGAGAG
X
X

4
2
2
AGTAACGTC
AAAGGT
GAGTGAAAA
X
X

4
2
2
AGCATGGTC
AATTTC
TAGTGAGGG
X
X

4
2
2
AGCAGTGTG
GAGTG
GAGTGAGAG
X
X

4
2
2
AGCACCATC
CCCAT
GAGTGAGTC
X
X

4
2
2
AGCAACGTG
AGACAG
TAGTGAGAA
X
X

4
2
2
AGCAACGGC
CCTGGG
CAGTGAGGG
X
X

4
2
2
AGTAGAGTC
ATGGA
GAGTGAGAG
X
X

4
2
2
GGCACCGTC
GCTGA
GAGTGAGTC
X
X

4
2
2
AGCATGGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGCATAGTC
AGGTTC
TAGTGAGGG
X
X

4
2
2
AGTAACGTC
TCCCT
GAGTGTGGG
X
X

4
3
1
AGCATAGTG
GTTAG
GAGTGAGGG
X
X

4
3
1
ATCAGGGTG
GGTAG
GAGTGAGGC
X
X

4
3
1
TACAGAGTC
TCCAG
GAGTGAGGG
X
X

4
3
1
ATGAGGGTC
TCATA
GAGTGAGGT
X
X

4
3
1
AGCAAATTC
TTCAG
GAGTGAGGT
X
X

4
3
1
AGCAAAGTG
CTCAAA
GAGTGAGGC
X
X

4
3
1
ATAAGTGTC
ATTGAA
GAGTGAGGC
X
X

4
3
1
AGTAGTCTC
TTGAT
GAGTGAGGG
X
X

4
3
1
CGCAGCAAC
AGCGGT
GAGTGAGGG
X
X

4
3
1
AGCAATGTG
TGCTT
GAGTGAGGC
X
X

4
3
1
ACCAAAGTC
TTTGAT
GAGTGAGGG
X
X

4
3
1
AGTAGTGTT
TCAAGA
GAGTGAGGC
X
X

4
3
1
AGCATAGTG
GGGTAG
GAGTGAGGG
X
X

4
3
1
ATCACCATC
CTAAGT
GAGTGAGGG
X
X

4
3
1
AGAATCGTT
TGAAA
GAGTGAGGG
X
X

4
3
1
AGTAACATC
GGAAAA
GAGTGAGGT
X
X

4
3
1
AGGACAGTC
AGTTG
GAGTGAGGT
X
X

4
3
1
GGCAGTGTT
GACAG
GAGTGAGGC
X
X

4
3
1
AGTTGTGTC
GTTTT
GAGTGAGGT
X
X

4
3
1
CCCACCGTC
CCGCCC
GAGTGAGGG
X
X

4
3
1
AGTACCGGC
TTCACA
GAGTGAGGT
X
X

4
3
1
AGCAACTTT
GGAATG
GAGTGAGGG
X
X

4
3
1
AGCAAGGGC
AGTGA
GAGTGAGGC
X
X

4
3
1
GTCAGGGTC
ATAAGA
GAGTGAGGC
X
X

4
3
1
AGGAAAGTC
TAACA
GAGTGAGGT
X
X

4
3
1
CACAGTGTC
AGGCT
GAGTGAGGT
X
X

4
3
1
GTCAGTGTC
CAAGAA
GAGTGAGGT
X
X

4
3
1
ATCACCATC
CAGAGA
GAGTGAGGG
X
X

4
3
1
ATCAACATC
TTTGG
GAGTGAGGC
X
X

4
3
1
CCGAGCGTC
TGAAA
GAGTGAGGT
X
X

4
3
1
AGCACAGTG
AGCACT
GAGTGAGGG
X
X

4
3
1
AACATTGTC
TAAGG
GAGTGAGGT
X
X

4
3
1
AACATTGTC
TAAGG
GAGTGAGGT
X
X

4
3
1
AACATTGTC
TAAGG
GAGTGAGGT
X
X

4
3
1
AGTACCGGC
ATCCAT
GAGTGAGGT
X
X

4
3
1
AGTACAGTC
TCTGTT
GAGTGAGAA
X
X

4
3
1
AACAACATC
ACGGG
GAGTGAGGT
X
X

4
3
1
TCCCGCGTC
CGGGAA
GAGTGAGGT
X
X

4
3
1
AGGGGAGTC
AGATGC
GAGTGAGGG
X
X

4
3
1
AGTAGCTGC
GGCCA
GAGTGAGGC
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
GGAAGGGTC
AGTGC
GAGTGAGGG
X
X

4
3
1
CTCAGTGTC
TCCCA
GAGTGAGGC
X
X

4
3
1
AGTAAAGTC
ACAAG
GAGTGAGGT
X
X

4
3
1
AACGGGGTC
TGGGA
GAGTGAGGT
X
X

4
3
1
GGGAGGGTC
CCCAT
GAGTGAGGG
X
X

4
3
1
GGCAGGGTT
AAGATT
GAGTGAGGC
X
X

4
3
1
AGGGGAGTC
TGAGGG
GAGTGAGGG
X
X

4
3
1
AACAATGTC
ATGTT
GAGTGAGGG
X
X

4
3
1
AGCTTGGTC
TGGCT
GAGTGAGGT
X
X

4
3
1
ATGAGGGTC
TCATA
GAGTGAGGT
X
X

4
3
1
GCCAGTGTC
TCTTAG
GAGTGAGGT
X
X

4
3
1
ATCACAGTC
TCTGG
GAGTGAGGC
X
X

4
3
1
GACAGGGTC
TTAAT
GAGTGAGGC
X
X

4
3
1
AGCCTTGTC
GTAACT
GAGTGAGGT
X
X

4
3
1
GGCAGCGGT
GTTCA
GAGTGAGGG
X
X

4
3
1
TCCAGTGTC
TATGG
GAGTGAGGC
X
X

4
3
1
AGCAGCTGT
GATGT
GAGTGAGGG
X
X

4
3
1
AGCAGCTCA
CATGG
GAGTGAGGT
X
X

4
3
1
GGCAACGGC
ACACA
GAGGGAGGA
X
X

4
3
1
AGCTGAGTT
AAGCA
GAGTGAGGT
X
X

4
3
1
AGCAGCACA
AAGCTG
GAGTGAGGG
X
X

4
3
1
AGCAACCTT
GAGAT
GAGTGAGGC
X
X

4
3
1
AGCAAATTC
GGGCCC
GAGTGAGGT
X
X

4
3
1
AGACGGGTC
GGCCC
GAGTGAGGT
X
X

4
3
1
GCCAGAGTC
TGCACA
GAGTGAGGG
X
X

4
3
1
AGCAACAGC
ATTTGG
GAGTGAGGG
X
X

4
3
1
AACCGAGTC
ACTCAA
GAGTGAGGG
X
X

4
3
1
AGCAGCTCA
CCAGCA
GAGTGAGGT
X
X

4
3
1
GGAAGGGTC
CTGTGT
GAGTGAGGG
X
X

4
3
1
AGAACGGTC
CAGCA
GAGTGAGGC
X
X

4
3
1
AGCAAGGTA
AGGAA
AAGTGAGGA
X
X

4
3
1
AGAATGGTC
AGTGGG
GAGTGAGGG
X
X

4
3
1
AGAATGGTC
CAAAT
GAGTGAGGG
X
X

4
3
1
AGCAAGGGC
TCCGT
GAGTGAGGG
X
X

4
3
1
TGCTGAGTC
TCCATG
GAGTGAGGG
X
X

4
3
1
AGCATTGTT
TCTGGG
GAGTGAGGG
X
X

4
3
1
AGCATTGTG
GTGAG
GAGTGAGGG
X
X

4
3
1
GCTAGCGTC
CATGG
GAGTGAGGC
X
X

4
3
1
AGCAACTTT
CCACTG
GAGTGAGGC
X
X

4
3
1
AGTAGGGTT
GGTGG
GAGTGAGGG
X
X

4
3
1
GGCAGTGTT
TCCCAG
GAGTGAGGC
X
X

4
3
1
AACTGAGTC
TCTGG
GAGTGAGGT
X
X

4
3
1
AGCATTGTG
ATGAG
GAGTGAGGG
X
X

4
3
1
AGCAAGGTT
TATGT
GAGTGAGCA
X
X

4
3
1
GGCAACGTT
TGTAT
GAGTGAGGT
X
X

4
3
1
AACAACCTC
GCCTAT
GAGTGAGGG
X
X

4
3
1
AGGGACGTC
CAAGG
GAGTGAGGG
X
X

4
3
1
TCCAGTGTC
ACATCA
GAGTGAGGC
X
X

4
3
1
AGCATGGTT
GGAGTA
GAGTGAGGG
X
X

4
3
1
AATAGGGTC
AAAAT
GAGTGAGGT
X
X

4
3
1
AGTATAGTC
TTTAGG
GAGTGAGGC
X
X

4
3
1
TGCAATGTC
CTTGG
GAGTGAGGC
X
X

4
3
1
AGCTACATC
TACAGG
GAGTGAGGG
X
X

4
3
1
AGCAAAGTA
AAGAGA
GAGTGAGGC
X
X

4
4
0
CACCCCGTC
TACCTG
GAGTGAGGA
X
X

4
4
0
AGGCACGTT
AGGCA
GAGTGAGGA
X
X

4
4
0
CACCCCGTC
GACGTC
GAGTGAGGA
X
X

4
4
0
GCAAGAGTC
TGGCT
GAGTGAGGA
X
X

4
4
0
AGTGCAGTC
CCTTA
GAGTGAGGA
X
X

4
4
0
ATCCACGTT
ATGCTG
GAGTGAGGA
X
X

4
4
0
ATCCACGTT
TTGGG
GAGTGAGGA
X
X

3
1
2
AGCAGCTTC
TGCCAT
GAGTGAAGT
X

X

3
1
2
AGCAGGGTC
TGCAGT
GAGAGAGGC
X

X

3
1
2
AGCAGCTTC
CAGGA
GAGTGAAGT
X

X

3
1
2
AGCAGGGTC
TGTTTT
GAGTGAGTT
X

X

4
3
1
AGCAACTGC
ATTTT
GAGTGAGGG
X

X

4
3
1
AGCAACTGC
ATCTT
GAGTGAGGG
X

X

3
1
2
AGCAGCTTC
CCAAAA
ATGTGAGGA
X

X

3
3
0
AGGTGCCTC
CCCATG
GAGTGAGGA
X

X

5
3
2
AGCTCAGTC
CACAG
GAGTGAGTC
X

X

2
1
1
AGCAGCGTG
CAGAA
GAGAGAGGA
X

2
1
1
AGCAGCGTG
GATGGA
GAGAGAGGA
X

2
1
1
AGCAGCGTG
GATGGA
GAGAGAGGA
X

2
1
1
AGCAGCGTG
GATGGA
GAGAGAGGA
X

2
1
1
AGCAGCCTC
TGCCAG
GGGTGAGGA
X

2
1
1
AGCAGCCTC
CCATA
GAGGGAGGA
X

2
1
1
AGGAGCGTC
CCTTGG
GAGTGATGA
X

2
1
1
AGCAGCGAC
AGCCA
GAGTGACGA
X

2
1
1
AGCTGCGTC
CTGTA
GCGTGAGGA
X

2
1
1
AGCAGGGTC
TGCCT
GAGTCAGGA
X

2
1
1
AGCAGCATC
TGGGA
GAATGAGGA
X

2
1
1
AGGAGCGTC
CAGTGC
GACTGAGGA
X

2
1
1
AGCAGCGTG
GATGGA
GAGAGAGGA
X

2
1
1
AGCAGCGTG
GATGGA
GAGAGAGGA
X

2
1
1
AGCAGCATC
ACAGAC
GCGTGAGGA
X

2
1
1
ACCAGCGTC
TGCTTT
GGGTGAGGA
X

2
1
1
AGCAGGGTC
ATTGA
GAATGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AGGAGCGAC
GGGGG
GAGTGAGGA
X

2
2
0
AACAGCCTC
CTTCC
GAGTGAGGA
X

2
2
0
AGAAGCATC
CGAAGG
GAGTGAGGA
X

2
2
0
AGAAGCCTC
CATTCC
GAGTGAGGA
X

3
0
3
AGCAGCGTC
AGGGG
AAATTAGGA
X

3
0
3
AGCAGCGTC
TTGGAA
GACCGAGGT
X

3
0
3
AGCAGCGTC
CTGTG
GCGTGGCGA
X

3
0
3
AGCAGCGTC
TCAGCG
GGTGGAGGA
X

3
0
3
AGCAGCGTC
CGCCGA
GAGTCAGCC
X

3
0
3
AGCAGCGTC
AGGGAG
AAGTCAGGT
X

3
0
3
AGCAGCGTC
AACAGT
GCCTGATGA
X

3
0
3
AGCAGCGTC
AGTAGA
GACAGAGAA
X

3
0
3
AGCAGCGTC
GGGTGG
GTTTGGGGA
X

3
0
3
AGCAGCGTC
TCCGAA
GAGACAGCA
X

3
0
3
AGCAGCGTC
CCGAG
GAGCTGGGA
X

3
0
3
AGCAGCGTC
CGGCC
GCGGCAGGA
X

3
0
3
AGCAGCGTC
CGGCC
GCGGCAGGA
X

3
0
3
AGCAGCGTC
ACTCCC
AAGCGAGTA
X

3
0
3
AGCAGCGTC
CCCTG
CAGAGAGCA
X

3
0
3
AGCAGCGTC
TCTCTG
GGCTGGGGA
X

3
0
3
AGCAGCGTC
CAGGAG
GGCTGGGGA
X

3
0
3
AGCAGCGTC
AGGGTG
GAGTCATGT
X

3
0
3
AGCAGCGTC
TGATTG
GCGGGGGGA
X

3
0
3
AGCAGCGTC
TGGGG
AATTGGGGA
X

3
0
3
AGCAGCGTC
CGCCGA
GAGTCAGCC
X

3
1
2
AGCAGTGTC
AGTTG
GCGGGAGGA
X

3
1
2
AGCAGAGTC
CAAAAG
GGGTGAGGC
X

3
1
2
ATCAGCGTC
CAGAG
GAGTGAACA
X

3
1
2
AGCAGAGTC
TCAGAG
GAGTGAAGC
X

3
1
2
AACAGCGTC
CTGGGA
GAGTGTGCA
X

3
1
2
TGCAGCGTC
TTCTT
TAGTGAGCA
X

3
1
2
AGCAGCTTC
CAACAA
TAGTAAGGA
X

3
1
2
AGCAGTGTC
CCCTAT
AAGTGAGAA
X

3
1
2
AGCAGCATC
AATCT
GAGTGTGGG
X

3
1
2
AGCAGTGTC
AACAT
CAGTGAGAA
X

3
1
2
AGCAGCTTC
TCCCA
GGGTGAGGC
X

3
1
2
AGCAGAGTC
AGGCA
GGGTGAGGC
X

3
1
2
AGCAGGGTC
TGCAGG
GAGTGTGGT
X

3
1
2
AGCTGCGTC
CTCTA
GAGGGAGGG
X

3
1
2
AGCAGCGTA
CCTGG
GTGTGAGAA
X

3
1
2
AGCAGCCTC
AGAAAT
AGGTGAGGA
X

3
1
2
AGCAGCGTT
CCTCT
CAGTGATGA
X

3
1
2
AGCAGCCTC
TGGAGG
GAGGGAGGG
X

3
1
2
AGCAGTGTC
AGATGG
TGGTGAGGA
X

3
1
2
AGCAGTGTC
TTGTTA
AAGTGAAGA
X

3
1
2
AGCAGCATC
TGGGTA
GAGTGAAGG
X

3
1
2
AGCAGCATC
CTCCT
GGGTAAGGA
X

3
1
2
AGCAGGGTC
CCTCT
GAGTGGGGC
X

3
1
2
ATCAGCGTC
TTTCTT
GAGTGATAA
X

3
1
2
AGCAGCATC
CTCCT
GGGTAAGGA
X

3
1
2
AGCAGCATC
CTCCT
GGGTAAGGA
X

3
1
2
AGCAGCATC
CTCCT
GGGTAAGGA
X

3
1
2
AGCAGCATC
CTCCT
GGGTAAGGA
X

3
1
2
AGCAGTGTC
TTAGGG
GAATGAGGC
X

3
1
2
AGCAGCTTC
CAGGCA
GAGGGAGAA
X

3
1
2
AGCAGCGTG
CTGCGA
GAGTGTGAA
X

3
1
2
AGTAGCGTC
CTTGG
GATTGAAGA
X

3
1
2
AGCAGCTTC
CAGACT
GAGGGAGAA
X

3
1
2
AGCAGCGTG
GAGGA
GAGAGAGGC
X

3
1
2
ATCAGCGTC
ATCCA
GAAGGAGGA
X

3
1
2
AGCAGCATC
AAAGAG
GAGAGAGGG
X

3
1
2
AGCAGTGTC
TTCCAT
GAGTGGGTA
X

3
1
2
AGCAGCGAC
TGTAG
AAATGAGGA
X

3
1
2
AGCAGTGTC
GATACA
TGGTGAGGA
X

3
1
2
AGCAGCGTG
GAGAG
GAGGAAGGA
X

3
1
2
AGCAGCTTC
ACTGT
GACTGAAGA
X

3
1
2
AGCAGAGTC
CTCTT
TTGTGAGGA
X

3
1
2
AGCAGCTTC
TCCAG
CAGTGATGA
X

3
1
2
AGCAGTGTC
ATACT
AAGGGAGGA
X

3
1
2
AGCCGCGTC
TCCAA
GAGTCAGTA
X

3
1
2
TGCAGCGTC
AAATTG
GAGTAAGGG
X

3
1
2
AGCAGCATC
AGAGGT
GTGTGAGAA
X

3
1
2
AGCAGCGTG
TTCATG
GAGTGCGGC
X

3
1
2
AGCAGTGTC
CTTTG
CAGTGAGAA
X

3
1
2
AGCAGCGCC
TCTCA
GAGTGAACA
X

3
1
2
AGCAGCATC
TTGGG
AACTGAGGA
X

3
1
2
AGCAGCCTC
TTTTTG
GAGGGAGGG
X

3
1
2
GGCAGCGTC
GCAGG
GAGTGGGAA
X

3
1
2
AGCAGCCTC
GGAAAC
AAGTGAGGG
X

3
1
2
AGCAGAGTC
TGATAT
GAGTGAGCT
X

3
1
2
TGCAGCGTC
AGCAT
GAGTGGGGC
X

3
1
2
AGCAGGGTC
TGGAGG
GAGACAGGA
X

3
1
2
AGCAGAGTC
ACGAGA
GAATGGGGA
X

3
1
2
AGCAGGGTC
CTGCA
GGGTGAGGC
X

3
1
2
AGCAGCCTC
AGGGAT
GAGGGAGGT
X

3
1
2
AGCAGCGGC
ATCGG
GGGCGAGGA
X

3
1
2
AGCAGGGTC
ATCACA
GAGGGAAGA
X

3
1
2
AGCAGTGTC
TGGTGT
GAGGGAGCA
X

3
1
2
AGCAGCGGC
TGGGGG
GAGGCAGGA
X

3
1
2
AGCAGCATC
CCTGGA
GAGGGAGAA
X

3
1
2
AGCAGGGTC
GGTGTC
TGGTGAGGA
X

3
1
2
AGCAGGGTC
CAGGT
AAGAGAGGA
X

3
1
2
AGCAGTGTC
ATCTCT
GAGTGGAGA
X

3
1
2
AGCAGCCTC
CGTCTA
GAGGGAGGT
X

3
1
2
AGCAGCGCC
AGCCTC
AAGTGAGGG
X

3
1
2
AGCAGCGAC
ATTGT
GAGTAAGCA
X

3
1
2
AGCAGCTTC
CGGTG
TAGTGATGA
X

3
1
2
AGCAGGGTC
CCAGCA
GAGAAAGGA
X

3
1
2
AGCAGCGAC
TCCGG
GAGTGCAGA
X

3
1
2
AGCAGCGTG
GGAAA
GAGGAAGGA
X

3
1
2
GGCAGCGTC
TATGGA
GAATGAGAA
X

3
1
2
AGCAGCCTC
CACACT
GAGGGAGGT
X

3
1
2
AGCAGCCTC
CCTCTT
GTGTGAGGG
X

3
1
2
TGCAGCGTC
GCTGA
AAGTGAGAA
X

3
1
2
AGCAGTGTC
TTGTAT
GACTGAGGT
X

3
1
2
AGCAACGTC
AGCAAA
GTGTCAGGA
X

3
1
2
AGCAGCATC
AGCAG
GAGTGTGAA
X

3
1
2
AGCAGCCTC
ATTGG
GAGTGAGTG
X

3
1
2
AGCAGGGTC
TTGGAT
GAGTTAAGA
X

3
1
2
AGCAGCGGC
AGACT
GAGCGAGCA
X

3
1
2
AGCAGGGTC
CTGTTG
GAGACAGGA
X

3
1
2
AGCAGCATC
AGCAT
CAGTTAGGA
X

3
1
2
AGCAGAGTC
AGAAAT
GAGTGAAGC
X

3
1
2
AGCAGCGCC
CACCCT
TGGTGAGGA
X

3
1
2
AGCAGCGGC
TGATG
GAGGCAGGA
X

3
1
2
AGCAGCCTC
GCTTTG
AGGTGAGGA
X

3
1
2
AGCATCGTC
ATCCTA
GAGTCAGCA
X

3
1
2
GGCAGCGTC
GGGCA
GAGGGAGAA
X

3
1
2
AGCAGCCTC
ATCCT
GTGAGAGGA
X

3
1
2
AGCAGTGTC
TTCCAT
GAGTGGGTA
X

3
1
2
GGCAGCGTC
CAATCT
CAGTGAGAA
X

3
1
2
AGCAGTGTC
ACCTCT
GAGTGGGTA
X

3
1
2
AGCAGCATC
TATAGC
GACTGAGGT
X

3
1
2
AGCAGTGTC
TGGTTT
GGGGGAGGA
X

3
1
2
AGCAGAGTC
GGAGT
GAGAGAGGG
X

3
1
2
AGTAGCGTC
TAGGC
AAGTGAGCA
X

3
1
2
AGCAGCCTC
TACAT
GAGTGAGAC
X

3
1
2
AGCAGTGTC
AATAA
GAGAGTGGA
X

3
1
2
AGCAGCGTT
TCTCA
AAGTGCGGA
X

3
1
2
AGCAGCGAC
TGTGA
AAGTGAGAA
X

3
1
2
AGCAGAGTC
CCTGT
GAGTGAAGG
X

3
1
2
GGCAGCGTC
CTTTC
CAGCGAGGA
X

3
1
2
AGCAGGGTC
AATGTC
TGGTGAGGA
X

3
1
2
AGCAGCATC
AGGCT
GAGTGTGGT
X

3
1
2
AGCAGTGTC
TCGTT
AGGTGAGGA
X

3
1
2
AGCAGGGTC
AGCAAA
GAATGAGGC
X

3
1
2
AGCAGAGTC
ACAAA
GAATGAGTA
X

3
1
2
AGCAGCGTG
GGGCTG
GAGGGAGAA
X

3
1
2
AGCAGCGTG
TTCATG
GAGTGCGGC
X

3
1
2
AGCAGCATC
TAACAG
GAGGGAGGG
X

3
1
2
AGCAGCCTC
CTAGG
GAGGGAGGG
X

3
1
2
AGCAGCTTC
TGAGC
TAGTGAAGA
X

3
1
2
ATCAGCGTC
TACTAA
GAGAGTGGA
X

3
1
2
AGCAGCATC
ACCTGC
GAGGGAGGG
X

3
1
2
AGCAGCATC
GAGTT
GGGTGAGGT
X

3
1
2
TGCAGCGTC
CAAGCT
CAGTGAGGC
X

3
1
2
AGCAGCTTC
ATTTT
GAATGAGGG
X

3
1
2
AGCAGCCTC
TTTTGG
GAGTGGGGG
X

3
1
2
AGCAGCGCC
TCCCA
GAGTGGGGC
X

3
1
2
AGCAGGGTC
CCCCA
GAGAAAGGA
X

3
1
2
AGCAGCCTC
CCGGA
GAGGGAGGG
X

3
1
2
GGCAGCGTC
GGGTGG
GAGAGAGAA
X

3
1
2
AGCAGAGTC
TACCTT
GAGTGAAAA
X

3
1
2
AGCAGCGAC
CCAAG
GAGTAAGAA
X

3
1
2
AGCAGTGTC
TTTAGA
AAGTGAGCA
X

3
1
2
AGCAGGGTC
GGGCC
TGGTGAGGA
X

3
1
2
AGCAGCGGC
TGAATC
CTGTGAGGA
X

3
1
2
TGCAGCGTC
TGGCAT
GAGTGGGGC
X

3
1
2
AGAAGCGTC
ATGCT
GAGTGAAAA
X

3
1
2
AGCAGGGTC
CAGGGA
GAGGGAAGA
X

3
1
2
AGCAGCATC
CCTGT
GAGTGAGTG
X

3
1
2
AGTAGCGTC
AATGAT
AAGTGTGGA
X

3
1
2
AGCAGGGTC
CAGGT
AAGAGAGGA
X

3
1
2
AGCAGGGTC
CAGGT
AAGAGAGGA
X

3
1
2
AGCAGGGTC
CAGGT
AAGAGAGGA
X

3
2
1
AGCAACCTC
ACCCCA
GAGAGAGGA
X

3
2
1
AGCAACGTG
TGTTGG
GAGAGAGGA
X

3
2
1
ATCAGGGTC
AGGTTT
TAGTGAGGA
X

3
2
1
AGCAAAGTC
TGTAT
GAGTGAGCA
X

3
2
1
AGCAGTGTA
AAGGAG
TAGTGAGGA
X

3
2
1
AGCAGAGTA
AAGCAG
GTGTGAGGA
X

3
2
1
AGCAGCCTG
GGAGA
GAGTGAGGG
X

3
2
1
AGCAACCTC
CTGGGT
GAGAGAGGA
X

3
2
1
AACAGCTTC
AGTACA
CAGTGAGGA
X

3
2
1
AGTAGTGTC
AATGAA
GAGTGAAGA
X

3
2
1
ATCAGGGTC
TAGGGA
GAGTGTGGA
X

3
2
1
GGCAGGGTC
CCCGG
GAGGGAGGA
X

3
2
1
AGCTGGGTC
TGAAGG
GTGTGAGGA
X

3
2
1
AGCTGGGTC
CTCAG
GAGAGAGGA
X

3
2
1
AGCAGCTCC
AGGGCC
GAGTGAGAA
X

3
2
1
AGCAACATC
CGCTCT
GAGTGGGGA
X

3
2
1
AACAGCTTC
ACAGG
CAGTGAGGA
X

3
2
1
ATCAGCGCC
CAACAC
CAGTGAGGA
X

3
2
1
AGCAGGGGC
AGTGG
GAGTGAGTA
X

3
2
1
AGCATGGTC
TGGTT
GGGTGAGGA
X

3
2
1
GGCAGCGTG
CTCTGA
GAGAGAGGA
X

3
2
1
AGCAGAGCC
CCCTG
GAGTGAGGG
X

3
2
1
AGCACCGTG
CTTCAA
AAGTGAGGA
X

3
2
1
CCCAGCGTC
AGCAG
GAGTCAGGA
X

3
2
1
AGGAGCGTG
GACACA
GAGTGAGGT
X

3
2
1
AGCCGAGTC
TGTCCC
GAGTGTGGA
X

3
2
1
AGTAGAGTC
TCTGTT
GAGTGAGTA
X

3
2
1
ACCAGGGTC
ATGGC
AAGTGAGGA
X

3
2
1
TGCAGGGTC
AGATTG
AAGTGAGGA
X

3
2
1
AGCAGCGGG
GAGAGA
GAGCGAGGA
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
AGTAGAGTC
TGGCT
GAGGGAGGA
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
AGTAGGGTC
ACACTA
GAGTGAAGA
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
TGCAGCGCC
GAGGT
GAGTGAGGG
X

3
2
1
AGCAGGGTA
AAGCAA
GAGTGAGAA
X

3
2
1
AGCAGCGGG
GACCGG
GAGCGAGGA
X

3
2
1
AGCAGGTTC
AGTGTC
TAGTGAGGA
X

3
2
1
GGCATCGTC
TGCAGT
AAGTGAGGA
X

3
2
1
AATAGCGTC
AGCCCC
AAGTGAGGA
X

3
2
1
AGCAGCATG
GTATG
GAGGGAGGA
X

3
2
1
AGCAGCCTG
CTGCA
GAGTGAGGG
X

3
2
1
GGCAGCGTG
GTGGT
GAGAGAGGA
X

3
2
1
AGCAGAGTT
GGTGTC
TAGTGAGGA
X

3
2
1
AACAGAGTC
GGGAA
GAGTAAGGA
X

3
2
1
AACAGCGGC
GTCCT
GAGTGTGGA
X

3
2
1
AGCAGGGTG
TGAGA
GAGGGAGGA
X

3
2
1
AGCTGCATC
AAACT
TAGTGAGGA
X

3
2
1
GGCAGGGTC
TCCCG
GAGGGAGGA
X

3
2
1
AGCAGCTTT
TCAGA
GAGTGAAGA
X

3
2
1
AGCAGGGCC
CTGCT
GAGTGAGGG
X

3
2
1
AGCAGGGCC
CTGCT
GAGTGAGGG
X

3
2
1
GGCAGCGTT
GGGAT
GTGTGAGGA
X

3
2
1
AACAGAGTC
ACAGT
GAGTAAGGA
X

3
2
1
AGCAGGGCC
GGGCA
GAGTGAGGG
X

3
2
1
GGGAGCGTC
TGCCC
CAGTGAGGA
X

3
2
1
ATCAGTGTC
TAAAAT
GGGTGAGGA
X

3
2
1
AGCGGCTTC
TGCCT
GAGTGAGGG
X

3
2
1
AGCAATGTC
TGCCTT
GGGTGAGGA
X

3
2
1
AGCAAAGTC
ACCAG
GAGTGAGCA
X

3
2
1
AGCAATGTC
AATCAG
GAGAGAGGA
X

3
2
1
AGCAGGGTG
GAAAG
GAATGAGGA
X

3
2
1
ACCAGCCTC
CTGAGG
GAGTGAGGG
X

3
2
1
AGAAGCGGC
GTTGT
AAGTGAGGA
X

3
2
1
AGCAGTGTG
GTAGA
CAGTGAGGA
X

3
2
1
AGCAATGTC
AGTCT
GAGTTAGGA
X

3
2
1
AGCAGGGTG
TTGGAG
GAATGAGGA
X

3
2
1
AGCAGCATG
GAAAA
GAGGGAGGA
X

3
2
1
AGCAGCTTT
GTAGA
GAGTGAAGA
X

3
2
1
AGCAAGGTC
TGGGA
GAGTCAGGA
X

3
2
1
AGCAGCCTG
CCAAG
GAGTGAGGG
X

3
2
1
AGCAGTGGC
TAAGA
GAGTGAGCA
X

3
2
1
AACAGCGTG
TGTGA
AAGTGAGGA
X

3
2
1
AGCATCCTC
TATGCT
GTGTGAGGA
X

3
2
1
AGCAGAGCC
ATGAAG
GAGTGAGGC
X

3
2
1
AGCAGCCGC
CTGAG
CAGTGAGGA
X

3
2
1
AGCAGCGAG
GGAGG
AAGTGAGGA
X

3
2
1
AGCCGGGTC
TTCCG
AAGTGAGGA
X

3
2
1
AGCCTCGTC
CCCAGA
GAGGGAGGA
X

3
2
1
AGGAGAGTC
CCATGA
GAGTGAGAA
X

3
2
1
AGCAATGTC
AGATAG
GGGTGAGGA
X

3
2
1
AGCATCGGC
CTCTCT
GAGTGACGA
X

3
2
1
AGCATCTTC
AGTTG
AAGTGAGGA
X

3
2
1
GGCAGCGTG
TATGAT
GAGAGAGGA
X

3
2
1
AGCAGGGTA
AAGAGT
GAGTGAGAA
X

3
2
1
AACAGAGTC
AGCCCT
TAGTGAGGA
X

3
2
1
AGCACAGTC
CGGAT
GAGTGAGCA
X

3
2
1
ATTAGCGTC
ACTTAG
AAGTGAGGA
X

3
2
1
AACAGAGTC
AGAGA
TAGTGAGGA
X

3
2
1
AGCAGCCTG
GCATG
GAGTGAGGG
X

3
2
1
AACACCGTC
ACCTGT
GGGTGAGGA
X

3
2
1
AGCAGCGGA
AATAA
GGGTGAGGA
X

3
2
1
GGCAGCGTG
AACCCA
GAGTGAGTA
X

3
2
1
AACACCGTC
CTGCCA
GTGTGAGGA
X

3
2
1
AGCAGCGAT
GTTGT
AAGTGAGGA
X

3
2
1
AGCAGGGTG
GGAAAG
GAGGGAGGA
X

3
2
1
AGCTGGGTC
AGAGGT
GAGAGAGGA
X

3
2
1
AGCAGCTCC
AGGGA
GAGTGAGAA
X

3
2
1
AGCAATGTC
TTCCTT
GGGTGAGGA
X

3
2
1
AGCACAGTC
TGAACA
GAGTGAGCA
X

3
2
1
AGCAGCGGA
GGATCT
GGGTGAGGA
X

3
2
1
AGCAGCTTT
TGGGA
GAGTGAGCA
X

3
2
1
AGCAGCGAT
TTGAAG
AAGTGAGGA
X

3
2
1
AGCAGCAGC
ACAAA
GAGTGAGTA
X

3
2
1
AGGAGCGGC
AGGTGA
TAGTGAGGA
X

3
2
1
AGCACGGTC
CAAAG
GAGAGAGGA
X

3
2
1
AGCTGGGTC
ATTCCC
CAGTGAGGA
X

3
2
1
AGCTGAGTC
AGCCAA
GTGTGAGGA
X

3
2
1
AGTAGGGTC
AACGTT
GAGTGAAGA
X

3
2
1
AGTAGAGTC
AACAGT
GAGTGATGA
X

3
2
1
AGGAGAGTC
GCTCT
GAGTGAGAA
X

3
2
1
AGCGCCGTC
TCTGG
AAGTGAGGA
X

3
2
1
AGCTGTGTC
CCTCCT
GAGGGAGGA
X

3
2
1
AGCTGCCTC
CGTGGG
GAGTGAGGC
X

3
2
1
AGCAGCCTG
CTGCA
GAGTGAGGG
X

3
2
1
AGCAGCCTG
CTGCA
GAGTGAGGG
X

3
2
1
GGCAGAGTC
GTGCA
TAGTGAGGA
X

3
2
1
AGCATTGTC
AATATT
GACTGAGGA
X

3
2
1
AGCAGGGTG
GGTAA
GAGTGAGAA
X

3
2
1
GGCAGGGTC
TCTGG
GAGGGAGGA
X

3
2
1
AGTAGAGTC
CAGTA
GAGTGATGA
X

3
2
1
AGCAGGGCC
CTGCT
GAGTGAGGG
X

3
2
1
AGCAAAGTC
TTTAG
GAGAGAGGA
X

3
2
1
AGCAGTGCC
CTGAA
GAGTGAGAA
X

3
2
1
GGCAGGGTC
CGAGCC
CAGTGAGGA
X

3
2
1
AGCTGGGTC
TGGCT
GAGTGTGGA
X

3
2
1
AGCAGCTTT
CATGG
AAGTGAGGA
X

3
2
1
ATCATCGTC
ATCGT
GAGAGAGGA
X

3
2
1
AGCCGCGTG
AGGGC
AAGTGAGGA
X

3
2
1
AGCAGGGTG
GGCAAG
GAGGGAGGA
X

3
2
1
AGCATGGTC
AAGTTT
GGGTGAGGA
X

3
2
1
ATCAGAGTC
AGAGA
AAGTGAGGA
X

3
2
1
AGCAGTGGC
AGAAT
AAGTGAGGA
X

3
2
1
AGGAGTGTC
TGCAA
AAGTGAGGA
X

3
2
1
TGCAGGGTC
AAGCC
AAGTGAGGA
X

3
2
1
AGCAGGTTC
AGTGTC
TAGTGAGGA
X

3
2
1
AGCAGCGGA
AATAA
GGGTGAGGA
X

3
2
1
AGCAGGGTG
CTCGG
GAGGGAGGA
X

3
2
1
AGCAACCTC
CCCACA
GAGGGAGGA
X

3
2
1
AGCAGGGTG
GGGGA
GAGGGAGGA
X

3
2
1
AGCAACCTC
TGCTCA
GAGAGAGGA
X

3
2
1
TGCAGGGTC
TGCGG
AAGTGAGGA
X

3
2
1
AGCAGGTTC
AGACTG
AAGTGAGGA
X

3
2
1
AGCAATGTC
ACCAT
GAGTGTGGA
X

3
2
1
AGCACGGTC
CCCAAG
GAGGGAGGA
X

3
2
1
AGCAGCGCT
CGGGC
GAGCGAGGA
X

3
2
1
AGCAGGGAC
TGGTCA
GAGTGAGGT
X

3
2
1
AGCAGCCAC
ACAATC
CAGTGAGGA
X

3
2
1
AGTAGAGTC
AAGAGG
GAGTGAGTA
X

3
2
1
AGCCTCGTC
TTGGT
GAGGGAGGA
X

3
2
1
GGCAGCGGC
CTGGAG
GGGTGAGGA
X

3
2
1
AGCAGAGTT
GGTTTC
TAGTGAGGA
X

3
2
1
AGCATCTTC
ACCTG
AAGTGAGGA
X

3
2
1
AGCAACATC
ATAAT
GAGTGGGGA
X

3
2
1
AGCACAGTC
CCTAA
GAGTGAGCA
X

3
3
0
AGGAGTTTC
CAGTT
GAGTGAGGA
X

3
3
0
GGCAGCAGC
CATCA
GAGTGAGGA
X

3
3
0
AGCAGGTTG
TTGGAG
GAGTGAGGA
X

3
3
0
AACAGTGCC
CTGGT
GAGTGAGGA
X

3
3
0
TGGAGCGTG
GGGGGA
GAGTGAGGA
X

3
3
0
TGGAGCGTG
GAAGAG
GAGTGAGGA
X

3
3
0
AGCTGAGGC
ACAGG
GAGTGAGGA
X

3
3
0
TGCAGGGTG
GACCCA
GAGTGAGGA
X

3
3
0
AACAGAGTG
AGGCT
GAGTGAGGA
X

3
3
0
AGCAACTTA
TTGCT
GAGTGAGGA
X

3
3
0
AGCACAATC
TTTTTG
GAGTGAGGA
X

3
3
0
TGGAGGGTC
GGTGGA
GAGTGAGGA
X

3
3
0
AGCCGTGTG
GCTACG
GAGTGAGGA
X

3
3
0
TGCTGCTTC
TGCCGT
GAGTGAGGA
X

3
3
0
AACAGAGTA
ACACA
GAGTGAGGA
X

3
3
0
ACCAACTTC
ATGTA
GAGTGAGGA
X

3
3
0
AGGAGAGTG
AGTGT
GAGTGAGGA
X

3
3
0
GGCAGGGTG
GCGAAG
GAGTGAGGA
X

3
3
0
GGCAGGGTG
GCCGGG
GAGTGAGGA
X

3
3
0
AGCAGGGCT
CCTGGT
GAGTGAGGA
X

3
3
0
TACAGTGTC
AGCAGT
GAGTGAGGA
X

3
3
0
ATCACCTTC
TTTCAT
GAGTGAGGA
X

3
3
0
TTCAGTGTC
TGACGG
GAGTGAGGA
X

3
3
0
AGCAGCTCA
GGTTAG
GAGTGAGGA
X

3
3
0
AGGAGAGTA
GGGCT
GAGTGAGGA
X

3
3
0
ACCTGGGTC
TGAGCA
GAGTGAGGA
X

3
3
0
ATCAGTGTG
TTTTT
GAGTGAGGA
X

3
3
0
TGGAGGGTC
AGAGGA
GAGTGAGGA
X

3
3
0
GGCAGGGTG
CGAGG
GAGTGAGGA
X

3
3
0
AGGAGAGTG
AATGT
GAGTGAGGA
X

3
3
0
AGCAGTGCA
CCCAA
GAGTGAGGA
X

3
3
0
AGCAGGTTG
AAGACT
GAGTGAGGA
X

3
3
0
AGGAGAGTG
AGAAGT
GAGTGAGGA
X

3
3
0
AGCAGCCGT
AACAAA
GAGTGAGGA
X

3
3
0
AGCAGGGCA
GGGCA
GAGTGAGGA
X

3
3
0
GCCAGCCTC
AGGCT
GAGTGAGGA
X

3
3
0
AGCAGGGCT
TGGTGG
GAGTGAGGA
X

3
3
0
AGTAGCAAC
TATTA
GAGTGAGGA
X

3
3
0
AACAGCGGA
GATTT
GAGTGAGGA
X

3
3
0
AGGACCATC
CGAGA
GAGTGAGGA
X

3
3
0
AGGACCATC
CCAGG
GAGTGAGGA
X

3
3
0
AGGACCATC
CCAGG
GAGTGAGGA
X

3
3
0
AGGACCATC
CCAGG
GAGTGAGGA
X

3
3
0
AGCAGGTTA
ACAGG
GAGTGAGGA
X

3
3
0
TGCAGGGTG
AGCCT
GAGTGAGGA
X

3
3
0
AGAAGGGTA
GAAAG
GAGTGAGGA
X

3
3
0
AGATGCGGC
CAGTA
GAGTGAGGA
X

3
3
0
AATAGGGTC
AGGTAG
GAGTGAGGA
X

3
3
0
AGCAGTGAA
GGTGG
GAGTGAGGA
X

3
3
0
AGAAACGTG
GAAAA
GAGTGAGGA
X

3
3
0
AACAGGGAC
CTTAT
GAGTGAGGA
X

3
3
0
AGCAAGGAC
TTAAA
GAGTGAGGA
X

3
3
0
AGCAGATGC
CCTTG
GAGTGAGGA
X

3
3
0
AGCAGCTGT
GCATA
GAGTGAGGA
X

3
3
0
AGAAGGGTT
TGTGCA
GAGTGAGGA
X

3
3
0
AACAGAGTG
GTTTA
GAGTGAGGA
X

3
3
0
GGCAGTGGC
AGTGG
GAGTGAGGA
X

3
3
0
AGCACCGAG
CCCCT
GAGTGAGGA
X

3
3
0
ATCAGCATG
AAATG
GAGTGAGGA
X

3
3
0
AGCTGTGTG
ACCCT
GAGTGAGGA
X

3
3
0
TGCAGGGTG
GGAATA
GAGTGAGGA
X

3
3
0
TGCAGGGTG
TAGTG
GAGTGAGGA
X

3
3
0
AGGAGGTTC
TGGGAG
GAGTGAGGA
X

3
3
0
AGGAATGTC
CTGGTC
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGAAGGGTG
GGAGGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGCTGC
CTTTGG
GAGTGAGGA
X

3
3
0
AGTAGAGGC
TGGAG
GAGTGAGGA
X

3
3
0
GGCAGCAGC
AATAGA
GAGTGAGGA
X

3
3
0
AGCAGCACA
AGCACT
GAGTGAGGA
X

3
3
0
TGCATCGTA
AGCAT
GAGTGAGGA
X

3
3
0
GGCAGGGTG
GGGGT
GAGTGAGGA
X

3
3
0
AGCAGCTGA
AAGAGG
GAGTGAGGA
X

3
3
0
TGGAGCGTG
GGAGGA
GAGTGAGGA
X

3
3
0
TCCAGGGTC
ACTAAT
GAGTGAGGA
X

3
3
0
TGCAGCGAA
AGGCA
GAGTGAGGA
X

3
3
0
AGCAGGTTG
GGGAA
GAGTGAGGA
X

3
3
0
AGCTGAGGC
TGGCA
GAGTGAGGA
X

3
3
0
AACAGTGGC
AAATGA
GAGTGAGGA
X

3
3
0
GGCAGTGCC
TGAAGG
GAGTGAGGA
X

3
3
0
GGCAGTGCC
TGAAGG
GAGTGAGGA
X

3
3
0
GGCAGTGCC
TGAAGG
GAGTGAGGA
X

3
3
0
AGGAGAGTA
TGGAG
GAGTGAGGA
X

3
3
0
CGCAGCATT
GCAGCG
GAGTGAGGA
X

3
3
0
GGAAGTGTC
CTTCAA
GAGTGAGGA
X

3
3
0
AGCTGCATA
AGGAAA
GAGTGAGGA
X

3
3
0
ACTAGGGTC
TTTGGA
GAGTGAGGA
X

3
3
0
AGCTGTGTG
CCAGG
GAGTGAGGA
X

3
3
0
ACCACTGTC
AGCTGT
GAGTGAGGA
X

3
3
0
GGTAGCTTC
TCCTG
GAGTGAGGA
X

3
3
0
AGCAGGGCT
GGGCAG
GAGTGAGGA
X

3
3
0
AGCTGTGTG
ATGGGA
GAGTGAGGA
X

3
3
0
TGAAGAGTC
CAAGG
GAGTGAGGA
X

3
3
0
TGAAGAGTC
CAAGG
GAGTGAGGA
X

3
3
0
ACGAGGGTC
CATAG
GAGTGAGGA
X

3
3
0
AGAAGCGGT
GGAGT
GAGTGAGGA
X

3
3
0
GGCAGAGTT
GTACTG
GAGTGAGGA
X

3
3
0
AGCAGTTAC
GGCAAA
GAGTGAGGA
X

3
3
0
TGCAGTGTG
CAAGGA
GAGTGAGGA
X

3
3
0
CTCTGCGTC
TGGAA
GAGTGAGGA
X

3
3
0
AGGAGAGTG
AGAGAA
GAGTGAGGA
X

3
3
0
AGGAGAGTG
AGAGAA
GAGTGAGGA
X

3
3
0
AATAGGGTC
AGGTAG
GAGTGAGGA
X

4
0
4
AGCAGCGTC
TCCGAA
GACTCATGT
X

4
0
4
AGCAGCGTC
ACATAA
TAGTGGAGC
X

4
0
4
AGCAGCGTC
CAGGA
GTGGGAGTC
X

4
0
4
AGCAGCGTC
TGGTCT
GGCGGAGGC
X

4
0
4
AGCAGCGTC
TTAGA
AGGTGACAA
X

4
0
4
AGCAGCGTC
AGAGGA
GGGAGACCA
X

4
0
4
AGCAGCGTC
ACTGGT
AAGACATGA
X

4
0
4
AGCAGCGTC
CCTGG
CATGGAGCA
X

4
0
4
AGCAGCGTC
TGACAG
CAGTGAAAC
X

4
0
4
AGCAGCGTC
TCCAGG
GTGTGCTGC
X

4
0
4
AGCAGCGTC
TCAGA
GGTAGAGCA
X

4
0
4
AGCAGCGTC
GAGACC
CATGGAGCA
X

4
0
4
AGCAGCGTC
GTGGC
AGGGCAGGA
X

4
0
4
AGCAGCGTC
CTGGG
GAGCGCGTC
X

4
0
4
AGCAGCGTC
GTTCGG
GGCTGAGAT
X

4
0
4
AGCAGCGTC
AGGCT
GTGGGAGCC
X

4
0
4
AGCAGCGTC
CACTG
TGGTAAGCA
X

4
0
4
AGCAGCGTC
TGCATG
GTGTGTTGC
X

4
0
4
AGCAGCGTC
TAATAC
AATTGAGTT
X

4
0
4
AGCAGCGTC
AACTGT
GTGAGTTGA
X

4
0
4
AGCAGCGTC
AAGTCT
GTGTGCTGC
X

4
0
4
AGCAGCGTC
TACAGT
GACTGCCGT
X

4
0
4
AGCAGCGTC
TGTGC
CATGGAGCA
X

4
0
4
AGCAGCGTC
TCCTT
GAGCGGTGC
X

4
0
4
AGCAGCGTC
TCCTTG
GGCAGAGGT
X

4
0
4
AGCAGCGTC
ACGTG
CCGCTAGGA
X

4
1
3
AGCCGCGTC
GCGGA
GAGGGCGGC
X

4
1
3
AGCAGTGTC
CTGAGG
GTGTGAAGG
X

4
1
3
AGCAGTGTC
AGATT
AAGTGAGCC
X

4
1
3
AGCATCGTC
AATTA
CAGTGAAAA
X

4
1
3
AGCAGCGGC
TGTGG
CAGTGTGGT
X

4
1
3
AGCAACGTC
GTGACA
GAGCCTGGA
X

4
1
3
AGCAGTGTC
ACAGT
GTGTGAGAG
X

4
1
3
AGCAGCGGC
TCCCAG
GAGAGGGGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGTAGCGTC
TCGCT
GTGTGAGTG
X

4
1
3
AGCAACGTC
AGCAGA
GTCTCAGGA
X

4
1
3
AGCAGCGTT
ATTCT
GAGTGATAT
X

4
1
3
AGCAGTGTC
CAGTA
GTGTAAGGT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
GGCAGCGTC
GGGATA
TGGTGAGGG
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGAGTC
GCTCA
CTGTGAGGC
X

4
1
3
AGCAGCGGC
AGCGGC
GAGGGCGGC
X

4
1
3
AGCAGTGTC
AGAGCA
GAGAGAGCC
X

4
1
3
AGCATCGTC
TGATCC
TTGTGAGGG
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGGGTC
TCCTG
TAGTGAGTC
X

4
1
3
ACCAGCGTC
TGCTTC
TGGTGAGGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGCATC
AGCTG
GAGGAAGGG
X

4
1
3
AGCAGCGGC
AACGAT
GAGCAAGAA
X

4
1
3
AGCAGTGTC
AGCAGC
AAGTGTGGT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGCGGC
CACAGA
GGTTGAGGC
X

4
1
3
AGCAGCGGC
ACCTG
GGGAGAGGC
X

4
1
3
AGCAGTGTC
AGTGGT
GGAGGAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGAGTC
CTGGGA
GACTGAACA
X

4
1
3
AGCAGTGTC
AGATA
GAGGGAGCC
X

4
1
3
AGCAGTGTC
CATTTG
AAGGGAGGT
X

4
1
3
TGCAGCGTC
TGTGT
GAGTGTCGT
X

4
1
3
GGCAGCGTC
TGTCT
GTGTGAGCT
X

4
1
3
AGCAGCGTG
TTTTAA
GAGTGAAAG
X

4
1
3
AGCAGCGGC
TGTGAA
AGGTGAGGT
X

4
1
3
AGCAGTGTC
CAGGA
GGAGGAGGA
X

4
1
3
AGCAGTGTC
TTGCAT
GTGGGAGGT
X

4
1
3
ACCAGCGTC
TGCTTC
TGGTGAGGC
X

4
1
3
AGCAACGTC
CATCCT
GAGAGATGG
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
ACAGGT
GAGTTGAGA
X

4
1
3
AGCAACGTC
CAGAA
AATTGAGCA
X

4
1
3
AGCAGTGTC
TTTTT
GAGTAGGCA
X

4
1
3
AGCAGCGGC
AGCAT
TAGGGAGGT
X

4
1
3
AGCAGTGTC
CTCATG
GGAGGAGGA
X

4
1
3
AGCAGCGGC
CAAGA
GAGTGAATT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGAGTC
AGGGA
GACTGAGTC
X

4
1
3
AGCAGTGTC
CAGCGT
GAGGGAGAT
X

4
1
3
AGCACCGTC
TGGGA
GTATGAGGC
X

4
1
3
ACCAGCGTC
CACTTC
TGGTGAGGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGAAAA
GTCTCAGGA
X

4
1
3
AGCAGGGTC
CAAAA
GAGTGATTT
X

4
1
3
AGCAGTGTC
AGCCCA
GAGTGAATT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGTGTC
AACTAG
GAGTAGGCA
X

4
1
3
AGCAGCGGC
ATTAC
GAGTAAGCT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AACAAA
GTCTCAGGA
X

4
1
3
AGCAGCTTC
CTCTG
GGGAGTGGA
X

4
1
3
AGCAGTGTC
TCCCC
GAGGGAAAA
X

4
1
3
AGCATCGTC
CGGGG
AGGTGAGAA
X

4
1
3
AGCAGCGGC
TCTCA
AAGTGTGGT
X

4
1
3
AGCATCGTC
CGGGG
AGGTGAGAA
X

4
1
3
AGCAGCGTT
CACACT
CAGAGAGGT
X

4
1
3
AGCAGCGGC
CGGAGC
AAGAGAGGG
X

4
1
3
AACAGCGTC
AATGT
GTGTGAGAG
X

4
1
3
AGCATCGTC
CGGGG
AGGTGAGAA
X

4
1
3
AGCATCGTC
CGGGG
AGGTGAGAA
X

4
1
3
AGCATCGTC
TGGGG
AGGTGAGAA
X

4
1
3
AGCATCGTC
CGGGG
AGGTGAGAA
X

4
1
3
AGCAGCATC
AGCGA
GAGGAAGGG
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCACCGTC
CAGTGT
GGGTGAAGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AACAGCGTC
AACGT
GAGTGAATT
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCACCGTC
TCCTGA
GGGTGAGTG
X

4
1
3
AGCACCGTC
CTTTCC
GTGTGGGGT
X

4
1
3
AGCAGGGTC
AAAAAG
TAGTGTTGA
X

4
1
3
AGCAACGTC
CCTCAT
GAATAAAGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGCTTC
TCTGA
GGGAGTGGA
X

4
1
3
GGCAGCGTC
TGGGAT
GAGGAAGGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGCGGC
AACTT
AAGAGTGGA
X

4
1
3
AGCAGCGGC
CTCAG
AAGTGAGCC
X

4
1
3
AGCAGTGTC
TGCACA
GAGTAGGCA
X

4
1
3
AGCAGTGTC
CCGAGG
CTGTGAGGC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGTGTC
CAGCA
CAGTGAGAT
X

4
1
3
AGCAACGTC
CAGAGG
GAGGAAAGA
X

4
1
3
AGCAGCGTG
TTAATT
AAGTGAGTC
X

4
1
3
AGCAGGGTC
TAAGG
GAGTGATTT
X

4
1
3
AGCACCGTC
TGGGA
GTTTCAGGA
X

4
1
3
AGCACCGTC
TGGGA
GTTTCAGGA
X

4
1
3
ATCAGCGTC
CAGCGT
GAGGTAGGC
X

4
1
3
AGCATCGTC
AATTA
TAGTGAGAC
X

4
1
3
AGCAACGTC
AGCAAA
GTCTCAGGA
X

4
1
3
AGCAGCGAC
ATCCT
GAGTGGGCT
X

4
1
3
AGCACCGTC
CAGACA
GAGCAGGGA
X

4
1
3
AGCAGTGTC
ATTTTC
TGGTGAGGG
X

4
1
3
AGCAGTGTC
CTGTG
GAGTGTTGG
X

4
1
3
AGCAGCGGC
GAGGT
TAGTGTGGT
X

4
1
3
AGCAGGGTC
CACAGT
GTGTGAGAT
X

4
2
2
AGCACCGGC
CGGCC
GAGGGAGGG
X

4
2
2
AGCAGAGTG
CCAGG
GAGTGAGAT
X

4
2
2
AGCAAGGTC
TGCATT
GAGAGAGGC
X

4
2
2
AGCATGGTC
CAGCA
GAGTGAGCC
X

4
2
2
ATCAGTGTC
ATCCTG
GAGTAAGGT
X

4
2
2
AGCATGGTC
GTGGA
AAGTGAGTA
X

4
2
2
AGCAATGTC
TGTGG
GAGGGAGGC
X

4
2
2
AGCATTGTC
TGCAGT
GAGTGTGGG
X

4
2
2
AGCATTGTC
TCCCTC
CAGTGAGGG
X

4
2
2
AGCAAGGTC
AGTGTC
TAGTGAGGG
X

4
2
2
AGCAGGGTA
GTGGT
GAGTAAGGT
X

4
2
2
AGCAGCGCA
GGCCG
GGGTGAGGG
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
AGCTGCATC
ACCTT
GAGTGAGTC
X

4
2
2
AGAAACGTC
CAGGTA
GAGTGAAAA
X

4
2
2
TGCAGTGTC
CCATG
GAGGGAGGT
X

4
2
2
AACAACGTC
CAGCAG
GAGTGTGAA
X

4
2
2
AGCAAGGTC
TTAAA
GAGCGAGTA
X

4
2
2
AGCAGTGTG
GGGCA
GTGTGAGGC
X

4
2
2
AGTAGTGTC
CTGTG
GAGGGAGGC
X

4
2
2
AGCAGGGTT
GGTTTC
TAGTGAGGC
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCACCGTA
TTCTGC
TAGTGAGGG
X

4
2
2
AGCTGTGTC
TGGTGT
GAGTGAGAG
X

4
2
2
AGCCGGGTC
CCCAC
GAGTGAGTG
X

4
2
2
AACAGGGTC
AGAGAA
GAGTGAGAC
X

4
2
2
AGCACTGTC
TTGGA
AAGTGAGGG
X

4
2
2
AGCAACGTG
GCAGAG
GAGGGAGGT
X

4
2
2
AGCAGGGTG
GGAACT
GAGGGAGGT
X

4
2
2
AGCACAGTC
TTGGG
GAGAGAGGC
X

4
2
2
AGCATTGTC
ACACA
GAGTGAATA
X

4
2
2
ATCAGAGTC
AGCTTA
GAGTGAGAG
X

4
2
2
AGCAACCTC
CAGGT
GAGGGAGGC
X

4
2
2
AGCGGAGTC
GCTGGG
GAGAGAGGG
X

4
2
2
AGCATGGTC
CATTTC
TAGTGAGGC
X

4
2
2
TGCAGTGTC
CACAGC
AAGTGAGGT
X

4
2
2
GGCACCGTC
CTCCTG
GAGGGAGGC
X

4
2
2
AGCAAAGTC
TCTAAA
GAGTGTGGT
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAGCATT
GCACGG
GGGTGAGGT
X

4
2
2
AGCAGTGAC
AGCGG
GAGTGAGCC
X

4
2
2
AGCAGTGAC
CAATCT
GAGTGAGCC
X

4
2
2
AGCAATGTC
AACAGA
GGGTGAGGG
X

4
2
2
AGCAACATC
TACTAA
GAGTGAGCC
X

4
2
2
TGCAGGGTC
AGGGT
GTGTGAGGC
X

4
2
2
AGCAACGGC
GACTG
GAGTGACCA
X

4
2
2
AGCATGGTC
CAGTTC
CAGTGAGGG
X

4
2
2
GGCAGTGTC
CTCCCA
CAGTGAGGC
X

4
2
2
AGCACCGGC
CCTGGG
CAGTGAGGG
X

4
2
2
AACAGTGTC
TATAAA
TAGTGAGGG
X

4
2
2
AGCAAAGTC
AGAGG
GAGTGATGT
X

4
2
2
AGCAATGTC
TGCAT
GAGGGAGGT
X

4
2
2
AGCAGTCTC
CAGGC
GAGAGAGGG
X

4
2
2
AGCAAAGTC
CTTGGT
AAGTGAGGG
X

4
2
2
AGCAGCAGC
TTAGA
GAGTGAGCC
X

4
2
2
AACATCGTC
AGTGG
GAGTGTGAA
X

4
2
2
AGCAACATC
CTTGGG
GAGTGAAGT
X

4
2
2
AGCCCCGTC
AAGCA
GAGGGAGGC
X

4
2
2
AGCAGCGGT
TCTCA
GAGTGTGGC
X

4
2
2
AGCAAGGTC
TGAGAA
GAGTGGTGA
X

4
2
2
AACAGAGTC
AGAGAG
GTGTGAGGC
X

4
2
2
GGCAGCGTG
TGACAG
AAGTGAGGG
X

4
2
2
AGCATAGTC
TCCCA
GAGTGAGTG
X

4
2
2
AGCCGTGTC
CCCTT
AAGTGAGGG
X

4
2
2
AGCATGGTC
AGGTT
CAGTGAGGG
X

4
2
2
AGTAGTGTC
TGGTG
GAGTGAGTT
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAGCATT
TCAAGA
GAGTGAGAG
X

4
2
2
CGCAGTGTC
TGGTCA
CAGTGAGGC
X

4
2
2
AGCAGGGTG
GGGAA
GAGGGAGGT
X

4
2
2
AGCAGGGTA
ATGTGA
GAGTGAGTG
X

4
2
2
AGCATAGTC
ACTTA
GAGTGTGGG
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
TCCAGCGTC
GTGACA
GAGTGAGAC
X

4
2
2
AGCACTGTC
CTGTCA
GAGTGTGGC
X

4
2
2
AGCATAGTC
CAGTT
CAGTGAGGC
X

4
2
2
AGCAGTGTG
CACCAC
GAGAGAGGC
X

4
2
2
AGCAACGGC
AGGAGA
GAGAGGGGA
X

4
2
2
AGCCGGGTC
ACCGA
GAGTGAGTG
X

4
2
2
AGCAATGTC
AATTTT
CAGTGAGCA
X

4
2
2
AGCAACGTG
TGGAG
CAGTGAGGG
X

4
2
2
AGCACGGTC
AGTCTT
CAGTGAGGG
X

4
2
2
AGCATGGTC
ATGTTA
TAGTGAGTA
X

4
2
2
AGCAGGGTA
GGGAG
GAGTGAGTG
X

4
2
2
AGCGGTGTC
TGAAAA
AAGTGAGGG
X

4
2
2
AGCAAGGTC
CATCCA
GAGAGAGGC
X

4
2
2
AGCACCTTC
TAGGGA
GTGTGAGGC
X

4
2
2
AGCAAAGTC
TCACAG
GAGGGAGGC
X

4
2
2
AGCAAGGTC
TGGGA
GAGTGATGT
X

4
2
2
AGCAGCAGC
TGCCGG
GAGCGAGGC
X

4
2
2
AGCAACCTC
CTGGG
GAGTGTGGG
X

4
2
2
TGCAGCGAC
TGAAGT
GAGTGAGTG
X

4
2
2
GGCAGCTTC
CCAGT
GAGTAAGGT
X

4
2
2
AACAGTGTC
AGTGAT
TAGTGAGGG
X

4
2
2
AGCTTCGTC
CAGAG
CAGTGAGGG
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAACGTG
ATGAAA
GAGTGAGAT
X

4
2
2
AGCAATGTC
AGTCTC
AAGTGTGGA
X

4
2
2
TGCAGTGTC
CCTGG
GAGGGAGGT
X

4
2
2
AGCAACGGC
CAGTCC
CAGGGAGGA
X

4
2
2
AGCATCGGC
TCCTC
AAGTGAGGC
X

4
2
2
AGCATCGGC
TCCTC
AAGTGAGGC
X

4
2
2
AGCATCGGC
TCCTC
AAGTGAGGC
X

4
2
2
AGCAAGGTC
AGAGA
GTGTGAGGC
X

4
2
2
AGCGGAGTC
CAGAG
AAGTGAGGG
X

4
2
2
AGCACCATC
AGCAC
CAGTGAGGT
X

4
2
2
AGCTGCTTC
CCCTA
GAGTGAGAG
X

4
2
2
AGCAACATC
ACTTT
GAGTAAGGC
X

4
2
2
AACAGTGTC
AAATC
AAGTGAGGT
X

4
2
2
AGCATCGTA
CCTCAA
GAGACAGGA
X

4
2
2
AGCATGGTC
GGTTTC
CAGTGAGGG
X

4
2
2
AACAGCTTC
CCAGCT
TAGTGAGGC
X

4
2
2
AGCAACTTC
CCTGGA
GGGTGAGGG
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAGGGTG
GGGTGT
GAGGGAGGC
X

4
2
2
AGCATTGTC
TGAAG
GAGAGGGGA
X

4
2
2
GGCAGCGTG
TGTGA
GAGTGAGCT
X

4
2
2
AGCTGTGTC
CCCCA
GAGTGAGAG
X

4
2
2
AGCAGCATT
CATGT
GAGTGAGAT
X

4
2
2
AGCAGTGTT
TCTCT
GAGTGTGGC
X

4
2
2
AGCACAGTC
ACCCA
TAGTGAGGC
X

4
2
2
GGCAGCTTC
AGGGC
AAATGAGGA
X

4
2
2
AGCATTGTC
ATAATA
GAGAGAGGT
X

4
2
2
AGCATGGTC
ATGGA
AAGTGAGTA
X

4
2
2
AGCAGGGTG
GTAAA
GAGGGAGGT
X

4
2
2
AGCAACTTC
TCCAC
TAGTGAGGG
X

4
2
2
AGCAGCAGC
CGGTG
GTGTGAGGC
X

4
2
2
TGCAGGGTC
TCTTA
GAGTGAGTT
X

4
2
2
TGCAGCGTT
GGGCT
CAGTGAGGG
X

4
2
2
AGCAGCATA
TAATA
GAGTGAGTC
X

4
2
2
AGCAGTGTG
CTAAG
GAGAGAGGC
X

4
2
2
AACAGCATC
TCAGCT
GGGTGAGGC
X

4
2
2
AGCAGTGTG
CCTTGG
GTGTGAGGG
X

4
2
2
AACAGAGTC
GTTCA
GTGTGAGGC
X

4
2
2
AGCAACGTT
AGCAG
GAGTGTGGT
X

4
2
2
AGCAAAGTC
TGTAAA
GAGTGTGTA
X

4
2
2
TGCATCGTC
CTATG
GAGGGAGGT
X

4
2
2
AGCAAGGTC
TTGTTG
GAGGGAGGG
X

4
2
2
GGCACCGTC
ATCCT
GAGTGGGGC
X

4
2
2
AGCAGAGTA
AGGGAG
GAGTGAGAG
X

4
2
2
AGCAAAGTC
ACAGG
GAGTGAGCG
X

4
2
2
AGAAGTGTC
ACTGTC
CAGTGAGGC
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAAAGTC
AGCCA
GAGGGAGAA
X

4
2
2
AGCAAAGTC
TGGAGT
GAGTGTGTA
X

4
2
2
GGCAGTGTC
CGGCT
GAGGGAGGG
X

4
2
2
AGCAGCAAC
AGTGT
GAGTGAGTT
X

4
2
2
AGCATTGTC
TAGCA
GGGTGAGAA
X

4
2
2
AGCAAGGTC
ACTGAG
GAGGGAGGC
X

4
2
2
AGCATCGGC
AGCTTG
GAGAGAGGT
X

4
2
2
AGCAGGGTG
GTAGGG
GAGGGAGGT
X

4
2
2
AGCAGCGCT
TCTCA
AAGTGAGGC
X

4
2
2
AGCAGGGTG
GTGTGA
GAGTGAGTG
X

4
2
2
TGCAGCGTG
GCCACA
GAGTGAGAC
X

4
2
2
TGCAGTGTC
ATTTGA
GAGTAAGGT
X

4
2
2
AGCAGGGTG
AGCACT
AAGTGAGGC
X

4
2
2
AACAGGGTC
AGTGGG
GAGAGAGGC
X

4
2
2
AACAGCGGC
CTATT
GTGTGAGGG
X

4
2
2
AGCAACGTT
CAGCT
CAGTGAGGT
X

4
2
2
AGCAGTGTT
GCCCCA
GGGTGAGGT
X

4
2
2
AGCACCGTG
TGGGGA
GAGGGAGGT
X

4
2
2
AGCAACGTT
CTGTG
GAATGAGCA
X

4
2
2
AGCCACGTC
GAATG
GATTGAGGG
X

4
2
2
AGCAGGGTG
GAGCGC
GAGGGAGGC
X

4
2
2
TGCAGCGGC
CTCAG
AAGTGAGGG
X

4
2
2
AGCATTGTC
TCCCTT
GAGTATGGA
X

4
2
2
GGCACCGTC
CTTTG
CAGTGAGGT
X

4
2
2
AGCATGGTC
GGGCAC
TAGTGAGGC
X

4
2
2
AGCACCTTC
ATGAAT
GTGTGAGGC
X

4
2
2
AGTAGTGTC
TAATAG
GTGTGAGGT
X

4
2
2
AGCACCATC
AAGATA
GTGTGAGGC
X

4
2
2
AGCCACGTC
ACCTG
AGGTGAGGA
X

4
2
2
AGCAACATC
TGTGTA
GAGCGAGGT
X

4
2
2
AGCCGAGTC
CTTGT
GGGTGAGGC
X

4
2
2
ACCAGTGTC
CTGCAG
TAGTGAGGC
X

4
2
2
AGCAACGAC
GGGCT
GCGTGTGGA
X

4
2
2
AGCAGCATT
GACCT
GAGTGAGAT
X

4
2
2
AGCAGCATT
GACCT
GAGTGAGAT
X

4
2
2
CGCAGTGTC
TTCCC
CAGTGAGGC
X

4
2
2
TGCATCGTC
AGAGA
GTGTGAGGG
X

4
2
2
AGCTGAGTC
CCCGGC
AAGTGAGGC
X

4
2
2
AGCAACGTG
TGCCA
GTGTGAGGG
X

4
2
2
AGCAGTGGC
TGGGCA
TAGTGAGGC
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCACCATC
TAGGCA
GAGGGAGGC
X

4
2
2
AGCACAGTC
ATGGTG
GAGTAAGGG
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
AGTAACGTC
ATTTCA
GAGTGCAGA
X

4
2
2
AGCAACTTC
TAGGAT
GAGTGTGAA
X

4
2
2
AGCAGCATT
GACAT
GAGTGAGAT
X

4
2
2
AGCAATGTC
TGCTGT
GGGTGAGGG
X

4
2
2
AGCAATGTC
TGCCAT
GAGTGTGAA
X

4
2
2
AGCAGATTC
GGAATT
GAGTGAGTG
X

4
2
2
CACAGCGTC
GGAGG
GAGGGAGGG
X

4
2
2
AGCAGCGAT
CTAAT
GAGGGAGAA
X

4
2
2
AGCACCGTG
AGACTT
GAGTGAGCC
X

4
2
2
ATCAGTGTC
CTGGG
GAGTGTGGT
X

4
2
2
AGCAACCTC
ACGGG
GAGGGAGGC
X

4
2
2
AGCAACTTC
AGAAGT
GAGTTAGGG
X

4
2
2
AGCAACTTC
CACTA
GAGAGAGGC
X

4
2
2
AGCAACGTG
GCAGAT
GAGAGAGGT
X

4
2
2
AACAGCATC
AAATGC
GGGTGAGGC
X

4
2
2
ACAAGCGTC
TGTAA
GAGTGAGTC
X

4
2
2
TCCAGCGTC
ACCTA
AAGTGAGGG
X

4
2
2
AGCAAGGTC
AGGAA
GAGAGAGGC
X

4
2
2
AGTAGCGTT
TTGTC
CAGTGAGGT
X

4
2
2
AGCAGTGTT
TGCTAA
CAGTGAGGC
X

4
2
2
AGCATGGTC
AGGTTC
CAGTGAGGG
X

4
2
2
AGCAGCGGA
GGTCA
GAGTGAGTT
X

4
2
2
AGCACCGAC
TCCAT
CAGTGAGGT
X

4
2
2
AGCAGTGAC
ATGAG
GAGTGAGCC
X

4
2
2
AGCAGGGTT
TCTGCA
GTGTGAGGT
X

4
2
2
AGCAGCATG
GTTAG
GAGTGAGAT
X

4
2
2
ATCAGAGTC
AAAGG
GAGGGAGGC
X

4
2
2
AGCAGGGTT
GGAAGA
AAGTGAGGG
X

4
2
2
AGCAGGGTG
GGCAA
GAGGGAGGC
X

4
2
2
GGCAGTGTC
TCAAAC
GAGGGAGGG
X

4
2
2
GGCATCGTC
ACTCTT
GAGTGAGAG
X

4
2
2
AGCACCGTG
ACTTC
GAGGGAGGT
X

4
2
2
AGCAGAGTT
TAAAA
TAGTGAGGG
X

4
3
1
GACAGCCTC
ATTAT
GAGTGAGGC
X

4
3
1
AGGGGGGTC
TTGGGA
GAGTGAGGT
X

4
3
1
AGCCTGGTC
CGTGA
GTGTGAGGA
X

4
3
1
GGCAGCGAT
GAGATT
GAGTGAGGG
X

4
3
1
AACAAGGTC
ATAAA
GAGGGAGGA
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
GGCAGAGTG
GAGGAA
GAGTGAGGC
X

4
3
1
AGCTGGGTT
GGAGTG
GAGTGAGGG
X

4
3
1
AGCAAAGGC
TAAAGA
GTGTGAGGA
X

4
3
1
AGTAACGGC
GGGGCT
GAGGGAGGA
X

4
3
1
AGCATTGTT
CTCAG
AAGTGAGGA
X

4
3
1
CACAGCATC
AGCAG
GAGTGAGGG
X

4
3
1
AGCCACATC
AGTCT
GAGTAAGGA
X

4
3
1
AGCAGCACA
CAGGCC
GAGTGAGGT
X

4
3
1
AGCATTGCC
TTTTG
GAGTGAGGG
X

4
3
1
AGAAGTGCC
ATCTGG
GAGTGAGGG
X

4
3
1
ATCAGCATA
CAGGG
GAGTGAGGC
X

4
3
1
AGCAGGTAC
GTGCCT
GAGTGAGGC
X

4
3
1
AACTACGTC
CACCA
GAGTGGGGA
X

4
3
1
AGAAGTGCC
ATCTAG
GAGTGAGGG
X

4
3
1
AGGAGTCTC
ATACT
GAGTGAGGT
X

4
3
1
TCCAGCGGC
CACAG
GAGTGAGGT
X

4
3
1
AGCTCAGTC
TCCCA
GGGTGAGGA
X

4
3
1
AGCTCAGTC
TCTCA
GGGTGAGGA
X

4
3
1
AACAGTATC
TATTCT
GAGTGAGGC
X

4
3
1
GGAAGTGTC
TTACTG
GAGTGAGGT
X

4
3
1
CTCAGAGTC
AAACA
GAGTGAGGT
X

4
3
1
AACAGTGTT
TTGGCC
GAGTGAGGG
X

4
3
1
CTCAGCTTC
CTGTG
GAGTGAGGC
X

4
3
1
AGCAGCTGT
AGGGA
GAGTGAGGT
X

4
3
1
AGCTGTGTG
ATCCT
GAGTGAGGG
X

4
3
1
AGGTGTGTC
TTTGGA
GAGTGAGGC
X

4
3
1
ATTAGAGTC
TGGGTT
GGGTGAGGA
X

4
3
1
AGCCGGCTC
GCGAGT
GAGTGAGGG
X

4
3
1
AGCACCAGC
CCGGGT
GAGTGAGGT
X

4
3
1
TTCAGCGTT
GTGAA
GAGTGAGGC
X

4
3
1
AGCTCCTTC
GAGGA
GAGTGAGGC
X

4
3
1
AAGAGTGTC
CTGGTT
GAGTGAGGC
X

4
3
1
TGCAGGGTA
GTTGG
GAGTGAGGT
X

4
3
1
AGGATCATC
CAGAGT
GAGTGAGGC
X

4
3
1
GTCTGCGTC
CGAAGG
GAGTGAGGG
X

4
3
1
ATGAGCGAC
TGATG
GAGTGAGGG
X

4
3
1
CCCAGGGTC
CACAGA
GAGTGAGGC
X

4
3
1
AGTACAGTC
CATTTG
GAGGGAGGA
X

4
3
1
AGCTTCCTC
CATCTT
GAGTGAGGC
X

4
3
1
AGAAGTGCC
TCCTG
GAGTGAGGG
X

4
3
1
GGCAGAGTG
GATCA
GAGTGAGGC
X

4
3
1
AGCAGTTCC
TAAAA
GAGTGAGGG
X

4
3
1
GGCACTGTC
GCTCA
GAGTGAGGT
X

4
3
1
AGCAGGCAC
AGCCTG
GAGTGAGGC
X

4
3
1
AGTGGAGTC
CCCTA
GAGTGAGAA
X

4
3
1
AGGACAGTC
GCAGA
GAGTGAGGC
X

4
3
1
AGCTGTGTG
CTGCCA
GAGTGAGGC
X

4
3
1
AGCAAGGTG
GGTGGC
GTGTGAGGA
X

4
3
1
TGCTGTGTC
CCCAGT
GAGTGAGGG
X

4
3
1
GGCACAGTC
TGACA
GAGAGAGGA
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
GTCAGTGTC
ATGCTT
GAGTGAGGC
X

4
3
1
GGAAGGGTC
CCAGTG
GAGTGAGGT
X

4
3
1
AGGAGCAAC
AAAGA
GAGTGAGGG
X

4
3
1
AGCGGTTTC
AGTGA
GAGTGAGGC
X

4
3
1
AGCAGCACG
GGGTG
AAGTGAGGA
X

4
3
1
AGAAGGGTG
GAGAAG
GAGTGAGGT
X

4
3
1
TGCTGTGTC
CATCCA
GAGTGAGGG
X

4
3
1
AGCTCAGTC
AACTG
GGGTGAGGA
X

4
3
1
AGCAAGGTT
AGGTTC
TAGTGAGGA
X

4
3
1
AGCTCAGTC
TCTCA
GGGTGAGGA
X

4
3
1
AGCACGGTG
GTCAA
GAGTGAGGC
X

4
3
1
AGCAGGGAT
TTGCA
GAGTGAGGC
X

4
3
1
ATCAGCTTT
GGGGTT
GAGTGAGGT
X

4
3
1
AGCACAGAC
AGCAT
GAGTGAGGC
X

4
3
1
CCCAGCTTC
TCAGG
GAGTGAGGC
X

4
3
1
CGCCCCGTC
TGGGA
AAGTGAGGA
X

4
3
1
AGCAGAGGT
TCCCA
GAGTGAGGC
X

4
3
1
AGCCACCTC
CCCTGC
GAGTAAGGA
X

4
3
1
AGCCCTGTC
TGTTAA
GAGTGAGGT
X

4
3
1
AGCAGCAGT
CTCTG
GAGTGAGGT
X

4
3
1
AGCCACTTC
TAGGGA
GAGTGAGTA
X

4
3
1
AGGTGCGGC
AGGTA
GAGTGAGGG
X

4
3
1
AGCTGTGTG
GTTGG
GAGTGAGGG
X

4
3
1
AGGCGCTTC
ATTTAT
GAGTGAGGT
X

4
3
1
AGGAGTCTC
ACGATA
GAGTGAGGT
X

4
3
1
ATCATCCTC
CGCACT
GAGTGAGGG
X

4
3
1
AGCCGGGTA
GGGGAT
GAGTGAGGC
X

4
3
1
AGCAACTGC
TTTGTG
GAGTGAGGT
X

4
3
1
GGCAGCATT
TGAAGG
GAGTGAGGG
X

4
3
1
CACAGCATC
TGAGGT
GAGTGAGGG
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
ACCCGTGTC
ACAGTT
GAGTGAGGG
X

4
3
1
AGCCCTGTC
TGCTGG
GAGTGAGGG
X

4
3
1
GGACGCGTC
AGGCT
GAGTGAGGT
X

4
3
1
AGGAACCTC
GTGCG
GAGTGAGGC
X

4
3
1
AGCTGTGTG
GCCTT
GAGTGAGGC
X

4
3
1
CGCTGCGAC
CTTCA
GAGTGAGGC
X

4
3
1
GGTAGAGTC
AGACA
GAGTGAGGG
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
ACCAACCTC
CTGTCA
GAGTGAGGC
X

4
3
1
AGCAGTCTG
CTGCAG
GAGTGAGGG
X

4
3
1
TGCTGTGTC
CTCACA
TAGTGAGGA
X

4
3
1
AGAAACTTC
AAGAAG
GAGTGAGGT
X

4
3
1
AACAATGTC
GTCACA
GAGTGAGTA
X

4
3
1
AGAAGGGTG
AATAAG
GAGTGAGGT
X

4
3
1
TGCAGCGGA
GGCAG
GAGTGAGGG
X

4
3
1
AGCTGTGTG
ACCTC
GAGTGAGGC
X

4
3
1
AATAGAGTC
CTGGG
GAGTGAGGC
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGTAGCATT
TTTAGT
GAGTGAGGG
X

4
3
1
ACCGGAGTC
ATCCCT
GAGTGAGGG
X

4
3
1
AGCAGTCTG
AAGGG
GAGTGAGGG
X

4
3
1
AGCAGCACA
CAGGCC
GAGTGAGGT
X

4
3
1
AGCAGCCAT
CAGAG
GAGTGAGGC
X

4
3
1
GCCAGGGTC
CAAATG
GAGTGAGGC
X

4
3
1
AGCATCTTA
GTGAT
GAGTGAGGT
X

4
3
1
AGGAGCAAC
AGAGA
GAGTGAGGG
X

4
3
1
AGCAGGTTT
ATTAGG
GAGTGAGGG
X

4
3
1
GACAGCCTC
TCCCA
GAGTGAGGC
X

4
3
1
AGCAGCAAT
GGCAG
GAGTGAGGT
X

4
3
1
GGCAGCGGT
AGAGA
TAGTGAGGA
X

4
3
1
AGTGGAGTC
CTGGA
GAGTGAGTA
X

4
3
1
AGCCTGGTC
TGGCC
GTGTGAGGA
X

4
3
1
AGAACCGAC
CAGCCA
GAGTGAGGG
X

4
3
1
AGCAACATG
ACCCA
GAGTGAGGG
X

4
3
1
AGCTCAGTC
TTGCA
GGGTGAGGA
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
TGCAATGTC
AAGCTT
GAGTGAGAA
X

4
3
1
GGCCCCGTC
ACGGT
GAGTGAGGG
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
AGCAATGTA
GGGAGG
GAGTGAGGG
X

4
3
1
AGTAACATC
CTGTTT
GTGTGAGGA
X

4
3
1
ATCATTGTC
TCCACT
GAGTGAGAA
X

4
3
1
AGTAGAGTT
TAGGG
GAGTGAGGG
X

4
3
1
AGCAGGGGT
CAGCTG
GAGTGAGGG
X

4
3
1
TGCTGTGTC
TTCCTG
GAGTGAGGC
X

4
3
1
ATTAGAGTC
AGAGCA
GGGTGAGGA
X

4
3
1
AGAAGGGTG
AGCAA
GAGTGAGGT
X

4
3
1
CTCAGTGTC
TCTGTG
AAGTGAGGA
X

4
3
1
AGCTGTGTT
CTGGAT
GAGTGAGGT
X

4
3
1
AGTACAGTC
TAGCCA
GAGGGAGGA
X

4
3
1
AGCCGCTTT
ATTCAA
GAGTGAGGG
X

4
3
1
ACCGGTGTC
GTCGT
GAGTGAGGG
X

4
3
1
AGCAGTGCT
GAGGC
GAGTGAGGC
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
ATCTGCATC
TCTCTT
GAGTGAGGT
X

4
3
1
AGCACAATC
CCCCAA
GAGTGAGGG
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
ATCATCATC
TTGGA
GAGTGAGGC
X

4
3
1
GGTAGAGTC
ACTGTA
GAGTGAGGG
X

4
3
1
AGCTGTGTG
CTGGGG
GAGTGAGGC
X

4
3
1
ATGAGTGTC
AGGTG
GAGTGAGGG
X

4
3
1
GGCAGAGTG
GTCCAG
GAGTGAGGC
X

4
3
1
AGGAGTCTC
CAGGGG
GAGTGAGGC
X

4
3
1
AGCCAAGTC
CTGAG
GGGTGAGGA
X

4
3
1
CGCTGAGTC
CAGAG
GAGTGAGGC
X

4
3
1
GGCTCCGTC
TTATGT
GAGTGAGGC
X

4
3
1
AGCAGCAGT
GAGGA
GAGTGAGGC
X

4
3
1
AGTACTGTC
AACTA
CAGTGAGGA
X

4
3
1
ATGAGCGGC
CGGTAG
GAGTGAGGT
X

4
3
1
TGCAAGGTC
AGGAT
AAGTGAGGA
X

4
3
1
AGTACAGTC
ACTGT
TAGTGAGGA
X

4
3
1
ATCATTGTC
AGGTT
GAGTGAGAA
X

4
3
1
CTCAGCGGC
TGCTGT
GAGTGAGGG
X

4
3
1
AGCAGTCCC
ATCCAA
GAGTGAGGG
X

4
3
1
AGCACAGGC
TGGACA
GAGTGAGGT
X

4
3
1
AGCAACCAC
CTCCTG
GAGGGAGGA
X

4
3
1
AGTAAGGTC
AAGGA
GAGGGAGGA
X

4
3
1
CGCCCCGTC
TGGAG
AAGTGAGGA
X

4
3
1
TGCACAGTC
ACATG
GTGTGAGGA
X

4
3
1
AGCAGCAAG
TGGCA
GAGTGAGGC
X

4
3
1
AGCTCAGTC
TCACA
GGGTGAGGA
X

4
3
1
GGCAGGGTT
TCTCA
GAGTGAGGT
X

4
3
1
AGGATGGTC
CTTCC
AAGTGAGGA
X

4
3
1
AGCAACCCC
ATTTT
GAGTGAGGG
X

4
3
1
AGAAGCCAC
ATCAGT
GAGTGAGGG
X

4
3
1
ACCAATGTC
ACCTGT
GTGTGAGGA
X

4
3
1
AGGTGCGTG
GAGTG
GAGTGAGGG
X

4
3
1
AGCAGTGAA
GGGAA
GAGTGAGGC
X

4
3
1
AGCTGAGTG
ACAGCT
GAGTGAGGG
X

4
3
1
AGCAGTGCG
TGCAT
GAGTGAGGG
X

4
3
1
GGCGGGGTC
TGCTC
GAGTGAGGC
X

4
3
1
AGAATAGTC
TTAGA
CAGTGAGGA
X

4
3
1
AGCAGGGAT
TTGCA
GAGTGAGGC
X

4
3
1
GGAAGTGTC
CAAGG
GAGTGAGGT
X

4
3
1
ATCAATGTC
CTCTGT
GAGTGAGGG
X

4
3
1
CCCAGCTTC
CTGGG
GAGTGAGGC
X

4
3
1
AGGTGCGGC
AGGTA
GAGTGAGGG
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGCAACATG
GCTCA
GAGTGAGGG
X

4
3
1
TGCGCCGTC
TACTAG
GAGTGAGGC
X

4
3
1
AGCAAAGTT
TAACAA
GAGTGAGAA
X

4
3
1
AGCAAAGTT
TAACAA
GAGTGAGAA
X

4
3
1
AGCAAAGTT
TAACAA
GAGTGAGAA
X

4
3
1
AGCAAAGTT
TAACAA
GAGTGAGAA
X

4
3
1
AGCAAAGTT
TAACAA
GAGTGAGAA
X

4
3
1
AGTATCATC
CGGCT
GAGTGAGGT
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGGAGCAAC
CACAGG
GAGTGAGGG
X

4
3
1
AGCAGCTCG
CTGAG
GAGTGAGGG
X

4
3
1
AGCTGAGAC
TTAGA
GAGTGAGGT
X

4
3
1
AGCAATGTG
AGTTGT
GAGTGAGGG
X

4
3
1
AGAAGCGGT
GCGTCT
GAGTGAGGT
X

4
3
1
AGAAGTGCC
ATCTGT
GAGTGAGGG
X

4
4
0
GGATGAGTC
TGGAG
GAGTGAGGA
X

4
4
0
ACAGGTGTC
CAAGAT
GAGTGAGGA
X

4
4
0
CTGGGCGTC
CCTCCA
GAGTGAGGA
X

4
4
0
CCCGGGGTC
TTCAGT
GAGTGAGGA
X

4
4
0
TGGCACGTC
TGAGG
GAGTGAGGA
X

4
4
0
AGCTCAGTA
CAAAAA
GAGTGAGGA
X

4
4
0
AAAAGGTTC
AGAGG
GAGTGAGGA
X

4
4
0
GACATCATC
AGAACT
GAGTGAGGA
X

4
4
0
AGCACTATT
CTATTA
GAGTGAGGA
X

4
4
0
CCCTGAGTC
TGAGG
GAGTGAGGA
X

4
4
0
TGGGGAGTC
AGTGC
GAGTGAGGA
X

4
4
0
AACAGGGCT
TCTGA
GAGTGAGGA
X

4
4
0
AGCAAAGCT
CGAGA
GAGTGAGGA
X

4
4
0
AACATTGTT
TCAGT
GAGTGAGGA
X

4
4
0
AGACACTTC
ATGAAT
GAGTGAGGA
X

4
4
0
GCCCACGTC
TTCGTG
GAGTGAGGA
X

4
4
0
AACATGGTT
GTGTGG
GAGTGAGGA
X

4
4
0
GGTACAGTC
TTCGCC
GAGTGAGGA
X

4
4
0
GGCATGGTG
AGAGTG
GAGTGAGGA
X

4
4
0
GGAAGTCTC
AGGAT
GAGTGAGGA
X

4
4
0
ATCTTGGTC
AGGGCA
GAGTGAGGA
X

4
4
0
ATCAGGTCC
CAATT
GAGTGAGGA
X

4
4
0
GGCATGGTG
TAAAGA
GAGTGAGGA
X

4
4
0
TGAAACGTT
GCAGG
GAGTGAGGA
X

4
4
0
TGAATCGGC
AACAA
GAGTGAGGA
X

4
4
0
ATACACGTC
TCCTG
GAGTGAGGA
X

4
4
0
GGGAAGGTC
CTTGG
GAGTGAGGA
X

4
4
0
CACTGTGTC
GGGTGA
GAGTGAGGA
X

4
4
0
ATCTTTGTC
TTCCT
GAGTGAGGA
X

4
4
0
CTGAGGGTC
ATTGG
GAGTGAGGA
X

4
4
0
ATGTGAGTC
TTCTT
GAGTGAGGA
X

4
4
0
AAAGTCGTC
AGCTAT
GAGTGAGGA
X

4
4
0
AACAATGTT
CGCCT
GAGTGAGGA
X

4
4
0
GGGAAGGTC
CTATGG
GAGTGAGGA
X

4
4
0
GGATGTGTC
TTCAGG
GAGTGAGGA
X

4
4
0
TCCACAGTC
TGGGT
GAGTGAGGA
X

4
4
0
AGCAAAGCT
ATATGG
GAGTGAGGA
X

4
4
0
CCCTGGGTC
CCAGGG
GAGTGAGGA
X

4
4
0
GTGAGGGTC
TCTGGA
GAGTGAGGA
X

4
4
0
AGCCAGGTT
GAAAAG
GAGTGAGGA
X

4
4
0
AGCATGGCT
TATGG
GAGTGAGGA
X

4
4
0
AGCTCAGGC
AGGGG
GAGTGAGGA
X

4
4
0
CCCTGGGTC
TGCTG
GAGTGAGGA
X

4
4
0
AGCAACAGA
TGAAG
GAGTGAGGA
X

4
4
0
AGCATGGCT
GGAATG
GAGTGAGGA
X

4
4
0
AGCTAAGTT
CTTGTA
GAGTGAGGA
X

4
4
0
AACTTTGTC
CTGAA
GAGTGAGGA
X

4
4
0
AACATGGTT
CCTTCT
GAGTGAGGA
X

4
4
0
CGCCACGGC
TGGGAG
GAGTGAGGA
X

4
4
0
CTCATTGTC
CAGGA
GAGTGAGGA
X

4
4
0
CCCTGGGTC
ATGTGA
GAGTGAGGA
X

5
1
4
AGCAACGTC
AAAGAT
CACTGATCA
X

5
1
4
AGCAGCGGC
GACAGC
AGAGGAGGA
X

5
1
4
AGCAGCGGC
AAGTGG
GAGTAGGAT
X

5
1
4
AGCAGCGGC
GGCACC
ACGTGCGCA
X

5
1
4
AGCACCGTC
AATCAG
GTGCGAGTC
X

5
1
4
AGCACCGTC
AAGAGT
CAGTGTTTA
X

5
2
3
AGCACAGTC
ACCTCT
GAGTGACAC
X

5
2
3
AGCAACGTA
TCGAT
GAGGGTAGA
X

5
2
3
AGCATCGGC
AGGCA
GAGTAAGTC
X

5
2
3
AACAACGTC
CTGAAC
GTGAGAGAA
X

5
2
3
AGCATAGTC
CGTGTA
GTGAGAGAA
X

5
2
3
AGCATGGTC
TTAATG
GAGTGATAG
X

5
2
3
AGCTGTGTC
TGCCTT
GGGTGATGC
X

5
2
3
AGCAATGTC
ATGTC
CAGTGAGCC
X

5
2
3
AGCATTGTC
CAAGGA
GAGTAAGTG
X

5
2
3
AGCAGCTGC
TCTCAA
GAGTATGGG
X

5
2
3
TGCAGTGTC
TGGAGT
GTGTCAGGC
X

5
2
3
AGCATTGTC
CTCCTC
TGGTGAGGT
X

5
2
3
AGCATTGTC
CCAAAA
GTGAGGGGA
X

5
2
3
AGCAATGTC
TACCA
CAGTGAGAC
X

5
2
3
AGCAACGTT
CTTTAT
GTAAGAGGA
X

5
2
3
AGCAACTTC
ACTTAG
GCGTGGGAA
X

5
3
2
AGGCGAGTC
TCTTTA
GTGTGAGGC
X

5
3
2
AGCCACGTT
AGGGGT
AAGTGAGGG
X

5
3
2
AGTATCGTG
ATTGA
AAGTGAGGC
X

5
3
2
AGCAAGGTA
GCTTG
GAGTGAGAC
X

5
3
2
TGCAGCTGC
AAAAG
AAGTGAGGG
X

5
3
2
AGTATCTTC
TGGTGT
GAGTGAGAT
X

5
3
2
TGCAGTTTC
TCAAAG
GAGAGTGGA
X

5
3
2
ATCAGGGGC
CCACTA
GAGTAAGGG
X

5
3
2
AGTTGCTTC
TGCATT
GAGTAACGA
X

5
3
2
AGCTACGTG
CCCGGC
CAGTGAGGG
X

5
3
2
AGCTTAGTC
TGAGT
GTGTGAGGT
X

5
3
2
ATCAGGGGC
TGAAG
GAGTAAGGG
X

5
3
2
ATCAGGGGC
TGAAG
GAGTAAGGG
X

5
3
2
AGCAACCCC
TCTGCT
GAGGGAGGC
X

5
3
2
AGCATGGTA
TGATGT
AAGTGAGGG
X

5
3
2
CATAGCGTC
AGATTG
GAGTAAGGT
X

5
3
2
TGCAGCTGC
TGTCAG
AAGTGAGGG
X

5
3
2
AGCTAGGTC
CCCTG
CAGTGAGGG
X

5
3
2
AGCTTGGTC
AGTGAA
GAGAGAGGT
X

5
3
2
AGCAACTAC
ATATCT
GTGTGAGGC
X

5
3
2
AGCAACCCC
TCTGCT
GAGGGAGGC
X

5
3
2
GTCAGTGTC
CTGGAA
AAGTGAGGG
X

5
3
2
TGCAGTGTA
GCTGGA
GAGGGAGGT
X

5
3
2
CTCATCGTC
CAGGCT
GAGTGAGTC
X

5
3
2
AGTAACATC
AAGTCA
TAGTGAGGC
X

5
3
2
AGCTATGTC
CTAAAG
AAGTGAGGG
X

5
3
2
GTCCGCGTC
TTGTTT
GAGTAAGGG
X

5
3
2
AGCCTTGTC
ACTGA
AAGTGAGGC
X

5
3
2
AGCACAGCC
ACATCT
GTGTGAGGC
X

5
3
2
AGCAACATT
CTAAGC
GAGTGAGTC
X

5
4
1
AGTGTGGTC
GGAGCA
GAGTGAGGG
X

5
4
1
ACTAATGTC
ATGCTA
GAGTGAGGT
X

5
4
1
TACATTGTC
TAGGAG
GAGTGAGGG
X

5
4
1
ATCAATGGC
CAGAT
GAGTGAGGG
X

5
4
1
CGGGGAGTC
CCAGGG
GAGTGAGGG
X

5
4
1
AGCAGGTCA
CATCG
GAGTGAGGG
X

5
4
1
AGCTAGGTT
GGCCC
GAGTGAGGC
X

5
4
1
AGTGTGGTC
AGAGAG
AAGTGAGGA
X

5
4
1
AGTATGGTA
ACAGCA
GAGTGAGGG
X

5
4
1
ATCCGTCTC
TTCTG
GTGTGAGGA
X

5
4
1
AACAGTATT
GCAAT
GAGTGAGGG
X

5
4
1
ATCAGCAGT
GAACA
AAGTGAGGA
X

5
4
1
GGCCAAGTC
AGCGG
GAGTGAGGC
X

5
4
1
GCCAGTGTT
TCTCA
GAGTGAGGT
X

5
4
1
ATCAGGGCA
GGCCAG
GAGTGAGGG
X

5
4
1
AGTAGATGC
AGTTA
GAGTGAGGT
X

5
4
1
GGCCTGGTC
AGGAGG
GAGTGAGGG
X

5
4
1
AGCAACTCA
TTCTGT
GAGTGAGGG
X

5
4
1
GGGGGAGTC
TTGCGG
GAGTGAGGT
X

5
4
1
ATCAGTCTA
GCAGCA
GAGTGAGGC
X

5
4
1
AGTAGATGC
ATAGG
GAGTGAGGT
X

5
4
1
ACCAGTGGT
GGGGGT
GAGTGAGGT
X

5
4
1
GGCCTTGTC
CCCTA
GAGTGAGGG
X

5
4
1
CTCATTGTC
TTGCTG
GAGTGAGGC
X

5
4
1
AGTATGGTA
AAAGGA
GAGTGAGGG
X

5
4
1
AGAGAGGTC
AGGGTA
GAGTGAGGG
X

5
4
1
GGCCTGGTC
AGATTT
GAGTGAGGG
X

5
4
1
TGTTGAGTC
CGTATG
GAGTGAGGG
X

5
4
1
AGCACCACT
GACAG
GAGTGAGGG
X

5
4
1
AAAACAGTC
ATCCT
GAGTGAGGG
X

5
4
1
AACAGTATT
AAGGA
GAGTGAGGG
X

5
4
1
GCCAACATC
CACAT
GAGTGAGGT
X

5
4
1
GGCCAAGTC
TCTCA
GAGTGAGGC
X

5
4
1
AAAACAGTC
TTTCGA
GAGTGAGGG
X

5
4
1
AATCCCGTC
ATGGA
GAGTGAGGT
X

6
4
2
GGTTACGTC
CGGAA
AAGTGAGGC
X

6
4
2
AGTTACTTC
TATAA
AAGTGAGGG
X

6
4
2
AGTTACTTC
CCTCA
AAGTGAGGG
X

3
2
1
GGCATCGTC
CACTC
CAGTGAGGA

X
X

4
2
2
ATCAGGGTC
CAGCT
CAGTGAGGC

X
X

4
3
1
AGCTCAGTC
ACTCCT
GAGTGAGGG

X
X

4
3
1
AGCTCAGTC
CTGGG
GAGTGAGGG

X
X

4
3
1
AGCATGGTT
TTCTG
GAGTGAGGC

X
X

4
3
1
AGATGGGTC
TTGCT
GAGTGAGGC

X

X

4
3
1
AGATGGGTC
TTGCT
GAGTGAGGC

X

X

2
1
1
AGCAGAGTC
AGGAT
GAATGAGGA

X

2
1
1
AGCAGAGTC
ATGAA
GATTGAGGA

X

3
0
3
AGCAGCGTC
TGAAAG
TAGAGATGA

X

3
0
3
AGCAGCGTC
AGCTTC
AAGTATGGA

X

3
0
3
AGCAGCGTC
AACATT
TAGTAATGA

X

3
0
3
AGCAGCGTC
AACATT
TAGTAATGA

X

3
1
2
AGCAGTGTC
TTAGGA
AAGAGAGGA

X

3
1
2
AGCAGCTTC
AGATGG
GAGAGAGAA

X

3
1
2
AGCAGTGTC
CAGCA
AAGAGAGGA

X

3
1
2
TGCAGCGTC
AATGT
GAGTGAAAA

X

3
1
2
AGCAGTGTC
AGGTAT
GAGAGGGGA

X

3
1
2
AGCAGCTTC
AGGGA
GAGTGTGGG

X

3
1
2
AGCAGTGTC
CTTGCC
GAAGGAGGA

X

3
1
2
AGCAGCTTC
ATGAAG
GAGAGAGAA

X

3
1
2
AGCAGCGTG
GAGGT
GAGTGGGGT

X

3
1
2
AGCAGCGTT
ACTCAG
GAGAGAGAA

X

3
1
2
AGAAGCGTC
ACTGA
GAGTGAGTT

X

3
1
2
AGCAGCATC
TTGAG
GGGTGAGGC

X

3
1
2
AGCAGCGGC
ACAAA
GAGGGACGA

X

3
1
2
AGCATCGTC
TGAAG
GGGTGAGCA

X

3
1
2
AGCAGCTTC
CACCA
GAGGGAGTA

X

3
1
2
AGCAGCGTT
CTGTCT
AAGTGAAGA

X

3
1
2
AGCAGCATC
TGCTTC
GGGTGAGGC

X

3
1
2
AGCAGGGTC
GGGGA
GGGTGAGAA

X

3
1
2
AGCAGGGTC
AGCTGG
GAGTAAGAA

X

3
1
2
AGCAGCGCC
GGAAGA
GAGCGAGGG

X

3
1
2
AGCACCGTC
CCTAA
GACTGAGCA

X

3
1
2
AGCAGAGTC
ACAGCT
GAATGAGGC

X

3
1
2
AGCAGCGTG
GACCCA
AAGAGAGGA

X

3
1
2
AGCAGGGTC
CACAT
GAGTCAGGG

X

3
1
2
AGCAGGGTC
GGGGTG
GAGGGAGAA

X

3
1
2
GGCAGCGTC
CAGGTA
GACTGAGGG

X

3
1
2
AGCAGTGTC
CTAAAG
GAAGGAGGA

X

3
1
2
AGCAGCCTC
TTCTG
TAATGAGGA

X

3
1
2
AGCAGCGTT
GGGAA
GAGAGAGAA

X

3
1
2
AGCAGCGAC
AGGGCA
GAATGAGGC

X

3
1
2
AGCAGAGTC
GAGCA
AGGTGAGGA

X

3
1
2
AGCAGCATC
GAGTGG
AAGTGGGGA

X

3
2
1
AGCTGAGTC
CAGAA
GAGTGGGGA

X

3
2
1
GGCAGTGTC
AGTAG
GTGTGAGGA

X

3
2
1
AGCAACTTC
AGAAT
GAGTTAGGA

X

3
2
1
AGCATCTTC
AGCTA
TAGTGAGGA

X

3
2
1
GGCAGGGTC
ACCCGA
AAGTGAGGA

X

3
2
1
AGCAGTGTG
TGCCCA
GAGTGAGTA

X

3
2
1
AGCAGTGTA
CCATGC
GAGTGAGCA

X

3
2
1
AGCTGGGTC
TATTTG
GAGTCAGGA

X

3
2
1
AGCAGCGAG
GTGGG
GAGTGAGTA

X

3
2
1
AGCAGCTTG
GATTCA
GAGTGAGAA

X

3
2
1
AGCAGCAGC
AACGAG
GAGCGAGGA

X

3
2
1
AGCACCATC
TTTGAA
AAGTGAGGA

X

3
2
1
AGCAGAGTT
TGAATT
GAGTTAGGA

X

3
2
1
GGCAGGGTC
AAGGA
AAGTGAGGA

X

3
2
1
GGCAGTGTC
CAGGAG
GTGTGAGGA

X

3
2
1
TGCAACGTC
ACAAGT
GAGAGAGGA

X

3
2
1
AACAGTGTC
TTTCAA
AAGTGAGGA

X

3
2
1
AGCAGTGTA
GACCCA
GAGTGAGCA

X

3
2
1
AGCTGTGTC
CCCTT
GAGAGAGGA

X

3
2
1
AGCAGCGGA
GGTGGG
GAGGGAGGA

X

3
2
1
AACAGCTTC
TCATT
GAGTGAGTA

X

3
2
1
AGTAGAGTC
AGGCCT
GAATGAGGA

X

3
2
1
AGCAGCGAA
GCCGG
AAGTGAGGA

X

3
2
1
AACTGCGTC
CCAGG
AAGTGAGGA

X

3
2
1
AGAAGCCTC
TGCTAT
GAGTGAGGC

X

3
2
1
AGCAGTGTG
CAATG
GAGTGAGTA

X

3
2
1
AGTAGAGTC
CCTGG
GAGTGAGCA

X

3
2
1
GGCAGTGTC
ATGTGT
GAGGGAGGA

X

3
2
1
AGCACTGTC
ACTGTT
GAGTGATGA

X

3
2
1
AGCTGGGTC
TGGGAG
GAGTCAGGA

X

3
2
1
AGCAGCTTT
CCAAGA
GAGTGAGAA

X

3
2
1
AGCAGTGTA
GACCCA
GAGTGAGCA

X

3
2
1
GGCAGCGTG
GGGATG
CAGTGAGGA

X

3
2
1
AGCAGCAGC
AGAGG
GAGCGAGGA

X

3
2
1
AGTAGCTTC
CCTCT
GTGTGAGGA

X

3
2
1
TGCGGCGTC
TCCTGG
GAGTGAAGA

X

3
2
1
AACAGAGTC
TGGCA
GAGTGAGCA

X

3
2
1
GGCAGCGGC
CTGGG
GAGTGTGGA

X

3
2
1
AGCAGGCTC
CTTGT
TAGTGAGGA

X

3
3
0
ATCACCATC
ATACCT
GAGTGAGGA

X

3
3
0
AGCAGTTTA
ATTCT
GAGTGAGGA

X

3
3
0
AACAGCAAC
AAAAA
GAGTGAGGA

X

3
3
0
AGCTGAGTA
GAATG
GAGTGAGGA

X

3
3
0
AGCAACCTG
GGGCT
GAGTGAGGA

X

3
3
0
AGCAACCTG
GAAAA
GAGTGAGGA

X

3
3
0
TGCAGGCTC
CTGTG
GAGTGAGGA

X

3
3
0
CGCAGTATC
CCACT
GAGTGAGGA

X

3
3
0
AGAAACATC
AGATG
GAGTGAGGA

X

3
3
0
ACCTGTGTC
TCCTG
GAGTGAGGA

X

3
3
0
GGCAGGGCC
TCAAGG
GAGTGAGGA

X

3
3
0
AGAAACATC
TAAGAG
GAGTGAGGA

X

3
3
0
AGGTGCATC
CCTCA
GAGTGAGGA

X

3
3
0
GGCAGGGCC
TTCTT
GAGTGAGGA

X

3
3
0
GGCAGCTGC
TTTTT
GAGTGAGGA

X

3
3
0
AGCATGGCC
CAGGAG
GAGTGAGGA

X

4
0
4
AGCAGCGTC
TTCAGC
AAGTGGAGG

X

4
0
4
AGCAGCGTC
TGGGGC
AGTGGAGGA

X

4
0
4
AGCAGCGTC
TCATA
GAGTTAACC

X

4
0
4
AGCAGCGTC
CCTGA
AATTGTGCA

X

4
1
3
AGCAACGTC
AGGGAA
GAGGGACCA

X

4
1
3
AGCAGGGTC
CACTCA
GAGGGAGTC

X

4
1
3
AGCAGCGTG
TGGCT
GTGTGTGGC

X

4
1
3
AGCAGCGTT
GGCTGA
AACTGAGGT

X

4
1
3
AGCAACGTC
TCCAGG
GACTGAAGC

X

4
1
3
AGCAGGGTC
ATTTAG
GAGTGACAT

X

4
1
3
AGCAGTGTC
TTGTCA
GAGTGTGTC

X

4
1
3
AGCAACGTC
CTCAAG
GAGGCAAGA

X

4
1
3
AGCATCGTC
CACCTG
GCGAGAGGC

X

4
1
3
AGCAGCTTC
TAACA
AAGTGAGAC

X

4
1
3
AGCAACGTC
AGGGAG
GAGAGGGCA

X

4
1
3
AGCAGCGTT
TTCAT
GTGTGTGTA

X

4
1
3
AGCAGCGTT
TAACT
GAGTGAAAG

X

4
1
3
AGCAGGGTC
AGCAG
GAGGGAGTC

X

4
1
3
AGCAGTGTC
ATTAC
GAGTGCGAC

X

4
1
3
AGCAGTGTC
AGTGC
AAGTGCGGG

X

4
1
3
AGCAGCTTC
CATCG
TGGTGTGGA

X

4
1
3
GGCAGCGTC
TAGGG
GTGTGATAA

X

4
1
3
AGCAGCTTC
CGGTC
GAGTGATTT

X

4
1
3
AGCAGGGTC
CGGCTT
GTGTGCGGC

X

4
1
3
AGCAGCGGC
AAGAA
GAGGGTGGT

X

4
1
3
AGCAGCCTC
ACTCA
GAGTGGGAC

X

4
1
3
AGCAACGTC
TCCACA
GAGACAGGC

X

4
1
3
AGCAGCGTG
GGGGGA
GTGTGGGGG

X

4
1
3
AGCAGGGTC
TGCAGG
GACTGAGAG

X

4
1
3
AGCAGTGTC
TTTTC
CAGTAAGGT

X

4
1
3
AGCAGCGGC
AAGCAC
AAGCAAGGA

X

4
1
3
AGCAGCTTC
CTCCAG
GGGAGAGGT

X

4
1
3
AGCAGCTTC
GCCTGC
TGGTGTGGA

X

4
1
3
AGCAGCGAC
TCACAC
AAGTGAGAT

X

4
1
3
AGCAGCGGC
CCCAGC
GAGTGTGTC

X

4
1
3
AGCAGTGTC
TGCAAC
TAGTGAGCT

X

4
1
3
AGCAGCGGC
CTGGGG
ACGAGAGGA

X

4
1
3
AGCAGCGGC
TGCCA
GAGGGTGGT

X

4
1
3
AGCAACGTC
CATTCT
GAGGCAAGA

X

4
2
2
AGCATTGTC
GGATTC
TGGTGAGGA

X

4
2
2
AGCATGGTC
ACAAA
GGGTGAGGT

X

4
2
2
AGCAACATC
ACAGA
GAGAGAGGG

X

4
2
2
AGCAATGTC
CCTTG
GAGTGTGGG

X

4
2
2
AGCAGCTGC
CAGAG
GAGGGAGGC

X

4
2
2
AGCTGGGTC
CTAGA
AAGTGAGGT

X

4
2
2
AGCAGCTGC
AGTGA
GAGTGAGCT

X

4
2
2
AGCATTGTC
AATGA
CAGTGAGAA

X

4
2
2
AGCAAAGTC
TAAGA
GAGTGTGGC

X

4
2
2
AGCAGGGTG
GAGAA
GAGCGAGGG

X

4
2
2
ATCAACGTC
CTTTGA
GAGAAAGGA

X

4
2
2
AGCAGCTTT
TTTCC
GAGTGAGAG

X

4
2
2
GGCAGCGTT
TCCTGT
GAGCAAGGA

X

4
2
2
AGCACCATC
AGGAG
GAGGGAGGG

X

4
2
2
ATCAGAGTC
TGCAG
GCGTGAGGC

X

4
2
2
AGCACCGGC
CTCTTG
GAGGGAGGT

X

4
2
2
GGCAGGGTC
AGTGG
GAGTGAGTC

X

4
2
2
AGCACCTTC
TCCTGG
TAGTGAGGC

X

4
2
2
AGCGGTGTC
ATCCAG
GAGTGAGCG

X

4
2
2
AGCAATGTC
TATAA
AAGTGAGGC

X

4
2
2
AGCAGGGTA
AGTAC
AAGTGAGGC

X

4
2
2
AGCAACGTG
ATCGG
GAGGGAGGG

X

4
2
2
AGCAGGGTA
GATGG
GAGAGAGGG

X

4
2
2
AGCAATGTC
TGGGT
GAGTGTGGG

X

4
2
2
AGCAATGTC
TGAAA
TAGTGAGTA

X

4
2
2
TGCAGAGTC
AAGGAA
GAGTGAGAT

X

4
2
2
AGCATAGTC
TCCTAG
GAGAGAGGC

X

4
2
2
AGCAGGGTA
ATGGG
GAGAGAGGG

X

4
2
2
ATCACCGTC
GAGGG
GAGGGAGGG

X

4
2
2
GGCAGCTTC
GGTGTC
CAGTGAGGC

X

4
2
2
AGCTGGGTC
TCATTG
CAGTGAGGT

X

4
2
2
AGCAACGTA
CTGTT
AAGTGAGAA

X

4
2
2
AGCAAAGTC
AAGAA
GAGTGAAAA

X

4
2
2
GGCAGGGTC
TCTCA
AAGTGAGGT

X

4
2
2
TGCAGGGTC
ATGCAA
GTGTGAGGT

X

4
2
2
AGCAAAGTC
AGAGCT
GAGTGAGCC

X

4
2
2
GGCAGTGTC
ATTTTT
GAGTAAGGG

X

4
2
2
AGCAGCTGC
TGTGG
GAGGGAGGC

X

4
2
2
AGCAGCGGT
GGTATC
TAGTGAGGC

X

4
2
2
AGCAACATC
TGGAAC
GAGTGAATA

X

4
2
2
AGCAGTGTG
ATCTT
GAGTAAGGC

X

4
2
2
GGCAGCTTC
AGCAC
CAGTGAGGC

X

4
2
2
AGCAGAGTT
GCTTAA
GAGTGAGAG

X

4
2
2
AGCACCTTC
TGCCAA
GAGTGAGAT

X

4
2
2
AGCAGCTGC
GGGCA
GAGTGAGCT

X

4
2
2
AGTAGAGTC
TTTGTT
GTGTGAGGT

X

4
2
2
AGCATGGTC
GTTGGG
GGGTGAGGC

X

4
2
2
AGCATTGTC
TCTTGT
GTGTGAGGT

X

4
2
2
ATCAGAGTC
AATTTG
TAGTGAGGT

X

4
2
2
AGCAGCTTA
GAGGG
GAGAGAGGT

X

4
2
2
GACAGCGTC
CTCCG
GGGTGAGGC

X

4
2
2
TGCAGAGTC
AGCCCT
GAGTGAGAT

X

4
2
2
AGCAGAGTT
GGAAG
GAGTGAGAG

X

4
2
2
AGCAGGGTA
GGTCA
GAGAGAGGG

X

4
3
1
TGCAGTGAC
TGTCCA
GAGTGAGGC

X

4
3
1
AGCAGAGGT
GAGGT
GAGTGAGGG

X

4
3
1
AGCAGTTTA
AATTT
GAGTGAGGC

X

4
3
1
AGAAAGGTC
ATAAT
GAGTGAGGG

X

4
3
1
AGCACAATC
CCAAAG
GAGTGAGGC

X

4
3
1
AGCAAAGGC
AGGAG
GAGTGAGGT

X

4
3
1
AGCCACATC
CCCTA
GAGTGAGGT

X

4
3
1
TGCTGGGTC
TACAG
GAGTGAGGC

X

4
3
1
GGCAGTGTG
AGCTG
GAGTGAGGG

X

4
3
1
AGTAGTGTG
CTGAA
GAGTGAGGG

X

4
3
1
TGCATGGTC
AGAGGT
GAGTGAGGG

X

4
3
1
AGCATAGTT
TAGGAT
CAGTGAGGA

X

4
3
1
AGCAGCAGG
ATGAGA
GAGTGAGGC

X

4
3
1
AGCACCATT
AAATTG
GAGTGAGGC

X

4
3
1
ATCAGGGTT
AAGCA
GAGTGAGGG

X

4
3
1
AGCAAAGTG
GAGAG
GAGGGAGGA

X

4
3
1
AGCAACACC
AATGAA
GAGTGAAGA

X

4
3
1
GGCAGTGGC
TCTGT
GAGTGAGGT

X

4
3
1
AGTATCGGC
TGTGGT
GAGTGAGGG

X

4
3
1
GGCAGCTCC
GCCTCC
GAGTGAGGG

X

4
3
1
AGCAAAGGC
TGGGTG
GAGTGAGGT

X

4
3
1
AGCAAGTTC
CACTG
GAGTGTGGA

X

4
3
1
AGCAAAGGC
AGTCA
GAGTGAGGG

X

4
3
1
CGCAGCAAC
GCTCTG
GAGTGAGGC

X

4
3
1
GGCAGCGGT
TGGGG
GAGTGAGGC

X

4
3
1
AGCAACTGC
TTTTA
GAGTGAGCA

X

4
3
1
AGAAGAGTA
AAGCA
GAGTGAGGT

X

4
3
1
AGCAACATA
ATAACA
GAGTGAGGT

X

4
3
1
CGCACCTTC
CTGTAT
GAGTGAGGC

X

4
3
1
GTCCGCGTC
GCCCA
GAGTGAGAA

X

4
3
1
GGCAGTGTG
CTTGAT
GAGTGAGGG

X

4
3
1
CCCACCGTC
CTAAAG
AAGTGAGGA

X

4
3
1
AACAACGTG
AAACCA
GAGTGAGGC

X

4
3
1
AGCAACCAC
AAAAA
AAGTGAGGA

X

4
3
1
AGCCCCTTC
AGCATA
GAGTGAGGG

X

4
3
1
AGCCGCTGC
AGCAGG
GAGTGAGGT

X

4
3
1
AGCCGCTGC
AGCAGG
GAGTGAGGT

X

4
3
1
AGCCGCTGC
AGCAGG
GAGTGAGGT

X

4
3
1
AGCCGCTGC
AGCAGG
GAGTGAGGT

X

4
3
1
AGAGGGGTC
TGCAG
GAGTGAGGG

X

4
3
1
AGCAAAGGC
AAATA
GAGTGAGGG

X

4
3
1
GGCAACTTC
CAAGA
AAGTGAGGA

X

4
3
1
GCCAGCTTC
CATACA
GAGTGAGGC

X

4
3
1
AGAAGGGTG
ATTAG
GAGTGAGGC

X

4
3
1
AGCTACGAC
TCAGGA
GAGTGAGGT

X

4
3
1
AGCAAGGTG
GGCGG
GAGTGAGGG

X

4
3
1
AGGAGAGTT
AGAAGA
GAGTGAGGT

X

4
3
1
TGCTCCGTC
CTGGCT
GAGTGAGGT

X

4
3
1
AGCACTGTT
TGCCC
GAGTGAGGC

X

4
3
1
AGTACCATC
AGGGCT
GAGTGAGGC

X

4
3
1
AGCAGCAGG
GCAGT
GAGTGAGGC

X

4
3
1
GGCAGGGAC
CATAT
GAGTGAGGC

X

4
3
1
AGCAAGGTT
CCCCG
GAGTGAGTA

X

4
3
1
AGCATGGGC
AGGGG
GAGTGAGGC

X

4
3
1
AGCTGAGTA
GCTAA
GAGTGAGGC

X

4
3
1
AGCGACTTC
ATATCT
GAGTGAGGT

X

4
3
1
AGGAGAGTT
TAAAG
GAGTGAGGT

X

4
3
1
GACAGCATC
AGTCTG
GAGTGAGGG

X

4
3
1
AGCAACTCC
ATTTC
GAGTGAGGC

X

4
3
1
AGTCGCTTC
ACTTTG
GAGTGAGAA

X

4
3
1
AGTAACATC
TTTACT
GAGGGAGGA

X

4
3
1
AGCAACTGC
AATGGT
GAGTGAGCA

X

4
3
1
AGCATTGTG
CTAGG
CAGTGAGGA

X

4
3
1
AGAAAAGTC
TTGAAG
GAGTGAGGG

X

4
3
1
GGCAGTGTA
GGGAG
GAGTGAGGT

X

4
3
1
AGCAAGGTA
AAGGAG
GAGTGAGGT

X

4
3
1
AGCATCTGC
AGATG
GAGTGAGGC

X

4
3
1
TGCATAGTC
TTGGG
GAGTGAGGG

X

4
3
1
AGAAGGGTG
AGGTGG
GAGTGAGGC

X

4
3
1
AGCCGAGTG
GTTAA
GAGTGAGGG

X

4
3
1
CTCAGGGTC
ATTAGT
GAGTGAGGG

X

4
3
1
AACAGGGTT
GGCCT
GAGTGAGGC

X

4
3
1
AGCCTAGTC
ACACCT
GAGTGAGGG

X

4
3
1
AGCAATGTT
TTGCT
GAGTGAGAA

X

4
3
1
AGCAGCAAA
TCTGCT
GAGTGAGGT

X

4
3
1
AGCAGTCCC
TGCCCA
GAGTGAGGC

X

4
3
1
TGCAATGTC
TTTGA
GAGTGAGGT

X

4
3
1
TGCAGGTTC
TTTGG
GAGTGAGGG

X

4
3
1
AGCTAAGTC
TGTAGG
CAGTGAGGA

X

4
3
1
AGCATAGTT
GGGAG
CAGTGAGGA

X

4
3
1
AGCATGGTA
GAGACT
GAGTGAGGG

X

4
3
1
AGCAAGGAC
TGGGCT
GAGTGAGGC

X

4
3
1
AGGTGGGTC
CCCAGA
GAGTGAGGC

X

4
3
1
AGCAGCTGT
CAATCA
GAGTGAGGC

X

4
3
1
TGCATGGTC
CTGGAG
GAGTGAGGG

X

4
3
1
AGCATAGTA
CTTAA
GAGTGAGGG

X

4
3
1
AGCAAGGTA
ATTAG
GAGTGAGTA

X

4
3
1
TGCACCTTC
ATGCCT
GAGTGAGGG

X

4
3
1
AGCACCGAG
GTCGGA
GAGTGAGGG

X

4
3
1
TGGAGAGTC
AGCAG
GAGTGAGTA

X

4
3
1
AGAAGAGTT
AGGTGG
GAGTGAGGT

X

4
3
1
ATCAGGGTT
AGGAT
GAGTGAGGG

X

4
3
1
GGCAGTGCC
CAGCAG
GAGTGAGGC

X

4
3
1
AGTAAGGTC
TTAAA
TAGTGAGGA

X

4
3
1
AGCAGCAGG
CCAGT
GAGTGAGGC

X

4
4
0
AGCCATGTG
CAAGT
GAGTGAGGA

X

4
4
0
GGTAGTGTT
ATGAAT
GAGTGAGGA

X

4
4
0
TACAAAGTC
GATGA
GAGTGAGGA

X

4
4
0
AGCCATGTA
CATGT
GAGTGAGGA

X

4
4
0
GACTGGGTC
TGTCAT
GAGTGAGGA

X

4
4
0
AGCACAGCA
GATGA
GAGTGAGGA

X

4
4
0
TGAATAGTC
TTGGAA
GAGTGAGGA

X

4
4
0
GTCAGGTTC
ACACAT
GAGTGAGGA

X

4
4
0
GGTAAAGTC
TGGTCA
GAGTGAGGA

X

4
4
0
AGTATAGTG
GCAGA
GAGTGAGGA

X

4
4
0
ATGGGGGTC
AGAGGG
GAGTGAGGA

X

4
4
0
CCCAAAGTC
GTAAG
GAGTGAGGA

X

4
4
0
CAAATCGTC
TACAT
GAGTGAGGA

X

4
4
0
AATAAGGTC
ATAGCA
GAGTGAGGA

X

4
4
0
AGTATAGTT
CAGAT
GAGTGAGGA

X

4
4
0
AGAGAGGTC
AAGGA
GAGTGAGGA

X

4
4
0
TGGTGAGTC
ACCAC
GAGTGAGGA

X

4
4
0
TGCCTGGTC
ACTTGG
GAGTGAGGA

X

4
4
0
AGCCATGTG
GGAAG
GAGTGAGGA

X

4
4
0
AACAAGGTT
CGCAGA
GAGTGAGGA

X

4
4
0
AGCAATTTA
TGTACA
GAGTGAGGA

X

4
4
0
AGGCATGTC
TCAGCA
GAGTGAGGA

X

4
4
0
TACAAAGTC
CTTAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGAGAG
GAGTGAGGA

X

4
4
0
AATAAAGTC
AGATAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGATAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AAATAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGATG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGATAG
GAGTGAGGA

X

4
4
0
AGCACAGCA
GGCAG
GAGTGAGGA

X

4
4
0
GGAAAGGTC
AGTTAT
GAGTGAGGA

X

4
4
0
AGCCATTTC
AACAA
GAGTGAGGA

X

4
4
0
AATAAGGTC
ACGGTG
GAGTGAGGA

X

4
4
0
ATCAGCACT
TCAGA
GAGTGAGGA

X

4
4
0
GGTGGGGTC
ATGGA
GAGTGAGGA

X

4
4
0
CACACAGTC
AGTGTA
GAGTGAGGA

X

4
4
0
AATATTGTC
TCTGT
GAGTGAGGA

X

4
4
0
GGAATAGTC
TGGTTA
GAGTGAGGA

X

4
4
0
AGCAACAAT
CGTAC
GAGTGAGGA

X

4
4
0
AATAAGGTC
ACAGTG
GAGTGAGGA

X

4
4
0
GACTGTGTC
CTTCA
GAGTGAGGA

X

4
4
0
AATAAAGTC
AGATAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGAGAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGACAA
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGATAG
GAGTGAGGA

X

4
4
0
AATAAGGTC
AGATG
GAGTGAGGA

X

5
1
4
AGCAGCTTC
CCCTG
CAGAAAGGT

X

5
2
3
GGCAACGTC
ATCTC
TAGTGAGAC

X

5
2
3
AGCAGTTTC
TTTTAC
TTGTGAGGG

X

5
2
3
AGCAGTTTC
AGTATC
TTGTGAGGG

X

5
2
3
AGCAGCAGC
CGAAC
GAGGGAGAT

X

5
2
3
AGCAGCAGC
CCAGG
GAGGGAGAT

X

5
2
3
AGCAACTTC
TCTAA
TTGTGAGGT

X

5
2
3
AGCAACTTC
CACAG
TTGTGAGGT

X

5
2
3
AGCAAGGTC
AGTGA
TAGTGAATA

X

5
2
3
AGCAGTTTC
GGTGTT
TTGTGAGGG

X

5
2
3
AGCAGCAGC
AGGAA
GAGGGAGAT

X

5
2
3
AGCATTGTC
TTAGA
AAGTAAGGG

X

5
3
2
AGCCCAGTC
TCAGG
GAGTGAGAG

X

5
3
2
AGCTACATC
TGCATT
GAGTGAGTC

X

5
3
2
AGCATGGTT
TGAAAG
GAGTGAGCC

X

5
3
2
GACAGGGTC
CACTTG
GAGTGAGTC

X

5
3
2
ATCCTCGTC
CTGCA
GAGTGAGTC

X

5
3
2
CAGAGCGTC
CAGGT
GAGTGAGTC

X

5
3
2
AGCAAAGGC
CTGAAG
GAGTAAGGG

X

5
3
2
AGCATCGAT
TAAAA
GAGTGAGAG

X

5
3
2
ATCATGGTC
ACTTT
GAGGGAGGG

X

5
3
2
AGCCCAGTC
CCCCTA
GAGTGAGAG

X

5
3
2
TGCATAGTC
AATTT
GAGTGAGAT

X

5
3
2
AGCCATGTC
AGCTT
GAGGGAGGT

X

5
3
2
AGCATTGTA
GGGGAC
GAGTGTGGT

X

5
3
2
ATCATGGTC
CAGGA
GAGGGAGGG

X

5
3
2
AGCAAAGGC
CAAGT
GAGTAAGGG

X

5
3
2
ATAAGAGTC
ATGCAG
GAGTGAGTG

X

5
3
2
AGCCATGTC
CCAAGG
GAGGGAGGT

X

5
3
2
AGCAAAGGC
AATGA
GAGTAAGGG

X

5
3
2
AGCCCAGTC
AGGAT
GAGTGAGAG

X

5
4
1
TTCCACGTC
AACAT
GAGTGAGGG

X

5
4
1
AGTCAGGTC
CCCACA
GAGTGAGGT

X

5
4
1
CTGAGGGTC
GGTAG
GAGTGAGGC

X

5
4
1
ATGACAGTC
TATGCA
GAGTGAGGC

X

5
4
1
AACAGTCTA
CCTGA
GAGTGAGGC

X

5
4
1
CTCAGTTTC
CTGAG
GAGTGAGGG

X

5
4
1
AGTCAGGTC
TTCCAT
GAGTGAGGG

X

5
4
1
GTGGGCGTC
CACTAA
GAGTGAGGC

X

5
4
1
GGTGGGGTC
CTTGAA
GAGTGAGGC

X

5
4
1
AGTTAAGTC
TCTAGA
GAGTGAGGG

X

5
4
1
TTCACCTTC
CACCAT
GAGTGAGGC

X

5
4
1
TCCTGAGTC
TTGGTA
GAGTGAGGC

X

5
4
1
ATAATAGTC
TCCAT
GAGTGAGGC

X

5
4
1
AGCAAAGGT
GGGGTG
GAGTGAGGT

X

5
4
1
AGTTTAGTC
CTTGG
GAGTGAGGT

X

5
4
1
ACAAAGGTC
CTCCA
GAGTGAGGC

X

5
4
1
TGCAGTCCC
AATCA
GAGTGAGGT

X

5
4
1
AGTCATGTC
GTTAA
GAGTGAGGC

X

5
4
1
CACCACGTC
AAGGTA
GAGAGAGGA

X

5
4
1
CTCAGTTTC
AAAAGC
GAGTGAGGG

X

5
4
1
GAAAGTGTC
CAAGTG
GAGTGAGGC

X

5
4
1
GGGTGGGTC
TAGAGG
GAGTGAGGT

X

5
4
1
AGAGTTGTC
CCCCAA
GAGTGAGGC

X

6
4
2
AGAAGGGGT
AGGAG
GAGTGAGAG

X

3
1
2
AGCAGAGTC
ATATT
GAGTCAGGG

X

3
3
0
ACCATCTTC
ATCAG
GAGTGAGGA

X

4
2
2
AGGAACGTC
TCCAA
GGGTGAGGG

X

4
2
2
AGCACCTTC
AGAGG
GAGTGTGGC

X

4
2
2
GGCAGGGTC
GGTCA
GAGTGAGAG

X

4
2
2
GGCAGGGTC
ACAGGT
GAGTGAGAG

X

4
2
2
AGCACAGTC
AAGCT
GAGGGAGGT

X

4
2
2
GGCAGGGTC
TAGGCA
GAGTGAGAG

X

4
2
2
AGCAAGGTC
TACTCG
GGGTGAGGC

X

4
3
1
AGCAAGTTC
CGTTAA
GAGTGAGGT

X

4
3
1
AGCAGTTTT
TGCAGT
GAGTGAGGC

X

2
1
1
AGCTGCGTC
ACATG
GACTGAGGA

X

3
1
2
AGCAGGGTC
TGAGCT
GTGTGGGGA

X

3
1
2
AGCAGGGTC
AGCTG
GTGTGGGGA

X

3
2
1
AGAAGCCTC
AAGGAT
GAGTGAGGT

X

3
2
1
AGAAGCCTC
ATAAGT
GAGTGAGGT

X

3
3
0
AGCATTTTC
AATTT
GAGTGAGGA

X

4
0
4
AGCAGCGTC
CCTCC
GACACTGGA

X

4
1
3
AGCAGTGTC
ACCGAC
AGGTGAGGC

X

4
1
3
AGCAGTGTC
TGGGA
GAGGGTAGA

X

4
2
2
AGCAACTTC
TTCCT
GGGTGAGGC

X

4
3
1
AGCCCGGTC
TGAAAG
GAGTGAAGA

X

4
3
1
AGTAACTTC
TGAGTG
GAGTGAGGC

X

4
3
1
AGTAACTTC
AAAAT
GAGTGAGGC

X

4
3
1
ACCTGCTTC
AAAGT
GAGTGAGGG

X

4
3
1
AGCATTTTC
CCCCTA
AAGTGAGGA

X

4
3
1
AGTAACTTC
AGTATA
GAGTGAGGC

X

4
3
1
AGCAATGTT
TGAGT
GAGTGATGA

X

4
3
1
AGCATTTTC
CTTTA
AAGTGAGGA

X

4
3
1
AGCCACGGC
TGCCTG
GAGTGAGGG

X

4
4
0
CCTAGAGTC
CAGGA
GAGTGAGGA

X

5
4
1
ATCATAGTG
ACCAC
GAGTGAGGC

X

Claims

1. A library of synthetic nucleic acid molecules comprising a plurality of nucleic acid molecules, wherein each of the synthetic nucleic acid molecules comprises multiple copies of a DNA sequence linked in series, wherein each of the multiple copies of the DNA sequence linked in series in each of the synthetic nucleic acid molecules is the same and has the following structure:5′-[(candidate nuclease target site)-(constant insert sequence)]x-3′, wherein x is at least 5;wherein the nucleotide sequence of the constant insert sequence in each of the synthetic nucleic acid molecules is the same; andwherein the candidate nuclease target site of each of the synthetic nucleic acid molecules of the library comprises the following structure:5′-[left-half site]-[spacer sequence]-[right-half site]-3′ (LSR) structure, and wherein the nucleotide sequence of the LSR structure of each of the synthetic nucleic acid molecules is the same.
2. The library of claim 1, wherein the left-half site and the right-half site comprise different nucleic acid sequences.
3. The library of claim 1, wherein the left-half site and/or the right-half site are/is 10-18 nucleotides long.
4. The library of claim 1, wherein some of the synthetic nucleic acid molecules of the library comprise the candidate nuclease target site that can be cleaved by a nuclease comprising a FokI cleavage domain.
5. The library of claim 1, wherein some of the synthetic nucleic acid molecules of the library comprise the candidate nuclease target site that can be cleaved by a Zinc Finger Nuclease (ZFN) or a Transcription Activator-Like Effector Nuclease (TALEN).
6. The library of claim 1, wherein the library comprises at least 105 different synthetic nucleic acid molecules.
7. The library of claim 1, wherein the library of synthetic nucleic acid molecules comprises nucleic acid molecules having a molecular weight of at least 5 kDa.
8. The library of claim 1, wherein the left-half site is a partially randomized left-half site, the right-half site is a partially randomized right-half site, and/or the spacer sequence is a partially randomized spacer sequence.
9. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site are/is based on a known target site of a nuclease of interest.
10. The library of claim 9, wherein the nuclease of interest is a ZEN, a TALEN, or a derivative thereof.
11. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site differ/differs from a consensus site by more than 5% on average.
12. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site differ/differs from a consensus site by no more than 10% on average.
13. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site differ/differs from a consensus site by no more than 15% on average.
14. The library of claim 1, wherein the spacer sequence is a randomized spacer sequence.
15. The library of claim 1, wherein the candidate nuclease target site is located within a genomic sequence.
16. The library of claim 15, wherein the genomic sequence is known to be associated with a disease or disorder.
17. The library of claim 16, wherein the disease or disorder is human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), or a proliferative disease.
18. The library of claim 15, wherein the genomic sequence is a C-C chemokine receptor type 5 (CCRS5) sequence or vascular endothelial growth factor type A (VEGFA) sequence.
19. The library of claim 1, wherein each of the synthetic nucleic acid molecules of the library comprises at least ten copies of the DNA sequence linked in series.
20. The library of claim 1, wherein each of the synthetic nucleic acid molecules of the library comprises at least 100 copies of the DNA sequence linked in series.
21. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site differ/differs from a consensus site by one, two, three, four, or five nucleotide residue/residues.
22. The library of claim 8, wherein the partially randomized left-half site and/or the partially randomized right-half site differ/differs from a consensus site by three nucleotide residues.
23. The library of claim 1, wherein the synthetic nucleic acid molecules of the library comprise other candidate nuclease target sites that can be cleaved by an enediyne, a dynemicin, a neocarzinostatin, a calicheamicin, an esperamicin, or a bleomycin.

RELATED APPLICATIONS

This application is a divisional of and claims priority under 35 U.S.C. § 120 to U.S. Ser. No. 14/234,031, filed Mar. 24, 2014, which is a national stage filing under 35 U.S.C. § 371 of International PCT Application, PCT/US2012/047778, filed Jul. 22, 2012, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application 61/510,841, filed Jul. 22, 2011, the entire contents of each of which are incorporated herein by reference.

GOVERNMENT SUPPORT

This invention was made with government support under GM065400, GM088040, OD006862 awarded by the National Institutes of Health, and HR0011-11-2-0003 awarded by the Department of Defense. The government has certain rights in the invention.

US Referenced Citations (538)

Number	Name	Date	Kind
4182449	Kozlow	Jan 1980	A
4186183	Steck et al.	Jan 1980	A
4217344	Vanlerberghe et al.	Aug 1980	A
4235871	Papahadjopoulos et al.	Nov 1980	A
4261975	Fullerton et al.	Apr 1981	A
4485054	Mezei et al.	Nov 1984	A
4501728	Geho et al.	Feb 1985	A
4663290	Weis et al.	May 1987	A
4737323	Martin et al.	Apr 1988	A
4774085	Fidler	Sep 1988	A
4797368	Carter et al.	Jan 1989	A
4837028	Allen	Jun 1989	A
4873316	Meade et al.	Oct 1989	A
4880635	Janoff et al.	Nov 1989	A
4889818	Gelfand et al.	Dec 1989	A
4897355	Eppstein et al.	Jan 1990	A
4906477	Kurono et al.	Mar 1990	A
4911928	Wallach	Mar 1990	A
4917951	Wallach	Apr 1990	A
4920016	Allen et al.	Apr 1990	A
4921757	Wheatley et al.	May 1990	A
4946787	Eppstein et al.	Aug 1990	A
4965185	Grischenko et al.	Oct 1990	A
5017492	Kotewicz et al.	May 1991	A
5047342	Chatterjee	Sep 1991	A
5049386	Eppstein et al.	Sep 1991	A
5079352	Gelfand et al.	Jan 1992	A
5139941	Muzyczka et al.	Aug 1992	A
5173414	Lebkowski et al.	Dec 1992	A
5223409	Ladner et al.	Jun 1993	A
5244797	Kotewicz et al.	Sep 1993	A
5270179	Chatterjee	Dec 1993	A
5374553	Gelfand et al.	Dec 1994	A
5405776	Kotewicz et al.	Apr 1995	A
5436149	Barnes	Jul 1995	A
5449639	Wei et al.	Sep 1995	A
5496714	Comb et al.	Mar 1996	A
5512462	Cheng	Apr 1996	A
5580737	Polisky et al.	Dec 1996	A
5614365	Tabor et al.	Mar 1997	A
5652094	Usman et al.	Jul 1997	A
5658727	Barbas et al.	Aug 1997	A
5668005	Kotewicz et al.	Sep 1997	A
5677152	Birch et al.	Oct 1997	A
5767099	Harris et al.	Jun 1998	A
5780053	Ashley et al.	Jul 1998	A
5830430	Unger et al.	Nov 1998	A
5834247	Comb et al.	Nov 1998	A
5835699	Kimura	Nov 1998	A
5844075	Kawakami et al.	Dec 1998	A
5849548	Haseloff et al.	Dec 1998	A
5851548	Dattagupta et al.	Dec 1998	A
5855910	Ashley et al.	Jan 1999	A
5856463	Blankenborg et al.	Jan 1999	A
5962313	Podsakoff et al.	Oct 1999	A
5981182	Jacobs, Jr. et al.	Nov 1999	A
6015794	Haseloff et al.	Jan 2000	A
6057153	George et al.	May 2000	A
6063608	Kotewicz et al.	May 2000	A
6077705	Duan et al.	Jun 2000	A
6156509	Schellenberger	Dec 2000	A
6183998	Ivanov et al.	Feb 2001	B1
6355415	Wagner et al.	Mar 2002	B1
6429298	Ellington et al.	Aug 2002	B1
6453242	Eisenberg et al.	Sep 2002	B1
6479264	Louwrier	Nov 2002	B1
6503717	Case et al.	Jan 2003	B2
6534261	Cox, III et al.	Mar 2003	B1
6589768	Kotewicz et al.	Jul 2003	B1
6599692	Case et al.	Jul 2003	B1
6607882	Cox, III et al.	Aug 2003	B1
6610522	Kotewicz et al.	Aug 2003	B1
6689558	Case	Feb 2004	B2
6716973	Baskerville et al.	Apr 2004	B2
6824978	Cox, III et al.	Nov 2004	B1
6933113	Case et al.	Aug 2005	B2
6979539	Cox, III et al.	Dec 2005	B2
7013219	Case et al.	Mar 2006	B2
7045337	Schultz et al.	May 2006	B2
7067650	Tanaka	Jun 2006	B1
7070928	Liu et al.	Jul 2006	B2
7078208	Smith et al.	Jul 2006	B2
7083970	Schultz et al.	Aug 2006	B2
7163824	Cox, III et al.	Jan 2007	B2
7192739	Liu et al.	Mar 2007	B2
7223545	Liu et al.	May 2007	B2
7354761	Schultz et al.	Apr 2008	B2
7368275	Schultz et al.	May 2008	B2
7442160	Liu et al.	Oct 2008	B2
7476500	Liu et al.	Jan 2009	B1
7476734	Liu	Jan 2009	B2
7479573	Chu et al.	Jan 2009	B2
7491494	Liu et al.	Feb 2009	B2
7541450	Liu et al.	Jun 2009	B2
7557068	Liu et al.	Jul 2009	B2
7595179	Chen et al.	Sep 2009	B2
7638300	Schultz et al.	Dec 2009	B2
7670807	Lampson et al.	Mar 2010	B2
7678554	Liu et al.	Mar 2010	B2
7713721	Schultz et al.	May 2010	B2
7771935	Liu et al.	Aug 2010	B2
7794931	Breaker et al.	Sep 2010	B2
7807408	Liu et al.	Oct 2010	B2
7851658	Liu et al.	Dec 2010	B2
7915025	Schultz et al.	Mar 2011	B2
7919277	Russell et al.	Apr 2011	B2
7993672	Huang et al.	Aug 2011	B2
7998904	Liu et al.	Aug 2011	B2
8012739	Schultz et al.	Sep 2011	B2
8017323	Liu et al.	Sep 2011	B2
8017755	Liu et al.	Sep 2011	B2
8030074	Schultz et al.	Oct 2011	B2
8067556	Hogrefe et al.	Nov 2011	B2
8114648	Schultz et al.	Feb 2012	B2
8173364	Schultz et al.	May 2012	B2
8173392	Schultz et al.	May 2012	B2
8183012	Schultz et al.	May 2012	B2
8183178	Liu et al.	May 2012	B2
8206914	Liu et al.	Jun 2012	B2
8361725	Russell et al.	Jan 2013	B2
8394604	Liu et al.	Mar 2013	B2
8440431	Voytas et al.	May 2013	B2
8440432	Voytas et al.	May 2013	B2
8450471	Voytas et al.	May 2013	B2
8492082	De Franciscis et al.	Jul 2013	B2
8546553	Terns et al.	Oct 2013	B2
8569256	Heyes et al.	Oct 2013	B2
8586363	Voytas et al.	Nov 2013	B2
8680069	de Fougerolles et al.	Mar 2014	B2
8691729	Liu et al.	Apr 2014	B2
8691750	Constien et al.	Apr 2014	B2
8697359	Zhang	Apr 2014	B1
8697853	Voytas et al.	Apr 2014	B2
8709466	Coady et al.	Apr 2014	B2
8728526	Heller	May 2014	B2
8748667	Budzik et al.	Jun 2014	B2
8758810	Okada et al.	Jun 2014	B2
8759103	Kim et al.	Jun 2014	B2
8759104	Unciti-Broceta et al.	Jun 2014	B2
8771728	Huang et al.	Jul 2014	B2
8790664	Pitard et al.	Jul 2014	B2
8795965	Zhang	Aug 2014	B2
8822663	Schrum et al.	Sep 2014	B2
8835148	Janulaitis et al.	Sep 2014	B2
8846578	McCray et al.	Sep 2014	B2
8871445	Cong et al.	Oct 2014	B2
8900814	Yasukawa et al.	Dec 2014	B2
8993233	Zhang et al.	Mar 2015	B2
8999641	Zhang et al.	Apr 2015	B2
9023594	Liu et al.	May 2015	B2
9068179	Liu et al.	Jun 2015	B1
9163284	Liu et al.	Oct 2015	B2
9181535	Liu et al.	Nov 2015	B2
9228207	Liu et al.	Jan 2016	B2
9234213	Wu	Jan 2016	B2
9267127	Liu et al.	Feb 2016	B2
9322006	Liu et al.	Apr 2016	B2
9322037	Liu et al.	Apr 2016	B2
9340799	Liu et al.	May 2016	B2
9340800	Liu et al.	May 2016	B2
9359599	Liu et al.	Jun 2016	B2
9388430	Liu et al.	Jul 2016	B2
9394537	Liu et al.	Jul 2016	B2
9458484	Ma et al.	Oct 2016	B2
9512446	Joung et al.	Dec 2016	B1
9526724	Oshlack et al.	Dec 2016	B2
9526784	Liu et al.	Dec 2016	B2
9534210	Park et al.	Jan 2017	B2
9737604	Liu et al.	Aug 2017	B2
9771574	Liu et al.	Sep 2017	B2
9783791	Hogrefe et al.	Oct 2017	B2
9816093	Donohoue et al.	Nov 2017	B1
9840690	Karli et al.	Dec 2017	B2
9840699	Liu et al.	Dec 2017	B2
9873907	Zeiner et al.	Jan 2018	B2
9879270	Hittinger et al.	Jan 2018	B2
9938288	Kishi et al.	Apr 2018	B1
9944933	Storici et al.	Apr 2018	B2
9982279	Gill et al.	May 2018	B1
9999671	Liu et al.	Jun 2018	B2
10059940	Zhong	Aug 2018	B2
10077453	Liu et al.	Sep 2018	B2
10113163	Liu et al.	Oct 2018	B2
10167457	Liu et al.	Jan 2019	B2
10179911	Liu et al.	Jan 2019	B2
10202658	Parkin et al.	Feb 2019	B2
10227581	Liu et al.	Mar 2019	B2
10323236	Liu et al.	Jun 2019	B2
10336997	Liu et al.	Jul 2019	B2
10392674	Liu et al.	Aug 2019	B2
10465176	Liu et al.	Nov 2019	B2
10508298	Liu et al.	Dec 2019	B2
10583201	Chen et al.	Mar 2020	B2
10597679	Liu et al.	Mar 2020	B2
10612011	Liu et al.	Apr 2020	B2
10640767	Maianti et al.	May 2020	B2
10682410	Liu et al.	Jun 2020	B2
10704062	Liu et al.	Jul 2020	B2
10745677	Maianti et al.	Aug 2020	B2
10858639	Liu et al.	Dec 2020	B2
10912833	Liu et al.	Feb 2021	B2
10947530	Liu et al.	Mar 2021	B2
10954548	Liu et al.	Mar 2021	B2
11046948	Liu et al.	Jun 2021	B2
11053481	Liu et al.	Jul 2021	B2
11124782	Liu et al.	Sep 2021	B2
11214780	Liu et al.	Jan 2022	B2
11268082	Liu et al.	Mar 2022	B2
11299755	Liu et al.	Apr 2022	B2
11306324	Liu et al.	Apr 2022	B2
11319532	Liu et al.	May 2022	B2
11447770	Liu et al.	Sep 2022	B1
11542496	Liu et al.	Jan 2023	B2
11542509	Maianti et al.	Jan 2023	B2
11560566	Liu et al.	Jan 2023	B2
11578343	Liu et al.	Feb 2023	B2
11643652	Liu et al.	May 2023	B2
11661590	Liu et al.	May 2023	B2
11702651	Liu et al.	Jul 2023	B2
20030082575	Schultz et al.	May 2003	A1
20030087817	Cox et al.	May 2003	A1
20030096337	Hillman et al.	May 2003	A1
20030108885	Schultz et al.	Jun 2003	A1
20030119764	Loeb et al.	Jun 2003	A1
20030167533	Yadav et al.	Sep 2003	A1
20030203480	Kovesdi et al.	Oct 2003	A1
20040003420	Kuhn et al.	Jan 2004	A1
20040115184	Smith et al.	Jun 2004	A1
20040197892	Moore et al.	Oct 2004	A1
20040203109	Lal et al.	Oct 2004	A1
20050136429	Guarente et al.	Jun 2005	A1
20050222030	Allison	Oct 2005	A1
20050260626	Lorens et al.	Nov 2005	A1
20060088864	Smolke et al.	Apr 2006	A1
20060104984	Littlefield et al.	May 2006	A1
20060246568	Honjo et al.	Nov 2006	A1
20070015238	Snyder et al.	Jan 2007	A1
20070264692	Liu et al.	Nov 2007	A1
20070269817	Shapero	Nov 2007	A1
20080008697	Mintier et al.	Jan 2008	A1
20080051317	Church et al.	Feb 2008	A1
20080124725	Barrangou et al.	May 2008	A1
20080182254	Hall et al.	Jul 2008	A1
20080220502	Schellenberger et al.	Sep 2008	A1
20080241917	Akita et al.	Oct 2008	A1
20080268516	Perreault et al.	Oct 2008	A1
20090130718	Short	May 2009	A1
20090215878	Tan et al.	Aug 2009	A1
20090234109	Han et al.	Sep 2009	A1
20100076057	Sontheimer et al.	Mar 2010	A1
20100093617	Barrangou et al.	Apr 2010	A1
20100104690	Barrangou et al.	Apr 2010	A1
20100273857	Thakker et al.	Oct 2010	A1
20100305197	Che	Dec 2010	A1
20100316643	Eckert et al.	Dec 2010	A1
20110016540	Weinstein et al.	Jan 2011	A1
20110059160	Essner et al.	Mar 2011	A1
20110059502	Chalasani	Mar 2011	A1
20110104787	Church et al.	May 2011	A1
20110177495	Liu et al.	Jul 2011	A1
20110189775	Ainley	Aug 2011	A1
20110189776	Terns et al.	Aug 2011	A1
20110217739	Terns et al.	Sep 2011	A1
20110301073	Gregory et al.	Dec 2011	A1
20120129759	Liu et al.	May 2012	A1
20120141523	Castado et al.	Jun 2012	A1
20120244601	Bertozzi et al.	Sep 2012	A1
20120270273	Zhang et al.	Oct 2012	A1
20120322861	Byrne et al.	Dec 2012	A1
20130022980	Nelson et al.	Jan 2013	A1
20130059931	Petersen-Mahrt et al.	Mar 2013	A1
20130117869	Duchateau et al.	May 2013	A1
20130130248	Haurwitz et al.	May 2013	A1
20130158245	Russell et al.	Jun 2013	A1
20130165389	Schellenberger et al.	Jun 2013	A1
20130212725	Kuhn et al.	Aug 2013	A1
20130309720	Schultz et al.	Nov 2013	A1
20130344117	Mirosevich et al.	Dec 2013	A1
20130345064	Liu et al.	Dec 2013	A1
20140004280	Loomis	Jan 2014	A1
20140005269	Ngwuluka et al.	Jan 2014	A1
20140017214	Cost	Jan 2014	A1
20140018404	Chen et al.	Jan 2014	A1
20140044793	Goll et al.	Feb 2014	A1
20140065711	Liu et al.	Mar 2014	A1
20140068797	Doudna et al.	Mar 2014	A1
20140127752	Zhou et al.	May 2014	A1
20140128449	Liu et al.	May 2014	A1
20140141094	Smyth et al.	May 2014	A1
20140141487	Feldman et al.	May 2014	A1
20140179770	Zhang et al.	Jun 2014	A1
20140186843	Zhang et al.	Jul 2014	A1
20140186919	Zhang et al.	Jul 2014	A1
20140186958	Zhang et al.	Jul 2014	A1
20140201858	Ostertag et al.	Jul 2014	A1
20140234289	Liu et al.	Aug 2014	A1
20140248702	Zhang et al.	Sep 2014	A1
20140273037	Wu	Sep 2014	A1
20140273226	Wu	Sep 2014	A1
20140273230	Chen et al.	Sep 2014	A1
20140273234	Zhang et al.	Sep 2014	A1
20140283156	Zador et al.	Sep 2014	A1
20140295556	Joung et al.	Oct 2014	A1
20140295557	Joung et al.	Oct 2014	A1
20140342456	Mali et al.	Nov 2014	A1
20140342457	Mali et al.	Nov 2014	A1
20140342458	Mali et al.	Nov 2014	A1
20140349400	Jakimo et al.	Nov 2014	A1
20140356867	Peter et al.	Dec 2014	A1
20140356956	Church et al.	Dec 2014	A1
20140356958	Mali et al.	Dec 2014	A1
20140356959	Church et al.	Dec 2014	A1
20140357523	Zeiner et al.	Dec 2014	A1
20140377868	Joung et al.	Dec 2014	A1
20150010526	Liu et al.	Jan 2015	A1
20150031089	Lindstrom	Jan 2015	A1
20150031132	Church et al.	Jan 2015	A1
20150031133	Church et al.	Jan 2015	A1
20150044191	Liu et al.	Feb 2015	A1
20150044192	Liu et al.	Feb 2015	A1
20150044772	Zhao	Feb 2015	A1
20150050699	Siksnys et al.	Feb 2015	A1
20150056177	Liu et al.	Feb 2015	A1
20150056629	Guthrie-Honea	Feb 2015	A1
20150064138	Lu et al.	Mar 2015	A1
20150064789	Paschon et al.	Mar 2015	A1
20150071898	Liu et al.	Mar 2015	A1
20150071899	Liu et al.	Mar 2015	A1
20150071900	Liu et al.	Mar 2015	A1
20150071901	Liu et al.	Mar 2015	A1
20150071902	Liu et al.	Mar 2015	A1
20150071903	Liu et al.	Mar 2015	A1
20150071906	Liu et al.	Mar 2015	A1
20150079680	Bradley et al.	Mar 2015	A1
20150079681	Zhang	Mar 2015	A1
20150098954	Hyde et al.	Apr 2015	A1
20150118216	Liu et al.	Apr 2015	A1
20150132269	Orkin et al.	May 2015	A1
20150140664	Byrne et al.	May 2015	A1
20150159172	Miller et al.	Jun 2015	A1
20150165054	Liu et al.	Jun 2015	A1
20150166980	Liu et al.	Jun 2015	A1
20150166981	Liu et al.	Jun 2015	A1
20150166982	Liu et al.	Jun 2015	A1
20150166983	Liu et al.	Jun 2015	A1
20150166984	Liu et al.	Jun 2015	A1
20150166985	Liu et al.	Jun 2015	A1
20150191744	Wolfe et al.	Jul 2015	A1
20150197759	Xu et al.	Jul 2015	A1
20150211058	Carstens	Jul 2015	A1
20150218573	Loque et al.	Aug 2015	A1
20150225773	Farmer et al.	Aug 2015	A1
20150252358	Maeder et al.	Sep 2015	A1
20150307889	Petolino et al.	Oct 2015	A1
20150315252	Haugwitz et al.	Nov 2015	A1
20160017393	Jacobson et al.	Jan 2016	A1
20160017396	Cann et al.	Jan 2016	A1
20160032292	Storici et al.	Feb 2016	A1
20160032353	Braman et al.	Feb 2016	A1
20160046952	Hittinger et al.	Feb 2016	A1
20160046961	Jinek et al.	Feb 2016	A1
20160046962	May et al.	Feb 2016	A1
20160053272	Wurtzel et al.	Feb 2016	A1
20160053304	Wurtzel et al.	Feb 2016	A1
20160074535	Ranganathan et al.	Mar 2016	A1
20160076093	Shendure et al.	Mar 2016	A1
20160090603	Carnes et al.	Mar 2016	A1
20160090622	Liu et al.	Mar 2016	A1
20160115488	Zhang et al.	Apr 2016	A1
20160138046	Wu	May 2016	A1
20160186214	Brouns et al.	Jun 2016	A1
20160200779	Liu et al.	Jul 2016	A1
20160201040	Liu et al.	Jul 2016	A1
20160201089	Gersbach et al.	Jul 2016	A1
20160206566	Lu et al.	Jul 2016	A1
20160208243	Zhang et al.	Jul 2016	A1
20160208288	Liu et al.	Jul 2016	A1
20160215275	Zhong	Jul 2016	A1
20160215276	Liu et al.	Jul 2016	A1
20160215300	May et al.	Jul 2016	A1
20160244784	Jacobson et al.	Aug 2016	A1
20160244829	Bang et al.	Aug 2016	A1
20160272593	Ritter et al.	Sep 2016	A1
20160272965	Zhang et al.	Sep 2016	A1
20160281072	Zhang	Sep 2016	A1
20160304846	Liu et al.	Oct 2016	A1
20160304855	Stark et al.	Oct 2016	A1
20160312304	Sorrentino et al.	Oct 2016	A1
20160333389	Liu et al.	Nov 2016	A1
20160340662	Zhang et al.	Nov 2016	A1
20160345578	Barrangou et al.	Dec 2016	A1
20160346360	Quake et al.	Dec 2016	A1
20160346361	Quake et al.	Dec 2016	A1
20160346362	Quake et al.	Dec 2016	A1
20160348074	Quake et al.	Dec 2016	A1
20160348096	Liu et al.	Dec 2016	A1
20160350476	Quake et al.	Dec 2016	A1
20160369262	Reik et al.	Dec 2016	A1
20170009224	Liu et al.	Jan 2017	A1
20170009242	McKinley et al.	Jan 2017	A1
20170014449	Bangera et al.	Jan 2017	A1
20170020922	Wagner et al.	Jan 2017	A1
20170037432	Donohoue et al.	Feb 2017	A1
20170044520	Liu et al.	Feb 2017	A1
20170044592	Peter et al.	Feb 2017	A1
20170053729	Kotani et al.	Feb 2017	A1
20170058271	Joung et al.	Mar 2017	A1
20170058272	Carter et al.	Mar 2017	A1
20170058298	Kennedy et al.	Mar 2017	A1
20170073663	Wang et al.	Mar 2017	A1
20170073670	Nishida et al.	Mar 2017	A1
20170087224	Quake	Mar 2017	A1
20170087225	Quake	Mar 2017	A1
20170088587	Quake	Mar 2017	A1
20170088828	Quake	Mar 2017	A1
20170107536	Zhang et al.	Apr 2017	A1
20170107560	Peter et al.	Apr 2017	A1
20170114367	Hu et al.	Apr 2017	A1
20170121693	Liu et al.	May 2017	A1
20170145394	Yeo et al.	May 2017	A1
20170145405	Tang et al.	May 2017	A1
20170145438	Kantor	May 2017	A1
20170152528	Zhang	Jun 2017	A1
20170152787	Kubo et al.	Jun 2017	A1
20170159033	Kamtekar et al.	Jun 2017	A1
20170166928	Vyas et al.	Jun 2017	A1
20170175104	Doudna et al.	Jun 2017	A1
20170175142	Zhang et al.	Jun 2017	A1
20170191047	Terns et al.	Jul 2017	A1
20170191078	Zhang et al.	Jul 2017	A1
20170198269	Zhang et al.	Jul 2017	A1
20170198277	Kmiec et al.	Jul 2017	A1
20170198302	Feng et al.	Jul 2017	A1
20170226522	Hu et al.	Aug 2017	A1
20170233703	Xie et al.	Aug 2017	A1
20170233756	Begemann et al.	Aug 2017	A1
20170247671	Yung et al.	Aug 2017	A1
20170247703	Sloan et al.	Aug 2017	A1
20170268022	Liu et al.	Sep 2017	A1
20170283797	Robb et al.	Oct 2017	A1
20170314016	Kim et al.	Nov 2017	A1
20170362635	Chamberlain et al.	Dec 2017	A1
20180064077	Dunham et al.	Mar 2018	A1
20180066258	Powell	Mar 2018	A1
20180068062	Zhang et al.	Mar 2018	A1
20180073012	Liu et al.	Mar 2018	A1
20180100147	Yates et al.	Apr 2018	A1
20180105867	Xiao et al.	Apr 2018	A1
20180119118	Lu et al.	May 2018	A1
20180127780	Liu et al.	May 2018	A1
20180155708	Church et al.	Jun 2018	A1
20180155720	Donohoue et al.	Jun 2018	A1
20180163213	Aneja et al.	Jun 2018	A1
20180170984	Harris et al.	Jun 2018	A1
20180179503	Maianti et al.	Jun 2018	A1
20180179547	Zhang et al.	Jun 2018	A1
20180201921	Malcolm	Jul 2018	A1
20180230464	Zhong	Aug 2018	A1
20180230471	Storici et al.	Aug 2018	A1
20180236081	Liu et al.	Aug 2018	A1
20180237758	Liu et al.	Aug 2018	A1
20180237787	Maianti et al.	Aug 2018	A1
20180245066	Yao et al.	Aug 2018	A1
20180265864	Li et al.	Sep 2018	A1
20180273939	Yu et al.	Sep 2018	A1
20180282722	Jakimo et al.	Oct 2018	A1
20180305688	Zhong	Oct 2018	A1
20180305704	Zhang	Oct 2018	A1
20180312825	Liu et al.	Nov 2018	A1
20180312828	Liu et al.	Nov 2018	A1
20180312835	Yao et al.	Nov 2018	A1
20180327756	Zhang et al.	Nov 2018	A1
20190093099	Liu et al.	Mar 2019	A1
20190185883	Liu et al.	Jun 2019	A1
20190225955	Liu et al.	Jul 2019	A1
20190233847	Savage et al.	Aug 2019	A1
20190241633	Fotin-Mleczek et al.	Aug 2019	A1
20190256842	Liu et al.	Aug 2019	A1
20190264202	Church et al.	Aug 2019	A1
20190276816	Liu et al.	Sep 2019	A1
20190322992	Liu et al.	Oct 2019	A1
20190352632	Liu et al.	Nov 2019	A1
20190367891	Liu et al.	Dec 2019	A1
20200010818	Liu et al.	Jan 2020	A1
20200010835	Maianti et al.	Jan 2020	A1
20200063127	Lu et al.	Feb 2020	A1
20200071722	Liu et al.	Mar 2020	A1
20200109398	Rubens et al.	Apr 2020	A1
20200172931	Liu et al.	Jun 2020	A1
20200181619	Tang et al.	Jun 2020	A1
20200190493	Liu et al.	Jun 2020	A1
20200216833	Liu et al.	Jul 2020	A1
20200255868	Liu et al.	Aug 2020	A1
20200277587	Liu et al.	Sep 2020	A1
20200323984	Liu et al.	Oct 2020	A1
20200399619	Maianti et al.	Dec 2020	A1
20200399626	Liu et al.	Dec 2020	A1
20210054416	Liu et al.	Feb 2021	A1
20210115428	Maianti et al.	Apr 2021	A1
20210196809	Maianti et al.	Jul 2021	A1
20210198330	Liu et al.	Jul 2021	A1
20210214698	Liu et al.	Jul 2021	A1
20210230577	Liu et al.	Jul 2021	A1
20210254127	Liu et al.	Aug 2021	A1
20210315994	Liu et al.	Oct 2021	A1
20210317440	Liu et al.	Oct 2021	A1
20220033785	Liu et al.	Feb 2022	A1
20220119785	Liu et al.	Apr 2022	A1
20220170013	Liu et al.	Jun 2022	A1
20220177877	Church et al.	Jun 2022	A1
20220204975	Liu et al.	Jun 2022	A1
20220213507	Liu et al.	Jul 2022	A1
20220220462	Liu et al.	Jul 2022	A1
20220238182	Shen et al.	Jul 2022	A1
20220249697	Liu et al.	Aug 2022	A1
20220282275	Liu et al.	Sep 2022	A1
20220290115	Liu et al.	Sep 2022	A1
20220307001	Liu et al.	Sep 2022	A1
20220307003	Liu et al.	Sep 2022	A1
20220315906	Liu et al.	Oct 2022	A1
20220356469	Liu et al.	Nov 2022	A1
20220380740	Liu et al.	Dec 2022	A1
20220389395	Liu et al.	Dec 2022	A1
20230002745	Liu et al.	Jan 2023	A1
20230021641	Liu et al.	Jan 2023	A1
20230056852	Liu et al.	Feb 2023	A1
20230058176	Liu et al.	Feb 2023	A1
20230078265	Liu et al.	Mar 2023	A1
20230086199	Liu et al.	Mar 2023	A1
20230090221	Liu et al.	Mar 2023	A1
20230108687	Liu et al.	Apr 2023	A1
20230123669	Liu et al.	Apr 2023	A1
20230127008	Liu et al.	Apr 2023	A1
20230159913	Liu et al.	May 2023	A1
20230193295	Maianti et al.	Jun 2023	A1
20230220374	Liu et al.	Jul 2023	A1
20230272425	Liu et al.	Aug 2023	A1
20230279443	Liu et al.	Sep 2023	A1

Foreign Referenced Citations (1608)

Number	Date	Country
2012244264	Nov 2012	AU
2012354062	Jul 2014	AU
2015252023	Nov 2015	AU
2015101792	Jan 2016	AU
112015013786	Jul 2017	BR
2894668	Jun 2014	CA
2894681	Jun 2014	CA
2894684	Jun 2014	CA
2 852 593	Nov 2015	CA
1069962	Mar 1993	CN
101460619	Jun 2009	CN
101873862	Oct 2010	CN
102892777	Jan 2013	CN
103224947	Jul 2013	CN
103233028	Aug 2013	CN
103388006	Nov 2013	CN
103614415	Mar 2014	CN
103642836	Mar 2014	CN
103668472	Mar 2014	CN
103820441	May 2014	CN
103820454	May 2014	CN
103911376	Jul 2014	CN
103923911	Jul 2014	CN
103088008	Aug 2014	CN
103981211	Aug 2014	CN
103981212	Aug 2014	CN
104004778	Aug 2014	CN
104004782	Aug 2014	CN
104017821	Sep 2014	CN
104109687	Oct 2014	CN
104178461	Dec 2014	CN
104342457	Feb 2015	CN
104404036	Mar 2015	CN
104450774	Mar 2015	CN
104480144	Apr 2015	CN
104498493	Apr 2015	CN
104504304	Apr 2015	CN
104531704	Apr 2015	CN
104531705	Apr 2015	CN
104560864	Apr 2015	CN
104561095	Apr 2015	CN
104593418	May 2015	CN
104593422	May 2015	CN
104611370	May 2015	CN
104651392	May 2015	CN
104651398	May 2015	CN
104651399	May 2015	CN
104651401	May 2015	CN
104673816	Jun 2015	CN
104725626	Jun 2015	CN
104726449	Jun 2015	CN
104726494	Jun 2015	CN
10474626	Jul 2015	CN
104762321	Jul 2015	CN
104805078	Jul 2015	CN
104805099	Jul 2015	CN
104805118	Jul 2015	CN
104846010	Aug 2015	CN
104894068	Sep 2015	CN
104894075	Sep 2015	CN
104928321	Sep 2015	CN
105039339	Nov 2015	CN
105039399	Nov 2015	CN
105063061	Nov 2015	CN
105087620	Nov 2015	CN
105112422	Dec 2015	CN
105112445	Dec 2015	CN
105112519	Dec 2015	CN
105121648	Dec 2015	CN
105132427	Dec 2015	CN
105132451	Dec 2015	CN
105177038	Dec 2015	CN
105177126	Dec 2015	CN
105210981	Jan 2016	CN
105219799	Jan 2016	CN
105238806	Jan 2016	CN
105255937	Jan 2016	CN
105274144	Jan 2016	CN
105296518	Feb 2016	CN
105296537	Feb 2016	CN
105316324	Feb 2016	CN
105316327	Feb 2016	CN
105316337	Feb 2016	CN
105331607	Feb 2016	CN
105331608	Feb 2016	CN
105331609	Feb 2016	CN
105331627	Feb 2016	CN
105400773	Mar 2016	CN
105400779	Mar 2016	CN
105400810	Mar 2016	CN
105441451	Mar 2016	CN
105462968	Apr 2016	CN
105463003	Apr 2016	CN
105463027	Apr 2016	CN
105492608	Apr 2016	CN
105492609	Apr 2016	CN
105505976	Apr 2016	CN
105505979	Apr 2016	CN
105518134	Apr 2016	CN
105518135	Apr 2016	CN
105518137	Apr 2016	CN
105518138	Apr 2016	CN
105518139	Apr 2016	CN
105518140	Apr 2016	CN
105543228	May 2016	CN
105543266	May 2016	CN
105543270	May 2016	CN
105567688	May 2016	CN
105567689	May 2016	CN
105567734	May 2016	CN
105567735	May 2016	CN
105567738	May 2016	CN
105593367	May 2016	CN
105594664	May 2016	CN
105602987	May 2016	CN
105624146	Jun 2016	CN
105624187	Jun 2016	CN
105646719	Jun 2016	CN
105647922	Jun 2016	CN
105647962	Jun 2016	CN
105647968	Jun 2016	CN
105647969	Jun 2016	CN
105671070	Jun 2016	CN
105671083	Jun 2016	CN
105695485	Jun 2016	CN
105779448	Jul 2016	CN
105779449	Jul 2016	CN
105802980	Jul 2016	CN
105821039	Aug 2016	CN
105821040	Aug 2016	CN
105821049	Aug 2016	CN
105821072	Aug 2016	CN
105821075	Aug 2016	CN
105821116	Aug 2016	CN
105838733	Aug 2016	CN
105861547	Aug 2016	CN
105861552	Aug 2016	CN
105861554	Aug 2016	CN
105886498	Aug 2016	CN
105886534	Aug 2016	CN
105886616	Aug 2016	CN
105907758	Aug 2016	CN
105907785	Aug 2016	CN
105925608	Sep 2016	CN
105950560	Sep 2016	CN
105950626	Sep 2016	CN
105950633	Sep 2016	CN
105950639	Sep 2016	CN
105985985	Oct 2016	CN
106011104	Oct 2016	CN
106011150	Oct 2016	CN
106011167	Oct 2016	CN
106011171	Oct 2016	CN
106032540	Oct 2016	CN
106047803	Oct 2016	CN
106047877	Oct 2016	CN
106047930	Oct 2016	CN
106086008	Nov 2016	CN
106086028	Nov 2016	CN
106086061	Nov 2016	CN
106086062	Nov 2016	CN
106109417	Nov 2016	CN
106119275	Nov 2016	CN
106119283	Nov 2016	CN
106148286	Nov 2016	CN
106148370	Nov 2016	CN
106148416	Nov 2016	CN
106167525	Nov 2016	CN
106167808	Nov 2016	CN
106167810	Nov 2016	CN
106167821	Nov 2016	CN
106172238	Dec 2016	CN
106190903	Dec 2016	CN
106191057	Dec 2016	CN
106191061	Dec 2016	CN
106191062	Dec 2016	CN
106191064	Dec 2016	CN
106191071	Dec 2016	CN
106191099	Dec 2016	CN
106191107	Dec 2016	CN
106191113	Dec 2016	CN
106191114	Dec 2016	CN
106191116	Dec 2016	CN
106191124	Dec 2016	CN
106222177	Dec 2016	CN
106222193	Dec 2016	CN
106222203	Dec 2016	CN
106244555	Dec 2016	CN
106244591	Dec 2016	CN
106244609	Dec 2016	CN
106282241	Jan 2017	CN
106318934	Jan 2017	CN
106318973	Jan 2017	CN
106350540	Jan 2017	CN
106367435	Feb 2017	CN
106399306	Feb 2017	CN
106399311	Feb 2017	CN
106399360	Feb 2017	CN
106399367	Feb 2017	CN
106399375	Feb 2017	CN
106399377	Feb 2017	CN
106434651	Feb 2017	CN
106434663	Feb 2017	CN
106434688	Feb 2017	CN
106434737	Feb 2017	CN
106434748	Feb 2017	CN
106434752	Feb 2017	CN
106434782	Feb 2017	CN
106446600	Feb 2017	CN
106479985	Mar 2017	CN
106480027	Mar 2017	CN
106480036	Mar 2017	CN
106480067	Mar 2017	CN
106480080	Mar 2017	CN
106480083	Mar 2017	CN
106480097	Mar 2017	CN
106544351	Mar 2017	CN
106544353	Mar 2017	CN
106544357	Mar 2017	CN
106554969	Apr 2017	CN
106566838	Apr 2017	CN
106701763	May 2017	CN
106701808	May 2017	CN
106701818	May 2017	CN
106701823	May 2017	CN
106701830	May 2017	CN
106754912	May 2017	CN
106755026	May 2017	CN
106755077	May 2017	CN
106755088	May 2017	CN
106755091	May 2017	CN
106755097	May 2017	CN
106755424	May 2017	CN
106801056	Jun 2017	CN
106834323	Jun 2017	CN
106834341	Jun 2017	CN
106834347	Jun 2017	CN
106845151	Jun 2017	CN
106868008	Jun 2017	CN
106868031	Jun 2017	CN
106906240	Jun 2017	CN
106906242	Jun 2017	CN
106916820	Jul 2017	CN
106916852	Jul 2017	CN
106939303	Jul 2017	CN
106947750	Jul 2017	CN
106947780	Jul 2017	CN
106957830	Jul 2017	CN
106957831	Jul 2017	CN
106957844	Jul 2017	CN
106957855	Jul 2017	CN
106957858	Jul 2017	CN
106967697	Jul 2017	CN
106967726	Jul 2017	CN
106978428	Jul 2017	CN
106987570	Jul 2017	CN
106987757	Jul 2017	CN
107012164	Aug 2017	CN
107012174	Aug 2017	CN
107012213	Aug 2017	CN
107012250	Aug 2017	CN
107022562	Aug 2017	CN
107034188	Aug 2017	CN
107034218	Aug 2017	CN
107034229	Aug 2017	CN
107043775	Aug 2017	CN
107043779	Aug 2017	CN
107043787	Aug 2017	CN
107058320	Aug 2017	CN
107058328	Aug 2017	CN
107058358	Aug 2017	CN
107058372	Aug 2017	CN
107083392	Aug 2017	CN
107099533	Aug 2017	CN
107099850	Aug 2017	CN
107119053	Sep 2017	CN
107119071	Sep 2017	CN
107129999	Sep 2017	CN
107130000	Sep 2017	CN
107142272	Sep 2017	CN
107142282	Sep 2017	CN
107177591	Sep 2017	CN
107177595	Sep 2017	CN
107177625	Sep 2017	CN
107177631	Sep 2017	CN
107190006	Sep 2017	CN
107190008	Sep 2017	CN
107217042	Sep 2017	CN
107217075	Sep 2017	CN
107227307	Oct 2017	CN
107227352	Oct 2017	CN
107236737	Oct 2017	CN
107236739	Oct 2017	CN
107236741	Oct 2017	CN
107245502	Oct 2017	CN
107254485	Oct 2017	CN
107266541	Oct 2017	CN
107267515	Oct 2017	CN
107287245	Oct 2017	CN
107298701	Oct 2017	CN
107299114	Oct 2017	CN
107304435	Oct 2017	CN
107312785	Nov 2017	CN
107312793	Nov 2017	CN
107312795	Nov 2017	CN
107312798	Nov 2017	CN
107326042	Nov 2017	CN
107326046	Nov 2017	CN
107354156	Nov 2017	CN
107354173	Nov 2017	CN
107356793	Nov 2017	CN
107362372	Nov 2017	CN
107365786	Nov 2017	CN
107365804	Nov 2017	CN
107384894	Nov 2017	CN
107384922	Nov 2017	CN
107384926	Nov 2017	CN
107400677	Nov 2017	CN
107418974	Dec 2017	CN
107435051	Dec 2017	CN
107435069	Dec 2017	CN
107446922	Dec 2017	CN
107446923	Dec 2017	CN
107446924	Dec 2017	CN
107446932	Dec 2017	CN
107446951	Dec 2017	CN
107446954	Dec 2017	CN
107460196	Dec 2017	CN
107474129	Dec 2017	CN
107475300	Dec 2017	CN
107488649	Dec 2017	CN
107502608	Dec 2017	CN
107502618	Dec 2017	CN
107513531	Dec 2017	CN
107519492	Dec 2017	CN
107523567	Dec 2017	CN
107523583	Dec 2017	CN
107541525	Jan 2018	CN
107557373	Jan 2018	CN
107557378	Jan 2018	CN
107557381	Jan 2018	CN
107557390	Jan 2018	CN
107557393	Jan 2018	CN
107557394	Jan 2018	CN
107557455	Jan 2018	CN
107574179	Jan 2018	CN
107586777	Jan 2018	CN
107586779	Jan 2018	CN
107604003	Jan 2018	CN
107619829	Jan 2018	CN
107619837	Jan 2018	CN
107630006	Jan 2018	CN
107630041	Jan 2018	CN
107630042	Jan 2018	CN
107630043	Jan 2018	CN
107641631	Jan 2018	CN
107653256	Feb 2018	CN
107686848	Feb 2018	CN
206970581	Feb 2018	CN
107760652	Mar 2018	CN
107760663	Mar 2018	CN
107760684	Mar 2018	CN
107760715	Mar 2018	CN
107784200	Mar 2018	CN
107794272	Mar 2018	CN
107794276	Mar 2018	CN
107815463	Mar 2018	CN
107828738	Mar 2018	CN
107828794	Mar 2018	CN
107828826	Mar 2018	CN
107828874	Mar 2018	CN
107858346	Mar 2018	CN
107858373	Mar 2018	CN
107880132	Apr 2018	CN
107881184	Apr 2018	CN
107893074	Apr 2018	CN
107893075	Apr 2018	CN
107893076	Apr 2018	CN
107893080	Apr 2018	CN
107893086	Apr 2018	CN
107904261	Apr 2018	CN
107937427	Apr 2018	CN
107937432	Apr 2018	CN
107937501	Apr 2018	CN
107974466	May 2018	CN
107988229	May 2018	CN
107988246	May 2018	CN
107988256	May 2018	CN
107988268	May 2018	CN
108018316	May 2018	CN
108034656	May 2018	CN
108048466	May 2018	CN
108102940	Jun 2018	CN
108103092	Jun 2018	CN
108103098	Jun 2018	CN
108103586	Jun 2018	CN
108148835	Jun 2018	CN
108148837	Jun 2018	CN
108148873	Jun 2018	CN
108192956	Jun 2018	CN
108251423	Jul 2018	CN
108251451	Jul 2018	CN
108251452	Jul 2018	CN
108342480	Jul 2018	CN
108359691	Aug 2018	CN
108359712	Aug 2018	CN
108384784	Aug 2018	CN
108396027	Aug 2018	CN
108410877	Aug 2018	CN
108410906	Aug 2018	CN
108410907	Aug 2018	CN
108410911	Aug 2018	CN
108424931	Aug 2018	CN
108441519	Aug 2018	CN
108441520	Aug 2018	CN
108486108	Sep 2018	CN
108486111	Sep 2018	CN
108486145	Sep 2018	CN
108486146	Sep 2018	CN
108486154	Sep 2018	CN
108486159	Sep 2018	CN
108486234	Sep 2018	CN
108504657	Sep 2018	CN
108504685	Sep 2018	CN
108504693	Sep 2018	CN
108546712	Sep 2018	CN
108546717	Sep 2018	CN
108546718	Sep 2018	CN
108559730	Sep 2018	CN
108559732	Sep 2018	CN
108559745	Sep 2018	CN
108559760	Sep 2018	CN
108570479	Sep 2018	CN
108588071	Sep 2018	CN
108588123	Sep 2018	CN
108588128	Sep 2018	CN
108588182	Sep 2018	CN
108610399	Oct 2018	CN
108611364	Oct 2018	CN
108624622	Oct 2018	CN
108642053	Oct 2018	CN
108642055	Oct 2018	CN
108642077	Oct 2018	CN
108642078	Oct 2018	CN
108642090	Oct 2018	CN
108690844	Oct 2018	CN
108707604	Oct 2018	CN
108707620	Oct 2018	CN
108707621	Oct 2018	CN
108707628	Oct 2018	CN
108707629	Oct 2018	CN
108715850	Oct 2018	CN
108728476	Nov 2018	CN
108728486	Nov 2018	CN
108753772	Nov 2018	CN
108753783	Nov 2018	CN
108753813	Nov 2018	CN
108753817	Nov 2018	CN
108753832	Nov 2018	CN
108753835	Nov 2018	CN
108753836	Nov 2018	CN
108795902	Nov 2018	CN
108822217	Nov 2018	CN
108823248	Nov 2018	CN
108823249	Nov 2018	CN
108823291	Nov 2018	CN
108841845	Nov 2018	CN
108853133	Nov 2018	CN
108866093	Nov 2018	CN
108893529	Nov 2018	CN
108913664	Nov 2018	CN
108913691	Nov 2018	CN
108913714	Nov 2018	CN
108913717	Nov 2018	CN
109 517 841	Mar 2019	CN
0264166	Apr 1988	EP
0321201	Jun 1989	EP
0519463	Dec 1992	EP
2604255	Jun 2013	EP
2840140	Feb 2015	EP
2966170	Jan 2016	EP
3009511	Apr 2016	EP
3031921	Jun 2016	EP
3045537	Jul 2016	EP
3 115 457	Jan 2017	EP
3144390	Mar 2017	EP
3199632	Aug 2017	EP
3216867	Sep 2017	EP
3252160	Dec 2017	EP
3450553	Dec 2019	EP
2528177	Jan 2016	GB
2531454	Apr 2016	GB
2542653	Mar 2017	GB
1208045	Feb 2016	HK
2007-501626	Feb 2007	JP
2008-515405	May 2008	JP
2010-033344	Feb 2010	JP
2010-535744	Nov 2010	JP
2010-539929	Dec 2010	JP
2011-081011	Apr 2011	JP
2011-523353	Aug 2011	JP
2012-525146	Oct 2012	JP
2012-210172	Nov 2012	JP
2012-531909	Dec 2012	JP
2016-534132	Nov 2016	JP
2017-500035	Jan 2017	JP
6629734	Jan 2020	JP
101584933	Jan 2016	KR
20160133380	Nov 2016	KR
20170037025	Apr 2017	KR
20170037028	Apr 2017	KR
101748575	Jun 2017	KR
2018-0022465	Mar 2018	KR
2016104674	Aug 2017	RU
2634395	Oct 2017	RU
2652899	May 2018	RU
2015128057	Mar 2019	RU
2015128098	Mar 2019	RU
2687451	May 2019	RU
2019112514	Jun 2019	RU
2019127300	Sep 2019	RU
2701850	Oct 2019	RU
10201707569	Oct 2017	SG
10201710486X	Jan 2018	SG
10201710487	Jan 2018	SG
10201710488	Jan 2018	SG
I608100	Dec 2017	TW
2018-29773	Aug 2018	TW
WO 2015164740	Oct 2015	WF
WO 9002809	Mar 1990	WO
WO 1991003162	Mar 1991	WO
WO 9116024	Oct 1991	WO
WO 9117271	Nov 1991	WO
WO 9117424	Nov 1991	WO
WO 9206188	Apr 1992	WO
WO 9206200	Apr 1992	WO
WO 1992007065	Apr 1992	WO
WO 1993015187	Aug 1993	WO
WO 9324641	Dec 1993	WO
WO 9418316	Aug 1994	WO
WO 94026877	Nov 1994	WO
WO 9604403	Feb 1996	WO
WO 9610640	Apr 1996	WO
WO 9832845	Jul 1998	WO
WO 2001036452	May 2001	WO
WO 2001038547	May 2001	WO
WO 2002059296	Aug 2002	WO
WO 2002068676	Sep 2002	WO
WO 2002103028	Dec 2002	WO
WO 2004007684	Jan 2004	WO
WO 200514791	Feb 2005	WO
WO 2005014791	Feb 2005	WO
WO 2005019415	Mar 2005	WO
WO 2006002547	Jan 2006	WO
WO 2006042112	Apr 2006	WO
WO 2007025097	Mar 2007	WO
WO 2007037444	Apr 2007	WO
WO 07066923	Jun 2007	WO
WO 2007136815	Nov 2007	WO
WO 08005529	Jan 2008	WO
WO 2008108989	Sep 2008	WO
WO 2009002418	Dec 2008	WO
WO 2009098290	Aug 2009	WO
WO 2010011961	Jan 2010	WO
WO 2010012902	Feb 2010	WO
WO 2010028347	Mar 2010	WO
WO 2010054108	May 2010	WO
WO 2010054154	May 2010	WO
WO 2010068289	Jun 2010	WO
WO 2010075424	Jul 2010	WO
WO 2010102257	Sep 2010	WO
WO 2010129019	Nov 2010	WO
WO 2010144150	Dec 2010	WO
WO 2011002503	Jan 2011	WO
WO 2011017293	Feb 2011	WO
WO 2011053868	May 2011	WO
WO 2011053982	May 2011	WO
WO 2011068810	Jun 2011	WO
WO 2011075627	Jun 2011	WO
WO 2011091311	Jul 2011	WO
WO 2011091396	Jul 2011	WO
WO 2011109031	Sep 2011	WO
WO 2011143124	Nov 2011	WO
WO 2011147590	Dec 2011	WO
WO 2011159369	Dec 2011	WO
WO 2012054726	Apr 2012	WO
WO 2012065043	May 2012	WO
WO 2012088381	Jun 2012	WO
WO 2012125445	Sep 2012	WO
WO 2012138927	Oct 2012	WO
WO 2012149470	Nov 2012	WO
WO 2012158985	Nov 2012	WO
WO 2012158986	Nov 2012	WO
WO 2012164565	Dec 2012	WO
WO 2012170930	Dec 2012	WO
WO 2013012674	Jan 2013	WO
WO 2013013105	Jan 2013	WO
WO 2013013105	Jan 2013	WO
WO 2013039857	Mar 2013	WO
WO 2013039861	Mar 2013	WO
WO 2013045632	Apr 2013	WO
WO 2013047844	Apr 2013	WO
WO 2013066438	May 2013	WO
WO 2013086441	Jun 2013	WO
WO 2013086444	Jun 2013	WO
WO 2013098244	Jul 2013	WO
WO 2013119602	Aug 2013	WO
WO 2013126794	Aug 2013	WO
WO 2013130824	Sep 2013	WO
WO 2013141680	Sep 2013	WO
WO 2013142578	Sep 2013	WO
WO 2013152359	Oct 2013	WO
WO 2013160230	Oct 2013	WO
WO 2013166315	Nov 2013	WO
WO 2013169398	Nov 2013	WO
WO 2013169802	Nov 2013	WO
WO 2013176772	Nov 2013	WO
WO 2013176915	Nov 2013	WO
WO 2013176916	Nov 2013	WO
WO 2013181440	Dec 2013	WO
WO 2013186754	Dec 2013	WO
WO 2013188037	Dec 2013	WO
WO 2013188522	Dec 2013	WO
WO 2013188638	Dec 2013	WO
WO 2013192278	Dec 2013	WO
WO 2013142378	Jan 2014	WO
WO 2014004336	Jan 2014	WO
WO 2014005042	Jan 2014	WO
WO 2014011237	Jan 2014	WO
WO 2014011901	Jan 2014	WO
WO 2014018423	Jan 2014	WO
WO 2014020608	Feb 2014	WO
WO 2014022120	Feb 2014	WO
WO 2014022702	Feb 2014	WO
WO 2014036219	Mar 2014	WO
WO 2014039513	Mar 2014	WO
WO 2014039523	Mar 2014	WO
WO 2014039585	Mar 2014	WO
WO 2014039684	Mar 2014	WO
WO 2014039692	Mar 2014	WO
WO 2014039702	Mar 2014	WO
WO 2014039872	Mar 2014	WO
WO 2014039970	Mar 2014	WO
WO 2014041327	Mar 2014	WO
WO 2014043143	Mar 2014	WO
WO 2014047103	Mar 2014	WO
WO 2014055782	Apr 2014	WO
WO 2014059173	Apr 2014	WO
WO 2014059255	Apr 2014	WO
WO 2014065596	May 2014	WO
WO 2014066505	May 2014	WO
WO 2014068346	May 2014	WO
WO 2014070887	May 2014	WO
WO 2014071006	May 2014	WO
WO 2014071219	May 2014	WO
WO 2014071235	May 2014	WO
WO 2014072941	May 2014	WO
WO 2014081729	May 2014	WO
WO 2014081730	May 2014	WO
WO 2014081855	May 2014	WO
WO 2014082644	Jun 2014	WO
WO 2014085261	Jun 2014	WO
WO 2014085593	Jun 2014	WO
WO 2014085830	Jun 2014	WO
WO 2014089212	Jun 2014	WO
WO 2014089290	Jun 2014	WO
WO 2014089348	Jun 2014	WO
WO 2014089513	Jun 2014	WO
WO 2014089533	Jun 2014	WO
WO 2014089541	Jun 2014	WO
WO 2014093479	Jun 2014	WO
WO 2014093595	Jun 2014	WO
WO 2014093622	Jun 2014	WO
WO 2014093635	Jun 2014	WO
WO 2014093655	Jun 2014	WO
WO 2014093661	Jun 2014	WO
WO 2014093694	Jun 2014	WO
WO 2014093701	Jun 2014	WO
WO 2014093709	Jun 2014	WO
WO 2014093712	Jun 2014	WO
WO 2014093718	Jun 2014	WO
WO 2014093736	Jun 2014	WO
WO 2014093768	Jun 2014	WO
WO 2014093852	Jun 2014	WO
WO 2014096972	Jun 2014	WO
WO 2014099744	Jun 2014	WO
WO 2014099750	Jun 2014	WO
WO 2014104878	Jul 2014	WO
WO 2014110006	Jul 2014	WO
WO 2014110552	Jul 2014	WO
WO 2014113493	Jul 2014	WO
WO 2014123967	Aug 2014	WO
WO 2014124226	Aug 2014	WO
WO 2014125668	Aug 2014	WO
WO 2014127287	Aug 2014	WO
WO 2014128324	Aug 2014	WO
WO 2014128659	Aug 2014	WO
WO 2014130706	Aug 2014	WO
WO 2014130955	Aug 2014	WO
WO 2014131833	Sep 2014	WO
WO 2014138379	Sep 2014	WO
WO 2014143381	Sep 2014	WO
WO 2014144094	Sep 2014	WO
WO 2014144155	Sep 2014	WO
WO 2014144288	Sep 2014	WO
WO 2014144592	Sep 2014	WO
WO 2014144761	Sep 2014	WO
WO 2014144951	Sep 2014	WO
WO 2014145599	Sep 2014	WO
WO 2014145736	Sep 2014	WO
WO 2014150624	Sep 2014	WO
WO 2014152432	Sep 2014	WO
WO 2014152940	Sep 2014	WO
WO 2014153118	Sep 2014	WO
WO 2014153470	Sep 2014	WO
WO 2014158593	Oct 2014	WO
WO 2014161821	Oct 2014	WO
WO 2014164466	Oct 2014	WO
WO 2014165177	Oct 2014	WO
WO 2014165349	Oct 2014	WO
WO 2014165612	Oct 2014	WO
WO 2014165707	Oct 2014	WO
WO 2014165825	Oct 2014	WO
WO 2014172458	Oct 2014	WO
WO 2014172470	Oct 2014	WO
WO 2014172489	Oct 2014	WO
WO 2014173955	Oct 2014	WO
WO 2014182700	Nov 2014	WO
WO 2014183071	Nov 2014	WO
WO 2014184143	Nov 2014	WO
WO 2014184741	Nov 2014	WO
WO 2014184744	Nov 2014	WO
WO 2014186585	Nov 2014	WO
WO 2014186686	Nov 2014	WO
WO 2014190181	Nov 2014	WO
WO 2014191128	Dec 2014	WO
WO 2014191518	Dec 2014	WO
WO 2014191521	Dec 2014	WO
WO 2014191525	Dec 2014	WO
WO 2014191527	Dec 2014	WO
WO 2014193583	Dec 2014	WO
WO 2014194190	Dec 2014	WO
WO 2014197568	Dec 2014	WO
WO 2014197748	Dec 2014	WO
WO 2014199358	Dec 2014	WO
WO 2014200659	Dec 2014	WO
WO 2014201015	Dec 2014	WO
WO 2014204578	Dec 2014	WO
WO 2014204723	Dec 2014	WO
WO 2014204724	Dec 2014	WO
WO 2014204725	Dec 2014	WO
WO 2014204726	Dec 2014	WO
WO 2014204727	Dec 2014	WO
WO 2014204728	Dec 2014	WO
WO 2014204729	Dec 2014	WO
WO 2014205192	Dec 2014	WO
WO 2014207043	Dec 2014	WO
WO 2015002780	Jan 2015	WO
WO 2015004241	Jan 2015	WO
WO 2015006290	Jan 2015	WO
WO 2015006294	Jan 2015	WO
WO 2015006437	Jan 2015	WO
WO 2015006498	Jan 2015	WO
WO 2015006747	Jan 2015	WO
WO 2015007194	Jan 2015	WO
WO 2015010114	Jan 2015	WO
WO 2015011483	Jan 2015	WO
WO 2015013583	Jan 2015	WO
WO 2015017866	Feb 2015	WO
WO 2015018503	Feb 2015	WO
WO 2015021353	Feb 2015	WO
WO 2015021426	Feb 2015	WO
WO 2015021990	Feb 2015	WO
WO 2015024017	Feb 2015	WO
WO 2015024986	Feb 2015	WO
WO 2015026883	Feb 2015	WO
WO 2015026885	Feb 2015	WO
WO 2015026886	Feb 2015	WO
WO 2015026887	Feb 2015	WO
WO 2015027134	Feb 2015	WO
WO 2015028969	Mar 2015	WO
WO 2015030881	Mar 2015	WO
WO 2015031619	Mar 2015	WO
WO 2015031775	Mar 2015	WO
WO 2015032494	Mar 2015	WO
WO 2015033293	Mar 2015	WO
WO 2015034872	Mar 2015	WO
WO 2015034885	Mar 2015	WO
WO 2015035136	Mar 2015	WO
WO 2015035139	Mar 2015	WO
WO 2015035162	Mar 2015	WO
WO 2015040075	Mar 2015	WO
WO 2015040402	Mar 2015	WO
WO 2015042393	Mar 2015	WO
WO 2015042585	Mar 2015	WO
WO 2015048577	Apr 2015	WO
WO 2015048690	Apr 2015	WO
WO 2015048707	Apr 2015	WO
WO 2015048801	Apr 2015	WO
WO 2015049897	Apr 2015	WO
WO 2015051191	Apr 2015	WO
WO 2015052133	Apr 2015	WO
WO 2015052231	Apr 2015	WO
WO 2015052335	Apr 2015	WO
WO 2015053995	Apr 2015	WO
WO 2015054253	Apr 2015	WO
WO 2015054315	Apr 2015	WO
WO 2015057671	Apr 2015	WO
WO 2015057834	Apr 2015	WO
WO 2015057852	Apr 2015	WO
WO 2015057976	Apr 2015	WO
WO 2015057980	Apr 2015	WO
WO 2015059265	Apr 2015	WO
WO 2015065964	May 2015	WO
WO 2015066119	May 2015	WO
WO 2015066634	May 2015	WO
WO 2015066636	May 2015	WO
WO 2015066637	May 2015	WO
WO 2015066638	May 2015	WO
WO 2015066643	May 2015	WO
WO 2015069682	May 2015	WO
WO 2015070083	May 2015	WO
WO 2015070193	May 2015	WO
WO 2015070212	May 2015	WO
WO 2015071474	May 2015	WO
WO 2015073683	May 2015	WO
WO 2015073867	May 2015	WO
WO 2015073990	May 2015	WO
WO 2015075056	May 2015	WO
WO 2015075154	May 2015	WO
WO 2015075175	May 2015	WO
WO 2015075195	May 2015	WO
WO 2015075557	May 2015	WO
WO 2015077058	May 2015	WO
WO 2015077290	May 2015	WO
WO 2015077318	May 2015	WO
WO 2015079056	Jun 2015	WO
WO 2015079057	Jun 2015	WO
WO 2015086795	Jun 2015	WO
WO 2015086798	Jun 2015	WO
WO 2015088643	Jun 2015	WO
WO 2015089046	Jun 2015	WO
WO 2015089077	Jun 2015	WO
WO 2015089277	Jun 2015	WO
WO 2015089351	Jun 2015	WO
WO 2015089354	Jun 2015	WO
WO 2015089364	Jun 2015	WO
WO 2015089406	Jun 2015	WO
WO 2015089419	Jun 2015	WO
WO 2015089427	Jun 2015	WO
WO 2015089462	Jun 2015	WO
WO 2015089465	Jun 2015	WO
WO 2015089473	Jun 2015	WO
WO 2015089486	Jun 2015	WO
WO 2015095804	Jun 2015	WO
WO 2015099850	Jul 2015	WO
WO 2015100929	Jul 2015	WO
WO 2015103057	Jul 2015	WO
WO 2015103153	Jul 2015	WO
WO 2015105928	Jul 2015	WO
WO 2015108993	Jul 2015	WO
WO 2015109752	Jul 2015	WO
WO 2015110474	Jul 2015	WO
WO 2015112790	Jul 2015	WO
WO 2015112896	Jul 2015	WO
WO 2015113063	Jul 2015	WO
WO 2015114365	Aug 2015	WO
WO 2015115903	Aug 2015	WO
WO 2015116686	Aug 2015	WO
WO 2015116969	Aug 2015	WO
WO 2015117021	Aug 2015	WO
WO 2015117041	Aug 2015	WO
WO 2015117081	Aug 2015	WO
WO 2015118156	Aug 2015	WO
WO 2015119941	Aug 2015	WO
WO 2015121454	Aug 2015	WO
WO 2015122967	Aug 2015	WO
WO 2015123339	Aug 2015	WO
WO 2015124715	Aug 2015	WO
WO 2015124718	Aug 2015	WO
WO 2015126927	Aug 2015	WO
WO 2015127428	Aug 2015	WO
WO 2015127439	Aug 2015	WO
WO 2015129686	Sep 2015	WO
WO 2015131101	Sep 2015	WO
WO 2015133554	Sep 2015	WO
WO 2015134121	Sep 2015	WO
WO 2015134812	Sep 2015	WO
WO 2015136001	Sep 2015	WO
WO 2015138510	Sep 2015	WO
WO 2015138739	Sep 2015	WO
WO 2015138855	Sep 2015	WO
WO 2015138870	Sep 2015	WO
WO 2015139008	Sep 2015	WO
WO 2015139139	Sep 2015	WO
WO 2015143046	Sep 2015	WO
WO 2015143177	Sep 2015	WO
WO 2015145417	Oct 2015	WO
WO 2015148431	Oct 2015	WO
WO 2015148670	Oct 2015	WO
WO 2015148680	Oct 2015	WO
WO 2015148761	Oct 2015	WO
WO 2015148860	Oct 2015	WO
WO 2015148863	Oct 2015	WO
WO 2015153760	Oct 2015	WO
WO 2015153780	Oct 2015	WO
WO 2015153789	Oct 2015	WO
WO 2015153791	Oct 2015	WO
WO 2015153889	Oct 2015	WO
WO 2015153940	Oct 2015	WO
WO 2015155341	Oct 2015	WO
WO 2015155686	Oct 2015	WO
WO 2015157070	Oct 2015	WO
WO 2015157534	Oct 2015	WO
WO 2015159068	Oct 2015	WO
WO 2015159086	Oct 2015	WO
WO 2015159087	Oct 2015	WO
WO 2015160683	Oct 2015	WO
WO 2015161276	Oct 2015	WO
WO 2015163733	Oct 2015	WO
WO 2015164748	Oct 2015	WO
WO 2015165274	Nov 2015	WO
WO 2015165275	Nov 2015	WO
WO 2015165276	Nov 2015	WO
WO 2015166272	Nov 2015	WO
WO 2015167766	Nov 2015	WO
WO 2015167956	Nov 2015	WO
WO 2015168125	Nov 2015	WO
WO 2015168158	Nov 2015	WO
WO 2015168404	Nov 2015	WO
WO 2015168547	Nov 2015	WO
WO 2015168800	Nov 2015	WO
WO 2015171603	Nov 2015	WO
WO 2015171894	Nov 2015	WO
WO 2015171932	Nov 2015	WO
WO 2015172128	Nov 2015	WO
WO 2015173436	Nov 2015	WO
WO 2015175642	Nov 2015	WO
WO 2015179540	Nov 2015	WO
2015200805	Dec 2015	WO
WO 2015183025	Dec 2015	WO
WO 2015183026	Dec 2015	WO
WO 2015183885	Dec 2015	WO
WO 2015184259	Dec 2015	WO
WO 2015184262	Dec 2015	WO
WO 2015184268	Dec 2015	WO
WO 2015188056	Dec 2015	WO
WO 2015188065	Dec 2015	WO
WO 2015188094	Dec 2015	WO
WO 2015188109	Dec 2015	WO
WO 2015188132	Dec 2015	WO
WO 2015188135	Dec 2015	WO
WO 2015188191	Dec 2015	WO
WO 2015189693	Dec 2015	WO
WO 2015191693	Dec 2015	WO
WO 2015191899	Dec 2015	WO
WO 2015191911	Dec 2015	WO
WO 2015193858	Dec 2015	WO
WO 2015195547	Dec 2015	WO
WO 2015195621	Dec 2015	WO
WO 2015195798	Dec 2015	WO
WO 2015198020	Dec 2015	WO
WO 2015200334	Dec 2015	WO
WO 2015200378	Dec 2015	WO
WO 2015200555	Dec 2015	WO
WO 2016001978	Jan 2016	WO
WO 2016004010	Jan 2016	WO
WO 2016007347	Jan 2016	WO
WO 2016007604	Jan 2016	WO
WO 2016007948	Jan 2016	WO
WO 2016011080	Jan 2016	WO
WO 2016011210	Jan 2016	WO
WO 2016011428	Jan 2016	WO
WO 2016012544	Jan 2016	WO
WO 2016012552	Jan 2016	WO
WO 2016014409	Jan 2016	WO
WO 2016014565	Jan 2016	WO
WO 2016014794	Jan 2016	WO
WO 2016014837	Jan 2016	WO
WO 2016016119	Feb 2016	WO
WO 2016016358	Feb 2016	WO
WO 2016019144	Feb 2016	WO
WO 2016020399	Feb 2016	WO
WO 2016021972	Feb 2016	WO
WO 2016021973	Feb 2016	WO
WO 2016022363	Feb 2016	WO
WO 2016022866	Feb 2016	WO
WO 2016022931	Feb 2016	WO
WO 2016025131	Feb 2016	WO
WO 2016025469	Feb 2016	WO
WO 2016025759	Feb 2016	WO
WO 2016026444	Feb 2016	WO
WO 2016028682	Feb 2016	WO
WO 2016028843	Feb 2016	WO
WO 2016028887	Feb 2016	WO
WO 2016033088	Mar 2016	WO
WO 2016033230	Mar 2016	WO
WO 2016033246	Mar 2016	WO
WO 2016033298	Mar 2016	WO
WO 2016035044	Mar 2016	WO
WO 2016036754	Mar 2016	WO
WO 2016037157	Mar 2016	WO
WO 2016040030	Mar 2016	WO
WO 2016040594	Mar 2016	WO
WO 2016044182	Mar 2016	WO
WO 2016044416	Mar 2016	WO
WO 2016046635	Mar 2016	WO
WO 2016049024	Mar 2016	WO
WO 2016049163	Mar 2016	WO
WO 2016049230	Mar 2016	WO
WO 2016049251	Mar 2016	WO
WO 2016049258	Mar 2016	WO
WO 2016053397	Apr 2016	WO
WO 2016054326	Apr 2016	WO
WO 2016057061	Apr 2016	WO
WO 2016057821	Apr 2016	WO
WO 2016057835	Apr 2016	WO
WO 2016057850	Apr 2016	WO
WO 2016057951	Apr 2016	WO
WO 2016057961	Apr 2016	WO
WO 2016061073	Apr 2016	WO
WO 2016061374	Apr 2016	WO
WO 2016061481	Apr 2016	WO
WO 2016061523	Apr 2016	WO
WO 2016064894	Apr 2016	WO
WO 2016069282	May 2016	WO
WO 2016069283	May 2016	WO
WO 2016069591	May 2016	WO
WO 2016069910	May 2016	WO
WO 2016069912	May 2016	WO
WO 2016070037	May 2016	WO
WO 2016070070	May 2016	WO
WO 2016070129	May 2016	WO
WO 2016072399	May 2016	WO
WO 2016072936	May 2016	WO
WO 2016073433	May 2016	WO
WO 2016073559	May 2016	WO
WO 2016073990	May 2016	WO
WO 2016075662	May 2016	WO
WO 2016076672	May 2016	WO
WO 2016077273	May 2016	WO
WO 2016077350	May 2016	WO
WO 2016080097	May 2016	WO
WO 2016080795	May 2016	WO
WO 2016081923	May 2016	WO
WO 2016081924	May 2016	WO
WO 2016082135	Jun 2016	WO
WO 2016083811	Jun 2016	WO
WO 2016084084	Jun 2016	WO
WO 2016084088	Jun 2016	WO
WO 2016086177	Jun 2016	WO
WO 2016089433	Jun 2016	WO
WO 2016089866	Jun 2016	WO
WO 2016089883	Jun 2016	WO
WO 2016090385	Jun 2016	WO
WO 2016094679	Jun 2016	WO
WO 2016094845	Jun 2016	WO
WO 2016094867	Jun 2016	WO
WO 2016094872	Jun 2016	WO
WO 2016094874	Jun 2016	WO
WO 2016094880	Jun 2016	WO
WO 2016094888	Jun 2016	WO
WO 2016097212	Jun 2016	WO
WO 2016097231	Jun 2016	WO
WO 2016097751	Jun 2016	WO
WO 2016099887	Jun 2016	WO
WO 2016100272	Jun 2016	WO
WO 2016100389	Jun 2016	WO
WO 2016100568	Jun 2016	WO
WO 2016100571	Jun 2016	WO
WO 2016100951	Jun 2016	WO
WO 2016100955	Jun 2016	WO
WO 2016100974	Jun 2016	WO
WO 2016103233	Jun 2016	WO
WO 2016104716	Jun 2016	WO
WO 2016106236	Jun 2016	WO
WO 2016106239	Jun 2016	WO
WO 2016106244	Jun 2016	WO
WO 2016106338	Jun 2016	WO
WO 2016108926	Jul 2016	WO
WO 2016109255	Jul 2016	WO
WO 2016109840	Jul 2016	WO
WO 2016110214	Jul 2016	WO
WO 2016110453	Jul 2016	WO
WO 2016110511	Jul 2016	WO
WO 2016110512	Jul 2016	WO
WO 2016111546	Jul 2016	WO
WO 2016112242	Jul 2016	WO
WO 2016112351	Jul 2016	WO
WO 2016112963	Jul 2016	WO
WO 2016114972	Jul 2016	WO
WO 2016115179	Jul 2016	WO
WO 2016115326	Jul 2016	WO
WO 2016115355	Jul 2016	WO
WO 2016116032	Jul 2016	WO
WO 2016120480	Aug 2016	WO
WO 2016123071	Aug 2016	WO
WO 2016123230	Aug 2016	WO
WO 2016123243	Aug 2016	WO
WO 2016123578	Aug 2016	WO
WO 2016126747	Aug 2016	WO
WO 2016130600	Aug 2016	WO
WO 2016130697	Aug 2016	WO
WO 2016131009	Aug 2016	WO
WO 2016132122	Aug 2016	WO
WO 2016133165	Aug 2016	WO
WO 2016135507	Sep 2016	WO
WO 2016135557	Sep 2016	WO
WO 2016135558	Sep 2016	WO
WO 2016135559	Sep 2016	WO
WO 2016137774	Sep 2016	WO
WO 2016137949	Sep 2016	WO
WO 2016141224	Sep 2016	WO
WO 2016141893	Sep 2016	WO
WO 2016142719	Sep 2016	WO
WO 2016145150	Sep 2016	WO
WO 2016148994	Sep 2016	WO
WO 2016149484	Sep 2016	WO
WO 2016149547	Sep 2016	WO
WO 2016150336	Sep 2016	WO
WO 2016150855	Sep 2016	WO
WO 2016154016	Sep 2016	WO
WO 2016154579	Sep 2016	WO
WO 2016154596	Sep 2016	WO
WO 2016155482	Oct 2016	WO
WO 2016161004	Oct 2016	WO
WO 2016161207	Oct 2016	WO
WO 2016161260	Oct 2016	WO
WO 2016161380	Oct 2016	WO
WO 2016161446	Oct 2016	WO
WO 2016164356	Oct 2016	WO
WO 2016164797	Oct 2016	WO
WO 2016166340	Oct 2016	WO
WO 2016167300	Oct 2016	WO
WO 2016168631	Oct 2016	WO
WO 2016170484	Oct 2016	WO
WO 2016172359	Oct 2016	WO
WO 2016172727	Oct 2016	WO
WO 2016174056	Nov 2016	WO
WO 2016174151	Nov 2016	WO
WO 2016174250	Nov 2016	WO
WO 2016176191	Nov 2016	WO
WO 2016176404	Nov 2016	WO
WO 2016176690	Nov 2016	WO
WO 2016177682	Nov 2016	WO
WO 2016178207	Nov 2016	WO
WO 2016179038	Nov 2016	WO
WO 2016179112	Nov 2016	WO
WO 2016181357	Nov 2016	WO
WO 2016182893	Nov 2016	WO
WO 2016182917	Nov 2016	WO
WO 2016182959	Nov 2016	WO
WO 2016183236	Nov 2016	WO
WO 2016183298	Nov 2016	WO
WO 2016183345	Nov 2016	WO
WO 2016183402	Nov 2016	WO
WO 2016183438	Nov 2016	WO
WO 2016183448	Nov 2016	WO
WO 2016184955	Nov 2016	WO
WO 2016184989	Nov 2016	WO
WO 2016185411	Nov 2016	WO
WO 2016186745	Nov 2016	WO
WO 2016186772	Nov 2016	WO
WO 2016186946	Nov 2016	WO
WO 2016186953	Nov 2016	WO
WO 2016187717	Dec 2016	WO
WO 2016187904	Dec 2016	WO
WO 2016191684	Dec 2016	WO
WO 2016191869	Dec 2016	WO
WO 2016196273	Dec 2016	WO
WO 2016196282	Dec 2016	WO
WO 2016196308	Dec 2016	WO
WO 2016196361	Dec 2016	WO
WO 2016196499	Dec 2016	WO
WO 2016196539	Dec 2016	WO
WO 2016196655	Dec 2016	WO
WO 2016196805	Dec 2016	WO
WO 2016196887	Dec 2016	WO
WO 2016197132	Dec 2016	WO
WO 2016197133	Dec 2016	WO
WO 2016197354	Dec 2016	WO
WO 2016197355	Dec 2016	WO
WO 2016197356	Dec 2016	WO
WO 2016197357	Dec 2016	WO
WO 2016197358	Dec 2016	WO
WO 2016197359	Dec 2016	WO
WO 2016197360	Dec 2016	WO
WO 2016197361	Dec 2016	WO
WO 2016197362	Dec 2016	WO
WO 2016198361	Dec 2016	WO
WO 2016198500	Dec 2016	WO
WO 2016200263	Dec 2016	WO
WO 2016201047	Dec 2016	WO
WO 2016201138	Dec 2016	WO
WO 2016201152	Dec 2016	WO
WO 2016201153	Dec 2016	WO
WO 2016201155	Dec 2016	WO
WO 2016205276	Dec 2016	WO
WO 2016205613	Dec 2016	WO
WO 2016205623	Dec 2016	WO
WO 2016205680	Dec 2016	WO
WO 2016205688	Dec 2016	WO
WO 2016205703	Dec 2016	WO
WO 2016205711	Dec 2016	WO
WO 2016205728	Dec 2016	WO
WO 2016205745	Dec 2016	WO
WO 2016205749	Dec 2016	WO
WO 2016205759	Dec 2016	WO
WO 2016205764	Dec 2016	WO
WO 2017001572	Jan 2017	WO
WO 2017001988	Jan 2017	WO
WO 2017004261	Jan 2017	WO
WO 2017004279	Jan 2017	WO
WO 2017004616	Jan 2017	WO
WO 2017005807	Jan 2017	WO
WO 2017009399	Jan 2017	WO
WO 2017010556	Jan 2017	WO
WO 2017011519	Jan 2017	WO
WO 2017011721	Jan 2017	WO
WO 2017011804	Jan 2017	WO
WO 2017015015	Jan 2017	WO
WO 2017015101	Jan 2017	WO
WO 2017015545	Jan 2017	WO
WO 2017015567	Jan 2017	WO
WO 2017015637	Jan 2017	WO
WO 2017017016	Feb 2017	WO
WO 2017019867	Feb 2017	WO
WO 2017019895	Feb 2017	WO
WO 2017023803	Feb 2017	WO
WO 2017023974	Feb 2017	WO
WO 2017024047	Feb 2017	WO
WO 2017024319	Feb 2017	WO
WO 2017024343	Feb 2017	WO
WO 2017024602	Feb 2017	WO
WO 2017025323	Feb 2017	WO
WO 2017027423	Feb 2017	WO
WO 2017028768	Feb 2017	WO
WO 2017029664	Feb 2017	WO
WO 2017031360	Feb 2017	WO
WO 2017031483	Feb 2017	WO
WO 2017035416	Mar 2017	WO
WO 2017040348	Mar 2017	WO
WO 2017040511	Mar 2017	WO
WO 2017040709	Mar 2017	WO
WO 2017040786	Mar 2017	WO
WO 2017040793	Mar 2017	WO
WO 2017040813	Mar 2017	WO
WO 2017043573	Mar 2017	WO
WO 2017043656	Mar 2017	WO
WO 2017044419	Mar 2017	WO
WO 2017044776	Mar 2017	WO
WO 2017044857	Mar 2017	WO
WO 2017049129	Mar 2017	WO
WO 2017050963	Mar 2017	WO
WO 2017053312	Mar 2017	WO
WO 2017053431	Mar 2017	WO
WO 2017053713	Mar 2017	WO
WO 2017053729	Mar 2017	WO
WO 2017053753	Mar 2017	WO
WO 2017053762	Mar 2017	WO
WO 2017053879	Mar 2017	WO
WO 2017054721	Apr 2017	WO
WO 2017058658	Apr 2017	WO
WO 2017059241	Apr 2017	WO
WO 2017062605	Apr 2017	WO
WO 2017062723	Apr 2017	WO
WO 2017062754	Apr 2017	WO
WO 2017062855	Apr 2017	WO
WO 2017062886	Apr 2017	WO
WO 2017062983	Apr 2017	WO
WO 2017064439	Apr 2017	WO
WO 2017064546	Apr 2017	WO
WO 2017064566	Apr 2017	WO
WO 2017066175	Apr 2017	WO
WO 2017066497	Apr 2017	WO
WO 2017066588	Apr 2017	WO
WO 2017066707	Apr 2017	WO
WO 2017068077	Apr 2017	WO
WO 2017068377	Apr 2017	WO
WO 2017069829	Apr 2017	WO
WO 2017070029	Apr 2017	WO
WO 2017070032	Apr 2017	WO
WO 2017070169	Apr 2017	WO
WO 2017070284	Apr 2017	WO
WO 2017070598	Apr 2017	WO
WO 2017070605	Apr 2017	WO
WO 2017070632	Apr 2017	WO
WO 2017070633	Apr 2017	WO
WO 2017072590	May 2017	WO
WO 2017074526	May 2017	WO
WO 2017074962	May 2017	WO
WO 2017075261	May 2017	WO
WO 2017075335	May 2017	WO
WO 2017075475	May 2017	WO
WO 2017077135	May 2017	WO
WO 2017077329	May 2017	WO
WO 2017078751	May 2017	WO
WO 2017079400	May 2017	WO
WO 2017079428	May 2017	WO
WO 2017079673	May 2017	WO
WO 2017079724	May 2017	WO
WO 2017081097	May 2017	WO
WO 2017081288	May 2017	WO
WO 2017083368	May 2017	WO
WO 2017083722	May 2017	WO
WO 2017083766	May 2017	WO
WO 2017087395	May 2017	WO
WO 2017090724	Jun 2017	WO
WO 2017091510	Jun 2017	WO
WO 2017091630	Jun 2017	WO
WO 2017092201	Jun 2017	WO
WO 2017093370	Jun 2017	WO
WO 2017095111	Jun 2017	WO
WO 2017096041	Jun 2017	WO
WO 2017096237	Jun 2017	WO
WO 2017100158	Jun 2017	WO
WO 2017100431	Jun 2017	WO
WO 2017104404	Jun 2017	WO
WO 2017105251	Jun 2017	WO
WO 2017105350	Jun 2017	WO
WO 2017105991	Jun 2017	WO
WO 2017106414	Jun 2017	WO
WO 2017106528	Jun 2017	WO
WO 2017106537	Jun 2017	WO
WO 2017106569	Jun 2017	WO
WO 2017106616	Jun 2017	WO
WO 2017106657	Jun 2017	WO
WO 2017106767	Jun 2017	WO
WO 2017109134	Jun 2017	WO
WO 2017109757	Jun 2017	WO
WO 2017112620	Jun 2017	WO
WO 2017115268	Jul 2017	WO
WO 2017117395	Jul 2017	WO
WO 2017118598	Jul 2017	WO
WO 2017118720	Jul 2017	WO
WO 2017123609	Jul 2017	WO
WO 2017123910	Jul 2017	WO
WO 2017124086	Jul 2017	WO
WO 2017124100	Jul 2017	WO
WO 2017124652	Jul 2017	WO
WO 2017126987	Jul 2017	WO
WO 2017127807	Jul 2017	WO
WO 2017131237	Aug 2017	WO
WO 2017132112	Aug 2017	WO
WO 2017132580	Aug 2017	WO
WO 2017136520	Aug 2017	WO
WO 2017136629	Aug 2017	WO
WO 2017136794	Aug 2017	WO
WO 2017139264	Aug 2017	WO
WO 2017139505	Aug 2017	WO
WO 2017141173	Aug 2017	WO
WO 2017142835	Aug 2017	WO
WO 2017142999	Aug 2017	WO
WO 2017143042	Aug 2017	WO
WO 2017147278	Aug 2017	WO
WO 2017147432	Aug 2017	WO
WO 2017147446	Aug 2017	WO
WO 2017147555	Aug 2017	WO
WO 2017151444	Sep 2017	WO
WO 2017152015	Sep 2017	WO
WO 2017155717	Sep 2017	WO
WO 2017157422	Sep 2017	WO
WO 2017158153	Sep 2017	WO
WO 2017160689	Sep 2017	WO
WO 2017160752	Sep 2017	WO
WO 2017160890	Sep 2017	WO
WO 2017161068	Sep 2017	WO
WO 2017165826	Sep 2017	WO
WO 2017165862	Sep 2017	WO
WO 2017172644	Oct 2017	WO
WO 2017172645	Oct 2017	WO
WO 2017172860	Oct 2017	WO
WO 2017173004	Oct 2017	WO
WO 2017173054	Oct 2017	WO
WO 2017173092	Oct 2017	WO
WO 2017174329	Oct 2017	WO
WO 2017176529	Oct 2017	WO
WO 2017176806	Oct 2017	WO
WO 2017178590	Oct 2017	WO
WO 2017180694	Oct 2017	WO
WO 2017180711	Oct 2017	WO
WO 2017180915	Oct 2017	WO
WO 2017180926	Oct 2017	WO
WO 2017181107	Oct 2017	WO
WO 2017181735	Oct 2017	WO
WO 2017182468	Oct 2017	WO
WO 2017184334	Oct 2017	WO
WO 2017184768	Oct 2017	WO
WO 2017184786	Oct 2017	WO
WO 2017186550	Nov 2017	WO
WO 2017189308	Nov 2017	WO
WO 2017189336	Nov 2017	WO
WO 2017190257	Nov 2017	WO
WO 2017190664	Nov 2017	WO
WO 2017191210	Nov 2017	WO
WO 2017192172	Nov 2017	WO
WO 2017192512	Nov 2017	WO
WO 2017192544	Nov 2017	WO
WO 2017192573	Nov 2017	WO
WO 2017193029	Nov 2017	WO
WO 2017193053	Nov 2017	WO
WO 2017196768	Nov 2017	WO
WO 2017197038	Nov 2017	WO
WO 2017197238	Nov 2017	WO
WO 2017197301	Nov 2017	WO
WO 2017201476	Nov 2017	WO
WO 2017205290	Nov 2017	WO
WO 2017205423	Nov 2017	WO
WO 2017207589	Dec 2017	WO
WO 2017208247	Dec 2017	WO
WO 2017209809	Dec 2017	WO
WO 2017213896	Dec 2017	WO
WO 2017213898	Dec 2017	WO
WO 2017214460	Dec 2017	WO
WO 2017216392	Dec 2017	WO
WO 2017216771	Dec 2017	WO
WO 2017218185	Dec 2017	WO
WO 2017219027	Dec 2017	WO
WO 2017219033	Dec 2017	WO
WO 2017220751	Dec 2017	WO
WO 2017222370	Dec 2017	WO
WO 2017222773	Dec 2017	WO
WO 2017222834	Dec 2017	WO
WO 2017223107	Dec 2017	WO
WO 2017223330	Dec 2017	WO
WO 2018000657	Jan 2018	WO
WO 2018002719	Jan 2018	WO
WO 2018005117	Jan 2018	WO
WO 2018005289	Jan 2018	WO
WO 2018005691	Jan 2018	WO
WO 2018005782	Jan 2018	WO
WO 2018005873	Jan 2018	WO
WO 201806693	Jan 2018	WO
WO 2018009520	Jan 2018	WO
WO 2018009562	Jan 2018	WO
WO 2018009822	Jan 2018	WO
WO 2018013821	Jan 2018	WO
WO 2018013990	Jan 2018	WO
WO 2018014384	Jan 2018	WO
WO 2018015444	Jan 2018	WO
WO 2018015936	Jan 2018	WO
WO 2018017754	Jan 2018	WO
WO 2018018979	Feb 2018	WO
WO 2018020248	Feb 2018	WO
WO 2018022480	Feb 2018	WO
WO 2018022634	Feb 2018	WO
WO 2018025206	Feb 2018	WO
WO 2018026723	Feb 2018	WO
WO 2018026976	Feb 2018	WO
WO 2018027078	Feb 2018	WO
WO 2018030608	Feb 2018	WO
WO 2018031683	Feb 2018	WO
WO 2018035250	Feb 2018	WO
WO 2018035300	Feb 2018	WO
WO 2018035423	Feb 2018	WO
WO 2018035503	Feb 2018	WO
WO 2018039145	Mar 2018	WO
WO 2018039438	Mar 2018	WO
WO 2018039440	Mar 2018	WO
WO 2018039448	Mar 2018	WO
WO 2018045630	Mar 2018	WO
WO 2018048827	Mar 2018	WO
WO 2018049168	Mar 2018	WO
WO 2018051347	Mar 2018	WO
WO 2018058064	Mar 2018	WO
WO 2018062866	Apr 2018	WO
WO 2018064352	Apr 2018	WO
WO 2018064371	Apr 2018	WO
WO 2018064516	Apr 2018	WO
WO 2018067546	Apr 2018	WO
WO 2018067846	Apr 2018	WO
WO 2018068053	Apr 2018	WO
WO 2018069474	Apr 2018	WO
WO 2018071623	Apr 2018	WO
WO 2018071663	Apr 2018	WO
WO 2018071868	Apr 2018	WO
WO 2018071892	Apr 2018	WO
WO 2018074979	Apr 2018	WO
WO 2018079134	May 2018	WO
WO 2018080573	May 2018	WO
WO 2018081504	May 2018	WO
WO 2018081535	May 2018	WO
WO 2018081728	May 2018	WO
WO 2018083128	May 2018	WO
WO 2018083606	May 2018	WO
WO 2018085288	May 2018	WO
WO 2018085414	May 2018	WO
WO 2018086623	May 2018	WO
WO 2018093990	May 2018	WO
WO 2018098383	May 2018	WO
WO 2018098480	May 2018	WO
WO 2018098587	Jun 2018	WO
WO 2018099256	Jun 2018	WO
WO 2018103686	Jun 2018	WO
WO 2018106268	Jun 2018	WO
WO 2018107028	Jun 2018	WO
WO 2018107103	Jun 2018	WO
WO 2018107129	Jun 2018	WO
WO 2018108272	Jun 2018	WO
WO 2018109101	Jun 2018	WO
WO 2018111946	Jun 2018	WO
WO 2018111947	Jun 2018	WO
WO 2018112336	Jun 2018	WO
WO 2018112446	Jun 2018	WO
WO 2018119354	Jun 2018	WO
WO 2018119359	Jun 2018	WO
WO 2018130830	Jul 2018	WO
WO 2018135838	Jul 2018	WO
WO 2018136396	Jul 2018	WO
WO 2018138385	Aug 2018	WO
WO 2018148246	Aug 2018	WO
WO 2018148256	Aug 2018	WO
WO 2018148647	Aug 2018	WO
WO 2018149418	Aug 2018	WO
WO 2018149888	Aug 2018	WO
WO 2018152418	Aug 2018	WO
WO 2018154380	Aug 2018	WO
WO 2018154387	Aug 2018	WO
WO 2018154412	Aug 2018	WO
WO 2018154413	Aug 2018	WO
WO 2018154418	Aug 2018	WO
WO 2018154439	Aug 2018	WO
WO 2018154459	Aug 2018	WO
WO 2018154462	Aug 2018	WO
WO 2018156372	Aug 2018	WO
WO 2018156824	Aug 2018	WO
WO 2018161009	Sep 2018	WO
WO 2018165504	Sep 2018	WO
WO 2018165629	Sep 2018	WO
WO 2018170015	Sep 2018	WO
WO 2018170340	Sep 2018	WO
WO 2018175502	Sep 2018	WO
WO 2018176009	Sep 2018	WO
WO 2018177351	Oct 2018	WO
WO 2018179578	Oct 2018	WO
WO 2018183403	Oct 2018	WO
WO 2018195402	Oct 2018	WO
WO 2018195545	Oct 2018	WO
WO 2018195555	Oct 2018	WO
WO 2018197020	Nov 2018	WO
WO 2018197495	Nov 2018	WO
WO 2018202800	Nov 2018	WO
WO 2018204493	Nov 2018	WO
WO 2018208755	Nov 2018	WO
WO 2018208998	Nov 2018	WO
WO 2018209158	Nov 2018	WO
WO 2018209320	Nov 2018	WO
WO 2018213708	Nov 2018	WO
WO 2018213726	Nov 2018	WO
WO 2018213771	Nov 2018	WO
WO 2018213791	Nov 2018	WO
WO 2018217852	Nov 2018	WO
WO 2018217981	Nov 2018	WO
WO 2018218166	Nov 2018	WO
WO 2018218188	Nov 2018	WO
WO 2018218206	Nov 2018	WO
WO 2019005884	Jan 2019	WO
WO 2019005886	Jan 2019	WO
WO 2019010384	Jan 2019	WO
WO 2019023680	Jan 2019	WO
WO 2019079347	Apr 2019	WO
WO 2019084062	May 2019	WO
WO 2019118949	Jun 2019	WO
WO 2019139645	Jul 2019	WO
WO 2019161251	Aug 2019	WO
WO 2019168953	Sep 2019	WO
WO 2019226953	Nov 2019	WO
WO 2019241649	Dec 2019	WO
WO 2020014261	Jan 2020	WO
WO 2020028555	Feb 2020	WO
WO 2020041751	Feb 2020	WO
WO 2020051360	Mar 2020	WO
WO 2020086908	Apr 2020	WO
WO 2020092453	May 2020	WO
WO 2020102659	May 2020	WO
WO 2020154500	Jul 2020	WO
WO 2020180975	Sep 2020	WO
WO 2020181178	Sep 2020	WO
WO 2020181180	Sep 2020	WO
WO 2020181193	Sep 2020	WO
WO 2020181195	Sep 2020	WO
WO 2020181202	Sep 2020	WO
WO 2020191153	Sep 2020	WO
WO 2020191171	Sep 2020	WO
WO 2020191233	Sep 2020	WO
WO 2020191234	Sep 2020	WO
WO 2020191239	Sep 2020	WO
WO 2020191241	Sep 2020	WO
WO 2020191242	Sep 2020	WO
WO 2020191243	Sep 2020	WO
WO 2020191245	Sep 2020	WO
WO 2020191246	Sep 2020	WO
WO 2020191248	Sep 2020	WO
WO 2020191249	Sep 2020	WO
WO 2020210751	Oct 2020	WO
WO 2020214842	Oct 2020	WO
WO 2020236982	Nov 2020	WO
WO 2021025750	Feb 2021	WO
WO 2021030666	Feb 2021	WO
WO 2021072328	Apr 2021	WO
WO 2021108717	Jun 2021	WO
WO 2021138469	Jul 2021	WO
WO 2021155065	Aug 2021	WO
WO 2021158921	Aug 2021	WO
WO 2021158995	Aug 2021	WO
WO 2021158999	Aug 2021	WO
WO 2021222318	Nov 2021	WO
WO 2021226558	Nov 2021	WO

Non-Patent Literature Citations (1574)

Entry
Durai et al. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Research, 33, 5978-5990, 2005.
“Human genome” and “Nucleic Acids Sizes and Molecular Weights”. Printed on Mar. 19, 2020.
Zinc Finger Nuclease“from Wikipedia and “Fok I” from New England Biolabs INC”. Printed on Mar. 19, 2020.
Dean et al., Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene. Science, 273, 1856-1862, 1996.
“Zinc Finger Nuclease” and “Transcription Activator-Like Effector Nuclease” from Wikipedia. Printed on Sep. 28, 2021.
Kim et al., Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Research, 19, 1279-1288, 2009.
Nucleic Acid Data from New England Biolabs. Printed on Sep. 28, 2021.
2002/2003 New England Biolabs Catalog (pp. 133 and 270-273).
Enediyne from Wikipedia. Print on Oct. 7, 2022.
U.S. Appl. No. 61/874,746, filed Sep. 6, 2013, Liu et al.
U.S. Appl. No. 61/874,682, filed Sep. 6, 2013, Liu et al.
U.S. Appl. No. 61/838,178, filed Jun. 21, 2013, Joung et al.
U.S. Appl. No. 61/837,481, filed Jun. 20, 2013, Cho et al.
U.S. Appl. No. 61/803,599, filed Mar. 20, 2013, Kim et al.
U.S. Appl. No. 61/794,422, filed Mar. 15, 2013, Knight et al.
U.S. Appl. No. 61/761,046, filed Feb. 5, 2013, Knight et al.
U.S. Appl. No. 61/758,624, filed Jan. 30, 2013, Chen et al.
U.S. Appl. No. 61/734,256, filed Dec. 6, 2012, Chen et al.
U.S. Appl. No. 61/717,324, filed Oct. 23, 2012, Cho et al.
U.S. Appl. No. 61/716,256, filed Oct. 19, 2012, Jinek et al.
U.S. Appl. No. 62/357,332, filed Jun. 30, 2016, Liu et al.
U.S. Appl. No. 62/288,661, filed Jan. 29, 2016, Muir et al.
[No Author Listed] Score result for SEQ 355 to W02017032580. Muir et al. 2016.
[No Author Listed], Thermo Fisher Scientific—How Cationic Lipid Mediated Transfection Works, retrieved from the internet Aug. 27, 2015. 2 pages.
Abudayyeh et al., C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science Aug. 2016;353(6299):aaf5573. DOI: 10.1126/science.aaf5573.
Addgene Plasmid # 44246. pdCas9-humanized, 2017, Stanley Qi.
Addgene Plasmid # 73021. PCMV-BE3, 2017, David Liu.
Addgene Plasmid # 79620. pcDNA3.1_pCMV-nCas-PmCDA1-ugi pH1-gRNA(HPRT), 2017, Akihiko Kondo.
Begley, Scientists unveil the ‘most clever CRISPR gadget’ so far. STAT, Apr. 20, 2016. https://statnews.com/2016/04/20/clever-crispr-advance-unveiled/.
Bibikova et al., Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Mol Cell Biol. Jan. 2001;21(1):289-97.
Bibikova et al., Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. Jul. 2002;161(3):1169-75.
Billon et al., CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of Stop Codons. Mol Cell. Sep. 21, 2017;67(6):1068-1079.e4. doi: 10.1016/j.molcel.2017.08.008. Epub Sep. 7, 2017.
Boch et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science. Dec. 1, 20091;326(5959):1509-12. Doi: 10.1126/science.1178811.
Borman, Improved route to single-base genome editing. Chemical & Engineering News, Apr. 25, 2016;94(17)p5. http://cen.acs.org/articles/94/117/Improved-route-single-base-genome.html.
Brouns et al., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. Aug. 1, 20085;321(5891):960-4. doi: 10.1126/science.1159689.
Bulyk et al., Exploring the DNA-binding specificities of zinc fingers with DNA microarrays. Proc Natl Acad Sci U S A. Jun. 19, 2001;98(13):7158-63. Epub Jun. 12, 2001.
Burstein et al., New CRISPR-Cas systems from uncultivated microbes. Nature Feb. 2017;542(7640):237-240.
Chadwick et al., In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. Arterioscler Thromb Vasc Biol. Sep. 2017;37(9):1741-1747. doi: 10.1161/ATVBAHA.117.309881. Epub Jul. 27, 2017.
Chaikind et al., A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells. Nucleic Acids Res. Nov. 16, 2016;44(20):9758-9770. Epub Aug. 11, 2016.
Chavez et al., Highly efficient Cas9-mediated transcriptional programming. Nat Methods. Apr. 2015;12(4):326-8. doi: 10.1038/nmeth.3312. Epub Mar. 2, 2015.
Chavez et al., Precise Cas9 targeting enables genomic mutation prevention. Jun. 14, 2016. doi:https://doi.org/10.1101/058974. 6 pages.
Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. Oct. 2013;65(10):1357-69. doi:10.1016/j.addr.2012.09.039. Epub Sep. 29, 2012.
Chen et al., Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature. Mar. 6, 2008;452(7183):116-9. doi: 10.1038/nature06638. Epub Feb. 20, 2008.
Chew et al., A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. Oct. 2016; 13(10):868-74. doi: 10.1038/nmeth.3993. Epub Sep. 5, 2016.
Chu et al., Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotech. Feb. 13, 2015;33:543-8.
Cobb et al., Directed evolution as a powerful synthetic biology tool. Methods. Mar. 15, 20135;60(1):81-90. doi: 10.1016/j.ymeth.2012.03.009. Epub Mar. 23, 2012.
Cobb et al., Directed evolution: an evolving and enabling synthetic biology tool. Curr Opin Chem Biol. Aug. 2012;16(3-4):285-91. doi:10.1016/j.cbpa.2012.05.186. Epub Jun. 4, 2012. Review.
Cong et al., Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains. Nat Commun. Jul. 24, 2012;3:968. doi: 10.1038/ncomms1962.
Cornu et al., DNA-binding specificity is a major determinant of the activity and toxicity of zinc-finger nucleases. Mol Ther. Feb. 2008;16(2):352-8. Epub Nov. 20, 2007.
Covino et al., The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy? Current Drug Targets Dec. 2016; 17(1):76-110. DOI : 10.2174/138945011701151217110917.
Cox et al., Therapeutic genome editing: prospects and challenges. Nat Med. Feb. 2015;21(2):121-31. doi: 10.1038/nm.3793.
Cradick et al., CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. Nov. 1, 2013;41(20):9584-92. doi: 10.1093/nar/gkt714. Epub Aug. 11, 2013.
Cradick et al., ZFN-site searches genomes for zinc finger nuclease target sites and off-target sites. BMC Bioinformatics. May 13, 2011;12:152. doi: 10.1186/1471-2105-12-152.
Davis et al., Small molecule-triggered Cas9 protein with improved genome-editing specificity. Nat Chem Biol. May 2015;11(5):316-8. doi: 10.1038/nchembio.1793. Epub Apr. 6, 2015.
Doench et al., Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. Feb. 2016;34(2):184-191. doi: 10.1038/nbt.3437.
Dormiani et al., Long-term and efficient expression of human β-globin gene in a hematopoietic cell line using a new site-specific integrating non-viral system. Gene Ther. Aug. 2015;22(8):663-74. doi: 10.1038/gt.2015.30. Epub Apr. 1, 2015.
Doudna et al., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. Nov. 28, 2014;346(6213):1258096. doi: 10.1126/science.1258096.
Doyon et al., Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods. Jan. 2011;8(1):74-9. Doi: 10.1038/nmeth.1539. Epub Dec. 5, 2010.
Dunaime, Breakthrough method means CRISPR just got a lot more relevant to human health. The Verge. Apr. 20, 2016. http://www.theverge.com/2016/4/20/11450262/crispr-base-editing- single-nucleotides-dna-gene-liu-harvard.
East-Seletsky et al., Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. Nature Oct. 2016;538(7624):270-3.
Edwards et al., Crystal structures of the thi-box riboswitch bound to thiamine pyrophosphate analogs reveal adaptive RNA-small molecule recognition. Structure. Sep. 2006;14(9):1459-68.
Ellington et al., In vitro selection of RNA molecules that bind specific ligands. Nature. Aug. 30, 1990;346(6287):818-22.
Extended European Search Report for EP 15830407.1, dated Mar. 2, 2018.
Fagerlund et al., The Cpf1 CRISPR-Cas protein expands genome-editing tools. Genome Biology Nov. 17, 2015;16:251. https://doi.org/10.1186/s13059-015-0824-9.
Felletti et al., Twister Ribozymes as Highly Versatile Expression Platforms for Artificial Riboswitches. Nat Commun. Sep. 27, 2016;7:12834. doi: 10.1038/ncomms12834.
Ferry et al., Rational design of inducible CRISPR guide RNAs for de novo assembly of transcriptional programs. Nat Commun. Mar. 3, 2017;8:14633. doi: 10.1038/ncomms14633.
Fine et al., Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Scientific Reports 2015;5(1):Article No. 10777. doi:10.1038/srep10777. With Supplementary Information.
Fonfara et al., Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems. Nucleic Acids Res. Feb. 2014;42(4):2577-90. doi: 10.1093/nar/gkt1074. Epub Nov. 22, 2013.
Gabriel et al., An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol. Aug. 7, 2011;29(9):816-23. doi: 10.1038/nbt.1948.
Gao et al., Crystal structure of a TALE protein reveals an extended N-terminal DNA binding region. Cell Res. Dec. 2012;22(12):1716-20. doi: 10.1038/cr.2012.156. Epub Nov. 13, 2012.
Gao et al., DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat Biotechnol. Jul. 2016;34(7):768-73. doi: 10.1038/nbt.3547. Epub May 2, 2016.
Genbank Submission; NIH/NCBI, Accession No. NC_018721.1. Feng et al., Jun. 11, 2013. 1 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_021284.1. Ku et al., Jul. 12, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NM_174936. Guo et al., Oct. 28, 2015. 6 pages.
Gordley et al., Evolution of programmable zinc finger-recombinases with activity in human cells. J Mol Biol. Mar. 3, 20070;367(3):802-13. Epub Jan. 12, 2007.
Guo et al., Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol. Jul. 2, 2010;400(1):96-107. doi: 10.1016/j.jmb.2010.04.060. Epub May 4, 2010.
Gupta et al., Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res. Jan. 2011;39(1):381-92. doi: 10.1093/nar/gkq787. Epub Sep. 14, 2010.
Haeussler et al., Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. Jul. 5, 2016;17(1):148. doi: 10.1186/s13059-016-1012-2.
Han, New CRISPR/Cas9-based Tech Edits Single Nucleotides Without Breaking DNA. Genome Web, Apr. 20, 2016. https://genomeweb.com/gene-silencinggene-editing/new-crisprcas9-based-tech-edits-single-nucleotides-without-breaking-dna.
Händel et al., Expanding or restricting the target site repertoire of zinc-finger nucleases: the inter-domain linker as a major determinant of target site selectivity. Mol Ther. Jan. 2009;17(1):104-11. doi: 10.1038/mt.2008.233. Epub Nov. 11, 2008.
Harrington et al., Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ. 2004;329(7470):839-842. doi: 10.1136/bmj.329.7470.839.
Hess et al., Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat Methods. Dec. 2016; 13(12):1036-1042. doi: 10.1038/nmeth.4038. Epub Oct. 31, 2016.
Hilton et al., Enabling functional genomics with genome engineering. Genome Res. Oct. 2015;25(10):1442-55. doi: 10.1101/gr.190124.115.
Hirano et al., Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9. Mol Cell. Mar. 17, 2016;61(6):886-94. doi: 10.1016/j.molcel.2016.02.018.
Hower et al., Shape-based peak identification for ChIP-Seq. BMC Bioinformatics. Jan. 12, 2011;12:15. doi: 10.1186/1471-2105-12-15.
Hsu et al., DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. Sep. 2013;31(9):827-32. doi: 10.1038/nbt.2647. Epub Jul. 21, 2013.
Hu et al., Chemical Biology Approaches to Genome Editing: Understanding, Controlling, and Delivering Programmable Nucleases. Cell Chem Biol. Jan. 21, 2016;23(1):57-73. doi: 10.1016/j.chembiol.2015.12.009.
Hurt et al., Highly specific zinc finger proteins obtained by directed domain shuffling and cell- based selection. Proc Natl Acad Sci U S A. Oct. 14, 2003;100(21):12271-6. Epub Oct. 3, 2003.
International Preliminary Report on Patentability for PCT/US2016/058344, dated May 3, 2018.
International Preliminary Report on Patentability for PCT/US2012/047778, dated Feb. 6, 2014.
International Preliminary Report on Patentability for PCT/US2014/052231, dated Mar. 3, 2016.
International Preliminary Report on Patentability for PCT/US2014/054247, dated Mar. 17, 2016.
International Preliminary Report on Patentability for PCT/US2014/054291, dated Mar. 17, 2016.
International Preliminary Report on Patentability for PCT/US2014/070038, dated Jun. 23, 2016.
International Preliminary Report on patentability for PCT/US2014/050283, dated Feb. 18, 2016.
International Preliminary Report on Patentability for PCT/US2015/042770, dated Dec. 19, 2016.
International Preliminary Report on Patentability for PCT/US2015/058479, dated May 11, 2017.
International Preliminary Report on Patentability or PCT/US2014/054252, dated Mar. 17, 2016.
International Search Report and Written Opinion for PCT/US2012/047778, dated May 30, 2013.
International Search Report and Written Opinion for PCT/US2014/052231, dated Dec. 4, 2014.
International Search Report and Written Opinion for PCT/US2014/052231, dated Jan. 30, 2015 (Corrected Version).
International Search Report and Written Opinion for PCT/US2014/050283, dated Nov. 6, 2014.
International Search Report and Written Opinion for PCT/US2014/054247, dated Mar. 27, 2015.
International Search Report and Written Opinion for PCT/US2014/054291, dated Mar. 27, 2015.
International Search Report and Written Opinion for PCT/US2014/054252, dated Mar. 5, 2015.
International Search Report and Written Opinion for PCT/US2014/070038, dated Apr. 14, 2015.
International Search Report and Written Opinion for PCT/US2015/042770, dated Feb. 23, 2016.
International Search Report and Written Opinion for PCT/US2015/058479, dated Feb. 11, 2016.
International Search Report and Written Opinion for PCT/US2016/044546, dated Dec. 28, 2016.
International Search Report and Written Opinion for PCT/US2016/058344, dated Apr. 20, 2017.
International Search Report and Written Opinion for PCT/US2017/046144, dated Oct. 10, 2017.
International Search Report and Written Opinion for PCT/US2017/045381, dated Oct. 26, 2017.
International Search Report and Written Opinion for PCT/US2017/056671, dated Feb. 20, 2018.
International Search Report and Written Opinion for PCT/US2017/068114, dated Mar. 20, 2018.
International Search Report and Written Opinion for PCT/US2017/068105, dated Apr. 4, 2018.
International Search Report and Written Opinion for PCT/US2017/48390, dated Jan. 9, 2018.
International Search Report for PCT/US2013/032589, dated Jul. 26, 2013.
International Search Report for PCT/US2018/021664, dated Jun. 21, 2018.
International Search Report for PCT/US2018/021878, dated Aug. 20, 2018.
International Search Report for PCT/US2018/021880, dated Jun. 20, 2018.
International Search Report for PCT/US2018/024208, dated Aug. 23, 2018.
International Search Report for PCT/US2018/025887, dated Jun. 21, 2018.
International Search Report for PCT/US2018/032460, dated Jul. 11, 2018.
Invitation to Pay Additional Fees for PCT/US2014/054291, dated Dec. 18, 2014.
Invitation to Pay Additional Fees for PCT/US2016/058344, dated Mar. 1, 2017.
Invitation to Pay Additional Fees for PCT/US2017/056671, dated Dec. 21, 2017.
Invitation to Pay Additional Fees for PCT/US2017/48390, dated Nov. 7, 2017.
Invitation to Pay Additional Fees for PCT/US2018/021878, dated Jun. 8, 2018.
Jenkins et al., Comparison of a preQ1 riboswitch aptamer in metabolite-bound and free states with implications for gene regulation. J Biol Chem. Jul. 15, 2011;286(28):24626-37. doi: 10.1074/jbc.M111.230375. Epub May 18, 2011.
Jiang et al., Structural Biology. A Cas9-guide RNA Complex Preorganized for Target DNA Recognition. Science. Jun. 26, 2015;348(6242):1477-81. doi: 10.1126/science.aab1452.
Jiang et al., Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science. Feb. 19, 2016;351(6275):867-71. doi: 10.1126/science.aad8282. Epub Jan. 14, 2016.
Jinek et al., Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. Mar. 1, 20144;343(6176):1247997. doi: 10.1126/science.1247997. Epub Feb. 6, 2014.
Karpinsky et al., Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat Biotechnol. Apr. 2016;34(4):401-9. doi: 10.1038/nbt.3467. Epub Feb. 22, 2016.
Kaya et al., A bacterial Argonaute with noncanonical guide RNA specificity. Proc. Natl. Acad. Sci. USA Apr. 2016;113(15):4057-62.
Kim et al., Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat Biotechnol. May 2017;35(5):475-480. doi: 10.1038/nbt.3852. Epub Apr. 10, 2017.
Kim et al., Highly efficient RNA-guided base editing in mouse embryos. Nat Biotechnol. May 2017;35(5):435-437. doi: 10.1038/nbt.3816. Epub Feb. 27, 2017.
Kim et al., Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. Feb. 6, 1996;93(3):1156-60.
Kim et al., Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions. Nat Biotechnol. Apr. 2017;35(4):371-376. doi: 10.1038/nbt.3803. Epub Feb. 13, 2017.
Kleinstiver et al., Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat Biotechnol. Dec. 2015;33(12):1293-1298. doi: 10.1038/nbt.3404. Epub Nov. 2, 2015.
Kleinstiver et al., Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. Jul. 23, 2015;523(7561):481-5. doi: 10.1038/nature14592. Epub Jun. 22, 2015.
Kleinstiver et al., High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. Jan. 28, 2016;529(7587):490-5. doi: 10.1038/nature16526. Epub Jan. 6, 2016.
Klug et al., Zinc fingers: a novel protein fold for nucleic acid recognition. Cold Spring Harb Symp Quant Biol. 1987;52:473-82.
Kobori et al., Deep Sequencing Analysis of Aptazyme Variants Based on a Pistol Ribozyme. ACS Synth Biol. Jul. 21, 2017;6(7):1283-1288. doi: 10.1021/acssynbio.7b00057. Epub Apr. 14, 2017.
Komor et al., CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes. Cell. Jan. 1, 20172;168(1-2):20-36. doi: 10.1016/j.cell.2016.10.044.
Komor et al., Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv. Aug. 30, 2017;3(8):eaao4774. doi: 10.1126/sciadv.aao4774. eCollection Aug. 2017.
Komor et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. Apr. 20, 2016;533(7603):420-4. doi: 10.1038/nature17946.
Koonin et al., Diversity, classification and evolution of CRISPR-Cas systems. Curr Opin Microbiol. 2017;37:67-78. doi: 10.1016/j.mib.2017.05.008.
Krishna et al., Structural classification of zinc fingers: survey and summary. Nucleic Acids Res. Jan. 15, 2003;31(2):532-50.
Kury et al., De Novo Disruption of the Proteasome Regulatory Subunit PSMD12 Causes a Syndromic Neurodevelopmental Disorder. Am J Hum Genet. Feb. 2, 2017;100(2):352-363. doi: 10.1016/j.ajhg.2017.01.003. Epub Jan. 26, 2017.
Kuscu et al., CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat Methods. Jul. 2017; 14(7):710-712. doi: 10.1038/nmeth.4327. Epub Jun. 5, 2017.
Kwon et al., Chemical basis of glycine riboswitch cooperativity. RNA. Jan. 2008;14(1):25-34. Epub Nov. 27, 2007.
Landrum et al., ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. Jan. 4, 2016;44(D1):D862-8. doi: 10.1093/nar/gkv1222. Epub Nov. 17, 2015.
Langer et al., New methods of drug delivery. Science. Sep. 28, 1990;249(4976): 1527-33.
Ledford, Gene-editing hack yields pinpoint precision. Nature, Apr. 20, 2016. http://www.nature.com/news/gene-editing-hack-yields-pinpoint-precision-1.19773.
Lee et al., An allosteric self-splicing ribozyme triggered by a bacterial second messenger. Science. Aug. 13, 2010;329(5993):845-8. doi: 10.1126/science.1190713.
Lee et al., Failure to detect DNA-guided genome editing using Natronobacterium gregoryi Argonaute. Nat Biotechnol. Nov. 28, 2016;35(1):17-18. doi: 10.1038/nbt.3753.
Lee et al., Ribozyme Mediated gRNA Generation for In Vitro and In Vivo CRISPR/Cas9 Mutagenesis. PLoS One. Nov. 1, 20160;11(11):e0166020. doi: 10.1371/journal.pone.0166020. eCollection 2016.
Lewis et al., Building the Class 2 CRISPR-Cas Arsenal. Mol Cell 2017;65(3);377-379.
Li et al., Base editing with a Cpf1-cytidine deaminase fusion. Nat Biotechnol. Apr. 2018;36(4):324-327. doi: 10.1038/nbt.4102. Epub Mar. 19, 2018.
Li et al., Generation of Targeted Point Mutations in Rice by a Modified CRISPR/Cas9 System. Mol Plant. Mar. 6, 2017;10(3):526-529. doi: 10.1016/j.molp.2016.12.001. Epub Dec. 8, 2016.
Li et al., Highly efficient and precise base editing in discarded human tripronuclear embryos. Protein Cell. Aug. 19, 2017. doi: 10.1007/s13238-017-0458-7. [Epub ahead of print].
Liang et al., Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. Send to; J Biotechnol. Aug. 20, 2015;208:44-53. doi: 10.1016/j.jbiotec.2015.04.024.
Lieber et al., Mechanism and regulation of human non-homologous DNA end-joining. Nat Rev Mol Cell Biol. Sep. 2003;4(9):712-20.
Lilley, D.M. The Varkud Satellite Ribozyme. RNA. Feb. 2004; 10(2):151-8.doi: 10.1261/rna.5217104.
Lin et al., Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. Dec. 15, 2014;3:e04766. doi: 10.7554/eLife.04766.
Liu et al., C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism. Molecular Cell Jan. 2017;65(2):310-22.
Lu et al., Precise Editing of a Target Base in the Rice Genome Using a Modified CRISPR/Cas9 System. Mol Plant. Mar. 6, 2017;10(3):523-525. doi: 10.1016/j.molp.2016.11.013. Epub Dec. 6, 2016.
Ma et al., Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes. Mol Cell. Nov. 5, 2015;60(3):398-407. doi: 10.1016/j.molcel.2015.10.030.
Ma et al., Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nature Methods. Oct. 2016; 13:1029-35. doi:10.1038/nmeth.4027.
Mak et al., The crystal structure of TAL effector PthXol bound to its DNA target. Science. Feb. 10, 2012;335(6069):716-9. doi: 10.1126/science.1216211. Epub Jan. 5, 2012.
Makarova et al., Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements. Biology Direct 2009;4:29.
Makarova et al., An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. Nov. 2015;13(11):722-36. doi: 10.1038/nrmicro3569. Epub Sep. 28, 2015.
Mandal et al., Riboswitches Control Fundamental Biochemical Pathways in Bacillus Subtilis and Other Bacteria. Cell. May 3, 20030;113(5):577-86. doi: 10.1016/s0092-8674(03)00391-x.
Marioni et al., DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. Jan. 30, 2015;16:25. doi: 10.1186/s13059-015-0584-6.
Maruyama et al., Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. May 2015;33(5):538-42. doi: 10.1038/nbt.3190. Epub Mar. 23, 2015.
Meckler et al., Quantitative analysis of TALE-DNA interactions suggests polarity effects. Nucleic Acids Res. Apr. 2013;41(7):4118-28. doi: 10.1093/nar/gkt085. Epub Feb. 13, 2013.
Mei et al., Recent Progress in CRISPR/Cas9 Technology. J Genet Genomics. Feb. 20, 2016;43(2):63-75. doi: 10.1016/j.jgg.2016.01.001. Epub Jan. 18, 2016.
Meng et al., Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method. Nucleic Acids Res. 2007;35(11):e81. Epub May 30, 2007.
Meyer et al., Confirmation of a second natural preQ1 aptamer class in Streptococcaceae bacteria. RNA. Apr. 2008;14(4):685-95. doi: 10.1261/rna.937308. Epub Feb. 27, 2008.
Mir et al., Two Active Site Divalent Ions in the Crystal Structure of the Hammerhead Ribozyme Bound to a Transition State Analogue. Biochemistry. . Feb. 2, 2016;55(4):633-6. doi: 10.1021/acs.biochem.5b01139. Epub Jan. 19, 2016.
Mootz et al., Conditional protein splicing: a new tool to control protein structure and function in vitro and in vivo. J Am Chem Soc. Sep. 3, 2003;125(35):10561-9.
Mootz et al., Protein splicing triggered by a small molecule. J Am Chem Soc. Aug. 7, 2002;124(31):9044-5.
Nahvi et al., Coenzyme B12 riboswitches are widespread genetic control elements in prokaryotes. Nucleic Acids Res. Jan. 2, 2004;32(1):143-50.
Narayanan et al., Clamping down on weak terminal base pairs: oligonucleotides with molecular caps as fidelity-enhancing elements at the 5′- and 3′-terminal residues. Nucleic Acids Res. May 2, 20040;32(9):2901-11. Print 2004.
Neel et al., Riboswitches: Classification, function and in silico approach, International Journal of Pharma Sciences and Research. 2010;1(9):409-420.
Ni et al., Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011;18(27):4206-14. Review.
Nishida et al., Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. Sep. 16, 2016;353(6305). pii: aaf8729. doi: 10.1126/science.aaf8729. Epub Aug. 4, 2016.
Nishida et al., Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science. Sep. 16, 2016;353(6305):1248. pii: aaf8729. doi: 10.1126/science.aaf8729. Epub Aug. 4, 2016.
Nishimasu et al., Crystal Structure of Staphylococcus aureus Cas9. Cell. Aug. 27, 2015;162(5):1113-26. doi: 10.1016/j.cell.2015.08.007.
Nowak et al., Guide RNA Engineering for Versatile Cas9 Functionality. Nucleic Acids Res. Nov. 16, 2016;44(20):9555-9564. doi: 10.1093/nar/gkw908. Epub Oct. 12, 2016.
O'Connell et al., Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. Dec. 11, 2014;516(7530):263-6. doi: 10.1038/nature13769. Epub Sep. 28, 2014.
Offord, Advances in Genome Editing. The Scientist, Apr. 20, 2016. http://www.the-scientist.com/?articles.view/articleNo/45903/title/Advances-in-Genome-Editing/.
Pabo et al., Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem. 2001;70:313-40.
Partial Supplementary European Search Report for Application No. EP 12845790.0, dated Mar. 18, 2015.
Pelletier, CRISPR-Cas systems for the study of the immune function. Nov. 15, 2016. https://doi.org/10.1002/9780470015902.a0026896.
Petek et al., Frequent endonuclease cleavage at off-target locations in vivo. Mol Ther. May 2010;18(5):983-6. Doi: 10.1038/mt.2010.35. Epub Mar. 9, 2010.
Petolino et al., Editing Plant Genomes: a new era of crop improvement. Plant Biotechnol J. Feb. 2016;14(2):435-6. doi: 10.1111/pbi.12542.
Plosky et al., CRISPR-Mediated Base Editing without DNA Double-Strand Breaks. Mol Cell. May 1, 20169;62(4):477-8. doi: 10.1016/j.molcel.2016.05.006.
Prykhozhij et al., CRISPR multitargeter: a web tool to find common and unique CRISPR single guide RNA targets in a set of similar sequences. PLoS One. Mar. 5, 2015;10(3):e0119372. doi: 10.1371/journal.pone.0119372. eCollection 2015.
Ran et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature. Apr. 9, 2015;520(7546):186-91. doi: 10.1038/nature14299. Epub Apr. 1, 2015.
Rees et al., Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat Commun. Jun. 6, 2017;8:15790. doi: 10.1038/ncomms15790.
Ren et al., In-line Alignment and Mg2? Coordination at the Cleavage Site of the env22 Twister Ribozyme. Nat Commun. Nov. 20, 2014;5:5534. doi: 10.1038/ncomms6534.
Ren et al., Pistol Ribozyme Adopts a Pseudoknot Fold Facilitating Site-Specific In-Line Cleavage. Nat Chem Biol. Sep. 2016;12(9):702-8. doi: 10.1038/nchembio.2125. Epub Jul. 11, 2016.
Reyon et al., FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. May 2012;30(5):460-5. doi: 10.1038/nbt.2170.
Richardson et al., Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. Mar. 2016; 34(3):339-44. doi: 10.1038/nbt.3481. Epub Jan. 20, 2016.
Saleh-Gohari et al., Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. Jul. 13, 2004;32(12):3683-8. Print 2004.
Segal et al., Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry. Feb. 25, 2003;42(7):2137-48.
Serganov et al., Coenzyme recognition and gene regulation by a flavin mononucleotide riboswitch. Nature. Mar. 12, 2009;458(7235):233-7. doi: 10.1038/nature07642. Epub Jan. 25, 2009.
Serganov et al., Structural basis for discriminative regulation of gene expression by adenine- and guanine-sensing mRNAs. Chem Biol. Dec. 2004; 11(12):1729-41.
Serganov et al., Structural basis for gene regulation by a thiamine pyrophosphate-sensing riboswitch. Nature. Jun. 29, 2006;441(7097):1167-71. Epub May 21, 2006.
Shah et al., Target-specific variants of Flp recombinase mediate genome engineering reactions in mammalian cells. FEBS J. Sep. 2015;282(17):3323-33. doi: 10.1111/febs.13345. Epub Jul. 1, 2015.
Shee et al., Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife. Oct. 2, 20139;2:e01222. doi: 10.7554/eLife.01222.
Shimantani et al., Targeted base editing in rice and tomato using a CRISPR-Cas9 cytidine deaminase fusion. Nat Biotechnol. May 2017;35(5):441-443. doi: 10.1038/nbt.3833. Epub Mar. 27, 2017.
Shimizu et al., Adding fingers to an engineered zinc finger nuclease can reduce activity. Biochemistry. Jun. 7, 2011;50(22):5033-41. doi: 10.1021/bi200393g. Epub May 11, 2011.
Shmakov et al., Discovery and Functional Characterization of Diverse Class 2 CRISPR Cas Systems. Molecular Cell Nov. 2015;60(3):385-97.
Skretas et al., Regulation of protein activity with small-molecule-controlled inteins. Protein Sci. Feb. 2005;14(2):523-32. Epub Jan. 4, 2005.
Slaymaker et al., Rationally engineered Cas9 nucleases with improved specificity. Science. Jan. 1, 2016;351(6268):84-8. doi: 10.1126/science.aad5227. Epub Dec. 1, 2015.
Song et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. Jun. 2005;23(6):709-17. Epub May 22, 2005.
Stevens et al., Design of a Split Intein with Exceptional Protein-Splicing Activity. J Am Chem Soc. Feb. 24, 2016;138(7):2162-5. doi: 10.1021/jacs.5b13528. Epub Feb. 8, 2016.
Sudarsan et al., An mRNA structure in bacteria that controls gene expression by binding lysine. Genes Dev. Nov. 1, 2003;17(21):2688-97.
Sudarsan et al., Riboswitches in eubacteria sense the second messenger cyclic di-GMP. Science. Jul. 18, 2008;321(5887):411-3. doi: 10.1126/science.1159519.
Suess et al., A theophylline responsive riboswitch based on helix slipping controls gene expression in vivo. Nucleic Acids Res. Mar. 5, 2004;32(4):1610-4.
Sun et al., Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol Biosyst. Apr. 2012;8(4):1255-63. doi: 10.1039/c2mb05461b. Epub Feb. 3, 2012.
Supplementary European Search Report for Application No. EP 12845790.0, dated Oct. 12, 2015.
Swarts et al., Argonaute of the archaeon Pyrococcus furiosus is a DNA-guided nuclease that targets cognate DNA. Nucleic Acids Res. May 26, 2015;43(10):5120-9. doi: 10.1093/nar/gkv415. Epub Apr. 29, 2015.
Tang et al., Aptazyme-embedded guide RNAs enable ligand-responsive genome editing and transcriptional activation. Nat Commun. Jun. 28, 2017;8:15939. doi: 10.1038/ncomms15939.
Thompson et al., Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells. Methods Enzymol. 2012;503:293-319. doi: 10.1016/B978-0-12-396962-0.00012-4.
Trausch et al., The structure of a tetrahydrofolate-sensing riboswitch reveals two ligand binding sites in a single aptamer. Structure. Oct. 12, 2011;19(10):1413-23. doi: 10.1016/j.str.2011.06.019. Epub Sep. 8, 2011.
Truong et al., Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. Jul. 27, 2015;43(13):6450-8. doi: 10.1093/nar/gkv601. Epub Jun. 16, 2015.
Tsai et al., GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. Feb. 2015;33(2):187-97. doi: 10.1038/nbt.3117. Epub Dec. 16, 2014.
UniProt Submission; UniProt, Accession No. P01011. Last modified Jun. 11, 2014, version 2. 15 pages.
UniProt Submission; UniProt, Accession No. P01011. Last modified Sep. 18, 2013, version 2. 15 pages.
UniProt Submission; UniProt, Accession No. P04264. Last modified Jun. 11, 2014, version 6. 15 pages.
UniProt Submission; UniProt, Accession No. P04275. Last modified Jul. 9, 2014, version 107. 29 pages.
Van Swieten et al., A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet. Jan. 2003;72(1):191-9. Epub Dec. 13, 2002.
Wang et al., CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report. Arterioscler Thromb Vasc Biol. May 2016;36(5):783-6. doi: 10.1161/ATVBAHA.116.307227. Epub Mar. 3, 2016.
Wang et al., Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc Natl Acad Sci U S A. Feb. 29, 2016. pii: 201520244. [Epub ahead of print].
Wang et al., Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res. Oct. 2017;27(1):1289-92. doi: 10.1038/cr.2017.111. Epub Aug. 29, 2017.
Wang et al., Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. Aug. 2008;26(8):901-8. doi: 10.1038/nbt.1484.
Wang et al., Riboswitches that sense S-adenosylhomocysteine and activate genes involved in coenzyme recycling. Mol Cell. Mar. 28, 2008;29(6):691-702. doi: 10.1016/j.molcel.2008.01.012.
Weinberg et al., New Classes of Self-Cleaving Ribozymes Revealed by Comparative Genomics Analysis. Nat Chem Biol. Aug. 2015;11(8):606-10. doi: 10.1038/nchembio.1846. Epub Jul. 13, 2015.
Weinberg et al., The aptamer core of SAM-IV riboswitches mimics the ligand-binding site of SAM-I riboswitches. RNA. May 2008;14(5):822-8. doi: 10.1261/rna.988608. Epub Mar. 27, 2008.
Winkler et al., An mRNA structure that controls gene expression by binding FMN. Proc Natl Acad Sci U S A. Dec. 10, 2002;99(25):15908-13. Epub Nov. 27, 2002.
Wood et al., Targeted genome editing across species using ZFNs and TALENs. Science. Jul. 15, 2011;333(6040):307. doi: 10.1126/science.1207773. Epub Jun. 23, 2011.
Xu et al., Sequence determinants of improved CRISPR sgRNA design. Genome Res. Aug. 2015;25(8):1147-57. doi: 10.1101/gr.191452.115. Epub Jun. 10, 2015.
Yahata et al., Unified, Efficient, and Scalable Synthesis of Halichondrins: Zirconium/Nickel-Mediated One-Pot Ketone Synthesis as the Final Coupling Reaction. Angew Chem Int Ed Engl. Aug. 28, 2017;56(36):10796-10800. doi: 10.1002/anie.201705523. Epub Jul. 28, 2017.
Yamano et al., Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA. Cell May 2016;165(4)949-62.
Yang et al., APOBEC: From mutator to editor. J Genet Genomics. Sep. 20, 2017;44(9):423-437. doi: 10.1016/j.jgg.2017.04.009. Epub Aug. 7, 2017.
Yang et al., Engineering and optimising deaminase fusions for genome editing. Nat Commun. Nov. 2, 2016;7:13330. doi: 10.1038/ncomms13330.
Yang et al., Genome editing with targeted deaminases. BioRxiv. Preprint. First posted online Jul. 28, 2016.
Yang et al., New CRISPR-Cas systems discovered. Cell Res. Mar. 2017;27(3):313-314. doi: 10.1038/cr.2017.21. Epub Feb. 21, 2017.
Yang et al., PAM-dependent Target DNA Recognition and Cleavage by C2C1 CRISPR-Cas endonuclease. Cell Dec. 2016;167(7):1814-28.
Zetsche et al., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat Biotechnol. Feb. 2015;33(2):139-42. doi: 10.1038/nbt.3149.
Zetsche et al., Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. Oct. 22, 2015;163(3):759-71. doi: 10.1016/j.cell.2015.09.038. Epub Sep. 25, 2015.
Zhang et al., Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol. Feb. 2011;29(2):149-53. doi: 10.1038/nbt. 1775. Epub Jan. 19, 2011.
Zhang et al., Programmable base editing of zebrafish genome using a modified CRISPR-Cas9 system. Nat Commun. Jul. 25, 2017;8(1):118. doi: 10.1038/s41467-017-00175-6.
Zheng et al., DNA editing in DNA/RNA hybrids by adenosine deaminases that act on RNA. Nucleic Acids Res. Apr. 7, 2017;45(6):3369-3377. doi: 10.1093/nar/gkx050.
Zhong et al., Rational Design of Aptazyme Riboswitches for Efficient Control of Gene Expression in Mammalian Cells. Elife. Nov. 2, 2016;5:e18858. doi: 10.7554/eLife.18858.
Zimmermann et al., Molecular interactions and metal binding in the theophylline-binding core of an RNA aptamer. RNA. May 2000;6(5):659-67.
Zong et al., Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion. Nat Biotechnol. May 2017;35(5):438-440. doi: 10.1038/nbt.3811. Epub Feb. 27, 2017.
Zorko et al., Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. Feb. 28, 2005;57(4):529-45. Epub Jan. 22, 2005.
Zuris et al., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol. 2015;33:73-80.
Partial European Search Report for Application No. EP 19187331.4, dated Dec. 19, 2019.
Extended European Search Report for EP 19187331.4, dated Mar. 25, 2020.
Extended European Search Report for EP18199195.1, dated Feb. 12, 2019.
Extended European Search Report for EP 19181479.7, dated Oct. 31, 2019.
International Preliminary Report on Patentability for PCT/US2014/048390, dated Mar. 7, 2019.
International Preliminary Report on Patentability for PCT/US2017/068114, dated Jul. 4, 2019.
International Preliminary Report on Patentability for PCT/US2017/068105, dated Jul. 4, 2019.
International Preliminary Report on Patentability for PCT/US2018/021880, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2017/046144, dated Feb. 21, 2019.
International Preliminary Report on Patentability for PCT/US2017/045381, dated Feb. 14, 2019.
International Preliminary Report on Patentability for PCT/US2018/021664, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2017/056671, dated Apr. 25, 2019.
International Preliminary Report on Patentability for PCT/US2018/021878, dated Sep. 19, 2019.
International Preliminary Report on Patentability for PCT/US2018/024208, dated Oct. 3, 2019.
International Search Report for PCT/US2018/048969, dated Jul. 31, 2019.
International Prelminary Report on Patentability for PCT/US2018/048969, dated Mar. 12, 2020.
International Preliminary Report on Patentability for PCT/US2018/032460, dated Nov. 21, 2019.
International Search Report and Written Opinion for PCT/US2018/044242, dated Nov. 21, 2019.
International Preliminary Report on Patentability for PCT/US2018/044242, dated Feb. 6, 2020.
Invitation to Pay Additional Fees for PCT/US20/20965, dated May 18, 2020.
Banerjee et al., Cadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2-MSH6 complex [published correction appears in Nucleic Acids Res. 2005;33(5):1738]. Nucleic Acids Res. 2005;33(4):1410-1419. Published Mar. 3, 2005. doi: 10.1093/nar/gki291.
Bertolotti et al., Toward genosafe endonuclease-boosted gene targeting using breakthrough CRISP/Cas9 for next generation stem cell gene therapy culminating in efficient ex VIVO in VIVO gene repair/genomic editing. Molecular Therapy. May 2015;23(Suppl1):S139. Abstract 350. 18th Ann Meeting of the American Society of Gene and Cell Therapy. ASGCT 2015. New Orleans, LA. May 13, 2015-May 16, 2015.
Biswas et al., A structural basis for allosteric control of DNA recombination by lambda integrase. Nature. Jun. 23, 2005;435(7045):1059-66. doi: 10.1038/nature03657.
Budker et al., Protein/amphipathic polyamine complexes enable highly efficient transfection with minimal toxicity. Biotechniques. Jul. 1997;23(1):139, 142-7. doi: 10.2144/97231rr02.
Fogg et al., New applications for phage integrases. J Mol Biol. Jul. 29, 2014;426(15):2703-16. doi: 10.1016/j.jmb.2014.05.014. Epub May 22, 2014.
Grainge et al., The integrase family of recombinase: organization and function of the active site. Mol Microbiol. Aug. 1999;33(3):449-56.
Hu et al., Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. Apr. 5, 2018;556(7699):57-63. doi: 10.1038/nature26155. Epub Feb. 28, 2018.
Mertens et al., Site-specific recombination in bacteriophage Mu: characterization of binding sites for the DNA invertase Gin. EMBO J. Apr. 1988;7(4):1219-27.
Mishina et al., Conditional gene targeting on the pure C57BL/6 genetic background. Neurosci Res. Jun. 2007;58(2):105-12. doi: 10.1016/j.neures.2007.01.004. Epub Jan. 18, 2007.
Numrych et al., A comparison of the effects of single-base and triple-base changes in the integrase arm-type binding sites on the site-specific recombination of bacteriophage lambda. Nucleic Acids Res. Jul. 11, 1990;18(13):3953-9. doi: 10.1093/nar/18.13.3953.
Pospísilová et al., Hydrolytic cleavage of N6-substituted adenine derivatives by eukaryotic adenine and adenosine deaminases. Biosci Rep. 2008;28(6):335-347. doi:10.1042/BSR20080081.
Rogozin et al., Evolution and diversification of lamprey antigen receptors: evidence for involvement of an AID-APOBEC family cytosine deaminase. Nat Immunol. Jun. 2007;8(6):647- 56. doi: 10.1038/ni1463. Epub Apr. 29, 2007.
Sun et al., The CRISPR/Cas9 system for gene editing and its potential application in pain research. Transl Periop & Pain Med. Aug. 3, 2016;1(3):22-33.
Wang et al. CRISPR-Cas9 and CRISPR-Assisted Cytidine Deaminase Enable Precise and Efficient Genome Editing in Klebsiella pneumoniae. Appl Environ Microbiol. 2018;84(23):e01834-18. Published Nov. 15, 2018. doi:10.1128/AEM.01834-18.
Wilson et al., Assessing annotation transfer for genomics: quantifying the relations between protein sequence, structure and function through traditional and probabilistic scores. J Mol Biol 2000;297:233-49.
Yu et al., Liposome-mediated in vivo E1A gene transfer uppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene. Oct. 5, 1995;11(7):1383-8.
U.S. Appl. No. 16/374,634, filed Apr. 30, 2019, Liu et al.
U.S. Appl. No. 16/492,548, filed Sep. 9, 2019, Liu et al.
Abremski et al., Bacteriophage P1 site-specific recombination. Purification and properties of the Cre recombinase protein. J Biol Chem. Feb. 10, 1984;259(3):1509-14.
Ada et al., Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect. Feb. 2003;9(2):79-85. doi: 10.1046/j.1469-0691.2003.00530.x.
Adams et al., New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications. J Am Chem Soc. May 29, 2002;124(21):6063-76. doi: 10.1021/ja017687n.
Ahmad et al., Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. Sep. 1, 1992;52(17):4817-20.
Aik et al., Structure of human RNA N ?-methyladenine demethylase ALKBH5 provides insights into its mechanisms of nucleic acid recognition and demethylation. Nucleic Acids Res. Apr. 2014;42(7):4741-54. doi: 10.1093/nar/gku085. Epub Jan. 30, 2014.
Akins et al., Mitochondrial plasmids of Neurospora: integration into mitochondrial DNA and evidence for reverse transcription in mitochondria. Cell. Nov. 21, 1986;47(4):505-16. doi: 10.1016/0092-8674(86)90615-x.
Akinsheye et al., Fetal hemoglobin in sickle cell anemia. Blood. Jul. 7, 2011;118(1):19-27. doi: 10.1182/blood-2011-03-325258. Epub Apr. 13, 2011.
Alarcón et al., N6-methyladenosine marks primary microRNAs for processing. Nature. Mar. 26, 2015;519(7544):482-5. doi: 10.1038/nature14281. Epub Mar. 18, 2015.
Alexander, HFE-associated hereditary hemochromatosis. Genet Med. May 2009;11(5):307-13. doi: 10.1097/GIM.0b013e31819d30f2.
Altschul et al., Basic local alignment search tool. J Mol Biol. Oct. 5, 1990;215(3):403-10. doi: 10.1016/S0022-2836(05)80360-2.
Amato et al., Interpreting elevated fetal hemoglobin in pathology and health at the basic laboratory level: new and known ?-gene mutations associated with hereditary persistence of fetal hemoglobin. Int J Lab Hematol. Feb. 2014;36(1):13-9. doi: 10.1111/ijlh.12094. Epub Apr. 29, 2013.
Amrann et al., Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli. Gene. Sep. 30, 1988;69(2):301-15.
Anders et al., Chapter One: In Vitro Enzymology of Cas9. in Methods in Enzymology, eds Doudna et al. 2014: 546:1-20.
Anderson, Human gene therapy. Science. May 8, 1992;256(5058):808-13. doi: 10.1126/science.1589762.
Aplan, Causes of oncogenic chromosomal translocation. Trends Genet. Jan. 2006;22(1):46-55. doi: 10.1016/j.tig.2005.10.002. Epub Oct. 28, 2005.
Araki et al., Comparative analysis of right element mutant lox sites on recombination efficiency in embryonic stem cells. BMC Biotechnol. Mar. 31, 2010;10:29. doi: 10.1186/1472-6750-10-29.
Araki et al., Site-specific recombinase, R, encoded by yeast plasmid pSR1. J Mol Biol. May 5, 1992;225(1):25-37. doi: 10.1016/0022-2836(92)91023-i.
Araki et al., Targeted integration of DNA using mutant lox sites in embryonic stem cells. Nucleic Acids Res. Feb. 15, 1997;25(4):868-72. doi: 10.1093/nar/25.4.868.
Arambula et al., Surface display of a massively variable lipoprotein by a Legionella diversity-generating retroelement. Proc Natl Acad Sci U S A. May 14, 2013;110(20):8212-7. doi: 10.1073/pnas.1301366110. Epub Apr. 30, 2013.
Arbab et al., Cloning-free CRISPR. Stem Cell Reports. Nov. 10, 2015;5(5):908-917. doi: 10.1016/j.stemcr.2015.09.022. Epub Oct. 29, 2015.
Arezi et al., Novel mutations in Moloney Murine Leukemia Virus reverse transcriptase increase thermostability through tighter binding to template-primer. Nucleic Acids Res. Feb. 2009;37(2):473-81. doi: 10.1093/nar/gkn952. Epub Dec. 4, 2008.
Auer et al., Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. Genome Res. Jan. 2014;24(1):142-53. doi: 10.1101/gr.161638.113. Epub Oct. 31, 2013.
Autieri et al., IRT-1, a novel interferon-gamma-responsive transcript encoding a growth-suppressing basic leucine zipper protein. J Biol Chem. Jun. 12, 1998;273(24):14731-7. doi: 10.1074/jbc.273.24.14731.
Avidan et al., The processivity and fidelity of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus. Eur J Biochem. Feb. 2002;269(3):859-67. doi: 10.1046/j.0014-2956.2001.02719.x.
Bacman et al., Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med. Sep. 2013;19(9):1111-3. doi: 10.1038/nm.3261. Epub Aug. 4, 2013.
Badran et al., Development of potent in vivo mutagenesis plasmids with broad mutational spectra. Nat Commun. Oct. 7, 2015;6:8425. doi: 10.1038/ncomms9425.
Bae et al., Microhomology-based choice of Cas9 nuclease target sites. Nat Methods. Jul. 2014;11(7):705-6. doi: 10.1038/nmeth.3015.
Balakrishnan et al., Flap endonuclease 1. Annu Rev Biochem. 2013;82:119-38. doi: 10.1146/annurev-biochem-072511-122603. Epub Feb. 28, 2013.
Baldari et al., A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 beta in Saccharomyces cerevisiae. EMBO J. Jan. 1987;6(1):229-34.
Banerji et al., A lymphocyte-specific cellular enhancer is located downstream of the joining region in immunoglobulin heavy chain genes. Cell. Jul. 1983;33(3):729-40. doi: 10.1016/0092-8674(83)90015-6.
Bannert et al., Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci U S A. Oct. 5, 2004;101 Suppl 2(Suppl 2):14572-9. doi: 10.1073/pnas.0404838101. Epub Aug. 13, 2004.
Baranauskas et al., Generation and characterization of new highly thermostable and processive M-MuLV reverse transcriptase variants. Protein Eng Des Sel. Oct. 2012;25(10):657- 68. doi: 10.1093/protein/gzs034. Epub Jun. 12, 2012.
Barnes et al., The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene. Mar. 1, 1992;112(1):29-35. doi: 10.1016/0378-1119(92)90299-5.
Bartlett et al., Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters. Proc Natl Acad Sci U S A. Aug. 20, 1996;93(17):8852-7. doi: 10.1073/pnas.93.17.8852.
Basturea et al., Substrate specificity and properties of the Escherichia coli 16S rRNA methyltransferase, RsmE. RNA. Nov. 2007;13(11):1969-76. doi: 10.1261/rna.700507. Epub Sep. 13, 2007.
Bebenek et al., Error-prone polymerization by HIV-1 reverse transcriptase. Contribution of template-primer misalignment, miscoding, and termination probability to mutational hot spots. J Biol Chem. May 15, 1993;268(14):10324-34.
Behr, Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjug Chem. Sep.-Oct. 1994;5(5):382-9. doi: 10.1021/bc00029a002.
Belshaw et al., Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol. Sep. 1996;3(9):731-8. doi: 10.1016/s1074-5521(96)90249-5.
Belshaw et al., Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A. May 14, 1996;93(10):4604-7. doi: 10.1073/pnas.93.10.4604.
Bennett et al., Painful and painless channelopathies. Lancet Neurol. Jun. 2014; 13(6):587-99. doi: 10.1016/S1474-4422(14)70024-9. Epub May 6, 2014.
Berger et al., Reverse transcriptase and its associated ribonuclease H: interplay of two enzyme activities controls the yield of single-stranded complementary deoxyribonucleic acid. Biochemistry. May 10, 1983;22(10):2365-72. doi: 10.1021/bi00279a010.
Berkhout et al., Identification of an active reverse transcriptase enzyme encoded by a human endogenous HERV-K retrovirus. J Virol. Mar. 1999;73(3):2365-75. doi: 10.1128/JVI.73.3.2365-2375.1999.
Bernhart et al., Local RNA base pairing probabilities in large sequences. Bioinformatics. Mar. 1, 2006;22(5):614-5. doi: 10.1093/bioinformatics/btk014. Epub Dec. 20, 2005.
Bernstein et al., Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. Jan. 18, 2001;409(6818):363-6. doi: 10.1038/35053110.
Bertrand et al., Localization of ASHI mRNA particles in living yeast. Mol Cell. Oct. 1998;2(4):437-45. doi: 10.1016/s1097-2765(00)80143-4.
Bi et al., Pseudo attP sites in favor of transgene integration and expression in cultured porcine cells identified by Streptomyces phage phiC31 integrase. BMC Mol Biol. Sep. 8, 2013;14:20. doi: 10.1186/1471-2199-14-20.
Bibb et al., Integration and excision by the large serine recombinase phiRv1 integrase. Mol Microbiol. Mar. 2005;55(6):1896-910. doi: 10.1111/j.1365-2958.2005.04517.x.
Blaese et al., Vectors in cancer therapy: how will they deliver? Cancer Gene Ther. Dec. 1995;2(4):291-7.
Blain et al., Nuclease activities of Moloney murine leukemia virus reverse transcriptase. Mutants with altered substrate specificities. J Biol Chem. Nov. 5, 1993;268(31):23585-92.
Blaisonneau et al., A circular plasmid from the yeast Torulaspora delbrueckii. Plasmid. 1997;38(3):202-9. doi: 10.1006/plas.1997.1315.
Blau et al., A proliferation switch for genetically?modified?cells. PNAS Apr. 1, 1997 94 (7) 3076-3081; https://doi.org/10.1073/pnas.94.7.3076.
Bloom et al., Evolving strategies for enzyme engineering. Curr Opin Struct Biol. Aug. 2005;15(4):447-52.
Bodi et al., Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment. PLoS One. Jul. 17, 2015;10(7):e0132090. doi: 10.1371/journal.pone.0132090.
Boersma et al., Selection strategies for improved biocatalysts. FEBS J. May 2007;274(9):2181-95.
Bolusani et al., Evolution of variants of yeast site-specific recombinase Flp that utilize native genomic sequences as recombination target sites. Nucleic Acids Res. 2006;34(18):5259-69. Epub Sep. 26, 2006.
Bondeson et al., Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome. Hum Mol Genet. Apr. 1995;4(4):615-21. doi: 10.1093/hmg/4.4.615.
Boutabout et al., DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Ty1. Nucleic Acids Res. Jun. 1, 2001;29(11):2217-22. doi: 10.1093/nar/29.11.2217.
Box et al., A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J Drug Target. Jul. 2003;11(6):333-43. doi: 10.1080/1061186310001634667.
Braun et al., Immunogenic duplex nucleic acids are nuclease resistant. J Immunol. Sep. 1, 19885;141(6):2084-9.
Brown et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. Jun. 30, 1994;369(6483):756-8. doi: 10.1038/369756a0.
Brown et al., Characterization of the genetic elements required for site-specific integration of plasmid pSE211 in Saccharopolyspora erythraea. J Bacteriol. Apr. 1990;172(4):1877-88. doi: 10.1128/jb.172.4.1877-1888.1990.
Brown et al., Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix. Nat Struct Mol Biol. Jul. 2014;21(7):633-40. doi: 10.1038/nsmb.2844. Epub Jun. 22, 2014.
Brzezicha et al., Identification of human tRNA:m5C methyltransferase catalysing intron-dependent m5C formation in the first position of the anticodon of the pre-tRNA Leu (CAA). Nucleic Acids Res. 2006;34(20):6034-43. doi: 10.1093/nar/gk1765. Epub Oct. 27, 2006.
Buchschacher et al., Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol. May 1992;66(5):2731-9. doi: 10.1128/JVI.66.5.2731-2739.1992.
Buckley et al., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1? interaction. J Am Chem Soc. Mar. 1, 20124;134(10):4465-8. doi: 10.1021/ja209924v. Epub Feb. 27, 2012.
Budworth et al., A brief history of triplet repeat diseases. Methods Mol Biol. 2013;1010:3-17. doi: 10.1007/978-1-62703-411-1_1.
Buskirk et al., In vivo evolution of an RNA-based transcriptional activator. Chem Biol. Jun. 2003; 10(6):533-40. doi: 10.1016/s1074-5521(03)00109-1.
Byrne et al., Multiplex gene regulation: a two-tiered approach to transgene regulation in transgenic mice. Proc Natl Acad Sci U S A. Jul. 1989;86(14):5473-7. doi: 10.1073/pnas.86.14.5473.
Cadwell et al., Randomization of genes by PCR mutagenesis. PCR Methods Appl. Aug. 1992;2(1):28-33. doi: 10.1101/gr.2.1.28.
Cai et al., Reconstruction of ancestral protein sequences and its applications. BMC Evol Biol. Sep. 17, 2004;4:33. doi: 10.1186/1471-2148-4-33.
Calame et al., Transcriptional controlling elements in the immunoglobulin and T cell receptor loci. Adv Immunol. 1988;43:235-75. doi: 10.1016/s0065-2776(08)60367-3.
Camarero et al., Biosynthesis of a Head-to-Tail Cyclized Protein with Improved Biological Activity. J. Am. Chem. Soc. May 29, 1999; 121(23):5597-5598. https://doi.org/10.1021/ja990929n.
Camper et al., Postnatal repression of the alpha-fetoprotein gene is enhancer independent. Genes Dev. Apr. 1989;3(4):537-46. doi: 10.1101/gad.3.4.537.
Camps et al., Targeted gene evolution in Escherichia coli using a highly error-prone DNA polymerase I. Proc Natl Acad Sci U S A. Aug. 19, 2003;100(17):9727-32. Epub Aug. 8, 2003.
Canchaya et al., Genome analysis of an inducible prophage and prophage remnants integrated in the Streptococcus pyogenes strain SF370. Virology. Oct. 25, 2002;302(2):245-58. doi: 10.1006/viro.2002.1570.
Canver et al., Customizing the genome as therapy for the ?-hemoglobinopathies. Blood. May 26, 2016;127(21):2536-45. doi: 10.1182/blood-2016-01-678128. Epub Apr. 6, 2016.
Carlson et al., Negative selection and stringency modulation in phage-assisted continuous evolution. Nat Chem Biol. Mar. 2014; 10(3):216-22. doi: 10.1038/nchembio.1453. Epub Feb. 2, 2014. With Supplementary Results.
Carr et al., Genome engineering. Nat Biotechnol. Dec. 2009;27(12):1151-62. doi: 10.1038/nbt.1590.
Carvalho et al., Evolution in health and medicine Sackler colloquium: Genomic disorders: a window into human gene and genome evolution. Proc Natl Acad Sci U S A. Jan. 26, 2010;107 Suppl 1(Suppl 1):1765-71. doi: 10.1073/pnas.0906222107. Epub Jan. 13, 2010.
Caspi et al., Distribution of split DnaE inteins in cyanobacteria. Mol Microbiol. Dec. 2003;50(5):1569-77. doi: 10.1046/j.1365-2958.2003.03825.x.
Cattaneo et al., SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia. 2005;7(11):1030-1038.
Chadalavada et al., Wild-type is the optimal sequence of the HDV ribozyme under cotranscriptional conditions. RNA. Dec. 2007;13(12):2189-201. doi: 10.1261/rna.778107. Epub Oct. 23, 2007.
Chalberg et al., Integration specificity of phage phiC31 integrase in the human genome. J Mol Biol. Mar. 17, 2006;357(1):28-48. doi: 10.1016/j.jmb.2005.11.098. Epub Dec. 22, 2005.
Chalberg et al., phiC31 integrase confers genomic integration and long-term transgene expression in rat retina. Invest Ophthalmol Vis Sci. Jun. 2005;46(6):2140-6. doi: 10.1167/iovs.04-1252.
Chapman et al., Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. Aug. 24, 2012;47(4):497-510. doi: 10.1016/j.molcel.2012.07.029.
Chaturvedi et al., Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages. Nucleic Acids Res. Jun. 15, 1996;24(12):2318-23.
Chen et al., A general strategy for the evolution of bond-forming enzymes using yeast display. Proc Natl Acad Sci U S A. Jul. 12, 2011;108(28):11399-404. doi: 10.1073/pnas.1101046108. Epub Jun. 22, 2011.
Chin, Expanding and reprogramming the genetic code of cells and animals. Annu Rev Biochem. 2014;83:379-408. doi: 10.1146/annurev-biochem-060713-035737. Epub Feb. 10, 2014.
Cho et al., Site-specific recombination of bacteriophage P22 does not require integration host factor. J Bacteriol. Jul. 1999; 181(14):4245-9. doi: 10.1128/JB.181.14.4245-4249.1999.
Choi et al., Protein trans-splicing and characterization of a split family B-type DNA polymerase from the hyperthermophilic archaeal parasite Nanoarchaeum equitans. J Mol Biol. Mar. 10, 2006;356(5):1093-106. doi: 10.1016/j.jmb.2005.12.036. Epub Dec. 27, 2005.
Chong et al., Modulation of protein splicing of the Saccharomyces cerevisiae vacuolar membrane ATPase intein. J Biol Chem. Apr. 24, 1998;273(17):10567-77. doi: 10.1074/jbc.273.17.10567.
Chong et al., Utilizing the C-terminal cleavage activity of a protein splicing element to purify recombinant proteins in a single chromatographic step. Nucleic Acids Res. Nov. 15, 1998;26(22):5109-15. doi: 10.1093/nar/26.22.5109.
Chong et al., Protein splicing involving the Saccharomyces cerevisiae VMA intein. The steps in the splicing pathway, side reactions leading to protein cleavage, and establishment of an in vitro splicing system. J Biol Chem. Sep. 6, 1996;271(36):22159-68. doi: 10.1074/jbc.271.36.22159.
Chong et al., Protein splicing of the Saccharomyces cerevisiae VMA intein without the endonuclease motifs. J Biol Chem. Jun. 20, 1997;272(25):15587-90. doi: 10.1074/jbc.272.25.15587.
Chong et al., Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element. Gene. Jun. 19, 1997;192(2):271-81. doi: 10.1016/s0378-1119(97)00105-4.
Choudhury et al., Engineering RNA endonucleases with customized sequence specificities. Nat Commun. 2012;3:1147. doi: 10.1038/ncomms2154.
Choulika et al., Induction of homologous recombination in mammalian chromosomes by using the I-Scel system of Saccharomyces cerevisiae. Mol Cell Biol. Apr. 1995;15(4):1968-73. doi: 10.1128/MCB.15.4.1968.
Christiansen et al., Characterization of the lactococcal temperate phage TP901-1 and its site-specific integration. J Bacteriol. Feb. 1994;176(4):1069-76. doi: 10.1128/jb.176.4.1069-1076.1994.
Chujo et al., Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs. RNA. Dec. 2012;18(12):2269-76. doi: 10.1261/rna.035600.112. Epub Oct. 24, 2012.
Clackson et al., Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. Sep. 1, 1998;95(18):10437-42. doi: 10.1073/pnas.95.18.10437.
Cokol et al., Finding nuclear localization signals. EMBO Rep. Nov. 2000;1(5):411-5. doi: 10.1093/embo-reports/kvd092.
Cole et al., Reconstructing evolutionary adaptive paths for protein engineering. Methods Mol Biol. 2013;978:115-25. doi: 10.1007/978-1-62703-293-3_8.
Collinge, Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci. 2001;24:519-50. doi: 10.1146/annurev.neuro.24.1.519.
Conrad et al., A Kaposi's sarcoma virus RNA element that increases the nuclear abundance of intronless transcripts. Embo J. May 18, 2005;24(10):1831-41. doi: 10.1038/sj.emboj.7600662. Epub Apr. 28, 2005.
Costa et al., Frequent use of the same tertiary motif by self-folding RNAs. EMBO J. Mar. 15, 1995;14(6):1276-85.
Cotton et al., Insertion of a Synthetic Peptide into a Recombinant Protein Framework:? A Protein Biosensor. J. Am. Chem. Soc. Jan. 22, 1999; 121(5):1100-1. https://doi.org/10.1021/ja983804b.
Cox, Proteins pinpoint double strand breaks. Elife. Oct. 29, 2013;2:e01561. doi: 10.7554/eLife.01561.
Crabtree et al., Three-part inventions: intracellular signaling and induced proximity. Trends Biochem Sci. Nov. 1996;21(11):418-22. doi: 10.1016/s0968-0004(96)20027-1.
Crick, On protein synthesis. Symp Soc Exp Biol. 1958;12:138-63.
Crystal, Transfer of genes to humans: early lessons and obstacles to success. Science. Oct. 20, 1995;270(5235):404-10. doi: 10.1126/science.270.5235.404.
Cupples et al., A set of lacZ mutations in Escherichia coli that allow rapid detection of each of the six base substitutions. Proc Natl Acad Sci U S A. Jul. 1989;86(14):5345-9.
Dahlgren et al., A novel mutation in ribosomal protein S4 that affects the function of a mutated RF1. Biochimie. Aug. 2000;82(8):683-91.
Das et al.,The crystal structure of the monomeric reverse transcriptase from Moloney murine leukemia virus. Structure. May 2004;12(5):819-29. doi: 10.1016/j.str.2004.02.032.
Dassa et al., Fractured genes: a novel genomic arrangement involving new split inteins and a new homing endonuclease family. Nucleic Acids Res. May 2009;37(8):2560-73. doi: 10.1093/nar/gkp095. Epub Mar. 5, 2009.
Dassa et al., Trans protein splicing of cyanobacterial split inteins in endogenous and exogenous combinations. Biochemistry. Jan. 9, 2007;46(1):322-30. doi: 10.1021/bi0611762.
Datsenko et al., One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. Jun. 6, 2000;97(12):6640-5.
De Felipe et al., Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem. Mar. 28, 2003;278(13):11441-8. doi: 10.1074/jbc.M211644200. Epub Jan. 8, 2003.
Dean et al., Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. Sep. 27, 1996;273(5283):1856-62. doi: 10.1126/science.273.5283.1856.
Delebecque et al., Organization of intracellular reactions with rationally designed RNA assemblies. Science. Jul. 22, 2011;333(6041):470-4. doi: 10.1126/science.1206938. Epub Jun. 23, 2011.
Deriano et al., Modernizing the nonhomologous end-joining repertoire: alternative and classical NHEJ share the stage. Annu Rev Genet. 2013;47:433-55. doi: 10.1146/annurev-genet-110711-155540. Epub Sep. 11, 2013.
Deussing, Targeted mutagenesis tools for modelling psychiatric disorders. Cell Tissue Res. Oct. 2013;354(1):9-25. doi: 10.1007/s00441-013-1708-5. Epub Sep. 10, 2013.
Dicarlo et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res. Apr. 2013;41(7):4336-43. doi: 10.1093/nar/gkt135. Epub Mar. 4, 2013.
Dickey et al., Single-stranded DNA-binding proteins: multiple domains for multiple functions. Structure. Jul. 2, 2013;21(7):1074-84. doi: 10.1016/j.str.2013.05.013.
Dickinson et al., Experimental interrogation of the path dependence and stochasticity of protein evolution using phage-assisted continuous evolution. Proc Natl Acad Sci USA. May 2013;110(22):9007-12.
Dillon, Regulating gene expression in gene therapy. Trends Biotechnol. May 1993;11(5):167-73. doi: 10.1016/0167-7799(93)90109-M.
Dingwall et al., Nuclear targeting sequences—a consensus? Trends Biochem Sci. Dec. 1991; 16(12):478-81. doi: 10.1016/0968-0004(91)90184-w.
Diver et al., Single-Step Synthesis of Cell-Permeable Protein Dimerizers That Activate Signal Transduction and Gene Expression. J. Am. Chem. Soc. Jun. 4, 1997;119(22):5106-5109. https://doi.org/10.1021/ja963891c.
Dominissini et al., Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. Apr. 29, 2012;485(7397):201-6. doi: 10.1038/nature11112.
Dorgan et al., An enzyme-coupled continuous spectrophotometric assay for S-adenosylmethionine-dependent methyltransferases. Anal Biochem. Mar. 15, 2006;350(2):249-55. doi: 10.1016/j.ab.2006.01.004. Epub Feb. 7, 2006.
Dorr et al., Reprogramming the specificity of sortase enzymes. Proc Natl Acad Sci U S A. Sep. 16, 2014;111(37):13343-8. doi: 10.1073/pnas.1411179111. Epub Sep. 3, 2014.
Dove et al., Conversion of the omega subunit of Escherichia coli RNA polymerase into a transcriptional activator or an activation target. Genes Dev. Mar. 1, 1998;12(5):745-54.
Doyon et al., Directed evolution and substrate specificity profile of homing endonuclease I-SceI. J Am Chem Soc. Feb. 22, 2006;128(7):2477-84.
Drake, A constant rate of spontaneous mutation in DNA-based microbes. Proc Natl Acad Sci USA. Aug. 15, 1991;88(16):7160-4.
Dupuy et al., Le syndrome de De La Chapelle [De La Chapelle syndrome]. Presse Med. Mar. 3, 2001;30(8):369-72. French.
Durai et al., A bacterial one-hybrid selection system for interrogating zinc finger-DNA interactions. Comb Chem High Throughput Screen. May 2006;9(4):301-11.
Durai et al., Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. Oct. 26, 2005;33(18):5978-90. doi: 10.1093/nar/gki912.
Edlund et al., Cell-specific expression of the rat insulin gene: evidence for role of two distinct 5′ flanking elements. Science. Nov. 22, 1985;230(4728):912-6. doi: 10.1126/science.3904002.
Engelward et al., Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc Natl Acad Sci U S A. Nov. 25, 1997;94(24):13087-92.
England, Unnatural amino acid mutagenesis: a precise tool for probing protein structure and function. Biochemistry. Sep. 21, 2004;43(37):11623-9.
Enyeart et al., Biotechnological applications of mobile group II introns and their reverse transcriptases: gene targeting, RNA-seq, and non-coding RNA analysis. Mobile DNA 5, 2 (2014). https://doi.org/10.1186/1759-8753-5-2. https://doi.org/10.1186/1759-8753-5-2.
Eriksson et al., Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. May 1, 20035;423(6937):293-8. doi: 10.1038/nature01629. Epub Apr. 25, 2003. PMID: 12714972.
Evans et al., Protein trans-splicing and cyclization by a naturally split intein from the dnaE gene of Synechocystis species PCC6803. J Biol Chem. Mar. 31, 2000;275(13):9091-4. doi: 10.1074/jbc.275.13.9091.
Evans et al., Semisynthesis of cytotoxic proteins using a modified protein splicing element. Protein Sci. Nov. 1998;7(11):2256-64. doi: 10.1002/pro.5560071103.
Evans et al., The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. J Biol Chem. Jun. 25, 1999;274(26):18359-63. doi: 10.1074/jbc.274.26.18359.
Evans et al., The in vitro ligation of bacterially expressed proteins using an intein from Methanobacterium thermoautotrophicum. J Biol Chem. Feb. 12, 1999;274(7):3923-6. doi: 10.1074/jbc.274.7.3923.
Falnes et al., DNA repair by bacterial AlkB proteins. Res Microbiol. Oct. 2003; 154(8):531-8. doi: 10.1016/S0923-2508(03)00150-5.
Falnes et al., Repair of methyl lesions in DNA and RNA by oxidative demethylation. Neuroscience. Apr. 14, 2007;145(4):1222-32. doi: 10.1016/j.neuroscience.2006.11.018. Epub Dec. 18, 2006.
Fawcett et al., Transposable elements controlling I-R hybrid dysgenesis in D. melanogaster are similar to mammalian LINEs. Cell. Dec. 26, 1986;47(6):1007-15. doi: 10.1016/0092-8674(86)90815-9.
Feldstein et al., Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA. Gene. Oct. 15, 1989;82(1):53-61. doi: 10.1016/0378-1119(89)90029-2.
Feng et al., Crystal structures of the human RNA demethylase Alkbh5 reveal basis for substrate recognition. J Biol Chem. Apr. 25, 2014;289(17):11571-11583. doi: 10.1074/jbc.M113.546168. Epub Mar. 10, 2014.
Feng et al., Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. Nov. 29, 1996;87(5):905-16. doi: 10.1016/s0092-8674(00)81997-2.
Feuk, Inversion variants in the human genome: role in disease and genome architecture. Genome Med. Feb. 12, 2010;2(2):11. doi: 10.1186/gm132.
Filippov et al., A novel type of RNase III family proteins in eukaryotes. Gene. Mar. 7, 2000;245(1):213-21. doi: 10.1016/s0378-1119(99)00571-5.
Fire et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. Feb. 19, 1998;391(6669):806-11. doi: 10.1038/35888.
Fischbach et al., Directed evolution can rapidly improve the activity of chimeric assembly-line enzymes. Proc Natl Acad Sci U S A. Jul. 17, 2007;104(29):11951-6. doi: 10.1073/pnas.0705348104. Epub Jul. 9, 2007.
Fitzjohn, Diversitree: comparative phylogenetic analyses of diversification in R. Methods in Evology and Evolution. Dec. 2012;3(6):1084-92 .doi: 10.1111/j.2041-210X.2012.00234.x.
Flajolet et al., Woodchuck hepatitis virus enhancer I and enhancer II are both involved in N-myc2 activation in woodchuck liver tumors. J Virol. Jul. 1998;72(7):6175-80. doi: 10.1128/JVI.72.7.6175-6180.1998.
Flaman et al., A rapid PCR fidelity assay. Nucleic Acids Res. Aug. 11, 1994;22(15):3259-60. doi: 10.1093/nar/22.15.3259.
Forster et al., Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell. Jul. 3, 1987;50(1):9-16. doi: 10.1016/0092-8674(87)90657-x.
Fouts et al., Sequencing Bacillus anthracis typing phages gamma and cherry reveals a common ancestry. J Bacteriol. May 2006;188(9):3402-8. doi: 10.1128/JB.188.9.3402-3408.2006.
Freitas et al., Mechanisms and signals for the nuclear import of proteins. Curr Genomics. Dec. 2009;10(8):550-7. doi: 10.2174/138920209789503941.
Fu et al., Promises and Pitfalls of Intracellular Delivery of Proteins. Bioconjugate Chemistry. Aug. 2014;25:1602-8.
Furukawa et al., In vitro selection of allosteric ribozymes that sense the bacterial second messenger c-di-GMP. Methods Mol Biol. 2014;1111:209-20. doi: 10.1007/978-1-62703-755-6_15.
Gaj et al., 3rd. Genome engineering with custom recombinases. Methods Enzymol. 2014;546:79-91. doi: 10.1016/B978-0-12-801185-0.00004-0.
Gao et al., Cationic liposome-mediated gene transfer. Gene Ther. Dec. 1995;2(10):710-22.
Gao et al., Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing. J Integr Plant Biol. Apr. 2014;56(4):343-9. doi: 10.1111/jipb.12152. Epub Mar. 6, 2014.
Garcia et al., Transglycosylation: a mechanism for RNA modification (and editing?). Bioorg Chem. Jun. 2005;33(3):229-51. doi: 10.1016/j.bioorg.2005.01.001. Epub Feb. 23, 2005.
Garibyan et al., Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. DNA Repair (Amst). May 13, 2003;2(5):593-608.
GenBank Accession No. J01600.1. Brooks et al., E.coli dam gene coding for DNA adenine methylase. Apr. 26, 1993.
GenBank Accession No. U07651.1. Lu, Escherichia coli K12 negative regulator of replication initiation (seqA) gene, complete cds. Jul. 19, 1994.
GenBank Submission; NIH/NCBI, Accession No. AAA66622.1. Martinelli et al., May 18, 1995. 2 pages.
GenBank Submission; NIH/NCBI, Accession No. AGT42196. Farzadfar et al., Nov. 2, 2013. 2 pages.
George et al., Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res. Jan. 2011;31(1):99-117. doi: 10.1089/jir.2010.0097. Epub Dec. 23, 2010. PMID: 21182352; PMCID: PMC3034097.
Gerard et al., Influence on stability in Escherichia coli of the carboxy-terminal structure of cloned Moloney murine leukemia virus reverse transcriptase. DNA. Aug. 1986;5(4):271-9. doi: 10.1089/dna.1986.5.271.
Gerard et al., Purification and characterization of the DNA polymerase and RNase H activities in Moloney murine sarcoma-leukemia virus. J Virol. Apr. 1975;15(4):785-97. doi: 10.1128/JVI.15.4.785-797.1975.
Gerard et al., The role of template-primer in protection of reverse transcriptase from thermal inactivation. Nucleic Acids Res. Jul. 15, 2002;30(14):3118-29. doi: 10.1093/nar/gkf417.
Gerber et al., An adenosine deaminase that generates inosine at the wobble position of tRNAs. Science. Nov. 5, 1999;286(5442):1146-9. doi: 10.1126/science.286.5442.1146.
Gibson et al., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. May 2009;6(5):343-5. doi: 10.1038/nmeth.1318. Epub Apr. 12, 2009.
Gil, Position-dependent sequence elements downstream of AAUAAA are required for efficient rabbit beta-globin mRNA 3′ end formation. Cell. May 8, 1987;49(3):399-406. doi: 10.1016/0092-8674(87)90292-3.
Glasgow et al.,DNA-binding properties of the Hin recombinase. J Biol Chem. Jun. 15, 1989;264(17):10072-82.
Glassner et al., Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. Proc Natl Acad Sci U S A. Aug. 18, 1998;95(17):9997-10002.
Goldberg et al., Epigenetics: a landscape takes shape. Cell. Feb. 23, 2007;128(4):635-8. doi: 10.1016/j.cell.2007.02.006.
Gong et al., Active DNA demethylation by oxidation and repair. Cell Res. Dec. 2011;21(12):1649-51. doi: 10.1038/cr.2011.140. Epub Aug. 23, 2011.
Goodnough et al., Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. Feb. 27, 2002;513(2-3):163-8.
Gregory et al., Integration site for Streptomyces phage phiBT1 and development of site-specific integrating vectors. J Bacteriol. Sep. 2003;185(17):5320-3. doi: 10.1128/jb.185.17.5320-5323.2003.
Griffiths, Endogenous retroviruses in the human genome sequence. Genome Biol. 2001;2(6):Reviews1017. doi: 10.1186/GB-2001-2-6-reviews1017. Epub Jun. 5, 2001.
Grishok et al., Genes and Mechanisms Related to RNA Interference Regulate Expression of the Small Temporal RNAs that Control C. elegans Developmental Timing. Jul. 13, 2001:106(1):P23-4.
Groth et al., Construction of transgenic Drosophila by using the site-specific integrase from phage phiC31. Genetics. Apr. 2004;166(4):1775-82. doi: 10.1534/genetics.166.4.1775.
Gruber et al., Strategies for measuring evolutionary conservation of RNA secondary structures. BMC Bioinformatics. Feb. 26, 2008;9:122. doi: 10.1186/1471-2105-9-122.
Grunebaum et al., Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol. Dec. 2013;13(6):630-8. doi: 10.1097/ACI.0000000000000006.
Guo et al., Facile functionalization of FK506 for biological studies by the thiol-ene ‘click’ reaction. RSC Advances. 2014;22:11400-3.
Gupta et al., Cross-talk between cognate and noncognate RpoE sigma factors and Zn(2+)-binding anti-sigma factors regulates photooxidative stress response in Azospirillum brasilense. Antioxid Redox Signal. Jan. 1, 2014;20(1):42-59. doi: 10.1089/ars.2013.5314. Epub Jul. 19, 2013.
Gupta et al., Sequences in attB that affect the ability of phiC31 integrase to synapse and to activate DNA cleavage. Nucleic Acids Res. 2007;35(10):3407-19. doi: 10.1093/nar/gkm206. Epub May 3, 2007.
Guzman et al., Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol. 1995;177(14):4121-4130.
Haddada et al., Gene therapy using adenovirus vectors. Curr Top Microbiol Immunol. 1995;199 ( Pt 3):297-306. doi: 10.1007/978-3-642-79586-2_14.
Halvas et al., Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity. J Virol. Nov. 2000;74(22):10349-58. doi: 10.1128/jvi.74.22.10349-10358.2000.
Harms et al., Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Nat Rev Genet. Aug. 2013;14(8):559-71. doi: 10.1038/nrg3540.
Hasegawa et al., Spontaneous mutagenesis associated with nucleotide excision repair in Escherichia coli. Genes Cells. May 2008;13(5):459-69. doi: 10.1111/j.1365-2443.2008.01185.x.
Heidenreich et al., Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells. EMBO J. May 1, 2003;22(9):2274-83. doi: 10.1093/emboj/cdg203.
Held et al., In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther. Mar. 2005;11(3):399-408. doi: 10.1016/j.ymthe.2004.11.001.
Hendricks et al., The S. cerevisiae Mag1 3-methyladenine DNA glycosylase modulates susceptibility to homologous recombination. DNA Repair (Amst). 2002;1(8):645-659.
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci U S A. Oct. 1984;81(20):6466-70. doi: 10.1073/pnas.81.20.6466.
Herschhorn et al., Retroviral reverse transcriptases. Cell Mol Life Sci. Aug. 2010;67(16):2717-47. doi: 10.1007/s00018-010-0346-2. Epub Apr. 1, 2010.
Hollis et al., Phage integrases for the construction and manipulation of transgenic mammals. Reprod Biol Endocrinol. Nov. 7, 2003;1:79. doi: 10.1186/1477-7827-1-79.
Holsinger et al., Signal transduction in T lymphocytes using a conditional allele of Sos. Proc Natl Acad Sci U S A. Oct. 10, 1995;92(21):9810-4. doi: 10.1073/pnas.92.21.9810.
Hoogenboom et al., Natural and designer binding sites made by phage display technology. Immunol Today. Aug. 2000;21(8):371-8.
Huggins et al., Flap endonuclease 1 efficiently cleaves base excision repair and DNA replication intermediates assembled into nucleosomes. Mol Cell. Nov. 2002;10(5):1201-11. doi: 10.1016/s1097-2765(02)00736-0.
Hung et al., Protein localization in disease and therapy. J Cell Sci. Oct. 15, 2011;124(Pt 20):3381-92. doi: 10.1242/jcs.089110.
Ibba et al., Relaxing the substrate specificity of an aminoacyl-tRNA synthetase allows in vitro and in vivo synthesis of proteins containing unnatural amino acids. FEBS Lett. May 15, 1995;364(3):272-5.
Ibba et al., Substrate specificity is determined by amino acid binding pocket size in Escherichia coli phenylalanyl-tRNA synthetase. Biochemistry. Jun. 14, 1994;33(23):7107-12.
Iida et al., A site-specific, conservative recombination system carried by bacteriophage P1. Mapping the recombinase gene cin and the cross-over sites cix for the inversion of the C segment. EMBO J. 1982;1(11):1445-53.
Iida et al., The Min DNA inversion enzyme of plasmid p15B of Escherichia coli 15T-: a new member of the Din family of site-specific recombinases. Mol Microbiol. Jun. 1990;4(6):991-7. doi: 10.1111/j.1365-2958.1990.tb00671.x.
Imburgio et al., Studies of promoter recognition and start site selection by T7 RNA polymerase using a comprehensive collection of promoter variants. Biochemistry. Aug. 29, 2000;39(34):10419-30.
Ingram, A specific chemical difference between the globins of normal human and sickle-cell anaemia haemoglobin. Nature. Oct. 13, 1956;178(4537):792-4. doi: 10.1038/178792a0.
Irion et al., Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol. Dec. 2007;25(12):1477-82. doi: 10.1038/nbt1362. Epub Nov. 25, 2007.
Iwai et al., Circular beta-lactamase: stability enhancement by cyclizing the backbone. FEBS Lett. Oct. 8, 1999;459(2):166-72. doi: 10.1016/s0014-5793(99)01220-x.
Iwai et al., Highly efficient protein trans-splicing by a naturally split DnaE intein from Nostoc punctiforme. FEBS Lett. Mar. 20, 2006;580(7):1853-8. doi: 10.1016/j.febslet.2006.02.045. Epub Feb. 24, 2006.
Jasin et al., Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol. Nov. 1, 2013;5(11):a012740. doi: 10.1101/cshperspect.a012740.
Jeggo, DNA breakage and repair. Adv Genet. 1998;38:185-218. doi: 10.1016/s0065-2660(08)60144-3.
Jemielity et al., Novel “anti-reverse” cap analogs with superior translational properties. RNA. Sep. 2003;9(9):1108-22. doi: 10.1261/rna.5430403.
Johann et al., GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol. Mar. 1992;66(3):1635-40. doi: 10.1128/JVI.66.3.1635-1640.1992.
Johansson et al., RNA Recognition by the MS2 Phage Coat Protein. Seminars in Virology. 1997;8(3):176-85. https://doi.org/10.1006/smvy.1997.0120.
Johansson et al., Selenocysteine in proteins-properties and biotechnological use. Biochim Biophys Acta. Oct. 30, 2005;1726(1):1-13. Epub Jun. 1, 2005.
Johns et al., The promise and peril of continuous in vitro evolution. J Mol Evol. Aug. 2005;61(2):253-63. Epub Jun. 27, 2005.
Joho et al., Identification of a region of the bacteriophage T3 and T7 RNA polymerases that determines promoter specificity. J Mol Biol. Sep. 5, 1990;215(1):31-9.
Joyce et al., Amplification, mutation and selection of catalytic RNA. Gene. Oct. 15, 1989;82(1):83-7. doi: 10.1016/0378-1119(89)90033-4.
Jyothy et al., Translocation Down syndrome. Indian J Med Sci. Mar. 2002;56(3):122-6.
Kacian et al., Purification of the DNA polymerase of avian myeloblastosis virus. Biochim Biophys Acta. Sep. 24, 1971;246(3):365-83. doi: 10.1016/0005-2787(71)90773-8.
Kaczmarczyk et al., Manipulating the Prion Protein Gene Sequence and Expression Levels with CRISPR/Cas9. PLoS One. Apr. 29, 2016;11(4):e0154604. doi: 10.1371/journal.pone.0154604.
Kadoch et al., Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. Mar. 28, 2013;153(1):71-85. doi: 10.1016/j.cell.2013.02.036.
Kahmann et al., G inversion in bacteriophage Mu DNA is stimulated by a site within the invertase gene and a host factor. Cell. Jul. 1985;41(3):771-80. doi: 10.1016/s0092-8674(85)80058-1.
Kao et al., Cleavage specificity of Saccharomyces cerevisiae flap endonuclease 1 suggests a double-flap structure as the cellular substrate. J Biol Chem. Apr. 26, 2002;277(17):14379-89. doi: 10.1074/jbc.M110662200. Epub Feb. 1, 2002.
Kato et al., Improved purification and enzymatic properties of three forms of reverse transcriptase from avian myeloblastosis virus. J Virol Methods. Dec. 1984;9(4):325-39. doi: 10.1016/0166-0934(84)90058-2.
Katoh et al., MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. Apr. 2013;30(4):772-80. doi: 10.1093/molbev/mst010. Epub Jan. 16, 2013.
Kaufman et al., Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells. EMBO J. Jan. 1987;6(1):187-93.
Kawarasaki et al., Enhanced crossover SCRATCHY: construction and high-throughput screening of a combinatorial library containing multiple non-homologous crossovers. Nucleic Acids Res. Nov. 1, 2003;31(21):e126.
Kelman, PCNA: structure, functions and interactions. Oncogene. Feb. 13, 1997;14(6):629-40. doi: 10.1038/sj.onc.1200886.
Keravala et al., A diversity of serine phage integrases mediate site-specific recombination in mammalian cells. Mol Genet Genomics. Aug. 2006;276(2):135-46. doi: 10.1007/s00438-006-0129-5. Epub May 13, 2006.
Kessel et al., Murine developmental control genes. Science. Jul. 27, 1990;249(4967):374-9. doi: 10.1126/science.1974085.
Kessler et al., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A. Nov. 26, 1996;93(24):14082-7. doi: 10.1073/pnas.93.24.14082.
Kilcher et al., Brochothrix thermosphacta bacteriophages feature heterogeneous and highly mosaic genomes and utilize unique prophage insertion sites. J Bacteriol. Oct. 2010; 192(20):5441-53. doi: 10.1128/JB.00709-10. Epub Aug. 13, 2010.
Kim et al., DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 2005;7(3):263-273.
Kim et al., High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One. 2011;6(4):e18556. doi: 10.1371/journal.pone.0018556. Epub Apr. 29, 2011.
Kim et al., Mycobacteriophage Bxb1 integrates into the Mycobacterium smegmatis groEL1 gene. Mol Microbiol. Oct. 2003;50(2):463-73. doi: 10.1046/j.1365-2958.2003.03723.x.
Kim et al., Structural and kinetic characterization of Escherichia coli TadA, the wobble-specific tRNA deaminase. Biochemistry. May 23, 2006;45(20):6407-16. doi: 10.1021/bi0522394. PMID: 16700551.
Klapacz et al., Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. Mol Cell. Mar. 26, 2010;37(6):843-53. doi: 10.1016/j.molcel.2010.01.038.
Kleiner et al., In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. J Am Chem Soc. Aug. 25, 2010;132(33):11779-91. doi: 10.1021/ja104903x.
Klement et al., Discrimination between bacteriophage T3 and T7 promoters by the T3 and T7 RNA polymerases depends primarily upon a three base-pair region located 10 to 12 base-pairs upstream from the start site. J Mol Biol. Sep. 5, 1990;215(1):21-9.
Kohli et al., A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J Biol Chem. Aug. 2, 20091;284(34):22898-904. doi: 10.1074/jbc.M109.025536. Epub Jun. 2, 20096.
Koike-Ysa et al., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. Mar. 2014;32(3):267-73. doi: 10.1038/nbt.2800. Epub Dec. 23, 2013.
Kolot et al., Site-specific recombination in mammalian cells expressing the Int recombinase of bacteriophage HK022. Mol Biol Rep. Aug. 1999;26(3):207-13. doi: 10.1023/a:1007096701720.
Kotewicz et al., Cloning and overexpression of Moloney murine leukemia virus reverse transcriptase in Escherichia coli. Gene. 1985;35(3):249-58. doi: 10.1016/0378-1119(85)90003-4.
Kotewicz et al., Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acids Res. Jan. 11, 1988;16(1):265-77. doi: 10.1093/nar/16.1.265.
Kotin, Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. Jul. 1994;5(7):793-801. doi: 10.1089/hum.1994.5.7-793.
Kozak, An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. Oct. 26, 1987;15(20):8125-48. doi: 10.1093/nar/15.20.8125.
Kremer et al., Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull. Jan. 1995;51(1):31-44. doi: 10.1093/oxfordjournals.bmb.a072951.
Krokan et al., Uracil in DNA—occurrence, consequences and repair. Oncogene. Dec. 16, 2002;21(58):8935-48. doi: 10.1038/sj.onc.1205996.
Krokan et al., Base excision repair. Cold Spring Harb Perspect Biol. Apr. 1, 2013;5(4):a012583. doi: 10.1101/cshperspect.a012583.
Kügler et al., Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area. Gene Ther. Feb. 2003;10(4):337-47. doi: 10.1038/sj.gt.3301905.
Kurjan et al., Structure of a yeast pheromone gene (MF alpha): a putative alpha-factor precursor contains four tandem copies of mature alpha-factor. Cell. Oct. 1982;30(3):933-43. doi: 10.1016/0092-8674(82)90298-7.
Lada et al., Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast. Biochemistry (Mosc). Jan. 2011;76(1):131-46.
Lakich et al., Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. Nov. 1993;5(3):236-41. doi: 10.1038/ng1193-236.
Lauer et al., Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol. Aug. 2002; 184(15):4177-86. doi: 10.1128/jb.184.15.4177-4186.2002.
Lawyer et al., High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods Appl. May 1993;2(4):275-87. doi: 10.1101/gr.2.4.275.
Lazarevic et al., Nucleotide sequence of the Bacillus subtilis temperate bacteriophage SPbetac2. Microbiology (Reading). May 1999;145 ( Pt 5): 1055-1067. doi: 10.1099/13500872-145-5-1055.
Le Grice et al., Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase. J Virol. Dec. 1991;65(12):7004-7. doi: 10.1128/JVI.65.12.7004-7007.1991.
Leaver-Fay et al., ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 2011;487:545-74. doi: 10.1016/B978-0-12-381270-4.00019-6.
Leconte et al., A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes. Biochemistry. Feb. 26, 2013;52(8): 1490-9. doi: 10.1021/bi3016185. Epub Feb. 14, 2013.
Lee et al., Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin. Proc Natl Acad Sci U S A. Apr. 15, 1991;88(8):3111-5. doi: 10.1073/pnas.88.8.3111.
Lee et al., Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res. Jan. 20, 2010: 81-89; Published in Advance Dec. 1, 2009, doi:10.1101/gr.099747.109.
Lee et al., Transcriptional regulation and its misregulation in disease. Cell. Mar. 14, 2013;152(6):1237-51. doi: 10.1016/j.cell.2013.02.014.
Lew et al., Protein splicing in vitro with a semisynthetic two-component minimal intein. J Biol Chem. Jun. 26, 1998;273(26):15887-90. doi: 10.1074/jbc.273.26.15887.
Li et al., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. Jul. 15, 2009;25(14):1754-60. doi: 10.1093/bioinformatics/btp324. Epub May 18, 2009.
Li et al., Lagging strand DNA synthesis at the eukaryotic replication fork involves binding and stimulation of FEN-1 by proliferating cell nuclear antigen. J Biol Chem. Sep. 22, 1995;270(38):22109-12. doi: 10.1074/jbc.270.38.22109.
Li et al., Loss of post-translational modification sites in disease. Pac Symp Biocomput. 2010:337-47. doi: 10.1142/9789814295291_0036.
Li et al., Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther. Sep. 2008;19(9):958-64. doi: 10.1089/hum.2008.009.
Li et al., RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. Aug. 4, 2011;12:323. doi: 10.1186/1471-2105-12-323.
Liang et al., Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci U S A. Apr. 28, 1998;95(9):5172-7. doi: 10.1073/pnas.95.9.5172.
Lienert et al., Two- and three-input TALE-based and logic computation in embryonic stem cells. Nucleic Acids Res. Nov. 2013;41(21):9967-75. doi: 10.1093/nar/gkt758. Epub Aug. 27, 2013.
Lim et al., Crystal structure of the moloney murine leukemia virus RNase H domain. J Virol. Sep. 2006;80(17):8379-89. doi: 10.1128/JVI.00750-06.
Liu et al., Split dnaE genes encoding multiple novel inteins in Trichodesmium erythraeum. J Biol Chem. Jul. 18, 2003;278(29):26315-8. doi: 10.1074/jbc.C300202200. Epub May 24, 2003.
Liu et al., A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. Feb. 2014;10(2):93-5. doi: 10.1038/nchembio.1432. Epub Dec. 6, 2013.
Liu et al., Adding new chemistries to the genetic code. Annu Rev Biochem. 2010;79:413-44. doi: 10.1146/annurev.biochem.052308.105824.
Liu et al., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. Aug. 23, 1991;66(4):807-15. doi: 10.1016/0092-8674(91)90124-h.
Liu et al., Distance determination by GIY-YIG intron endonucleases: discrimination between repression and cleavage functions. Nucleic Acids Res. Mar. 31, 2006;34(6): 1755-64. Print 2006.
Liu et al., Editing DNA Methylation in the Mammalian Genome. Cell. Sep. 22, 2016;167(1):233-247.e17. doi: 10.1016/j.cell.2016.08.056.
Liu et al., Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem. 2004;73:589-615. doi:10.1146/annurev.biochem.73.012803.092453.
Liu et al., Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods. Mar. 2007;4(3):239-44. Epub Feb. 25, 2007.
Liu et al., Probing N6-methyladenosine RNA modification status at single nucleotide resolution in mRNA and long noncoding RNA. RNA. Dec. 2013;19(12):1848-56. doi: 10.1261/rna.041178.113. Epub Oct. 18, 2013.
Liu et al., Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage. Science. Mar. 15, 2002;295(5562):2091-4. doi: 10.1126/science.1067467.
Liu et al., Saccharomyces cerevisiae flap endonuclease 1 uses flap equilibration to maintain triplet repeat stability. Mol Cell Biol. May 2004;24(9):4049-64. doi: 10.1128/MCB.24.9.4049-4064.2004.
Lopez-Girona et al., Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. Nov. 2012;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub May 3, 2012.
Lorenz et al., ViennaRNA Package 2.0. Algorithms Mol Biol. Nov. 24, 2011;6:26. doi: 10.1186/1748-7188-6-26.
Luan et al., Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. Cell. Feb. 26, 1993;72(4):595-605. doi: 10.1016/0092-8674(93)90078-5.
Luckow et al., High level expression of nonfused foreign genes with Autographa californica nuclear polyhedrosis virus expression vectors. Virology. May 1989;170(1):31-9. doi: 10.1016/0042-6822(89)90348-6.
Lukacsovich et al., Repair of a specific double-strand break generated within a mammalian chromosome by yeast endonuclease I-SceI. Nucleic Acids Res. Dec. 25, 1994;22(25):5649-57. doi: 10.1093/nar/22.25.5649.
Lüke et al., Partial purification and characterization of the reverse transcriptase of the simian immunodeficiency virus TYO-7 isolated from an African green monkey. Biochemistry. Feb. 20, 1990;29(7):1764-9. doi: 10.1021/bi00459a015.
Lynch, Evolution of the mutation rate. Trends Genet. Aug. 2010;26(8):345-52. doi: 10.1016/j.tig.2010.05.003. Epub Jun. 30, 2010.
Ma et al., Identification of pseudo attP sites for phage phiC31 integrase in bovine genome. Biochem Biophys Res Commun. Jul. 7, 2006;345(3):984-8. doi: 10.1016/j.bbrc.2006.04.145. Epub May 3, 2006.
Ma et al., In vitro protein engineering using synthetic tRNA(Ala) with different anticodons. Biochemistry. Aug. 10, 1993;32(31):7939-45.
Ma et al., PhiC31 integrase induces efficient site-specific recombination in the Capra hircus genome. DNA Cell Biol. Aug. 2014;33(8):484-91. doi: 10.1089/dna.2013.2124. Epub Apr. 22, 2014.
Maas et al., Identification and characterization of a human tRNA-specific adenosine deaminase related to the ADAR family of pre-mRNA editing enzymes. Proc Natl Acad Sci U S A. Aug. 3, 1999;96(16):8895-900. doi: 10.1073/pnas.96.16.8895.
MacBeth et al., Inositol hexakisphosphate is bound in the ADAR2 core and required for RNA editing. Science. Sep. 2, 2005;309(5740):1534-9. doi: 10.1126/science.1113150.
MacRae et al., Ribonuclease revisited: structural insights into ribonuclease III family enzymes. Curr Opin Struct Biol. Feb. 2007;17(1):138-45. doi: 10.1016/j.sbi.2006.12.002. Epub Dec. 27, 2006.
Magin et al., Corf, the Rev/Rex homologue of HTDV/HERV-K, encodes an arginine-rich nuclear localization signal that exerts a trans-dominant phenotype when mutated. Virology. Aug. 15, 2000;274(1): 11-6. doi: 10.1006/viro.2000.0438.
Makeyev et al., Evolutionary potential of an RNA virus. J Virol. Feb. 2004;78(4):2114-20.
Malashkevich et al., Crystal structure of tRNA adenosine deaminase TadA from Escherichia coli. Deposited: Mar. 10, 2005 Released: Feb. 21, 2006 doi:10.2210/pdb1z3a/pdb (2006).
Malito et al., Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. Proc Natl Acad Sci U S A. Apr. 3, 2012;109(14):5229-34. doi: 10.1073/pnas.1201964109. Epub Mar. 19, 2012.
Mandal et al., Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. Nov. 6, 2014;15(5):643-52. doi: 10.1016/j.stem.2014.10.004. Epub Nov. 6, 2014.
Marceau, Functions of single-strand DNA-binding proteins in DNA replication, recombination, and repair. Methods Mol Biol. 2012;922:1-21. doi: 10.1007/978-1-62703-032-8_1.
Maresca et al., Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res. Mar. 2013;23(3):539-46. Doi: 10.1101/gr.145441.112. Epub Nov. 14, 2012.
Martinez et al., Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci U S A. Dec. 6, 1994;91(25):11787-91. doi: 10.1073/pnas.91.25.11787.
Martsolf et al., Complete trisomy 17p a relatively new syndrome. Ann Genet. 1988;31(3):172-4.
Mascola et al., HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. Jul. 2013;254(1):225-44. doi: 10.1111/imr.12075.
Mathys et al., Characterization of a self-splicing mini-intein and its conversion into autocatalytic N- and C-terminal cleavage elements: facile production of protein building blocks for protein ligation. Gene. Apr. 29, 1999;231(1-2):1-13. doi: 10.1016/s0378-1119(99)00103-1.
Matsuura et al., A gene essential for the site-specific excision of actinophage r4 prophage genome from the chromosome of a lysogen. J Gen Appl Microbiol. 1995;41(1):53-61.
McCarroll et al., Copy-No. variation and association studies of human disease. Nat Genet. Jul. 2007;39(7 Suppl):S37-42. doi: 10.1038/ng2080.
McInerney et al., Error Rate Comparison during Polymerase Chain Reaction by DNA Polymerase. Mol Biol Int. 2014;2014:287430. doi: 10.1155/2014/287430. Epub Aug. 17, 2014.
McVey et al., MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings. Trends Genet. Nov. 2008;24(11):529-38. doi: 10.1016/j.tig.2008.08.007. Epub Sep. 21, 2008.
Mead et al., A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med. Nov. 19, 2009;361(21):2056-65. doi: 10.1056/NEJMoa0809716.
Menéndez-Arias, Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses. Dec. 2009;1(3):1137-65. doi: 10.3390/v1031137. Epub Dec. 4, 2009.
Meyer et al., Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell. Jun. 2, 20122;149(7):1635-46. doi: 10.1016/j.cell.2012.05.003. Epub May 1, 20127.
Meyer et al., Library generation by gene shuffling. Curr Protoc Mol Biol. Jan. 6, 2014;105:Unit 15.12.. doi: 10.1002/0471142727.mb1512s105.
Meyer et al., The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. May 2014; 15(5):313-26. doi: 10.1038/nrm3785. Epub Apr. 9, 2014.
Michel et al., Mitochondrial class II introns encode proteins related to the reverse transcriptases of retroviruses. Nature. Aug. 15-21, 1985;316(6029):641-3. doi: 10.1038/316641a0.
Mihai et al., PTEN inhibition improves wound healing in lung epithelia through changes in cellular mechanics that enhance migration. Am J Physiol Lung Cell Mol Physiol. 2012;302(3):L287-L299.
Mijakovic et al., Bacterial single-stranded DNA-binding proteins are phosphorylated on tyrosine. Nucleic Acids Res. Mar. 20, 2006;34(5):1588-96. doi: 10.1093/nar/gkj514.
Miller et al., Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol. May 1991;65(5):2220-4. doi: 10.1128/JVI.65.5.2220-2224.1991.
Miller, Human gene therapy comes of age. Nature. Jun. 11, 1992;357(6378):455-60. doi: 10.1038/357455a0.
Mills et al., Protein splicing in trans by purified N- and C-terminal fragments of the Mycobacterium tuberculosis RecA intein. Proc Natl Acad Sci U S A. Mar. 31, 1998;95(7):3543-8. doi: 10.1073/pnas.95.7.3543.
Mitani et al., Delivering therapeutic genes—matching approach and application. Trends Biotechnol. May 1993;11(5):162-6. doi: 10.1016/0167-7799(93)90108-L.
Mitton-Fry et al., Poly(A) tail recognition by a viral RNA element through assembly of a triple helix. Science. Nov. 26, 2010;330(6008):1244-7. doi: 10.1126/science.1195858.
Moede et al., Identification of a nuclear localization signal, RRMKWKK, in the homeodomain transcription factor PDX-1. FEBS Lett. Nov. 19, 1999;461(3):229-34. doi: 10.1016/s0014-5793(99)01446-5.
Mohr et al., Thermostable group II intron reverse transcriptase fusion proteins and their use in cDNA synthesis and next-generation RNA sequencing. RNA. Jul. 2013;19(7):958-70. doi: 10.1261/rna.039743.113. Epub May 22, 2013.
Monot et al., The specificity and flexibility of 11 reverse transcription priming at imperfect T-tracts. PLoS Genet. May 2013;9(5):e1003499. doi: 10.1371/journal.pgen.1003499. Epub May 9, 2013.
Morita et al., The site-specific recombination system of actinophage TG1. FEMS Microbiol Lett. Aug. 2009;297(2):234-40. doi: 10.1111/j.1574-6968.2009.01683.x.
Muir et al., Expressed protein ligation: a general method for protein engineering. Proc Natl Acad Sci U S A. Jun. 9, 1998;95(12):6705-10. doi: 10.1073/pnas.95.12.6705.
Muller et al., Nucleotide exchange and excision technology (NExT) DNA shuffling: a robust method for DNA fragmentation and directed evolution. Nucleic Acids Res. Aug. 1, 2005;33(13):e117. doi: 10.1093/nar/gni116. PMID: 16061932; PMCID: PMC1182171.
Mumtsidu et al., Structural features of the single-stranded DNA-binding protein of Epstein-Barr virus. J Struct Biol. Feb. 2008;161(2):172-87. doi: 10.1016/j.jsb.2007.10.014. Epub Nov. 1, 2007.
Muzyczka et al., Adeno-associated virus (AAV) vectors: will they work? J Clin Invest. Oct. 1994;94(4):1351. doi: 10.1172/JCI117468.
Myerowitz et al., The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem. Dec. 15, 1988;263(35):18587-9.
Myers et al., Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol. 1996;36:615-58. doi: 10.1146/annurev.pa.36.040196.003151.
Nabel et al., Direct gene transfer for immunotherapy and immunization. Trends Biotechnol. May 1993;11(5):211-5. doi: 10.1016/0167-7799(93)90117-R.
Nakamura et al., Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res. Jan. 1, 2000;28(1):292. doi: 10.1093/nar/28.1.292.
Nern et al., Multiple new site-specific recombinases for use in manipulating animal genomes. Proc Natl Acad Sci U S A. Aug. 23, 2011;108(34):14198-203. doi: 10.1073/pnas.1111704108. Epub Aug. 9, 2011.
Nishikura, Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem. 2010;79:321-349. doi:10.1146/annurev-biochem-060208-105251.
Nowak et al., Characterization of single-stranded DNA-binding proteins from the psychrophilic bacteria Desulfotalea psychrophila, Flavobacterium psychrophilum, Psychrobacter arcticus, Psychrobacter cryohalolentis, Psychromonas ingrahamii, Psychroflexus torquis, and Photobacterium profundum. BMC Microbiol. Apr. 14, 2014;14:91. doi: 10.1186/1471-2180-14-91.
Nowak et al., Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid. Nucleic Acids Res. Apr. 1, 2013;41(6):3874-87. doi: 10.1093/nar/gkt053. Epub Feb. 4, 2013.
Odsbu et al., Specific N-terminal interactions of the Escherichia coli SeqA protein are required to form multimers that restrain negative supercoils and form foci. Genes Cells. Nov. 2005;10(11):1039-49.
Oeemig et al., Solution structure of DnaE intein from Nostoc punctiforme: structural basis for the design of a new split intein suitable for site-specific chemical modification. FEBS Lett. May 6, 2009;583(9):1451-6.
Oh et al., Positional cloning of a gene for Hermansky-Pudlak syndrome, a disorder of cytoplasmic organelles. Nat Genet. Nov. 1996;14(3):300-6. doi: 10.1038/ng1196-300.
Ohe et al., Purification and properties of xanthine dehydrogenase from Streptomyces cyanogenus. J Biochem. Jul. 1979;86(1):45-53.
Olivares et al., Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat Biotechnol. Nov. 2002;20(11):1124-8. doi: 10.1038/nbt753. Epub Oct. 15, 2002.
O'Maille et al., Structure-based combinatorial protein engineering (Scope). J Mol Biol. Aug. 23, 2002;321(4):677-91.
Orlando et al., Zinc-finger nuclease-driven targeted integration into mammalian genomes using donors with limited chromosomal homology. Nucleic Acids Res. Aug. 2010;38(15):e152. doi: 10.1093/nar/gkq512. Epub Jun. 8, 2010.
Ortiz-Urda et al., Stable nonviral genetic correction of inherited human skin disease. Nat Med. Oct. 2002;8(10):1166-70. doi: 10.1038/nm766. Epub Sep. 16, 2002. Erratum in: Nat Med. Feb. 2003;9(2):237.
Ostermeier et al., A combinatorial approach to hybrid enzymes independent of DNA homology. Nat Biotechnol. Dec. 1999;17(12):1205-9.
Ostertag et al., Biology of mammalian L1 retrotransposons. Annu Rev Genet. 2001;35:501-38. doi: 10.1146/annurev.genet.35.102401.091032.
Otomo et al., Improved segmental isotope labeling of proteins and application to a larger protein. J Biomol NMR. Jun. 1999;14(2):105-14. doi: 10.1023/a:1008308128050.
Otomo et al., NMR observation of selected segments in a larger protein: central-segment isotope labeling through intein-mediated ligation. Biochemistry. Dec. 7, 1999;38(49):16040-4. doi: 10.1021/bi991902j.
Otto et al., The probability of fixation in populations of changing size. Genetics. Jun. 1997; 146(2):723-33.
Paige et al., RNA mimics of green fluorescent protein. Science. Jul. 29, 2011;333(6042):642-6. doi:10.1126/science.1207339.
Patel et al., Flap endonucleases pass 5′-flaps through a flexible arch using a disorder-thread- order mechanism to confer specificity for free 5′-ends. Nucleic Acids Res. May 2012;40(10):4507-19. doi: 10.1093/nar/gks051. Epub Feb. 8, 2012.
Pawson et al., Protein phosphorylation in signaling—50 years and counting. Trends Biochem Sci. Jun. 2005;30(6):286-90. doi: 10.1016/j.tibs.2005.04.013.
Perach et al., Catalytic features of the recombinant reverse transcriptase of bovine leukemia virus expressed in bacteria. Virology. Jun. 20, 1999;259(1):176-89. doi: 10.1006/viro.1999.9761.
Perler et al., Protein splicing and autoproteolysis mechanisms. Curr Opin Chem Biol. Oct. 1997; 1(3):292-9. doi: 10.1016/s1367-5931(97)80065-8.
Perler et al., Protein splicing elements: inteins and exteins—a definition of terms and recommended nomenclature. Nucleic Acids Res. Apr. 11, 1994;22(7):1125-7. doi: 10.1093/nar/22.7.1125.
Perler, InBase, the New England Biolabs Intein Database. Nucleic Acids Res. Jan. 1, 1999;27(1):346-7. doi: 10.1093/nar/27.1.346.
Perler, Protein splicing of inteins and hedgehog autoproteolysis: structure, function, and evolution. Cell. Jan. 9, 1998;92(1):1-4. doi: 10.1016/s0092-8674(00)80892-2.
Petersen-Mahrt et al., AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. Jul. 4, 2002;418(6893):99-103.
Peyrottes et al., Oligodeoxynucleoside phosphoramidates (P-NH2): synthesis and thermal stability of duplexes with DNA and RNA targets. Nucleic Acids Res. May 15, 1996;24(10):1841-8.
Pfeiffer et al., Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis. Jul. 2000;15(4):289-302. doi: 10.1093/mutage/15.4.289.
Pickart et al., Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. Nov. 29, 2004;1695(1-3):55-72. doi: 10.1016/j.bbamcr.2004.09.019.
Pinkert et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev. May 1987;1(3):268-76. doi: 10.1101/gad.1.3.268.
Pirakitikulr et al., PCRless library mutagenesis via oligonucleotide recombination in yeast. Protein Sci. Dec. 2010;19(12):2336-46. doi: 10.1002/pro.513.
Popp et al., Sortagging: a versatile method for protein labeling. Nat Chem Biol. Nov. 2007;3(11):707-8. doi: 10.1038/nchembio.2007.31. Epub Sep. 23, 2007.
Posnick et al., Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in Escherichia coli. J Bacteriol. Nov. 1999;181(21):6763-71.
Pruschy et al., Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. Chem Biol. Nov. 1994;1(3):163-72. doi: 10.1016/1074-5521(94)90006-x.
Queen et al., Immunoglobulin gene transcription is activated by downstream sequence elements. Cell. Jul. 1983;33(3):741-8. doi: 10.1016/0092-8674(83)90016-8.
Radany et al., Increased spontaneous mutation frequency in human cells expressing the phage PBS2-encoded inhibitor of uracil-DNA glycosylase. Mutat Res. Sep. 15, 2000;461(1):41-58. doi: 10.1016/s0921-8777(00)00040-9.
Rashel et al., A novel site-specific recombination system derived from bacteriophage phiMR11. Biochem Biophys Res Commun. Apr. 4, 2008;368(2):192-8. doi: 10.1016/j.bbrc.2008.01.045. Epub Jan. 22, 2008.
Rasila et al., Critical evaluation of random mutagenesis by error-prone polymerase chain reaction protocols, Escherichia coli mutator strain, and hydroxylamine treatment. Anal Biochem. May 1, 2009;388(1):71-80. doi: 10.1016/j.ab.2009.02.008. Epub Feb. 10, 2009.
Raskin et al., Substitution of a single bacteriophage T3 residue in bacteriophage T7 RNA polymerase at position 748 results in a switch in promoter specificity. J Mol Biol. Nov. 20, 1992;228(2):506-15.
Raskin et al., T7 RNA polymerase mutants with altered promoter specificities. Proc Natl Acad Sci U S A. Apr. 15, 1993;90(8):3147-51.
Ray et al., A compendium of RNA-binding motifs for decoding gene regulation. Nature. Jul. 11, 2013;499(7457):172-7. doi: 10.1038/nature12311.
Rebar et al., Phage display methods for selecting zinc finger proteins with novel DNA-binding specificities. Methods Enzymol. 1996;267:129-49.
Remy et al., Gene transfer with a series of lipophilic DNA-binding molecules. Bioconjug Chem. Nov.-Dec. 1994;5(6):647-54. doi: 10.1021/bc00030a021.
Ringrose et al., The Kw recombinase, an integrase from Kluyveromyces waltii. Eur J Biochem. Sep. 15, 1997;248(3):903-12. doi: 10.1111/j.1432-1033.1997.00903.x.
Risso et al., Hyperstability and substrate promiscuity in laboratory resurrections of Precambrian ?- lactamases. J Am Chem Soc. Feb. 27, 2013;135(8):2899-902. doi: 10.1021/ja311630a. Epub Feb. 14, 2013.
Robinson et al., The protein tyrosine kinase family of the human genome. Oncogene. Nov. 20, 2000;19(49):5548-57. doi: 10.1038/sj.onc.1203957.
Roth et al., A widespread self-cleaving ribozyme class is revealed by bioinformatics. Nat Chem Biol. Jan. 2014;10(1):56-60. doi: 10.1038/nchembio.1386. Epub Nov. 17, 2013.
Roth et al., Purification and characterization of murine retroviral reverse transcriptase expressed in Escherichia coli. J Biol Chem. Aug. 5, 1985;260(16):9326-35.
Rouet et al., Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A. Jun. 21, 1994;91(13):6064-8. doi: 10.1073/pnas.91.13.6064.
Rouet et al., Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Mol Cell Biol. Dec. 1994;14(12):8096-106. doi: 10.1128/mcb.14.12.8096.
Rowland et al., Sin recombinase from Staphylococcus aureus: synaptic complex architecture and transposon targeting. Mol Microbiol. May 2002;44(3):607-19. doi: 10.1046/j.1365-2958.2002.02897.x.
Rowley, Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer. Dec. 2001;1(3):245-50. doi: 10.1038/35106108.
Rubio et al., An adenosine-to-inosine tRNA-editing enzyme that can perform C-to-U deamination of DNA. Proc Natl Acad Sci U S A. May 8, 2007;104(19):7821-6. doi: 10.1073/pnas.0702394104. Epub May 1, 2007. PMID: 17483465; PMCID: PMC1876531.
Rubio et al., Transfer RNA travels from the cytoplasm to organelles. Wiley Interdiscip Rev RNA. Nov.-Dec. 2011;2(6):802-17. doi: 10.1002/wrna.93. Epub Jul. 11, 2011.
Rüfer et al., Non-contact positions impose site selectivity on Cre recombinase. Nucleic Acids Res. Jul. 1, 2002;30(13):2764-71. doi: 10.1093/nar/gkf399.
Rutherford et al., Attachment site recognition and regulation of directionality by the serine integrases. Nucleic Acids Res. Sep. 2013;41(17):8341-56. doi: 10.1093/nar/gkt580. Epub Jul. 2, 2013.
Sadowski, The Flp recombinase of the 2-microns plasmid of Saccharomyces cerevisiae. Prog Nucleic Acid Res Mol Biol. 1995;51:53-91.
Sakuma et al., MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems. Nat Protoc. Jan. 2016;11(1):118-33. doi: 10.1038/nprot.2015.140. Epub Dec. 17, 2015.
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol. Sep. 1989;63(9):3822-8. doi: 10.1128/JVI.63.9.3822-3828.1989.
Santoro et al., Directed evolution of the site specificity of Cre recombinase. Proc Natl Acad Sci U S A. Apr. 2, 2002;99(7):4185-90. Epub Mar. 19, 2002.
Saparbaev et al., Excision of hypoxanthine from DNA containing dIMP residues by the Escherichia coli, yeast, rat, and human alkylpurine DNA glycosylases. Proc Natl Acad Sci U S A. Jun. 21, 1994;91(13):5873-7. doi: 10.1073/pnas.91.13.5873.
Sarkar et al., HIV-1 proviral DNA excision using an evolved recombinase. Science. Jun. 29, 2007;316(5833):1912-5. doi: 10.1126/science.1141453.
Sasidharan et al., The selection of acceptable protein mutations. PNAS; Jun. 12, 2007;104(24):10080-5.pnas.org/cgi/doi/10.1073.pnas.0703737104.
Saville et al., A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell. May 18, 1990;61(4):685-96. doi: 10.1016/0092-8674(90)90480-3.
Schaaper et al., Base selection, proofreading, and mismatch repair during DNA replication in Escherichia coli. J Biol Chem. Nov. 15, 1993;268(32):23762-5.
Schaaper et al., Spectra of spontaneous mutations in Escherichia coli strains defective in mismatch correction: the nature of in vivo DNA replication errors. Proc Natl Acad Sci U S A. Sep. 1987;84(17):6220-4.
Schek et al., Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal by using in vitro analyses. Mol Cell Biol. Dec. 1992;12(12):5386-93. doi: 10.1128/mcb.12.12.5386.
Schenk et al., MPDU1 mutations underlie a novel human congenital disorder of glycosylation, designated type If. J Clin Invest. Dec. 2001;108(11):1687-95. doi: 10.1172/JCI13419.
Schmitz et al., Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrP(C) for the cytoskeleton. Prion. 2014;8(6):381-6. doi: 10.4161/19336896.2014.983746.
Schultz et al., Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus. Gene. 1987;54(1):113-23. doi: 10.1016/0378-1119(87)90353-2.
Schultz et al., Oligo-2′-fluoro-2′-deoxynucleotide N3′→P5′ phosphoramidates: synthesis and properties. Nucleic Acids Res. Aug. 1, 1996;24(15):2966-73.
Scott et al., Production of cyclic peptides and proteins in vivo. Proc Natl Acad Sci U S A. Nov. 23, 1999;96(24):13638-43. doi: 10.1073/pnas.96.24.13638.
Seed, An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature. Oct. 29-Nov. 4, 1987;329(6142):840-2. doi: 10.1038/329840a0.
Serrano-Heras et al., Protein p56 from the Bacillus subtilis phage phi29 inhibits DNA-binding ability of uracil-DNA glycosylase. Nucleic Acids Res. 2007;35(16):5393-401. Epub Aug. 13, 2007.
Severinov et al., Expressed protein ligation, a novel method for studying protein-protein interactions in transcription. J Biol Chem. Jun. 26, 1998;273(26):16205-9. doi: 10.1074/jbc.273.26.16205.
Shah et al., Protospacer recognition motifs: mixed identities and functional diversity. RNA Biol. May 2013;10(5):891-9. doi: 10.4161/rna.23764. Epub Feb. 12, 2013.
Sharer et al., The ARF-like 2 (ARL2)-binding protein, BART. Purification, cloning, and initial characterization. J Biol Chem. Sep. 24, 1999;274(39):27553-61. doi: 10.1074/jbc.274.39.27553.
Shaw et al., Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet. Apr. 1, 2004;13 Spec No. 1:R57-64. doi: 10.1093/hmg/ddh073. Epub Feb. 5, 2004.
Sherwood et al., Discovery of directional and nondirectional pioneer transcription factors by modeling DNase profile magnitude and shape. Nat Biotechnol. Feb. 2014;32(2):171-178. doi: 10.1038/nbt.2798. Epub Jan. 19, 2014.
Shindo et al., A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G. Biology (Basel). Aug. 2, 2012;1(2):260-76. doi: 10.3390/biology1020260.
Shingledecker et al., Molecular dissection of the Mycobacterium tuberculosis RecA intein: design of a minimal intein and of a trans-splicing system involving two intein fragments. Gene. Jan. 30, 1998;207(2):187-95. doi: 10.1016/s0378-1119(97)00624-0.
Shultz et al., A genome-wide analysis of FRT-like sequences in the human genome. PLoS One. Mar. 23, 2011;6(3):e18077. doi: 10.1371/journal.pone.0018077.
Silva et al., Selective disruption of the DNA polymerase III α-β complex by the umuD gene products. Nucleic Acids Res. Jul. 2012;40(12):5511-22. doi: 10.1093/nar/gks229. Epub Mar. 9, 2012.
Singh et al., Cross-talk between diverse serine integrases. J Mol Biol. Jan. 23, 2014;426(2):318-31. doi: 10.1016/j.jmb.2013.10.013. Epub Oct. 22, 2013.
Sivalingam et al., Biosafety assessment of site-directed transgene integration in human umbilical cord-lining cells. Mol Ther. Jul. 2010; 18(7):1346-56. doi: 10.1038/mt.2010.61. Epub Apr. 27, 2010.
Smith et al., Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol. Dec. 1983;3(12):2156-65. doi: 10.1128/mcb.3.12.2156.
Smith et al., Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. Jul. 15, 1988;67(1):31-40. doi: 10.1016/0378-1119(88)90005-4.
Sommerfelt et al., Receptor interference groups of 20 retroviruses plating on human cells. Virology. May 1990;176(1):58-69. doi: 10.1016/0042-6822(90)90230-o.
Southworth et al., Control of protein splicing by intein fragment reassembly. EMBO J. Feb. 16, 1998;17(4):918-26. doi: 10.1093/emboj/17.4.918.
Southworth et al., Purification of proteins fused to either the amino or carboxy terminus of the Mycobacterium xenopi gyrase A intein. Biotechniques. Jul. 1999;27(1):110-4, 116, 118-20. doi: 10.2144/99271st04.
Spencer et al., A general strategy for producing conditional alleles of Src-like tyrosine kinases. Proc Natl Acad Sci U S A. Oct. 10, 1995;92(21):9805-9. doi: 10.1073/pnas.92.21.9805.
Spencer et al., Controlling signal transduction with synthetic ligands. Science. Nov. 12, 1993;262(5136):1019-24. doi: 10.1126/science.7694365.
Spencer et al., Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol. Jul. 1, 1996;6(7):839-47. doi: 10.1016/s0960-9822(02)00607-3.
Srivastava et al., An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. Dec. 2, 20121;151(7):1474-87. doi: 10.1016/j.cell.2012.11.054.
Stadtman, Selenocysteine. Annu Rev Biochem. 1996;65:83-100.
Steele et al., The prion protein knockout mouse: a phenotype under challenge. Prion. Apr.-Jun. 2007;1(2):83-93. doi: 10.4161/pri.1.2.4346. Epub Apr. 25, 2007.
Sterne-Weiler et al., Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol. Jan. 23, 2014;15(1):201. doi: 10.1186/gb4150.
Stockwell et al., Probing the role of homomeric and heteromeric receptor interactions in TGF-beta signaling using small molecule dimerizers. Curr Biol. Jun. 18, 1998;8(13):761-70. doi: 10.1016/s0960-9822(98)70299-4.
Suzuki et al., VCre/VloxP and SCre/SloxP: new site-specific recombination systems for genome engineering. Nucleic Acids Res. Apr. 2011;39(8):e49. doi: 10.1093/nar/gkq1280. Epub Feb. 1, 2011.
Tajiri et al., Functional cooperation of MutT, MutM and MutY proteins in preventing mutations caused by spontaneous oxidation of guanine nucleotide in Escherichia coli. Mutat Res. May 1995;336(3):257-67. doi: 10.1016/0921-8777(94)00062-b.
Takimoto et al., Stereochemical basis for engineered pyrrolysyl-tRNA synthetase and the efficient in vivo incorporation of structurally divergent non-native amino acids. ACS Chem Biol. Jul. 15, 2011;6(7):733-43. doi: 10.1021/cb200057a. Epub May 5, 2011.
Tanenbaum et al., A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell. Oct. 23, 2014;159(3):635-46. doi: 10.1016/j.cell.2014.09.039. Epub Oct. 9, 2014.
Tanese et al., Expression of enzymatically active reverse transcriptase in Escherichia coli. Proc Natl Acad Sci U S A. Aug. 1985;82(15):4944-8. doi: 10.1073/pnas.82.15.4944.
Tassabehji, Williams-Beuren syndrome: a challenge for genotype-phenotype correlations. Hum Mol Genet. Oct. 15, 2003;12 Spec No. 2:R229-37. doi: 10.1093/hmg/ddg299. Epub Sep. 2, 2003.
Taube et al., Reverse transcriptase of mouse mammary tumour virus: expression in bacteria, purification and biochemical characterization. Biochem J. Feb. 1, 1998;329 ( Pt 3)(Pt 3):579-87. doi: 10.1042/bj3290579. Erratum in: Biochem J Jun. 15, 1998;332(Pt 3):808.
Tee et al., Polishing the craft of genetic diversity creation in directed evolution. Biotechnol Adv. Dec. 2013;31(8):1707-21. doi: 10.1016/j.biotechadv.2013.08.021. Epub Sep. 6, 2013.
Telenti et al., The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. J Bacteriol. Oct. 1997;179(20):6378-82. doi: 10.1128/jb.179.20.6378-6382.1997.
Telesnitsky et al., RNase H domain mutations affect the interaction between Moloney murine leukemia virus reverse transcriptase and its primer-template. Proc Natl Acad Sci U S A. Feb. 15, 1993;90(4):1276-80. doi: 10.1073/pnas.90.4.1276.
Thomson et al., Mutational analysis of loxP sites for efficient Cre-mediated insertion into genomic DNA. Genesis. Jul. 2003;36(3):162-7. doi: 10.1002/gene.10211.
Thyagarajan et al., Creation of engineered human embryonic stem cell lines using phiC31 integrase. Stem Cells. Jan. 2008;26(1):119-26. doi: 10.1634/stemcells.2007-0283. Epub Oct. 25, 2007.
Tinland et al., The T-DNA-linked VirD2 protein contains two distinct functional nuclear localization signals. Proc Natl Acad Sci U S A. Aug. 15, 1992;89(16):7442-6. doi: 10.1073/pnas.89.16.7442.
Tom et al., Mechanism whereby proliferating cell nuclear antigen stimulates flap endonuclease 1. J Biol Chem. Apr. 7, 2000;275(14):10498-505. doi: 10.1074/jbc.275.14.10498.
Tone et al., Single-stranded DNA binding protein Gp5 of Bacillus subtilis phage ?29 is required for viral DNA replication in growth-temperature dependent fashion. Biosci Biotechnol Biochem. 2012;76(12):2351-3. doi: 10.1271/bbb.120587. Epub Dec. 7, 2012.
Toor et al., Crystal structure of a self-spliced group II intron. Science. Apr. 4, 2008;320(5872):77-82. doi: 10.1126/science.1153803.
Torres et al., Non-integrative lentivirus drives high-frequency cre-mediated cassette exchange in human cells. PLoS One. 2011;6(5):e19794. doi: 10.1371/journal.pone.0019794. Epub May 23, 2011.
Townsend et al., Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet. Mar. 2, 2002;359(9308):786-90. doi: 10.1016/S0140-6736(02)07885-6.
Tracewell et al., Directed enzyme evolution: climbing fitness peaks one amino acid at a time. Curr Opin Chem Biol. Feb. 2009; 13(1):3-9. doi: 10.1016/j.cbpa.2009.01.017. Epub Feb. 25, 2009.
Tratschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. Mol Cell Biol. Oct. 1984;4(10):2072-81. doi: 10.1128/mcb.4.10.2072.
Tratschin et al., Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells. Mol Cell Biol. Nov. 1985;5(11):3251-60. doi: 10.1128/mcb.5.11.3251.
Tsang et al., Specialization of the DNA-cleaving activity of a group I ribozyme through in vitro evolution. J Mol Biol. Sep. 13, 1996;262(1):31-42. doi: 10.1006/jmbi.1996.0496.
Tsutakawa et al., Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily. Cell. Apr. 1, 20115;145(2):198-211. doi: 10.1016/j.cell.2011.03.004.
UNIPROTKB Submission; Accession No. F0NH53. May 3, 2011. 4 pages.
UNIPROTKB Submission; Accession No. F0NN87. May 3, 2011. 4 pages.
UNIPROTKB Submission; Accession No. T0D7A2. Oct. 16, 2013. 10 pages.
Urasaki et al., Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics. Oct. 2006;174(2):639-49. doi: 10.1534/genetics.106.060244. Epub Sep. 7, 2006.
Van Brunt et al., Molecular Farming: Transgenic Animals as Bioreactors. Biotechnology (N Y). 1988;6(10):1149-1154. doi: 10.1038/nbt1088-1149.
Varga et al., Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A. Feb. 28, 2006;103(9):3250-5. doi: 10.1073/pnas.0600012103. Epub Feb. 21, 2006.
Vellore et al., A group II intron-type open reading frame from the thermophile Bacillus (Geobacillus) stearothermophilus encodes a heat-stable reverse transcriptase. Appl Environ Microbiol. Dec. 2004;70(12):7140-7. doi: 10.1128/AEM.70.12.7140-7147.2004.
Vigne et al., Third-generation adenovectors for gene therapy. Restor Neurol Neurosci. Jan. 1, 1995;8(1):35-6. doi: 10.3233/RNN-1995-81208.
Vik et al., Endonuclease V cleaves at inosines in RNA. Nat Commun. 2013;4:2271. doi: 10.1038/ncomms3271.
Vilenchik et al., Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A. Oct. 28, 2003;100(22):12871-6. doi: 10.1073/pnas.2135498100. Epub Oct. 17, 2003.
Voigt et al., Rational evolutionary design: the theory of in vitro protein evolution. Adv Protein Chem. 2000;55:79-160.
Wang et al., AID upmutants isolated using a high-throughput screen highlight the immunity/cancer balance limiting DNA deaminase activity. Nat Struct Mol Biol. Jul. 2009;16(7):769-76. doi: 10.1038/nsmb.1623. Epub Jun. 21, 2009.
Wang et al., Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci U S A. Nov. 30, 2004;101(48):16745-9. Epub Nov. 19, 2004.
Wang et al., Expanding the genetic code. Annu Rev Biophys Biomol Struct. 2006;35:225-49. Review.
Wang et al., N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. Jan. 2, 2014;505(7481):117-20. doi: 10.1038/nature12730. Epub Nov. 27, 2013.
Wang et al., Programming cells by multiplex genome engineering and accelerated evolution. Nature. Aug. 13, 2009;460(7257):894-8. Epub Jul. 26, 2009.
Wang et al., Reading RNA methylation codes through methyl-specific binding proteins. RNA Biol. 2014;11(6):669-72. doi: 10.4161/rna.28829. Epub Apr. 24, 2014.
Wang et al., Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor. Nucleic Acids Res. Jan. 2014;42(2): 1354-64. doi: 10.1093/nar/gkt964. Epub Oct. 22, 2013.
Watowich, The erythropoietin receptor: molecular structure and hematopoietic signaling pathways. J Investig Med. Oct. 2011;59(7):1067-72. doi: 10.2310/JIM.0b013e31820fb28c.
Waxman et al., Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci. Feb. 2014;17(2):153-63. doi: 10.1038/nn.3602. Epub Jan. 28, 2014.
Wen et al., Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ?VP8* subunit parenteral vaccines. Vaccine. Jul. 31, 2014;32(35):4420-4427. doi: 10.1016/j.vaccine.2014.06.060. Epub Jun. 21, 2014.
West et al., Gene expression in adeno-associated virus vectors: the effects of chimeric mRNA structure, helper virus, and adenovirus VA1 Rna. Virology. Sep. 1987;160(1):38-47. doi: 10.1016/0042-6822(87)90041-9.
Wharton et al., A new-specificity mutant of 434 repressor that defines an amino acid-base pair contact. Nature. Apr. 30-May 6, 1987;326(6116):888-91.
Wharton et al., Changing the binding specificity of a repressor by redesigning an alpha-helix. Nature. Aug. 15-21, 1985;316(6029):601-5.
Williams et al., Assessing the accuracy of ancestral protein reconstruction methods. PLoS Comput Biol. Jun. 23, 2006;2(6):e69. doi: 10.1371/journal.pcbi.0020069. Epub Jun. 23, 2006.
Wilson et al., Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus. J Virol. May 1989;63(5):2374-8. doi: 10.1128/JVI.63.5.2374-2378.1989.
Winoto et al., A novel, inducible and T cell-specific enhancer located at the 3′ end of the T cell receptor alpha locus. EMBO J. Mar. 1989;8(3):729-33.
Wold, Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem. 1997;66:61-92. doi: 10.1146/annurev.biochem.66.1.61.
Wong et al., A statistical analysis of random mutagenesis methods used for directed protein evolution. J Mol Biol. Jan. 27, 2006;355(4):858-71. Epub Nov. 17, 2005.
Wong et al., The Diversity Challenge in Directed Protein Evolution. Comb Chem High Throughput Screen. May 2006;9(4):271-88.
Wright et al., Continuous in vitro evolution of catalytic function. Science. Apr. 25, 1997;276(5312):614-7.
Wu et al., Protein trans-splicing and functional mini-inteins of a cyanobacterial dnaB intein. Biochim Biophys Acta. Sep. 8, 1998;1387(1-2):422-32. doi: 10.1016/s0167-4838(98)00157-5.
Wu et al., Protein trans-splicing by a split intein encoded in a split DnaE gene of Synechocystis sp. PCC6803. Proc Natl Acad Sci U S A. Aug. 4, 1998;95(16):9226-31. doi: 10.1073/pnas.95.16.9226.
Wu, et al., Biochim. Biophys. Acta 35732:1 (1998b).
Xiao et al., Genetic incorporation of multiple unnatural amino acids into proteins in mammalian cells. Angew Chem Int Ed Engl. Dec. 23, 2013;52(52):14080-3. doi: 10.1002/anie.201308137. Epub Nov. 8, 2013.
Xie et al., Adjusting the attB site in donor plasmid improves the efficiency of ?C31 integrase system. DNA Cell Biol. Jul. 2012;31(7):1335-40. doi: 10.1089/dna.2011.1590. Epub Apr. 10, 2012.
Xiong et al., Origin and evolution of retroelements based upon their reverse transcriptase sequences. EMBO J. Oct. 1990;9(10):3353-62.
Xu et al., Chemical ligation of folded recombinant proteins: segmental isotopic labeling of domains for NMR studies. Proc Natl Acad Sci U S A. Jan. 19, 1999;96(2):388-93. doi: 10.1073/pnas.96.2.388.
Xu et al., Accuracy and efficiency define Bxb1 integrase as the best of fifteen candidate serine recombinases for the integration of DNA into the human genome. BMC Biotechnol. Oct. 20, 2013;13:87. doi: 10.1186/1472-6750-13-87.
Xu et al., Protein splicing: an analysis of the branched intermediate and its resolution by succinimide formation. Embo J. Dec. 1, 1994;13(23):5517-22.
Xu et al., Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N6-methyladenosine RNA demethylation. J Biol Chem. Jun. 20, 2014;289(25):17299-311. doi: 10.1074/jbc.M114.550350. Epub Apr. 28, 2014.
Xu et al., The mechanism of protein splicing and its modulation by mutation. EMBO J. Oct. 1, 1996;15(19):5146-53.
Yamamoto et al., The ons and offs of inducible transgenic technology: a review. Neurobiol Dis. Dec. 2001;8(6):923-32.
Yamazaki et al., Segmental Isotope Labeling for Protein NMR Using Peptide Splicing. J. Am. Chem. Soc. May 22, 1998; 120(22):5591-2. https://doi.org/10.1021/ja9807760.
Yang et al., Construction of an integration-proficient vector based on the site-specific recombination mechanism of enterococcal temperate phage phiFC1. J Bacteriol. Apr. 2002;184(7):1859-64. doi: 10.1128/jb.184.7.1859-1864.2002.
Yang et al., One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. Sep. 12, 2013;154(6):1370-9. doi: 10.1016/j.cell.2013.08.022. Epub Aug. 29, 2013.
Yang et al., Permanent genetic memory with >1-byte capacity. Nat Methods. Dec. 2014;11(12):1261-6. doi: 10.1038/nmeth.3147. Epub Oct. 26, 2014.
Yang et al., Preparation of RNA-directed DNA polymerase from spleens of Balb-c mice infected with Rauscher leukemia virus. Biochem Biophys Res Commun. Apr. 28, 1972;47(2):505- 11. doi: 10.1016/0006-291x(72)90743-7.
Yang et al., Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol. Jan. 1, 1998;8(1):11-8. doi: 10.1016/s0960-9822(98)70015-6.
Yang, PAML 4: phylogenetic analysis by maximum likelihood. Mol Biol Evol. Aug. 2007;24(8): 1586-91. doi: 10.1093/molbev/msm088. Epub May 4, 2007.
Yasui et al., Miscoding Properties of 2′-Deoxyinosine, a Nitric Oxide-Derived DNA Adduct, during Translesion Synthesis Catalyzed by Human DNA Polymerases. J Molec Biol. Apr. 4, 2008;377(4):1015-23.
Yasukawa et al., Characterization of Moloney murine leukaemia virus/avian myeloblastosis virus chimeric reverse transcriptases. J Biochem. Mar. 2009;145(3):315-24. doi: 10.1093/jb/mvn166. Epub Dec. 6, 2008.
Yokoe et al., Spatial dynamics of GFP-tagged proteins investigated by local fluorescence enhancement. Nat Biotechnol. Oct. 1996; 14(10):1252-6. doi: 10.1038/nbt1096-1252.
Yu et al., Circular permutation: a different way to engineer enzyme structure and function. Trends Biotechnol. Jan. 2011;29(1):18-25. doi: 10.1016/j.tibtech.2010.10.004. Epub Nov. 17, 2010.
Yu et al., Synthesis-dependent microhomology-mediated end joining accounts for multiple types of repair junctions. Nucleic Acids Res. Sep. 2010;38(17):5706-17. doi: 10.1093/nar/gkq379. Epub May 11, 2010.
Zettler et al., The naturally split Npu DnaE intein exhibits an extraordinarily high rate in the protein trans-splicing reaction. FEBS Lett. Mar. 4, 2009;583(5):909-14. doi: 10.1016/j.febslet.2009.02.003. Epub Feb. 10, 2009.
Zhang et al., A new strategy for the site-specific modification of proteins in vivo. Biochemistry. Jun. 10, 2003;42(22):6735-46.
Zhang et al., Circular intronic long noncoding RNAs. Mol Cell. Sep. 26, 2013;51(6):792-806. doi: 10.1016/j.molcel.2013.08.017. Epub Sep. 12, 2013.
Zhang et al., Copy number variation in human health, disease, and evolution. Annu Rev Genomics Hum Genet. 2009;10:451-81. doi: 10.1146/annurev.genom.9.081307.164217.
Zheng et al., ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. Jan. 10, 2013;49(1):18-29. doi: 10.1016/j.molcel.2012.10.015. Epub Nov. 21, 2012.
Zielenski, Genotype and phenotype in cystic fibrosis. Respiration. 2000;67(2):117-33. doi: 10.1159/000029497.
Zimmerly et al., Group II intron mobility occurs by target DNA-primed reverse transcription. Cell. Aug. 25, 1995;82(4):545-54. doi: 10.1016/0092-8674(95)90027-6.
Zufferey et al., Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. Apr. 1999;73(4):2886-92. doi: 10.1128/JVI.73.4.2886-2892.1999.
Zuker et al., Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. Jan. 10, 1981;9(1):133-48. doi: 10.1093/nar/9.1.133.
[No Author Listed] NCBI Accession No. XP_015843220.1. C →U editing enzyme APOBEC-1 [Peromyscus maniculatus bairdii], XP002793540. Mar. 21, 2016.
[No Author Listed] NCBI Accession No. XP_021505673.1. C →U editing enzyme APOBEC-1 [Meriones unguiculatus], XP002793541. Jun. 27, 2017.
[No Author Listed], EMBL Accession No. Q99ZW2. Nov. 2012. 2 pages.
[No Author Listed], Invitrogen Lipofectamine™ 2000 product sheets, 2002. 2 pages.
[No Author Listed], Invitrogen Lipofectamine™ 2000 product sheets, 2005. 3 pages.
[No Author Listed], Invitrogen Lipofectamine™ LTX product sheets, 2011. 4 pages.
Akopian et al., Chimeric recombinases with designed DNA sequence recognition. Proc Natl Acad Sci U S A. Jul. 22, 2003;100(15):8688-91. Epub Jul. 1, 2003.
Alexandrov et al., Signatures of mutational processes in human cancer. Nature. Aug. 22, 2013;500(7463):415-21. doi: 10.1038/nature12477. Epub Aug. 14, 2013.
Anders et al., Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature. Sep. 25, 2014;513(7519):569-73. doi: 10.1038/nature13579. Epub Jul. 27, 2014.
André et al., Axotomy-induced expression of calcium-activated chloride current in subpopulations of mouse dorsal root ganglion neurons. J Neurophysiol. Dec. 2003;90(6):3764-73. doi: 10.1152/jn.00449.2003. Epub Aug. 27, 2003.
Barnes et al., Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu Rev Genet. 2004;38:445-76.
Barrangou et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science. Mar. 23, 2007;315(5819):1709-12.
Barrangou, RNA-mediated programmable DNA cleavage. Nat Biotechnol. Sep. 2012;30(9):836-8. doi: 10.1038/nbt.2357.
Beale et al., Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. Mar. 26, 2004;337(3):585-96.
Bedell et al., In vivo genome editing using a high-efficiency TALEN system. Nature. Nov. 1, 2012;491(7422):114-8. Doi: 10.1038/nature11537. Epub Sep. 23, 2012.
Benarroch, HCN channels: function and clinical implications. Neurology. Jan. 15, 2013;80(3):304-10. doi: 10.1212/WNL.0b013e31827dec42.
Berges et al., Transduction of brain by herpes simplex virus vectors. Mol Ther. Jan. 2007;15(1):20-9. doi: 10.1038/sj.mt.6300018.
Bershtein et al., Advances in laboratory evolution of enzymes. Curr Opin; Chem Biol. Apr. 2008; 12(2):151-8. doi: 10.1016/j.cbpa.2008.01.027. Epub Mar. 7, 2008. Review.
Beumer et al., Efficient gene targeting in Drosophila with zinc-finger nucleases. Genetics. Apr. 2006;172(4):2391-403. Epub Feb. 1, 2006.
Bhagwat, DNA-cytosine deaminases: from antibody maturation to antiviral defense. DNA Repair (Amst). Jan. 5, 2004;3(1):85-9.
Birling et al., Site-specific recombinases for manipulation of the mouse genome. Methods Mol Biol. 2009;561:245-63. doi: 10.1007/978-1-60327-019-9_16.
Bitinaite et al., FokI dimerization is required for DNA cleavage. Proc Natl Acad Sci U S A. Sep. 1, 1998;95(18):10570-5.
Boch, TALEs of genome targeting. Nat Biotechnol. Feb. 2011;29(2):135-6. Doi: 10.1038/nbt.1767.
Boeckle et al., Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release. May 15, 2006;112(2):240-8. Epub Mar. 20, 2006.
Bogdanove et al., TAL effectors: customizable proteins for DNA targeting. Science. Sep. 30, 2011;333(6051):1843-6. doi: 10.1126/science.1204094.
Bohlke et al., Sense codon emancipation for proteome-wide incorporation of noncanonical amino acids: rare isoleucine codon AUA as a target for genetic code expansion. FEMS Microbiol Lett. Feb. 2014;351(2):133-44. doi: 10.1111/1574-6968.12371. Epub Jan. 27, 2014.
Bolotin et al., Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology. Aug. 2005;151(Pt 8):2551-61.
Bourinet et al., Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J. Jan. 26, 2005;24(2):315-24. doi: 10.1038/sj.emboj.7600515. Epub Dec. 16, 2004.
Branden and Tooze, Introduction to Protein Structure. 1999; 2nd edition. Garland Science Publisher: 3-12.
Briner et al., Guide RNA functional modules direct Cas9 activity and orthogonality. Mol Cell. Oct. 23, 2014;56(2):333-339. doi: 10.1016/j.molcel.2014.09.019.
Britt et al., Re-engineering plant gene targeting. Trends Plant Sci. Feb. 2003;8(2):90-5.
Brouns et al., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science. Aug. 15, 2008;321(5891):960-4. doi: 10.1126/science.1159689.
Brusse et al., Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Mov Disord. Mar. 2006;21(3):396-401.
Buchholz et al., Alteration of Cre recombinase site specificity by substrate-linked protein evolution. Nat Biotechnol. Nov. 2001;19(11):1047-52.
Buchwald et al., Long-term, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombosis. Surgery. Oct. 1980;88(4):507-16.
Budisa et al., Residue-specific bioincorporation of non-natural, biologically active amino acids into proteins as possible drug carriers: structure and stability of the per-thiaproline mutant of annexin V. Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):455-9.
Bulow et al., Multienzyme systems obtained by gene fusion. Trends Biotechnol. Jul. 1991;9(7):226-31.
Burke et al., Activating mutations of Tn3 resolvase marking interfaces important in recombination catalysis and its regulation. Mol Microbiol. Feb. 2004;51(4):937-48.
Burke et al., RNA Aptamers to the Adenosine Moiety of S-adenosyl Methionine: Structural Inferences From Variations on a Theme and the Reproducibility of SELEX. Nucleic Acids Res. May 15, 1997;25(10):2020-4. doi: 10.1093/nar/25.10.2020.
Burton et al., Gene delivery using herpes simplex virus vectors. DNA Cell Biol. Dec. 2002;21(12):915-36. doi: 10.1089/104454902762053864.
Böck et al., Selenocysteine: the 21st amino acid. Mol Microbiol. Mar. 1991;5(3):515-20.
Cade et al., Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res. Sep. 2012;40(16):8001-10. Doi: 10.1093/nar/gks518. Epub Jun. 7, 2012.
Caldecott et al., Single-strand break repair and genetic disease. Nat Rev Genet. Aug. 2008;9(8):619-31. doi: 10.1038/nrg2380.
Cameron, Recent advances in transgenic technology. Mol Biotechnol. Jun. 1997;7(3):253-65.
Caron et al., Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther. Mar. 2001;3(3):310-8.
Carroll et al., Gene targeting in Drosophila and Caenorhabditis elegans with zinc-finger nucleases. Methods Mol Biol. 2008;435:63-77. doi: 10.1007/978-1-59745-232-8_5.
Carroll et al., Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther. Nov. 2008;15(22):1463-8. doi: 10.1038/gt.2008.145. Epub Sep. 11, 2008.
Carroll, A CRISPR approach to gene targeting. Mol Ther. Sep. 2012;20(9):1658-60. doi: 10.1038/mt.2012.171.
Carroll, Genome engineering with zinc-finger nucleases. Genetics. Aug. 2011;188(4):773-82. doi: 10.1534/genetics.111.131433. Review.
Cermak et al., Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. Jul. 2011;39(12):e82. Doi: 10.1093/nar/gkr218. Epub Apr. 14, 2011.
Chan et al., The choice of nucleotide inserted opposite abasic sites formed within chromosomal DNA reveals the polymerase activities participating in translesion DNA synthesis. DNA Repair (Amst). Nov. 2013;12(11):878-89. doi: 10.1016/j.dnarep.2013.07.008. Epub Aug. 26, 2013.
Charpentier et al., Biotechnology: Rewriting a genome. Nature. Mar. 7, 2013;495(7439):50-1. doi: 10.1038/495050a.
Chelico et al., Stochastic properties of processive cytidine DNA deaminases AID and APOBEC3G. Philos Trans R Soc Lond B Biol Sci. Mar. 12, 2009;364(1517):583-93. doi: 10.1098/rstb.2008.0195.
Cheng et al., Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res. Oct. 2013;23(10):1163-71. doi: 10.1038/cr.2013.122. Epub Aug. 27, 2013.
Chester et al., The apolipoprotein B mRNA editing complex performs a multifunctional cycle and suppresses nonsense-mediated decay. EMBO J. Aug. 1, 2003;22(15):3971-82. doi: 10.1093/emboj/cdg369.
Chichili et al., Linkers in the structural biology of protein-protein interactions. Protein Science. 2013;22:153-67.
Cho et al., Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. Jan. 2014;24(1):132-41. doi: 10.1101/gr.162339.113. Epub Nov. 19, 2013.
Cho et al., Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. Mar. 2013;31(3):230-2. doi: 10.1038/nbt.2507. Epub Jan. 29, 2013.
Cho et al., The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci. May 27, 2012;15(7):1015-21. doi: 10.1038/nn.3111.
Christian et al., Targeting G with TAL effectors: a comparison of activities of TALENs constructed with NN and NK repeat variable di-residues. PLoS One. 2012;7(9):e45383. doi: 10.1371/journal.pone.0045383. Epub Sep. 24, 2012.
Christian et al., Targeting DNA double-strand breaks with TAL effector nucleases. Genetics. Oct. 2010;186(2):757-61. Doi: 10.1534/genetics.110.120717. Epub Jul. 26, 2010.
Chung-Il et al., Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA. May 2006;12(5):710-6. Epub Apr. 10, 2006.
Chylinski et al., The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. May 2013;10(5):726-37. doi: 10.4161/rna.24321. Epub Apr. 5, 2013.
Cobb et al., Directed evolution as a powerful synthetic biology tool. Methods. Mar. 15, 2013;60(1):81-90. doi: 10.1016/j.ymeth.2012.03.009. Epub Mar. 23, 2012.
Cong et al., Multiplex genome engineering using CRISPR/Cas systems. Science. Feb. 15, 2013;339(6121):819-23. doi: 10.1126/science.1231143. Epub Jan. 3, 2013.
Cox et al., An SCN9A channelopathy causes congenital inability to experience pain. Nature. Dec. 14, 2006;444(7121):894-8. doi: 10.1038/nature05413.
Cox et al., Conditional gene expression in the mouse inner ear using Cre-loxP. J Assoc Res Otolaryngol. Jun. 2012;13(3):295-322. doi: 10.1007/s10162-012-0324-5. Epub Apr. 24, 2012.
Cox et al., Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations. Hum Mutat. Sep. 2010;31(9):E1670-86. doi: 10.1002/humu.21325.
Cradick et al., Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther. May 2010;18(5):947-54. Doi: 10.1038/mt.2010.20. Epub Feb. 16, 2010.
Cronican et al., A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem Biol. Jul. 29, 2011;18(7):833-8. doi: 10.1016/j.chembiol.2011.07.003.
Cronican et al., Potent delivery of functional proteins into mammalian cells in vitro and in vivo using a supercharged protein. ACS Chem Biol. Aug. 20, 2010;5(8):747-52. doi: 10.1021/cb1001153.
Cui et al., Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol. Jan. 2011;29(1):64-7. Doi: 10.1038/nbt.1731. Epub Dec. 12, 2010.
Cunningham et al., Ensembl 2015. Nucleic Acids Res. Jan. 2015;43(Database issue):D662-9. doi: 10.1093/nar/gku1010. Epub Oct. 28, 2014.
D'Adda di Fagagna et al., The Gam protein of bacteriophage Mu is an orthologue of eukaryotic Ku. EMBO Rep. Jan. 2003;4(1):47-52.
Dahlem et al., Simple methods for generating and detecting locus-specific mutations induced with TALENs in the zebrafish genome. PLoS Genet. 2012;8(8):e1002861. doi: 10.1371/journal.pgen.1002861. Epub Aug. 16, 2012.
Database EBI Accession No. ADE34233 Jan. 29, 2004.
Database UniProt Accession No. G813E0. Jan. 14, 2012.
Davidson et al., Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci. May 2003;4(5):353-64. doi: 10.1038/nrn1104.
Davis et al., DNA double strand break repair via non-homologous end-joining. Transl Cancer Res. Jun. 2013;2(3):130-143.
De Souza, Primer: genome editing with engineered nucleases. Nat Methods. Jan. 2012;9(1):27.
Deltcheva et al., CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. Mar. 31, 2011;471(7340):602-7. doi: 10.1038/nature09886.
Devigili et al., Paroxysmal itch caused by gain-of-function Nav1.7 mutation. Pain. Sep. 2014;155(9):1702-1707. doi: 10.1016/j.pain.2014.05.006. Epub May 10, 2014.
Dianov et al., Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. Apr. 1, 2013;41(6):3483-90. doi: 10.1093/nar/gkt076. Epub Feb. 13, 2013.
Dicarlo et al., Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Research Apr. 2013;41(7):4336-43.
Ding et al., A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. Feb. 7, 2013;12(2):238-51. Doi: 10.1016/j.stem.2012.11.011. Epub Dec. 13, 2012.
Ding et al., Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. Aug. 15, 2014;115(5):488-92. doi: 10.1161/CIRCRESAHA.115.304351. Epub Jun. 10, 2014.
Doench et al., Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. Dec. 2014;32(12):1262-7. doi: 10.1038/nbt.3026. Epub Sep. 3, 2014.
Doyon et al., Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases. Nat Biotechnol. Jun. 2008;26(6):702-8. Doi: 10.1038/nbt1409. Epub May 25, 2008.
Dumas et al., Designing logical codon reassignment—Expanding the chemistry in biology. Chem Sci. Jan. 1, 2015;6(1):50-69. doi: 10.1039/c4sc01534g. Epub Jul. 14, 2014. Review.
During et al., Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol. Apr. 1989;25(4):351-6.
Edwards et al., An Escherichia coli tyrosine transfer RNA is a leucine-specific transfer RNA in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. Feb. 15, 1991;88(4):1153-6.
Eiler et al., Structural Basis for the Fast Self-Cleavage Reaction Catalyzed by the Twister Ribozyme. Proc Natl Acad Sci U S A. Sep. 9, 2014;111(36):13028-33. doi: 10.1073/pnas.1414571111. Epub Aug. 25, 2014.
Eltoukhy et al., Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles. Biomaterials. Aug. 2014;35(24):6454-61. doi: 10.1016/j.biomaterials.2014.04.014. Epub May 13, 2014.
Emery et al., HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science. Sep. 9, 2011;333(6048):1462-6. doi: 10.1126/science.1206243.
Endo et al., Toward establishing an efficient and versatile gene targeting system in higher plants. Biocatalysis and Agricultural Biotechnology 2014;3,(1):2-6.
Epstein, HSV-1-based amplicon vectors: design and applications. Gene Ther. Oct. 2005;12 Suppl 1:S154-8. doi: 10.1038/sj.gt.3302617.
Estacion et al., A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. Ann Neurol. Dec. 2009;66(6):862-6. doi: 10.1002/ana.21895.
Esvelt et al., A system for the continuous directed evolution of biomolecules. Nature. Apr. 28, 2011;472(7344):499-503. doi: 10.1038/nature09929. Epub Apr. 10, 2011.
Esvelt et al., Genome-scale engineering for systems and synthetic biology. Mol Syst Biol. 2013;9:641. doi: 10.1038/msb.2012.66.
Esvelt et al., Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods. Nov. 2013;10(11):1116-21. doi: 10.1038/nmeth.2681. Epub Sep. 29, 2013.
Fang et al., Synthetic Studies Towards Halichondrins: Synthesis of the Left Halves of Norhalichondrins and Homohalichondrins. Tetrahedron Letters 1992;33(12):1557-1560.
Farhood et al., Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes. Anal Biochem. Feb. 10, 1995;225(1):89-93.
Ferretti et al., Complete genome sequence of an M1 strain of Streptococcus pyogenes. Proc Natl Acad Sci U S A. Apr. 10, 2001;98(8):4658-63.
Fischer et al., Cryptic epitopes induce high-titer humoral immune response in patients with cancer. J Immunol. Sep. 1, 2010;185(5):3095-102. doi: 10.4049/jimmunol.0902166. Epub Jul. 26, 2010.
Fortini et al., Different DNA polymerases are involved in the short- and long-patch base excision repair in mammalian cells. Biochemistry. Mar. 17, 1998;37(11):3575-80. doi: 10.1021/bi972999h.
Freshney, Culture of Animal Cells. A Manual of Basic Technique. Alan R. Liss, Inc. New York. 1983;4.
Fu et al., Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. Mar. 2014;32(3):279-84. doi: 10.1038/nbt.2808. Epub Jan. 26, 2014.
Fu et al., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. Sep. 2013;31(9):822-6. doi: 10.1038/nbt.2623. Epub Jun. 23, 2013.
Fuchs et al., Polyarginine as a multifunctional fusion tag. Protein Sci. Jun. 2005;14(6):1538-44.
Fukui et al., DNA Mismatch Repair in Eukaryotes and Bacteria. J Nucleic Acids. Jul. 27, 2010;2010. pii: 260512. doi: 10.4061/2010/260512.
Fung et al., Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. PLoS One. 2011;6(5):e20514. doi: 10.1371/journal.pone.0020514. Epub May 25, 2011.
Gaj et al., A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells. Nucleic Acids Res. Feb. 6, 2013;41(6):3937-46.
Gaj et al., Enhancing the specificity of recombinase-mediated genome engineering through dimer interface redesign. J Am Chem Soc. Apr. 2, 2014;136(13):5047-56. doi: 10.1021/ja4130059. Epub Mar. 20, 2014.
Gaj et al., Expanding the scope of site-specific recombinases for genetic and metabolic engineering. Biotechnol Bioeng. Jan. 2014;111(1):1-15. doi: 10.1002/bit.25096. Epub Sep. 13, 2013.
Gaj et al., Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proc Natl Acad Sci U S A. Jan. 11, 2011;108(2):498-503. doi: 10.1073/pnas.1014214108. Epub Dec. 27, 2010.
Gaj et al., ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. Jul. 2013;31(7):397-405. doi: 10.1016/j.tibtech.2013.04.004. Epub May 9, 2013.
Gardlik et al., Vectors and delivery systems in gene therapy. Med Sci Monit. Apr. 2005;11(4):RA110-21. Epub Mar. 24, 2005.
Garneau et al., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. Nov. 4, 2010;468(7320):67-71. doi: 10.1038/nature09523.
Gasiunas et al., Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. Sep. 25, 2012;109(39):E2579-86. Epub Sep. 4, 2012. Supplementary materials included.
Gasiunas et al., RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing? Trends Microbiol. Nov. 2013;21(11):562-7. doi: 10.1016/j.tim.2013.09.001. Epub Oct. 1, 2013.
Genbank Submission; NIH/NCBI, Accession No. J04623. Kita et al., Apr. 26, 1993. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_002737.1. Ferretti et al., Jun. 27, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_015683.1. Trost et al., Jul. 6, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_016782.1. Trost et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_016786.1. Trost et al., Aug. 28, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017053.1. Fittipaldi et al., Jul. 6, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017317.1. Trost et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_017861.1. Heidelberg et al., Jun. 11, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_018010.1. Lucas et al., Jun. 11, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. NC_021314.1. Zhang et al., Jul. 15, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NC_021846.1. Lo et al., Jul. 22, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. NP_472073.1. Glaser et al., Jun. 27, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. P42212. Prasher et al., Mar. 19, 2014. 7 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_002342100.1. Bernardini et al., Jun. 10, 2013. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_002344900.1. Gundogdu et al., Mar. 19, 2014. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. YP_820832.1. Makarova et al., Aug. 27, 2013. 2 pages.
Gersbach et al., Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Res. Jul. 2010;38(12):4198-206. doi: 10.1093/nar/gkq125. Epub Mar. 1, 2010.
Gersbach et al., Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Res. Sep. 1, 2011;39(17):7868-78. doi: 10.1093/nar/gkr421. Epub Jun. 7, 2011.
Gilbert et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013 154(2):442-51.
Gilleron et al., Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. Jul. 2013;31(7):638-46. doi: 10.1038/nbt.2612. Epub Jun. 23, 2013.
Goldberg et al., Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. Apr. 2007;71(4):311-9. doi: 10.1111/j.1399-0004.2007.00790.x.
Gonzalez et al., An iCRISPR platform for rapid, multiplexable, and inducible genome editing in human pluripotent stem cells. Cell Stem Cell. Aug. 7, 2014;15(2):215-26. doi: 10.1016/j.stem.2014.05.018. Epub Jun. 12, 2014.
Gordley et al., Evolution of programmable zinc finger-recombinases with activity in human cells. J Mol Biol. Mar. 30, 2007;367(3):802-13. Epub Jan. 12, 2007.
Gordley et al., Synthesis of programmable integrases. Proc Natl Acad Sci U S A. Mar. 31, 2009;106(13):5053-8. doi: 10.1073/pnas.0812502106. Epub Mar. 12, 2009.
Grindley et al., Mechanisms of site-specific recombination. Annu Rev Biochem. 2006;75:567-605. doi: 10.1146/annurev.biochem.73.011303.073908.
Groher et al., Synthetic riboswitches—A tool comes of age. Biochim Biophys Acta. Oct. 2014; 1839(10):964-973. doi: 10.1016/j.bbagrm.2014.05.005. Epub May 17, 2014.
Groth et al., Phage integrases: biology and applications. J Mol Biol. Jan. 16, 2004;335(3):667-78.
Gruber et al., The Vienna RNA websuite. Nucleic Acids Res. Jul. 1, 2008;36(Web Server issue): W70-4. doi: 10.1093/nar/gkn188. Epub Apr. 19, 2008.
Guilinger et al., Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods. Apr. 2014;11(4):429-35. doi: 10.1038/nmeth.2845. Epub Feb. 16, 2014.
Guilinger et al., Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol. Jun. 2014;32(6):577-82. doi: 10.1038/nbt.2909. Epub Apr. 25, 2014.
Guo et al., Protein tolerance to random amino acid change. Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9205-10. Epub Jun. 14, 2004.
Guo et al., Structure of Cre recombinase complexed with DNA in a site-specific recombination synapse. Nature. Sep. 4, 1997;389(6646):40-6.
Hale et al., RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell. Nov. 25, 2009;139(5):945-56. doi: 10.1016/j.cell.2009.07.040.
Hamano-Takaku et al., A mutant Escherichia coli tyrosyl-tRNA synthetase utilizes the unnatural amino acid azatyrosine more efficiently than tyrosine. J Biol Chem. Dec. 22, 2000;275(51):40324-8.
Harris et al., RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Mol Cell. Nov. 2002; 10(5):1247-53.
Hartung et al., Cre mutants with altered DNA binding properties. J Biol Chem. Sep. 4, 1998;273(36):22884-91.
Hasadsri et al., Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem. Mar. 13, 2009;284(11):6972-81. doi: 10.1074/jbc.M805956200. Epub Jan. 7, 2009.
Hayes et al., Stop codons preceded by rare arginine codons are efficient determinants of SsrA tagging in Escherichia coli. Proc Natl Acad Sci U S A. Mar. 19, 2002;99(6):3440-5. Epub Mar. 12, 2002.
Heller et al., Replisome assembly and the direct restart of stalled replication forks. Nat Rev Mol Cell Biol. Dec. 2006;7(12):932-43. Epub Nov. 8, 2006.
Hickford et al., Antitumour polyether macrolides: four new halichondrins from the New Zealand deep-water marine sponge Lissodendoryx sp. Bioorg Med Chem. Mar. 15, 2009;17(6):2199-203. doi: 10.1016/j.bmc.2008.10.093. Epub Nov. 19, 2008.
Hida et al., Directed evolution for drug and nucleic acid; delivery. Adv Drug Deliv Rev. Dec. 22, 2007;59(15):1562-78. Epub Aug. 28, 2007.; Review.
Higgs et al., Genetic complexity in sickle cell disease. Proc Natl Acad Sci U S A. Aug. 19, 2008;105(33):11595-6. doi: 10.1073/pnas.0806633105. Epub Aug. 11, 2008.
Hill et al., Functional analysis of conserved histidines in ADP-glucose pyrophosphorylase from Escherichia coli.Biochem Biophys Res Commun. Mar. 17, 1998;244(2):573-7.
Hirano et al., Site-specific recombinases as tools for heterologous gene integration. Appl Microbiol Biotechnol. Oct. 2011;92(2):227-39. doi: 10.1007/s00253-011-3519-5. Epub Aug. 7, 2011. Review.
Hockemeyer et al., Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. Sep. 2009;27(9):851-7. doi: 10.1038/nbt.1562. Epub Aug. 13, 2009.
Hockemeyer et al., Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. Jul. 7, 2011;29(8):731-4. doi: 10.1038/nbt.1927.
Hoess et al., DNA specificity of the Cre recombinase resides in the 25 kDa carboxyl domain of the protein. J Mol Biol. Dec. 20, 1990;216(4):873-82. doi: 10.1016/S0022-2836(99)80007-2.
Holt et al., Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol. Aug. 2010;28(8):839-47. doi: 10.1038/nbt.1663. Epub Jul. 2, 2010.
Hondares et al., Peroxisome Proliferator-activated Receptor α (PPARα) Induces PPARγ Coactivator 1α (PGC-1α) Gene Expression and Contributes to Thermogenic Activation of Brown Fat. J Biol. Chem Oct. 2011; 286(50):43112-22. doi: 10.1074/jbc.M111.252775.
Horvath et al., CRISPR/Cas, the immune system of bacteria and archaea. Science. Jan. 8, 2010;327(5962):167-70. doi: 10.1126/science.1179555.
Horvath et al., Diversity, Activity, and Evolution of CRISPR Loci in Streptococcus thermophilus. J Bacteriol. Feb. 2008;190(4):1401-12. doi: 10.1128/JB.01415-07. Epub Dec. 7, 2007.
Hotta et al., [Neurotropic viruses—classification, structure and characteristics]. Nihon Rinsho. Apr. 1997;55(4):777-82. Japanese.
Hou et al., Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. Sep. 24, 2013;110(39):15644-9. doi: 10.1073/pnas.1313587110. Epub Aug. 12, 2013.
Houdebine, The methods to generate transgenic animals and to control transgene expression. J Biotechnol. Sep. 25, 2002;98(2-3):145-60.
Howard et al., Intracerebral drug delivery in rats with lesion-induced memory deficits. J Neurosurg. Jul. 1989;71(1):105-12.
Hsu et al., DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. Sep. 2013;31(9):827-32. doi: 10.1038/nbt.2647. Epub Jul. 21, 2013. Supplementary Information. 27 pages.
Huang et al., Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):699-700. doi: 10.1038/nbt.1939.
Humbert et al., Targeted gene therapies: tools, applications, optimization. Crit Rev Biochem Mol Biol. May-Jun. 2012;47(3):264-81. doi: 10.3109/10409238.2012.658112.
Husimi, Selection and evolution of bacteriophages in cellstat. Adv Biophys. ; 1989;25:1-43. Review.
Hwang et al., Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. Mar. 2013;31(3):227-9. doi: 10.1038/nbt.2501. Epub Jan. 29, 2013.
Hwang et al., Efficient In Vivo Genome Editing Using RNA-Guided Nucleases. Nat Biotechnol. Mar. 2013; 31(3): 227-229. doi: 10.1038/nbt.2501. Epub Jan. 29, 2013.
Ishino et al., Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. Dec. 1987; 169(12):5429-33.
Jamieson et al., Drug discovery with engineered zinc-finger proteins. Nat Rev Drug Discov. May 2003;2(5):361-8.
Jansen et al., Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol. Mar. 2002;43(6):1565-75.
Jeong et al., Measurement of deoxyinosine adduct: Can it be a reliable tool to assess oxidative or nitrosative DNA damage? Toxicol Lett. Oct. 17, 2012;214(2):226-33. doi: 10.1016/j.toxlet.2012.08.013. Epub Aug. 23, 2012.
Jiang et al., RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol. Mar. 2013;31(3):233-9. doi: 10.1038/nbt.2508. Epub Jan. 29, 2013.
Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. Aug. 17, 2012;337(6096):816-21. doi: 10.1126/science.1225829. Epub Jun. 28, 2012.
Jinek et al., RNA-programmed genome editing in human cells. Elife. Jan. 29, 2013;2:e00471. doi: 10.7554/eLife.00471.
Jinek et al., Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science. Mar. 14, 2014;343(6176):1247997. doi: 10.1126/science.1247997. Epub Feb. 6, 2014.
Jiricny, The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. May 2006;7(5):335-46. doi: 10.1038/nrm1907.
Jore et al., Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol. May 2011;18(5):529-36. doi: 10.1038/nsmb.2019. Epub Apr. 3, 2011.
Joung et al.,TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. Jan. 2013;14(1):49-55. doi: 10.1038/nrm3486. Epub Nov. 21, 2012.
Kaiser et al., Gene therapy. Putting the fingers on gene repair. Science. Dec. 23, 2005;310(5756):1894-6.
Kakiyama et al., A peptide release system using a photo-cleavable linker in a cell array format for cell-toxicity analysis. Polymer J. Feb. 27, 2013;45:535-9.
Kandavelou et al., Targeted manipulation of mammalian genomes using designed zinc finger nucleases. Biochem Biophys Res Commun. Oct. 9, 2009;388(1):56-61. doi: 10.1016/j.bbrc.2009.07.112. Epub Jul. 25, 2009.
Kappel et al., Regulating gene expression in transgenic animals.Curr Opin Biotechnol. Oct. 1992;3(5):548-53.
Karimova et al., Vika/vox, a novel efficient and specific Cre/loxP-like site-specific recombination system. Nucleic Acids Res. Jan. 2013;41(2):e37. doi: 10.1093/nar/gks1037. Epub Nov. 9, 2012.
Karpenshif et al., From yeast to mammals: recent advances in genetic control of homologous recombination. DNA Repair (Amst). Oct. 1, 2012;11(10):781-8. doi: 10.1016/j.dnarep.2012.07.001. Epub Aug. 11, 2012. Review.
Katafuchi et al., DNA polymerases involved in the incorporation of oxidized nucleotides into DNA: their efficiency and template base preference. Mutat Res. Nov. 28, 2010;703(1):24-31. doi: 10.1016/j.mrgentox.2010.06.004. Epub Jun. 11, 2010.
Kavli et al., Excision of cytosine and thymine from DNA by mutants of human uracil-DNA glycosylase. Embo J. Jul. 1, 1996;15(13):3442-7.
Kay et al., Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. Jan. 2001;7(1):33-40.
Kellendonk et al., Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res. Apr. 15, 1996;24(8):1404-11.
Ketha et al., Application of bioinformatics-coupled experimental analysis reveals a new transport-competent nuclear localization signal in the nucleoprotein of Influenza A virus strain. BMC Cell Biol. Apr. 28, 2008; 9:22. https://doi.org/10.1186/1471-2121-9-22.
Kiga et al., An engineered Escherichia coli tyrosyl-tRNA synthetase for site-specific incorporation of an unnatural amino acid into proteins in eukaryotic translation and its application in a wheat germ cell-free system. Proc Natl Acad Sci U S A. Jul. 23, 2002;99(15):9715-20. Epub Jul. 3, 2002.
Kilbride et al., Determinants of product topology in a hybrid Cre-Tn3 resolvase site-specific recombination system. J Mol Biol. Jan. 13, 2006;355(2):185-95. Epub Nov. 9, 2005.
Kim et al., A library of TAL effector nucleases spanning the human genome. Nat Biotechnol. Mar. 2013;31(3):251-8. Doi: 10.1038/nbt.2517. Epub Feb. 17, 2013.
Kim et al., Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. Jun. 2014;24(6):1012-9. doi: 10.1101/gr.171322.113. Epub Apr. 2, 2014.
Kim et al., TALENs and ZFNs are associated with different mutationsignatures. Nat Methods. Mar. 2013;10(3):185. doi: 10.1038/nmeth.2364. Epub Feb. 10, 2013.
Kim et al., Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res. Jul. 2009; 19(7):1279-88. doi: 10.1101/gr.089417.108. Epub May 21, 2009.
Kim et al., The role of apolipoprotein E in Alzheimer's disease. Neuron. Aug. 13, 2009;63(3):287-303. doi: 10.1016/j.neuron.2009.06.026.
Kim et al., Transcriptional repression by zinc finger peptides. Exploring the potential for applications in gene therapy. J Biol Chem. Nov. 21, 1997;272(47):29795-800.
Kitamura et al., Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog. 2013;9(5):e1003361. doi: 10.1371/journal.ppat. 1003361. Epub May 16, 2013.
Klauser et al., An engineered small RNA-mediated genetic switch based on a ribozyme expression platform. Nucleic Acids Res. May 1, 2013;41(10):5542-52. doi: 10.1093/nar/gkt253. Epub Apr. 12, 2013.
Kleinstiver et al., Monomeric site-specific nucleases for genome editing. Proc Natl Acad Sci U S A. May 22, 2012;109(21):8061-6. doi: 10.1073/pnas.1117984109. Epub May 7, 2012.
Klippel et al., Isolation and characterization of unusual gin mutants. EMBO J. Dec. 1, 1988;7(12):3983-9.
Klippel et al., The DNA invertase Gin of phage Mu: formation of a covalent complex with DNA via a phosphoserine at amino acid position 9. EMBO J. Apr. 1988;7(4):1229-37.
Kohli et al., Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification. J Biol Chem. Dec. 24, 2010;285(52):40956-64. doi: 10.1074/jbc.M110.177402. Epub Oct. 6, 2010.
Kouzminova et al., Patterns of chromosomal fragmentation due to uracil-DNA incorporation reveal a novel mechanism of replication-dependent double-stranded breaks. Mol Microbiol. Apr. 2008;68(1):202-15. doi: 10.1111/j.1365-2958.2008.06149.x.
Kowal et al., Exploiting unassigned codons in Micrococcus luteus for tRNA-based amino acid mutagenesis. Nucleic Acids Res. Nov. 15, 1997;25(22):4685-9.
Kunz et al., DNA Repair in mammalian cells: Mismatched repair: variations on a theme. Cell Mol Life Sci. Mar. 2009;66(6):1021-38. doi: 10.1007/s00018-009-8739-9.
Kuscu et al., Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. Jul. 2014;32(7):677-83. doi: 10.1038/nbt.2916. Epub May 18, 2014.
Köhrer et al., A possible approach to site-specific insertion of two different unnatural amino acids into proteins in mammalian cells via nonsense suppression. Chem Biol. Nov. 2003; 10(11):1095-102.
Köhrer et al., Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. Nucleic Acids Res. Dec. 1, 2004;32(21):6200-11. Print 2004.
Landrum et al., ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. Jan. 2014;42(Database issue):D980-5. doi: 10.1093/nar/gkt1113. Epub Nov. 14, 2013.
Langer et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review. Journal of Macromolecular Science, 2006;23(1):61-126. DOI: 10.1080/07366578308079439.
Langer et al., New methods of drug delivery. Science. Sep. 2, 19908;249(4976):1527-33.
Larson et al., CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nat Protoc. Nov. 2013;8(11):2180-96. doi: 10.1038/nprot.2013.132. Epub Oct. 17, 2013.
Lau et al., Molecular basis for discriminating between normal and damaged bases by the human alkyladenine glycosylase, AAG. Proc Natl Acad Sci U S A. Dec. 5, 2000;97(25):13573-8.
Lazar et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Mol Cell Biol. Mar. 1988;8(3):1247-52.
Lee et al., A chimeric thyroid hormone receptor constitutively bound to DNA requires retinoid X receptor for hormone-dependent transcriptional activation in yeast. Mol Endocrinol. Sep. 1994;8(9):1245-52.
Lee et al., Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim Biophys Acta. Jan. 31, 1992;1103(2):185-97.
Lei et al., Efficient targeted gene disruption in Xenopus embryos using engineered transcription activator-like effector nucleases (TALENs). Proc Natl Acad Sci U S A. Oct. 23, 2012;109(43):17484-9. Doi: 10.1073/pnas.1215421109. Epub Oct. 8, 2012.
Leipold et al., A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat Genet. Nov. 2013;45(11):1399-404. doi: 10.1038/ng.2767. Epub Sep. 15, 2013.
Levy et al., Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science. Apr. 12, 1985;228(4696):190-2.
Lewis et al., A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci U S A. Apr. 16, 1996;93(8):3176-81.
Li et al., Current approaches for engineering proteins with diverse biological properties. Adv Exp Med Biol. 2007;620:18-33.
Li et al., Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes. Nucleic Acids Res. Aug. 2011;39(14):6315-25. doi: 10.1093/nar/gkr188. Epub Mar. 31, 2011.
Li et al., Multiplex and homologous recombination-mediated genome editing in Arabidopsis and Nicotiana benthamiana using guide RNA and Cas9. Nat Biotechnol. Aug. 2013;31(8):688-91. doi: 10.1038/nbt.2654.
Li et al., TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res. Jan. 2011;39(1):359-72. doi: 10.1093/nar/gkq704. Epub Aug. 10, 2010.
Li, Mechanisms and functions of DNA mismatch repair. Cell Res. Jan. 2008;18(1):85-98. doi: 10.1038/cr.2007.115.
Lim et al., Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res. Jan. 2010;61(1):14-26. doi: 10.1016/j.phrs.2009.10.002. Epub Oct. 17, 2009.
Lin et al., The human REV1 gene codes for a DNA template-dependent dCMP transferase. Nucleic Acids Res. Nov. 15, 1999;27(22):4468-75. doi: 10.1093/nar/27.22.4468.
Link et al., Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches. Gene Ther. Oct. 2009;16(10):1189-201. doi: 10.1038/gt.2009.81. Epub Jul. 9, 2009. Review.
Liu et al., Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. Feb. 2013;9(2):106-18. doi: 10.1038/nrneurol.2012.263. Epub Jan. 8, 2013.
Liu et al., Balancing AID and DNA repair during somatic hypermutation. Trends Immunol. Apr. 2009;30(4):173-81. doi: 10.1016/j.it.2009.01.007.
Liu et al., Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS One. Jan. 20, 2014;9(1):e85755. doi: 10.1371/journal.pone.0085755. eCollection 2014.
Liu et al., Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A. May 27, 1997;94(11):5525-30.
Liu et al., Engineering a tRNA and aminoacyl-tRNA synthetase for the site-specific incorporation of unnatural amino acids into proteins in vivo. Proc Natl Acad Sci U S A. Sep. 16, 1997;94(19):10092-7.
Liu et al., Fast Colorimetric Sensing of Adenosine and Cocaine Based on a General Sensor Design Involving Aptamers and Nanoparticles. Angew Chem. Dec. 16, 2006;45(1):90-4. DOI: 10.1002/anie.200502589.
Liu et al., Fast Colorimetric Sensing of Adenosine and Cocaine Based on a General Sensor Design Involving Aptamers and Nanoparticles. Angew Chem. 2006;118(1):96-100.
Liu et al., Functional Nucleic Acid Sensors. Chem Rev. May 2009; 109(5):1948-98. doi: 10.1021/cr030183i.
Liu et al., Reverse transcriptase of foamy virus. Purification of the enzymes and immunological identification. Arch Virol. 1977;55(3):187-200. doi: 10.1007/BF01319905.
Loessner et al., Complete nucleotide sequence, molecular analysis and genome structure of bacteriophage A118 of Listeria monocytogenes: implications for phage evolution. Mol Microbiol. Jan. 2000;35(2):324-40. doi: 10.1046/j.1365-2958.2000.01720.x.
Lombardo et al., Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. Nov. 2007;25(11):1298-306. Epub Oct. 28, 2007.
Losey et al., Crystal structure of Staphylococcus sureus tRNA adenosine deaminase tadA in complex with RNA. Nature Struct. Mol. Biol. Feb. 2006;13(2):153-9.
Lundberg et al., Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. Sep. 2007;21(11):2664-71. Epub Apr. 26, 2007.
Lundquist et al., Site-directed mutagenesis and characterization of uracil-DNA glycosylase inhibitor protein. Role of specific carboxylic amino acids in complex formation with Escherichia coli uracil-DNA glycosylase. J Biol Chem. Aug. 22, 1997;272(34):21408-19.
Lyons et al., Efficient Recognition of an Unpaired Lesion by a DNA Repair Glycosylase. J. Am. Chem. Soc., 2009;131(49):17742-3. DOI: 10.1021/ja908378y.
Maeder et al., CRISPR RNA-guided activation of endogenous human genes. Nat Methods. Oct. 2013;10(10):977-9. doi: 10.1038/nmeth.2598. Epub Jul. 25, 2013.
Maeder et al., Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell. Jul. 25, 2008;31(2):294-301. doi:10.1016/j.molcel.2008.06.016.
Maeder et al., Robust, synergistic regulation of human gene expression using TALE activators. Nat Methods. Mar. 2013;10(3):243-5. doi: 10.1038/nmeth.2366. Epub Feb. 10, 2013.
Mahfouz et al., De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci U S A. Feb. 8, 2011;108(6):2623-8. doi: 10.1073/pnas.1019533108. Epub Jan. 24, 2011.
Makarova et al., Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol. Jun. 2011;9(6):467-77. doi: 10.1038/nrmicro2577. Epub May 9, 2011.
Makarova et al., Prokaryotic homologs of Argonaute proteins are predicted to function as key components of a novel system of defense against mobile genetic elements. Biology Direct 2009;4:29. doi: 10.1186/1745-6150-4-29.
Mali et al., Cas9 as a versatile tool for engineering biology. Nat Methods. Oct. 2013; 10(10):957-63. doi: 10.1038/nmeth.2649.
Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. Sep. 2013;31(9):833-8. doi: 10.1038/nbt.2675. Epub Aug. 1, 2013.
Mali et al., RNA-guided human genome engineering via Cas9. Science. Feb. 15, 2013;339(6121):823-6. doi: 10.1126/science.1232033. Epub Jan. 3, 2013.
Mandal et al., Riboswitches Control Fundamental Biochemical Pathways in Bacillus Subtilis and Other Bacteria. Cell. May 30, 2003;113(5):577-86. doi: 10.1016/s0092-8674(03)00391-x.
Mani et al., Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun. Sep. 23, 2005;335(2):447-57.
Marraffini et al., CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. Dec. 1, 20089;322(5909):1843-5. doi: 10.1126/science.1165771.
Mcdonald et al., Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics. Feb. 1, 1997;39(3):402-5. doi: 10.1006/geno.1996.4508.
McNaughton et al., Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Proc Natl Acad Sci U S A. Apr. 14, 2009;106(15):6111-6. doi: 10.1073/pnas.0807883106. Epub Mar. 23, 2009.
Meng et al., Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat Biotechnol. Jun. 2008;26(6):695-701. doi: 10.1038/nbt1398. Epub May 25, 2008.
Mercer et al., Chimeric TALE recombinases with programmable DNA sequence specificity. Nucleic Acids Res. Nov. 2012;40(21):11163-72. doi: 10.1093/nar/gks875. Epub Sep. 26, 2012.
Miller et al., A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. Feb. 2011;29(2):143-8. doi:10.1038/nbt.1755. Epub Dec. 22, 2010.
Miller et al., An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol. Jul. 2007;25(7):778-85. Epub Jul. 1, 2007.
Minoche et al., Evaluation of genomic high-throughput sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol. Nov. 8, 2011;12(11):R112. doi: 10.1186/gb-2011-12-11-r112.
Mojica et al., Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. Feb. 2005;60(2):174-82.
Mol et al., Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. Mar. 24, 1995;80(6):869-78. doi: 10.1016/0092-8674(95)90290-2.
Mol et al., Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA. Cell. Sep. 8, 1995;82(5):701-8.
Monahan et al., Site-specific incorporation of unnatural amino acids into receptors expressed in Mammalian cells. Chem Biol. Jun. 2003;10(6):573-80.
Moore et al., Improved somatic mutagenesis in zebrafish using transcription activator-like effector nucleases (TALENs). PloS One. 2012;7(5):e37877. Doi: 10.1371/journal.pone.0037877. Epub May 24, 2012.
Morbitzer et al., Assembly of custom TALE-type DNA binding domains by modular cloning. Nucleic Acids Res. Jul. 2011;39(13):5790-9. doi: 10.1093/nar/gkr151. Epub Mar. 18, 2011.
Moscou et al., A simple cipher governs DNA recognition by TAL effectors. Science. Dec. 11, 2009;326(5959):1501. doi: 10.1126/science.1178817.
Mullins et al., Transgenesis in nonmurine species. Hypertension. Oct. 1993;22(4):630-3.
Murphy, Phage recombinases and their applications. Adv Virus Res. 2012;83:367-414. doi: 10.1016/B978-0-12-394438-2.00008-6. Review.
Mussolino et al., A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res. Nov. 2011;39(21):9283-93. Doi: 10.1093/nar/gkr597. Epub Aug. 3, 2011.
Mussolino et al., TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol. Oct. 2012;23(5):644-50. doi: 10.1016/j.copbio.2012.01.013. Epub Feb. 17, 2012.
NCBI Reference Sequence: NM_002427.3. Wu et al., May 3, 2014. 5 pages.
Nelson et al., Filamentous phage DNA cloning vectors: a noninfective mutant with a nonpolar deletion in gene III. Virology. 1981; 108(2): 338-50.
Nguyen et al., IQ-TREE: a fast and effective stochastic algorithm for estimating maximum- likelihood phylogenies. Mol Biol Evol. Jan. 2015;32(1):268-74. doi: 10.1093/molbev/msu300. Epub Nov. 3, 2014.
Ni et al., A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52:76-86.
Nishimasu et al., Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. Feb. 27, 2014;156(5):935-49. doi: 10.1016/j.cell.2014.02.001. Epub Feb. 13, 2014.
Nomura et al., Controlling Mammalian Gene Expression by Allosteric Hepatitis Delta Virus Ribozymes. ACS Synth Biol. Dec. 20, 2013;2(12):684-9. doi: 10.1021/sb400037a. Epub May 22, 2013.
Nomura et al., Synthetic mammalian riboswitches based on guanine aptazyme. Chem Commun (Camb). Jul. 21, 2012;48(57):7215-7. doi: 10.1039/c2cc33140c. Epub Jun. 13, 2012.
O'Connell et al., Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature. Dec. 11, 2014;516(7530):263-6. doi: 10.1038/nature13769. Epub Sep. 29, 2014.
Oakes et al., Protein engineering of Cas9 for enhanced function. Methods Enzymol. 2014;546:491-511.
Olorunniji et al., Synapsis and catalysis by activated Tn3 resolvase mutants. Nucleic Acids Res. Dec. 2008;36(22):7181-91. doi: 10.1093/nar/gkn885. Epub Nov. 10, 2008.
Osborn et al., TALEN-based gene correction for epidermolysis bullosa. Mol Ther. Jun. 2013;21(6):1151-9. doi: 10.1038/mt.2013.56. Epub Apr. 2, 2013.
Pan et al., Biological and biomedical applications of engineered nucleases. Mol Biotechnol. Sep. 2013;55(1):54-62. doi: 10.1007/s12033-012-9613-9.
Parker et al., Admixture mapping identifies a quantitative trait locus associated with FEV1/FVC in the COPDGene Study. Genet Epidemiol. Nov. 2014;38(7):652-9. doi: 10.1002/gepi.21847. Epub Aug. 11, 2014.
Pattanayak et al., Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. Methods Enzymol. 2014;546:47-78. doi: 10.1016/B978-0-12-801185-0.00003-9.
Pattanayak et al., High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. Sep. 2013;31(9):839-43. doi: 10.1038/nbt.2673. Epub Aug. 11, 2013.
Pattanayak et al., Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods. Aug. 7, 2011;8(9):765-70. doi: 10.1038/nmeth.1670.
Pavletich et al., Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A. Science. May 10, 1991;252(5007):809-17.
Pearl, Structure and function in the uracil-DNA glycosylase superfamily. Mutat Res. Aug. 30, 2000;460(3-4):165-81.
Pennisi et al., The CRISPR craze. Science. Aug. 23, 2013;341(6148):833-6. doi: 10.1126/science.341.6148.833.
Pennisi et al., The tale of the TALEs. Science. Dec. 14, 2012;338(6113):1408-11. doi: 10.1126/science.338.6113.1408.
Perez et al., Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. Jul. 2008;26(7):808-16. Doi: 10.1038/nbt1410. Epub Jun. 29, 2008.
Perez-Pinera et al., Advances in targeted genome editing. Curr Opin Chem Biol. Aug. 2012; 16(3-4):268-77. doi: 10.1016/j.cbpa.2012.06.007. Epub Jul. 20, 2012.
Perez-Pinera et al., RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods. Oct. 2013;10(10):973-6. doi: 10.1038/nmeth.2600. Epub Jul. 25, 2013.
Phillips, The challenge of gene therapy and DNA delivery. J Pharm Pharmacol. Sep. 2001;53(9):1169-74.
Plasterk et al., DNA inversions in the chromosome of Escherichia coli and in bacteriophage Mu: relationship to other site-specific recombination systems. Proc Natl Acad Sci U S A. Sep. 1983;80(17):5355-8.
Pluciennik et al., PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair. Proc Natl Acad Sci U S A. Sep. 14, 2010;107(37):16066-71. doi: 10.1073/pnas.1010662107. Epub Aug. 16, 2010.
Porteus, Design and testing of zinc finger nucleases for use in mammalian cells. Methods Mol Biol. 2008;435:47-61. doi: 10.1007/978-1-59745-232-8_4.
Pourcel et al., CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology. Mar. 2005;151(Pt 3):653-63.
Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology 2013;31(9):833-8.
Prorocic et al., Zinc-finger recombinase activities in vitro. Nucleic Acids Res. Nov. 2011;39(21):9316-28. doi: 10.1093/nar/gkr652. Epub Aug. 17, 2011.
Putnam et al., Protein mimicry of DNA from crystal structures of the uracil-DNA glycosylase inhibitor protein and its complex with Escherichia coli uracil-DNA glycosylase. J Mol Biol. Mar. 26, 1999;287(2):331-46.
Qi et al., Engineering naturally occurring trans-acting non-coding RNAs to sense molecular signals. Nucleic Acids Res. Jul. 2012;40(12):5775-86. doi: 10.1093/nar/gks168. Epub Mar. 1, 2012.
Qi et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. Feb. 28, 2013;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022.
Rakonjac et al., Roles of PIII in filamentous phage assembly. J Mol Biol. 1998; 282(1)25-41.
Ramakrishna et al., Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. Jun. 2014;24(6):1020-7. doi: 10.1101/gr.171264.113. Epub Apr. 2, 2014.
Ramirez et al., Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res. Jul. 2012;40(12):5560-8. doi: 10.1093/nar/gks179. Epub Feb. 28, 2012.
Ramirez et al., Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods. May 2008;5(5):374-5. Doi: 10.1038/nmeth0508-374.
Ran et al., Double Nicking by RNA-guided CRISPR Cas9 for Enhanced Genome Editing Specificity. Cell. Sep. 12, 2013;154(6):1380-9. doi: 10.1016/j.cell.2013.08.021. Epub Aug. 29, 2013.
Ran et al., Genome engineering using the CRISPR-Cas9 system. Nat Protoc. Nov. 2013;8(11):2281-308. doi: 10.1038/nprot.2013.143. Epub Oct. 24, 2013.
Rath et al., Fidelity of end joining in mammalian episomes and the impact of Metnase on joint processing. BMC Mol Biol. Mar. 22, 2014;15:6. doi: 10.1186/1471-2199-15-6.
Ravishankar et al., X-ray analysis of a complex of Escherichia coli uracil DNA glycosylase (EcUDG) with a proteinaceous inhibitor. The structure elucidation of a prokaryotic UDG. Nuclei Acids Res. 26 (21): 4880-4887 (1998).
Ray et al., Homologous recombination: ends as the means. Trends Plant Sci. Oct. 2002;7(10):435-40.
Rebuzzini et al., New mammalian cellular systems to study mutations introduced at the break site by non-homologous end-joining. DNA Repair (Amst). May 2, 2005;4(5):546-55.
Relph et al., Recent developments and current status of gene therapy using viral vectors in the United Kingdom. BMJ. 2004;329(7470):839-842. doi:10.1136/bmj.329.7470.839.
Reynaud et al., What role for AID: mutator, or assembler of the immunoglobulin mutasome? Nat Immunol. Jul. 2003;4(7):631-8.
Richter et al., Function and regulation of clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR associated (Cas) systems. Viruses. Oct. 19, 2012;4(10):2291-311. doi: 10.3390/v4102291.
Riechmann et al., The C-terminal domain of TolA is the coreceptor for filamentous phage infection of E. coli. Cell. 1997; 90(2):351-60. PMID:9244308.
Robertson et al., DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol Life Sci. Mar. 2009;66(6):981-93. doi: 10.1007/s00018-009-8736-z.
Rong et al., Homologous recombination in human embryonic stem cells using CRISPR/Cas9 nickase and a long DNA donor template. Protein Cell. Apr. 2014;5(4):258-60. doi: 10.1007/s13238-014-0032-5.
Rongrong et al., Effect of deletion mutation on the recombination activity of Cre recombinase. Acta Biochim Pol. 2005;52(2):541-4. Epub May 15, 2005.
Rowland et al., Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. Mol Microbiol. Oct. 2009;74(2):282-98. doi: 10.1111/j.1365-2958.2009.06756.x. Epub Jun. 8, 2009.
Rudolph et al., Synthetic riboswitches for the conditional control of gene expression in Streptomyces coelicolor. Microbiology. Jul. 2013; 159(Pt 7):1416-22. doi: 10.1099/mic.0.067322-0. Epub May 15, 2013.
Sadelain et al., Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer. Dec. 1, 2011;12(1):51-8. doi: 10.1038/nrc3179.
Sale et al., Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol. Feb. 23, 2012;13(3):141-52. doi: 10.1038/nrm3289.
Samal et al., Cationic polymers and their therapeutic potential. Chem Soc Rev. Nov. 7, 2012;41(21):7147-94. doi: 10.1039/c2cs35094g. Epub Aug. 10, 2012.
Sander et al., CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. Apr. 2014;32(4):347-55. doi: 10.1038/nbt.2842. Epub Mar. 2, 2014.
Sander et al., In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. Nucleic Acids Res. Oct. 2013;41(19):e181. doi: 10.1093/nar/gkt716. Epub Aug. 14, 2013.
Sander et al., Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):697-8. doi: 10.1038/nbt.1934.
Sang, Prospects for transgenesis in the chick. Mech Dev. Sep. 2004;121(9):1179-86.
Sanjana et al., A transcription activator-like effector toolbox for genome engineering. Nat Protoc. Jan. 5, 2012;7(1):171-92. doi: 10.1038/nprot.2011.431.
Santiago et al., Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A. Apr. 15, 2008;105(15):5809-14. doi: 10.1073/pnas.0800940105. Epub Mar. 21, 2008.
Sapranauskas et al., The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. Nov. 2011;39(21):9275-82. doi: 10.1093/nar/gkr606. Epub Aug. 3, 2011.
Sapunar et al., Dorsal root ganglion—a potential new therapeutic target for neuropathic pain. J Pain Res. 2012;5:31-8. doi: 10.2147/JPR.S26603. Epub Feb. 16, 2012.
Saraconi et al., The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol. Jul. 3, 20141;15(7):417. doi: 10.1186/s13059-014-0417-z.
Sashital et al., Mechanism of foreign DNA selection in a bacterial adaptive immune system. Mol Cell. Jun. 8, 2012;46(5):606-15. doi: 10.1016/j.molcel.2012.03.020. Epub Apr. 19, 2012.
Saudek et al., A preliminary trial of the programmable implantable medication system for insulin delivery. N Engl J Med. Aug. 31, 1989;321(9):574-9.
Sauer et al., DNA recombination with a heterospecific Cre homolog identified from comparison of the pac-c1 regions of P1-related phages. Nucleic Acids Res. Nov. 18, 2004;32(20):6086-95. doi: 10.1093/nar/gkh941.
Savva et al., The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. Feb. 9, 1995;373(6514):487-93. doi: 10.1038/373487a0.
Schriefer et al., Low pressure DNA shearing: a method for random DNA sequence analysis. Nucleic Acids Res. Dec. 25, 1990;18(24):7455-6.
Schwank et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. Dec. 5, 2013;13(6):653-8. doi:10.1016/j.stem.2013.11.002.
Schwarze et al., In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. Sep. 3, 1999;285(5433):1569-72.
Sclimenti et al., Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res. Dec. 15, 2001;29(24):5044-51.
Sefton et al., Implantable pumps. Crit Rev Biomed Eng. 1987;14(3):201-40.
Segal et al., Toward controlling gene expression at will: selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target sequences. Proc Natl Acad Sci U S A. Mar. 16, 1999;96(6):2758-63.
Sells et al., Delivery of protein into cells using polycationic liposomes. Biotechniques. Jul. 1995;19(1):72-6, 78.
Semenova et al., Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc Natl Acad Sci U S A. Jun. 21, 2011;108(25):10098-103. doi: 10.1073/pnas.1104144108. Epub Jun. 6, 2011.
Seripa et al., The missing ApoE allele. Ann Hum Genet. Jul. 2007;71(Pt 4):496-500. Epub Jan. 22, 2007.
Shah et al., Inteins: nature's gift to protein chemists. Chem Sci. 2014;5(1):446-461.
Shah et al., Kinetic control of one-pot trans-splicing reactions by using a wild-type and designed split intein. Angew Chem Int Ed Engl. Jul. 11, 2011;50(29):6511-5. doi: 10.1002/anie.201102909. Epub Jun. 8, 2011.
Shaikh et al., Chimeras of the Flp and Cre recombinases: tests of the mode of cleavage by Flp and Cre. J Mol Biol. Sep. 8, 2000;302(1):27-48.
Shalem et al., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. Jan. 3, 2014;343(6166):84-7. doi: 10.1126/science.1247005. Epub Dec. 12, 2013.
Sharbeen et al., Ectopic restriction of DNA repair reveals that UNG2 excises AID-induced uracils predominantly or exclusively during G1 phase. J Exp Med. May 7, 2012;209(5):965-74. doi: 10.1084/jem.20112379. Epub Apr. 23, 2012.
Sharma et al., Efficient introduction of aryl bromide functionality into proteins in vivo. FEBS Lett. Feb. 4, 2000;467(1):37-40.
Shcherbakova et al., Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat Methods. Aug. 2013;10(8):751-4. doi: 10.1038/nmeth.2521. Epub Jun. 16, 2013.
Shee et al., Engineered proteins detect spontaneous DNA breakage in human and bacterial cells. Elife. Oct. 29, 2013;2:e01222. doi: 10.7554/eLife.01222.
Shen et al., Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. Nov. 2006;13(11):975-92. doi: 10.1038/sj.cgt.7700946. Epub Apr. 7, 2006.
Sheridan, First CRISPR-Cas patent opens race to stake out intellectual property. Nat Biotechnol. 2014;32(7):599-601.
Sheridan, Gene therapy finds its niche. Nat Biotechnol. Feb. 2011;29(2):121-8. doi: 10.1038/nbt.1769.
Shimojima et al., Spinocerebellar ataxias type 27 derived from a disruption of the fibroblast growth factor 14 gene with mimicking phenotype of paroxysmal non-kinesigenic dyskinesia. Brain Dev. Mar. 2012;34(3):230-3. doi: 10.1016/j.braindev.2011.04.014. Epub May 19, 2011.
Siebert et al., An improved PCR method for walking in uncloned genomic DNA. Nucleic Acids Res. Mar. 25, 1995;23(6):1087-8.
Simonelli et al., Base excision repair intermediates are mutagenic in mammalian cells. Nucleic Acids Res. Aug. 2, 2005;33(14):4404-11. Print 2005.
Sirk et al., Expanding the zinc-finger recombinase repertoire: directed evolution and mutational analysis of serine recombinase specificity determinants. Nucleic Acids Res. Apr. 2014;42(7):4755-66. doi: 10.1093/nar/gkt1389. Epub Jan. 21, 2014.
Sjoblom et al., The consensus coding sequences of human breast and colorectal cancers. Science. Oct. 13, 2006;314(5797):268-74. Epub Sep. 7, 2006.
Slupphaug et al., A nucleotide-flipping mechanism from the structure of human uracil-DNA glycosylase bound to DNA. Nature. Nov. 7, 1996;384(6604):87-92. doi: 10.1038/384087a0.
Smith et al., Diversity in the serine recombinases. Mol Microbiol. Apr. 2002;44(2):299-307. Review.
Smith et al., Expression of a dominant negative retinoic acid receptor γ in Xenopus embryos leads to partial resistance to retinoic acid. Roux Arch Dev Biol. Mar. 1994;203(5):254-265. doi: 10.1007/BF00360521.
Smith et al., Herpesvirus transport to the nervous system and back again. Annu Rev Microbiol. 2012;66:153-76. doi: 10.1146/annurev-micro-092611-150051. Epub Jun. 15, 2012.
Smith, Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. Jun. 14, 1985;228(4705):1315-7.
Steiner et al., The neurotropic herpes viruses: herpes simplex and varicella-zoster. Lancet Neurol. Nov. 2007;6(11):1015-28. doi: 10.1016/S1474-4422(07)70267-3.
Stenglein et al., APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. Feb. 2010;17(2):222-9. doi: 10.1038/nsmb.1744. Epub Jan. 10, 2010.
Stephens et al., The landscape of cancer genes and mutational processes in breast cancer. Nature Jun. 2012;486:400-404. doi: 10.1038/nature11017.
Sternberg et al., DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature.Mar. 6, 2014;507(7490):62-7. doi: 10.1038/nature13011. Epub Jan. 29, 2014.
Swarts et al., DNA-guided DNA interference by a prokaryotic Argonaute. Nature. Mar. 13, 2014;507(7491):258-61. doi: 10.1038/nature12971. Epub Feb. 16, 2014.
Swarts et al., The evolutionary journey of Argonaute proteins. Nat Struct Mol Biol. Sep. 2014;21(9):743-53. doi: 10.1038/nsmb.2879.
Szczepek et al., Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat Biotechnol. Jul. 2007;25(7):786-93. Epub Jul. 1, 2007.
Tagalakis et al., Lack of RNA-DNA oligonucleotide (chimeraplast) mutagenic activity in mouse embryos. Mol Reprod Dev. Jun. 2005;71(2):140-4.
Tebas et al., Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. Mar. 6, 2014;370(10):901-10. doi: 10.1056/NEJMoa1300662.
Teng et al., Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1). structure-function relationships of RNA editing and dimerization. J Lipid Res. Apr. 1999;40(4):623-35.
Tesson et al., Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol. Aug. 5, 2011;29(8):695-6. doi: 10.1038/nbt.1940.
Thorpe et al., Functional correction of episomal mutations with short DNA fragments and RNA-DNA oligonucleotides. J Gene Med. Mar.-Apr. 2002;4(2):195-204.
Thyagarajan et al., Mammalian genomes contain active recombinase recognition sites. Gene. Feb. 22, 2000;244(1-2):47-54.
Thyagarajan et al., Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol. Jun. 2001;21(12):3926-34.
Tirumalai et al., Recognition of core-type DNA sites by lambda integrase. J Mol Biol. Jun. 12, 1998;279(3):513-27.
Tourdot et al., A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol. Dec. 2000;30(12):3411-21.
Tsai et al., Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. Jun. 2014;32(6):569-76. doi: 10.1038/nbt.2908. Epub Apr. 25, 2014.
Turan et al., Recombinase-mediated cassette exchange (RMCE)—a rapidly-expanding toolbox for targeted genomic modifications. Gene. Feb. 15, 2013;515(1):1-27. doi: 10.1016/j.gene.2012.11.016. Epub Nov. 29, 2012.
Turan et al., Recombinase-mediated cassette exchange (RMCE): traditional concepts and current challenges. J Mol Biol. Mar. 25, 2011;407(2):193-221. doi: 10.1016/j.jmb.2011.01.004. Epub Jan. 15, 2011.
Turan et al., Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications. Faseb J. Dec. 2011;25(12):4088-107. doi: 10.1096/fj.11-186940. Epub Sep. 2, 2011. Review.
Urnov et al., Genome editing with engineered zinc finger nucleases. Nat Rev Genet. Sep. 2010;11(9):636-46. doi: 10.1038/nrg2842.
Urnov et al., Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. Jun. 2, 2005;435(7042):646-51. Epub Apr. 3, 2005.
Vagner et al., Efficiency of homologous DNA recombination varies along the Bacillus subtilis chromosome. J Bacteriol. Sep. 1988;170(9):3978-82.
Van Duyne et al., Teaching Cre to follow directions. Proc Natl Acad Sci U S A. Jan. 6, 2009;106(1):4-5. doi: 10.1073/pnas.0811624106. Epub Dec. 31, 2008.
Van Wijk et al., Identification of 51 novel exons of the Usher syndrome type 2A (USH2A) gene that encode multiple conserved functional domains and that are mutated in patients with Usher syndrome type II. Am J Hum Genet. Apr. 2004;74(4):738-44. doi: 10.1086/383096. Epub Mar. 10, 2004.
Vanamee et al., FokI requires two specific DNA sites for cleavage. J Mol Biol. May 25, 2001;309(1):69-78.
Venken et al., Genome-wide manipulations of Drosophila melanogaster with transposons, Flp recombinase, and ΦC31 integrase. Methods Mol Biol. 2012;859:203-28. doi: 10.1007/978-1-61779-603-6_12.
Verma, The reverse transcriptase. Biochim Biophys Acta. Mar. 21, 1977;473(1):1-38. doi: 10.1016/0304-419x(77)90005-1.
Wacey et al., Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53. Hum Genet. Jan. 1999; 104(1):15-22.
Wadia et al., Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci. Apr. 2003;4(2):97-104.
Wadia et al., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. Mar. 2004;10(3):310-5. Epub Feb. 8, 2004.
Wals et al., Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins. Front Chem. Apr. 1, 2014;2:15. doi: 10.3389/fchem.2014.00015. eCollection 2014.
Wang et al., Genetic screens in human cells using the CRISPR-Cas9 system. Science. Jan. 3, 2014;343(6166):80-4. doi: 10.1126/science.1246981. Epub Dec. 12, 2013.
Wang et al., Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature. Oct. 8, 2009;461(7265):754-61. doi: 10.1038/nature08434.
Wang et al., One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. May 9, 2013;153(4):910-8. doi: 10.1016/j.cell.2013.04.025. Epub May 2, 2013.
Wang et al., Recombinase technology: applications and possibilities. Plant Cell Rep. Mar. 2011;30(3):267-85. doi: 10.1007/s00299-010-0938-1. Epub Oct. 24, 2010.
Wang et al., Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res. Jul. 2012;22(7):1316-26. doi: 10.1101/gr.122879.111. Epub Mar. 20, 2012.
Wang et al., Uracil-DNA glycosylase inhibitor gene of bacteriophage PBS2 encodes a binding protein specific for uracil-DNA glycosylase. J Biol Chem. Jan. 15, 1989;264(2):1163-71.
Warren et al., A chimeric Cre recombinase with regulated directionality. Proc Natl Acad Sci USA. Nov. 25, 2008;105(47):18278-83. doi: 10.1073/pnas.0809949105. Epub Nov. 14, 2008.
Warren et al., Mutations in the amino-terminal domain of lambda-integrase have differential effects on integrative and excisive recombination. Mol Microbiol. Feb. 2005;55(4):1104-12.
Weber et al., Assembly of designer TAL effectors by Golden Gate cloning. PLoS One. 2011;6(5):e19722. doi: 10.1371/journal.pone.0019722. Epub May 19, 2011.
Weill et al., DNA polymerases in adaptive immunity. Nat Rev Immunol. Apr. 2008;8(4):302-12. doi: 10.1038/nri2281. Epub Mar. 14, 2008.
Weiss et al., Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature. Apr. 14, 2011;472(7342):186-90. doi: 10.1038/nature09975. Epub Mar. 23, 2011.
Wiedenheft et al., RNA-guided genetic silencing systems in bacteria and archaea. Nature. Feb. 15, 2012;482(7385):331-8. doi: 10.1038/nature10886. Review.
Wijesinghe et al., Efficient deamination of 5-methylcytosines in DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. Oct. 2012;40(18):9206-17. doi: 10.1093/nar/gks685. Epub Jul. 13, 2012.
Wijnker et al., Managing meiotic recombination in plant breeding. Trends Plant Sci. Dec. 2008;13(12):640-6. doi: 10.1016/j.tplants.2008.09.004. Epub Oct. 22, 2008.
Wilson et al., In Vitro Selection of Functional Nucleic Acids. Annu Rev Biochem. 1999;68:611-47. doi: 10.1146/annurev.biochem.68.1.611.
Winkler et al., Control of gene expression by a natural metabolite-responsive ribozyme. Nature. Mar. 18, 2004;428(6980):281-6.
Winkler et al., Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. Nature. Oct. 31, 2002;419(6910):952-6. Epub Oct. 16, 2002.
Wolf et al., tadA, an essential tRNA-specific adenosine deaminase from Escherichia coli. Embo J. Jul. 15, 2002;21(14):3841-51.
Wolfe et al., Analysis of zinc fingers optimized via phage display: evaluating the utility of a recognition code. J Mol Biol. Feb. 5, 1999;285(5):1917-34.
Wood et al., A genetic system yields self-cleaving inteins for bioseparations. Nat Biotechnol. Sep. 1999;17(9):889-92. doi: 10.1038/12879.
Woods et al., The phenotype of congenital insensitivity to pain due to the NaV1.9 variant p.L811P. Eur J Hum Genet. May 2015;23(5):561-3. doi: 10.1038/ejhg.2014.166. Epub Aug. 13, 2014.
Wu et al., Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell. Dec. 5, 2013;13(6):659-62. doi: 10.1016/j.stem.2013.10.016.
Wu et al., Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol. Jul. 2014;32(7):670-6. doi: 10.1038/nbt.2889. Epub Apr. 20, 2014.
Yamamoto et al., Virological and immunological bases for HIV-1 vaccine design. Uirusu 2007;57(2):133-139. https://doi.org/10.2222/jsv.57.133.
Yang et al., Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. Mar. 2004;41(3):171-4. doi: 10.1136/jmg.2003.012153.
Yang, Development of Human Genome Editing Tools for the Study of Genetic Variations and Gene Therapies. Doctoral Dissertation. Harvard University. 2013. Accessible via nrs.harvard.edu/urn-3:HUL.InstRepos:11181072. 277 pages.
Yang, Nucleases: diversity of structure, function and mechanism. Q Rev Biophys. Feb. 2011;44(1):1-93. doi: 10.1017/S0033583510000181. Epub Sep. 21, 2010.
Yanover et al., Extensive protein and DNA backbone sampling improves structure-based specificity prediction for C2H2 zinc fingers. Nucleic Acids Res. Jun. 2011;39(11):4564-76. doi: 10.1093/nar/gkr048. Epub Feb. 22, 2011.
Yasui, Alternative excision repair pathways. Cold Spring Harb Perspect Biol. Jun. 1, 2013;5(6):a012617. doi: 10.1101/cshperspect.a012617.
Yin et al., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. Jun. 2014;32(6):551-3. doi: 10.1038/nbt.2884. Epub Mar. 30, 2014.
Young et al., Beyond the canonical 20 amino acids: expanding the genetic lexicon. J Biol Chem. Apr. 9, 2010;285(15):11039-44. doi: 10.1074/jbc.R109.091306. Epub Feb. 10, 2010.
Yu et al., Progress towards gene therapy for HIV infection. Gene Ther. Jan. 1994;1(1):13-26.
Yuan et al., Laboratory-directed protein evolution. Microbiol Mol Biol Rev. 2005; 69(3):373-92. PMID: 16148303.
Yuan et al., Tetrameric structure of a serine integrase catalytic domain. Structure. Aug. 6, 2008;16(8):1275-86. doi: 10.1016/j.str.2008.04.018.
Yuen et al., Control of transcription factor activity and osteoblast differentiation in mammalian cells using an evolved small-molecule-dependent intein. J Am Chem Soc. Jul. 12, 2006;128(27):8939-46.
Zelphati et al., Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem. Sep. 14, 2001;276(37):35103-10. Epub Jul. 10, 2001.
Zhang et al., Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells. Sci Rep. Jun. 2014;4:5405.
Zhang et al., Conditional gene manipulation: Cre-ating a new biological era. J Zhejiang Univ Sci B. Jul. 2012;13(7):511-24. doi: 10.1631/jzus.B1200042. Review.
Zhang et al., CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. Sep. 15, 2014;23(R1):R40-6. doi: 10.1093/hmg/ddu125. Epub Mar. 20, 2014.
Zhang et al., Ribozymes and Riboswitches: Modulation of RNA Function by Small Molecules. Biochemistry. Nov. 2, 2010;49(43):9123-31. doi: 10.1021/bi1012645.
Zhang et al., Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther. Aug. 1999;6(8):1438-47.
Zou et al., Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. Jul. 2, 2009;5(1):97-110. doi: 10.1016/j.stem.2009.05.023. Epub Jun. 18, 2009.
[No Author Listed], Mus musculus (Mouse). UniProtKB Accession No. P51908 (ABEC1_MOUSE). Oct. 1, 1996. 10 pages.
Asokan et al., The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. Apr. 2012;20(4):699-708. doi: 10.1038/mt.2011.287. Epub Jan. 24, 2012.
Auricchio et al., Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet. Dec. 15, 2001;10(26):3075-81. doi: 10.1093/hmg/10.26.3075.
Baba et al., Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006;2:2006.0008. doi: 10.1038/msb4100050. Epub Feb. 21, 2006.
Badran et al., In vivo continuous directed evolution. Curr Opin Chem Biol. Feb. 2015;24:1- 10. doi: 10.1016/j.cbpa.2014.09.040. Epub Nov. 7, 2014.
Bae et al., Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. May 15, 2014;30(10):1473-5. doi: 10.1093/bioinformatics/btu048. Epub Jan. 24, 2014.
Bagal et al., Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. Aug. 15, 2014;24(16):3690-9. doi: 10.1016/j.bmcl.2014.06.038. Epub Jun. 21, 2014.
Barmania et al., C—C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection. Appl Transl Genom. May 26, 2013;2:3-16. doi: 10.1016/j.atg.2013.05.004.
Bass, B.L., RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem. 2002;71:817-46. doi: 10.1146/annurev.biochem.71.110601.135501. Epub Nov. 9, 2001.
Beaudry et al., Directed evolution of an RNA enzyme. Science. Jul. 31, 1992;257(5070):635- 41. doi: 10.1126/science.1496376.
Bell et al., Ribozyme-catalyzed excision of targeted sequences from within RNAs. Biochemistry. Dec. 24, 2002;41(51):15327-33. doi: 10.1021/bi0267386.
Bentin, T., A ribozyme transcribed by a ribozyme. Artif DNA PNA XNA. Apr. 2011;2(2):40- 42. doi: 10.4161/adna.2.2.16852.
Bibikova et al., Targeted chromosomal cleavage and mutagenesis in Drosophila using zinc-finger nucleases. Genetics. Jul. 2002;161(3):1169-75. doi: 10.1093/genetics/161.3.1169.
Blauw et al., SMN1 gene duplications are associated with sporadic ALS. Neurology. Mar. 13, 2012;78(11):776-80. doi: 10.1212/WNL.0b013e318249f697. Epub Feb. 8, 2012.
Brierley et al., Viral RNA pseudoknots: versatile motifs in gene expression and replication. Nat Rev Microbiol. Aug. 2007;5(8):598-610. doi: 10.1038/nrmicro1704.
Brutlag et al., Improved sensitivity of biological sequence database searches. Comput Appl Biosci. Jul. 1990;6(3):237-45. doi: 10.1093/bioinformatics/6.3.237.
Cao et al., Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. Jun. 29, 2011;3(89):89ra58. doi: 10.1126/scitranslmed.3002346.
Carlier et al., Genome Sequence of Burkholderia cenocepacia H111, a Cystic Fibrosis Airway Isolate. Genome Announc. Apr. 10, 2014;2(2):e00298-14. doi: 10.1128/genomeA.00298-14.
Cartegni et al., Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet. Jan. 2006;78(1):63-77. doi: 10.1086/498853. Epub Nov. 16, 2005.
Chang et al., Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int. Dec. 2004;45(7):1107-12. doi: 10.1016/j.neuint.2004.04.005.
Chavez et al., Therapeutic applications of the PhiC31 integrase system. Curr Gene Ther. Oct. 2011;11(5):375-81. Review.
Chen et al., Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol. May 2003;22(5):1033-43.
Cho et al., A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev. Mar. 1, 2010;24(5):438-42. doi: 10.1101/gad.1884910.
Choi et al., Translesion synthesis across abasic lesions by human B-family and Y-family DNA polymerases α, δ, η, ι, κ, and REV1. J Mol Biol. Nov. 19, 2010;404(1):34-44. doi: 10.1016/j.jmb.2010.09.015. Epub Oct. 1, 2010.
Corcia et al., The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral Scler. Oct.-Dec. 2009;10(5-6):436-40. doi: 10.3109/17482960902759162.
Corti et al., Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. Sci Transl Med. Dec. 19, 2012;4(165):165ra162. doi: 10.1126/scitranslmed.3004108.
Cucchiarini et al., Enhanced expression of the central survival of motor neuron (SMN) protein during the pathogenesis of osteoarthritis. J Cell Mol Med. Jan. 2014;18(1):115-24. doi: 10.1111/jcmm.12170. Epub Nov. 17, 2013.
Davis et al., Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. Proc Natl Acad Sci U S A. Mar. 11, 2014;111(10):E924-32. doi: 10.1073/pnas.1400236111. Epub Feb. 20, 2014.
De Sandre-Giovannoli et al., Lamin a truncation in Hutchinson-Gilford progeria. Science. Jun. 27, 2003;300(5628):2055. doi: 10.1126/science.1084125. Epub Apr. 17, 2003.
Dickinson et al., A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. Oct. 30, 2014;5:5352. doi: 10.1038/ncomms6352.
Dolan et al., Trans-splicing with the group I intron ribozyme from Azoarcus. RNA. Feb. 2014;20(2):202-13. doi: 10.1261/rna.041012.113. Epub Dec. 16, 2013.
Drenth et al., Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest. Dec. 2007;117(12):3603-9. doi: 10.1172/JCI33297.
Drost et al., Inactivation of DNA mismatch repair by variants of uncertain significance in the PMS2 gene. Hum Mutat. Nov. 2013;34(11):1477-80. doi: 10.1002/humu.22426. Epub Sep. 11, 2013.
Duan et al., Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol. Aug. 2001;75(16):7662-71. doi: 10.1128/JVI.75.16.7662-7671.2001.
Ekstrand et al., Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. Jun. 2010;9(2):125-9. doi: 10.1007/s10689-009-9293-1.
Entin-Meer et al., The role of phenylalanine-119 of the reverse transcriptase of mouse mammary tumour virus in DNA synthesis, ribose selection and drug resistance. Biochem J. Oct. 15, 2002;367(Pt 2):381-91. doi: 10.1042/BJ20020712.
Friedman, J. H., Greedy function approximation: A gradient boosting machine. Ann. Statist. Oct. 2001;29(5):1189-232. doi: 10.1214/aos/1013203451.
Genbank Submission; NIH/NCBI Accession No. 4UN5_B. Anders et al., Jul. 23, 2014. 5 pages.
Genbank Submission; NIH/NCBI, Accession No. AIT42264.1. Hyun et al., Oct. 15, 2014. 2 pages.
Genbank Submission; NIH/NCBI, Accession No. WP_002989955.1. No Author Listed, May 6, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_010922251.1. No Author Listed, May 15, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_011054416.1. No Author Listed, May 15, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_011284745.1. No Author Listed, May 16, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_011285506.1. No Author Listed, May 16, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_011527619.1. No Author Listed, May 16, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_012560673.1. No Author Listed, May 17, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_014407541.1. No Author Listed, May 18, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_020905136.1. No Author Listed, Jul. 25, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_023080005.1. No Author Listed, Oct. 27, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_023610282.1. No Author Listed, Nov. 27, 2013. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_030125963.1. No Author Listed, Jul. 9, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_030126706.1. No Author Listed, Jul. 9, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_031488318.1. No Author Listed., Aug. 5, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_032460140.1. No Author Listed, Oct. 4, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_032461047.1. No Author Listed, Oct. 4, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_032462016.1. Haft et al., Oct. 4, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_032462936.1. No Author Listed, Oct. 4, 2014. 1 page.
Genbank Submission; NIH/NCBI, Accession No. WP_032464890.1. No Author Listed, Oct. 4, 2014. 1 page.
Grati et al., Localization of PDZD7 to the stereocilia ankle-link associates this scaffolding protein with the Usher syndrome protein network. J Neurosci. Oct. 10, 2012;32(41):14288-93. doi: 10.1523/JNEUROSCI.3071-12.2012.
Guo et al., Evolution of Tetrahymena ribozyme mutants with increased structural stability. Nat Struct Biol. Nov. 2002;9(11):855-61. doi: 10.1038/nsb850.
Halbert et al., Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol. Feb. 2000;74(3):1524-32. doi: 10.1128/jvi.74.3.1524-1532.2000.
Hardt et al.,Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. Fam Cancer. Jun. 2011;10(2):273-84. doi: 10.1007/s10689-011-9431-4.
Hawley-Nelson et al., Transfection of Cultured Eukaryotic Cells Using Cationic Lipid Reagents. Curr Prot Mol Biol. Jan. 2008;9.4.1-9.4.17. doi: 10.102/0471142727.mb0904s81. 17 pages.
Heyer et al., Regulation of homologous recombination in eukaryotes. Annu Rev Genet. 2010;44:113-39. doi: 10.1146/annurev-genet-051710-150955. Author Manuscript. 33 pages.
Hilbers et al., New developments in structure determination of pseudoknots. Biopolymers. 1998;48(2-3):137-53. doi: 10.1002/(SICI)1097-0282(1998)48:2<137::AID-BIP4>3.0.CO;2-H.
Huang et al., Gain-of-function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain. Jun. 2014;137(Pt 6):1627-42. doi: 10.1093/brain/awu079. Epub Apr. 27, 2014.
Isaacs et al., Engineered riboregulators enable post-transcriptional control of gene expression. Nat Biotechnol. Jul. 2004;22(7):841-7. doi: 10.1038/nbt986. Epub Jun. 20, 2004.
Iyama et al., DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst). Aug. 2013;12(8):620-36. doi: 10.1016/j.dnarep.2013.04.015. Epub May 16, 2013.
Johnson et al., Trans insertion-splicing: ribozyme-catalyzed insertion of targeted sequences into RNAs. Biochemistry. Aug. 9, 2005;44(31):10702-10. doi: 10.1021/bi0504815.
Kim et al., RAD51 mutants cause replication defects and chromosomal instability. Mol Cell Biol. Sep. 2012;32(18):3663-80. doi: 10.1128/MCB.00406-12. Epub Jul. 9, 2012.
King et al., No gain, no pain: NaV1.7 as an analgesic target. ACS Chem Neurosci. Sep. 17, 2014;5(9):749-51. doi: 10.1021/cn500171p. Epub Aug. 11, 2014.
Konishi et al., Amino acid substitutions away from the RNase H catalytic site increase the thermal stability of Moloney murine leukemia virus reverse transcriptase through RNase H inactivation. Biochem Biophys Res Commun. Nov. 14, 2014;454(2):269-74. doi: 10.1016/j.bbrc.2014.10.044. Epub Oct. 17, 2014.
Kumar et al., Gene therapy for chronic neuropathic pain: how does it work and where do we stand today? Pain Med. May 2011;12(5):808-22. doi: 10.1111/j.1526-4637.2011.01120.x.
Langer et al., Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review. J Macromol Sci, Part C, 1983;23(1):61-126. doi: 10.1080/07366578308079439.
Le et al., SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet. Mar. 15, 2005;14(6):845-57. doi: 10.1093/hmg/ddi078. Epub Feb. 9, 2005.
Lee et al., A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. Cell. Jun. 5, 2014;157(6):1393-1404. doi: 10.1016/j.cell.2014.03.064. Epub May 22, 2014. Retraction in: Cell. Jun. 25, 2020;181(7):1695.
Lefebvre et al., Identification and characterization of a spinal muscular atrophy-determining gene. Cell. Jan. 13, 1995;80(1):155-65. doi: 10.1016/0092-8674(95)90460-3.
Lesinski et al., The potential for targeting the STAT3 pathway as a novel therapy for melanoma. Future Oncol. Jul. 2013;9(7):925-7. doi: 10.2217/fon.13.83. Author Manuscript. 4 pages.
Lin et al., [Construction and evaluation of DnaB split intein high expression vector and a six amino acids cyclic peptide library]. Sheng Wu Gong Cheng Xue Bao. Nov. 2008;24(11):1924-30. Chinese.
Lindahl, T., Instability and decay of the primary structure of DNA. Nature. Apr. 22, 1993;362(6422):709-15. doi: 10.1038/362709a0.
Liu et al., Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol. Oct. 2010; 17(10):1260-2. doi: 10.1038/nsmb.1904. Epub Aug. 22, 2010.
Liu et al., Usherin is required for maintenance of retinal photoreceptors and normal development of cochlear hair cells. Proc Natl Acad Sci U S A. Mar. 13, 2007;104(11):4413-8. doi: 10.1073/pnas.0610950104. Epub Mar. 5, 2007.
Lorson et al., A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. May 25, 1999;96(11):6307-11. doi: 10.1073/pnas.96.11.6307.
Lutz et al., Postsymptomatic restoration of SMN rescues the disease phenotype in a mouse model of severe spinal muscular atrophy. J Clin Invest. Aug. 2011;121(8):3029-41. doi: 10.1172/JCI57291. Epub Jul. 25, 2011.
Maerker et al., A novel Usher protein network at the periciliary reloading point between molecular transport machineries in vertebrate photoreceptor cells. Hum Mol Genet. Jan. 1, 2008;17(1):71-86. doi: 10.1093/hmg/ddm285. Epub Sep. 28, 2007.
Marcovitz et al., Frustration in protein-DNA binding influences conformational switching and target search kinetics. Proc Natl Acad Sci U S A. Nov. 1, 2011;108(44):17957-62. doi: 10.1073/pnas.1109594108. Epub Oct. 14, 2011.
Martz, L., Nav-i-gating antibodies for pain. Science-Business eXchange. Jun. 12, 2014;7(662):1-2. doi: 10.1038/scibx.2014.662.
Monani et al., A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet. Jul. 1999;8(7):1177-83. doi: 10.1093/hmg/8.7.1177.
Mootz et al., Protein splicing triggered by a small molecule. J Am Chem Soc. Aug. 7, 2002;124(31):9044-5 and Supporting Information. doi: 10.1021/ja0267690. 4 pages.
Murray et al., Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet. Apr. 1, 2008;17(7):949-62. doi: 10.1093/hmg/ddm367. Epub Dec. 8, 2007.
Nelson et al., The unstable repeats—three evolving faces of neurological disease. Neuron. Mar. 6, 2013;77(5):825-43. doi: 10.1016/j.neuron.2013.02.022.
Passini et al., Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med. Mar. 2, 2011;3(72):72ra18. doi: 10.1126/scitranslmed.3001777.
Pellegrini et al., Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature. Nov. 21, 2002;420(6913):287-93. doi: 10.1038/nature01230. Epub Nov. 10, 2002.
Perreault et al., Mixed deoxyribo- and ribo-oligonucleotides with catalytic activity. Nature. Apr. 5, 1990;344(6266):565-7. doi: 10.1038/344565a0.
Pieken et al., Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science. Jul. 19, 1991;253(5017):314-7. doi: 10.1126/science.1857967.
Porensky et al., A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet. Apr. 1, 2012;21(7):1625-38. doi: 10.1093/hmg/ddr600. Epub Dec. 20, 2011.
Prasad et al., Visualizing the assembly of human Rad51 filaments on double-stranded DNA. J Mol Biol. Oct. 27, 2006;363(3):713-28. doi: 10.1016/j.jmb.2006.08.046. Epub Aug. 22, 2006.
Raillard et al., Targeting sites within HIV-1 cDNA with a DNA-cleaving ribozyme. Biochemistry. Sep. 10, 1996;35(36):11693-701. doi: 10.1021/bi960845g.
Reiners et al., Scaffold protein harmonin (USH1C) provides molecular links between Usher syndrome type 1 and type 2. Hum Mol Genet. Dec. 15, 2005;14(24):3933-43. doi: 10.1093/hmg/ddi417. Epub Nov. 21, 2005.
Richardson et al., Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. Jun. 8, 2000;405(6787):697-700. doi: 10.1038/35015097.
Robertson et al., Selection in vitro of an RNA enzyme that specifically cleaves single- stranded DNA. Nature. Mar. 29, 1990;344(6265):467-8. doi: 10.1038/344467a0.
San Filippo et al., Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229-57. doi: 10.1146/annurev.biochem.77.061306.125255.
Schlacher et al., Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. May 13, 2011;145(4):529-42. doi: 10.1016/j.cell.2011.03.041. Erratum in: Cell. Jun. 10, 2011;145(6):993.
Schrank et al., Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA. Sep. 2, 1997;94(18):9920-5. doi: 10.1073/pnas.94.18.9920.
Sharma et al., Identification of novel methyltransferases, Bmt5 and Bmt6, responsible for the m3U methylations of 25S rRNA in Saccharomyces cerevisiae. Nucleic Acids Res. Mar. 2014;42(5):3246-60. doi: 10.1093/nar/gkt1281. Epub Dec. 11, 2013.
Shen et al., Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. Apr. 2014; 11(4):399-402. doi: 10.1038/nmeth.2857. Epub Mar. 2, 2014.
Singh et al., Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol. Feb. 2006;26(4):1333-46. doi: 10.1128/MCB.26.4.1333-1346.2006.
Stark et al., ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J Biol Chem. Jun. 7, 2002;277(23):20185-94. doi: 10.1074/jbc.M112132200. Epub Mar. 28, 2002.
Sullenger et al., Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature. Oct. 13, 1994;371(6498):619-22. doi: 10.1038/371619a0.
Talbot et al., Spinal muscular atrophy. Semin Neurol. Jun. 2001;21(2):189-97. doi: 10.1055/s-2001-15264.
Trojan et al., Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. Gastroenterology. Jan. 2002;122(1):211-9. doi: 10.1053/gast.2002.30296.
Usman et al., Exploiting the chemical synthesis of RNA. Trends Biochem Sci. Sep. 1992;17(9):334-9. doi: 10.1016/0968-0004(92)90306-t.
Vidal et al., Yeast forward and reverse ‘n’-hybrid systems. Nucleic Acids Res. Feb. 15, 1999;27(4):919-29. doi: 10.1093/nar/27.4.919.
Wills et al., Pseudoknot-dependent read-through of retroviral gag termination codons: importance of sequences in the spacer and loop 2. EMBO J. Sep. 1, 1994;13(17):4137-44. doi: 10.1002/j.1460-2075.1994.tb06731.x.
Wirth et al., Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. May 2006;119(4):422-8. doi: 10.1007/s00439-006-0156-7. Epub Mar. 1, 2006.
Wu et al., A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PLoS One. 2013;8(1):e55212. doi: 10.1371/journal.pone.0055212. Epub Jan. 31, 2013. 15 pages.
Yamane et al., Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat Immunol. Jan. 2011;12(1):62-9. doi: 10.1038/ni.1964. Epub Nov. 28, 2010.
Yang et al., BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science. Sep. 13, 2002;297(5588):1837-48. doi: 10.1126/science.297.5588.1837.
Yang et al., The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature. Feb. 10, 2005;433(7026):653-7. doi: 10.1038/nature03234.
Yu et al., Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. Mol Cell. Oct. 2003;12(4):1029-41. doi: 10.1016/s1097-2765(03)00394-0.
Zhang et al., Global analysis of small RNA and mRNA targets of Hfq. Mol Microbiol. Nov. 2003;50(4):1111-24. doi: 10.1046/j.1365-2958.2003.03734.x.
Zhou et al., GISSD: Group I Intron Sequence and Structure Database. Nucleic Acids Res. Jan. 2008;36(Database issue):D31-7. doi: 10.1093/nar/gkm766. Epub Oct. 16, 2007.
Zolotukhin et al., Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods. Oct. 2002;28(2):158-67. doi: 10.1016/s1046-2023(02)00220-7.
[No Author Listed], MutL homolog 1. UniProtKB Acc. No. F1MPG0. May 3, 2011. Accessible at https://rest.uniprot.org/unisave/F1MPG0?format=txt&versions=1. 1 page.
Acharya et al., hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A. Nov. 26, 1996;93(24):13629-34. doi: 10.1073/pnas.93.24.13629.
Bertsimas et al., Simulated annealing. Statistical Science. Feb. 1993;8(1):10-15. doi: 10.1214/ss/1177011077.
Chen et al., Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. Dec. 19, 2013;155(7):1479-91. doi: 10.1016/j.cell.2013.12.001. Erratum in: Cell. Jan. 16, 2014;156(1-2):373.
Fang et al., Human strand-specific mismatch repair occurs by a bidirectional mechanism similar to that of the bacterial reaction. J Biol Chem. Jun. 5, 1993;268(16):11838-44.
Feng et al., Efficient genome editing in plants using a CRISPR/Cas system. Cell Res. Oct. 2013;23(10):1229-32. doi: 10.1038/cr.2013.114. Epub Aug. 20, 2013.
Fishel et al., The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. Dec. 3, 1993;75(5):1027-38. doi: 10.1016/0092-8674(93)90546-3. Erratum in: Cell. Apr. 8, 1994;77(1):1 p following 166.
Fu et al., Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Methods Enzymol. 2014;546:21-45. doi: 10.1016/B978-0-12-801185-0.00002-7.
Geisberg et al., Global analysis of mRNA isoform half-lives reveals stabilizing and destabilizing elements in yeast. Cell. Feb. 13, 2014;156(4):812-24. doi: 10.1016/j.cell.2013.12.026.
Geng et al., In vitro studies of DNA mismatch repair proteins. Anal Biochem. Jun. 15, 2011;413(2):179-84. doi: 10.1016/j.ab.2011.02.017. Epub Feb. 15, 2011.
Genschel et al., Human exonuclease I is required for 5′ and 3′ mismatch repair. J Biol Chem. Apr. 12, 2002;277(15):13302-11. doi: 10.1074/jbc.M111854200. Epub Jan. 24, 2002.
Genschel et al., Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha. J Biol Chem. Jul. 31, 1998;273(31):19895-901. doi: 10.1074/jbc.273.31.19895. Erratum in: J Biol Chem Oct. 9, 1998;273(41):27034.
Green et al., Characterization of the mechanical unfolding of RNA pseudoknots. J Mol Biol. Jan. 11, 2008;375(2):511-28. doi: 10.1016/j.jmb.2007.05.058. Epub May 26, 2007.
Gueneau et al., Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site. Nat Struct Mol Biol. Apr. 2013;20(4):461-8. doi: 10.1038/nsmb.2511. Epub Feb. 24, 2013.
Guerrette et al., The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer. J Biol Chem. Mar. 5, 1999;274(10):6336-41. doi: 10.1074/jbc.274.10.6336.
Gupta et al., Mechanism of mismatch recognition revealed by human MutSβ bound to unpaired DNA loops. Nat Struct Mol Biol. Dec. 18, 2011;19(1):72-8. doi: 10.1038/nsmb.2175.
Houck-Loomis et al., An equilibrium-dependent retroviral mRNA switch regulates translational recoding. Nature. Nov. 27, 2011;480(7378):561-4. doi: 10.1038/nature10657.
Houseley et al., The many pathways of RNA degradation. Cell. Feb. 20, 2009;136(4):763-76. doi: 10.1016/j.cell.2009.01.019.
Iaccarino et al., hMSH2 and hMSH6 play distinct roles in mismatch binding and contribute differently to the ATPase activity of hMutSalpha. Embo J. May 1, 1998;17(9):2677-86. doi: 10.1093/emboj/17.9.2677.
Ibrahim et al., RNA recognition by 3′-to-5′ exonucleases: the substrate perspective. Biochim Biophys Acta. Apr. 2008;1779(4):256-65. doi: 10.1016/j.bbagrm.2007.11.004. Epub Dec. 3, 2007.
Iyer et al., DNA mismatch repair: functions and mechanisms. Chem Rev. Feb. 2006;106(2):302-23. doi: 10.1021/cr0404794.
Kadyrov et al., Endonucleolytic function of MutLalpha in human mismatch repair. Cell. Jul. 28, 2006;126(2):297-308. doi: 10.1016/j.cell.2006.05.039.
Kunkel et al., DNA mismatch repair. Annu Rev Biochem. 2005;74:681-710. doi: 10.1146/annurev.biochem.74.082803.133243.
Lahue et al., DNA mismatch correction in a defined system. Science. Jul. 14, 1989 ;245(4914):160-4. doi: 10.1126/science.2665076.
Leach et al., Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. Dec. 17, 1993;75(6):1215-25. doi: 10.1016/0092-8674(93)90330-s.
Lujan et al., Heterogeneous polymerase fidelity and mismatch repair bias genome variation and composition. Genome Res. Nov. 2014;24(11):1751-64. doi: 10.1101/gr.178335.114. Epub Sep. 12, 2014.
Mali et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. Sep. 2013;31(9):833-8, Supplemental Info. doi: 10.1038/nbt.2675. Epub Aug. 1, 2013.
Micozzi et al., Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol. Feb. 2014;63:64-74. doi: 10.1016/j.ijbiomac.2013.10.029. Epub Oct. 29, 2013. Erratum in: Int J Biol Macromol. Feb. 2014;63:262.
Millevoi et al., G-quadruplexes in RNA biology. Wiley Interdiscip Rev RNA. Jul.-Aug. 2012;3(4):495-507. doi: 10.1002/wrna. 1113. Epub Apr. 4, 2012.
Pandey et al., Effect of loops and G-quartets on the stability of RNA G-quadruplexes. J Phys Chem B. Jun. 13, 2013;117(23):6896-905. doi: 10.1021/jp401739m. Epub May 29, 2013. Supplementary Information, 21 pages.
Parsons et al., Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. Dec. 17, 1993;75(6):1227-36. doi: 10.1016/0092-8674(93)90331-j.
Petit et al., Powerful mutators lurking in the genome. Philos Trans R Soc Lond B Biol Sci. Mar. 12, 2009;364(1517):705-15. doi: 10.1098/rstb.2008.0272.
Piotukh et al., Directed evolution of sortase A mutants with altered substrate selectivity profiles. J Am Chem Soc. Nov. 9, 2011;133(44):17536-9. doi: 10.1021/ja205630g. Epub Oct. 13, 2011.
Plotz et al., N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalpha. Nucleic Acids Res. Jun. 15, 2003;31(12):3217-26. doi: 10.1093/nar/gkg420.
Räschle et al., Mutations within the hMLH1 and hPMS2 subunits of the human MutLalpha mismatch repair factor affect its ATPase activity, but not its ability to interact with hMutSalpha. J Biol Chem. Jun. 14, 2002;277(24):21810-20. doi: 10.1074/jbc.M108787200. Epub Apr. 10, 2002.
Shcherbakova et al., Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations. Mol Cell Biol. Apr. 1999;19(4):3177-83. doi: 10.1128/MCB.19.4.3177.
Strand et al., Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature. Sep. 16, 1993;365(6443):274-6. doi: 10.1038/365274a0. Erratum in: Nature Apr. 7, 1994;368(6471);569.
Su et al., Mispair specificity of methyl-directed DNA mismatch correction in vitro. J Biol Chem. May 15, 1988;263(14):6829-35. Erratum in: J Biol Chem Aug. 5, 1988;263(22):11015.
Sugawara et al., Heteroduplex rejection during single-strand annealing requires Sgs1 helicase and mismatch repair proteins Msh2 and Msh6 but not Pms1. Proc Natl Acad Sci U S A. Jun. 22, 2004;101(25):9315-20. doi: 10.1073/pnas.0305749101. Epub Jun. 15, 2004.
Thomas et al., Heteroduplex repair in extracts of human HeLa cells. J Biol Chem. Feb. 25, 1991;266(6):3744-51.
Tomer et al., Contribution of human mlh1 and pms2 ATPase activities to DNA mismatch repair. J Biol Chem. Jun. 14, 2002;277(24):21801-9. doi: 10.1074/jbc.M111342200. Epub Mar. 15, 2002.
Tran et al., Hypermutability of homonucleotide runs in mismatch repair and DNA polymerase proofreading yeast mutants. Mol Cell Biol. May 1997;17(5):2859-65. doi: 10.1128/MCB.17.5.2859.
Umar et al., DNA loop repair by human cell extracts. Science. Nov. 4, 1994;266(5186):814-6. doi: 10.1126/science.7973637.
Warren et al., Structure of the human MutSalpha DNA lesion recognition complex. Mol Cell. May 25, 2007;26(4):579-92. doi: 10.1016/j.molcel.2007.04.018.
Wu et al., MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors. Biomaterials. Sep. 2014;35(29):8416-26. doi: 10.1016/j.biomaterials.2014.06.006. Epub Jul. 3, 2014.
Yi et al., Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries. Proc Natl Acad Sci U S A. Apr. 30, 2013;110(18):7229-34. doi: 10.1073/pnas.1215994110. Epub Apr. 15, 2013.
Zhang et al., Reconstitution of 5′-directed human mismatch repair in a purified system. Cell. Sep. 9, 2005;122(5):693-705. doi: 10.1016/j.cell.2005.06.027.
U.S. Appl. No. 17/289,665, filed Apr. 28, 2021, Liu et al.
U.S. Appl. No. 16/756,432, filed Apr. 15, 2020, Liu et al.
U.S. Appl. No. 18/460,178, filed Sep. 1, 2023, Liu et al.
U.S. Appl. No. 16/772,747, filed Jun. 12, 2020, Shen et al.
U.S. Appl. No. 17/425,261, filed Jul. 22, 2021, Kim et al.
U.S. Appl. No. 17/057,398, filed Nov. 20, 2020, Liu et al.
U.S. Appl. No. 17/259,147, filed Jan. 8, 2021, Liu et al.
U.S. Appl. No. 17/270,396, filed Feb. 22, 2021, Liu et al.
U.S. Appl. No. 17/273,688, filed Mar. 4, 2021, Liu et al.
U.S. Appl. No. 17/294,287, filed May 14, 2021, Liu et al.
U.S. Appl. No. 17/288,504, filed Apr. 23, 2021, Liu et al.
U.S. Appl. No. 17/633,573, filed Feb. 7, 2022, Liu et al.
U.S. Appl. No. 17/910,552, filed Sep. 9, 2022, Liu et al.
U.S. Appl. No. 17/436,048, filed Sep. 2, 2021, Liu et al.
U.S. Appl. No. 17/219,590, filed Mar. 31, 2021, Liu et al.
U.S. Appl. No. 17/603,917, filed Oct. 14, 2021, Liu et al.
U.S. Appl. No. 17/797,700, filed Aug. 4, 2022, Liu et al.
U.S. Appl. No. 17/602,738, filed Oct. 8, 2021, Liu et al.
U.S. Appl. No. 17/613,025, filed Nov. 19, 2021, Liu et al.
U.S. Appl. No. 17/300,668, filed Sep. 17, 2021, Liu et al.
U.S. Appl. No. 17/795,819, filed Jul. 27, 2022, Liu et al.
U.S. Appl. No. 17/779,953, filed May 25, 2022, Liu et al.
U.S. Appl. No. 17/767,777, filed Apr. 8, 2022, Liu et al.
U.S. Appl. No. 17/797,701, filed Aug. 4, 2022, Liu et al.
U.S. Appl. No. 18/053,269, filed Nov. 7, 2022, Liu et al.
U.S. Appl. No. 17/797,697, filed Aug. 4, 2022, Liu et al.
U.S. Appl. No. 17/921,971, filed Oct. 27, 2022, Liu et al.
U.S. Appl. No. 17/219,635, filed Mar. 31, 2021, Liu et al.
U.S. Appl. No. 18/064,738, filed Dec. 12, 2022, Liu et al.
U.S. Appl. No. 18/326,588, filed May 31, 2023, Liu et al.
U.S. Appl. No. 18/326,634, filed May 31, 2023, Liu et al.
U.S. Appl. No. 18/326,689, filed May 31, 2023, Liu et al.
U.S. Appl. No. 18/326,708, filed May 31, 2023, Liu et al.
U.S. Appl. No. 17/219,672, filed Mar. 31, 2021, Liu et al.
U.S. Appl. No. 17/751,599, filed May 23, 2022, Liu et al.
U.S. Appl. No. 18/323,245, filed May 24, 2023, Liu et al.
U.S. Appl. No. 17/440,682, filed Sep. 17, 2021, Liu et al.
U.S. Appl. No. 18/028,183, filed Mar. 23, 2023, Liu et al.
U.S. Appl. No. 18/271,656, filed Jul. 10, 2023, Liu et al.
U.S. Appl. No. 18/286,547, filed Oct. 11, 2023, Liu et al.
U.S. Appl. No. 14/234,031, filed Mar. 24, 2014, Liu et al.
U.S. Appl. No. 14/320,271, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/320,519, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/913,458, filed Feb. 22, 2016, Liu et al.
U.S. Appl. No. 16/266,937, filed Feb. 4, 2019, Liu et al.
U.S. Appl. No. 14/320,370, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/320,413, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/874,123, filed Oct. 2, 2015, Liu et al.
U.S. Appl. No. 14/911,117, filed Feb. 9, 2016, Liu et al.
U.S. Appl. No. 17/160,329, filed Jan. 27, 2021, Liu et al.
U.S. Appl. No. 15/029,602, filed Apr. 14, 2016, Ritter et al.
U.S. Appl. No. 14/462,163, filed Aug. 18, 2014, Liu et al.
U.S. Appl. No. 14/462,189, filed Aug. 18, 2014, Liu et al.
U.S. Appl. No. 14/916,679, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 16/860,639, filed Apr. 28, 2020, Liu et al.
U.S. Appl. No. 14/320,498, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/320,467, filed Jun. 30, 2014, Liu et al.
U.S. Appl. No. 14/916,681, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 17/103,233, filed Nov. 24, 2020, Liu et al.
U.S. Appl. No. 17/937,203, filed Sep. 30, 2022, Liu et al.
U.S. Appl. No. 14/326,329, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,340, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,361, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/916,683, filed Mar. 4, 2016, Liu et al.
U.S. Appl. No. 16/796,323, filed Feb. 20, 2020, Liu et al.
U.S. Appl. No. 17/688,416, filed Mar. 7, 2022, Liu et al.
U.S. Appl. No. 14/325,815, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,109, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,140, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,269, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,290, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,318, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 14/326,303, filed Jul. 8, 2014, Liu et al.
U.S. Appl. No. 15/103,608, filed Jun. 10, 2016, Liu et al.
U.S. Appl. No. 16/374,634, filed Apr. 3, 2019, Liu et al.
U.S. Appl. No. 17/408,306, filed Aug. 20, 2021, Liu et al.
U.S. Appl. No. 15/329,925, filed Jan. 27, 2017, Liu et al.
U.S. Appl. No. 16/132,276, filed Sep. 14, 2018, Liu et al.
U.S. Appl. No. 16/888,646, filed May 29, 2020, Liu et al.
U.S. Appl. No. 18/069,898, filed Dec. 21, 2022, Liu et al.
U.S. Appl. No. 14/529,010, filed Oct. 30, 2014, Liu et al.
U.S. Appl. No. 15/958,721, filed Apr. 20, 2018, Liu et al.
U.S. Appl. No. 17/130,812, filed Dec. 22, 2020, Liu et al.
U.S. Appl. No. 15/331,852, filed Oct. 22, 2016, Liu et al.
U.S. Appl. No. 15/960,171, filed Apr. 23, 2018, Liu et al.
U.S. Appl. No. 17/527,011, filed Nov. 15, 2021, Liu et al.
U.S. Appl. No. 15/770,076, filed Apr. 20, 2018, Liu et al.
U.S. Appl. No. 16/327,744, filed Feb. 22, 2019, Maianti et al.
U.S. Appl. No. 18/055,274, filed Nov. 14, 2022, Maianti et al.
U.S. Appl. No. 15/852,891, filed Dec. 22, 2017, Maianti et al.
U.S. Appl. No. 16/926,436, filed Jul. 10, 2020, Maianti et al.
U.S. Appl. No. 18/484,381, filed Oct. 10, 2023, Maianti et al.
U.S. Appl. No. 15/852,526, filed Dec. 22, 2017, Maianti et al.
U.S. Appl. No. 16/492,534, filed Sep. 9, 2019, Liu et al.
U.S. Appl. No. 16/324,476, filed Feb. 8, 2019, Liu et al.
U.S. Appl. No. 18/324,394, filed May 26, 2002, Liu et al.
U.S. Appl. No. 15/791,085, filed Oct. 23, 2017, Liu et al.
U.S. Appl. No. 16/143,370, filed Sep. 26, 2018, Liu et al.
U.S. Appl. No. 17/148,059, filed Jan. 13, 2021, Liu et al.
U.S. Appl. No. 18/174,569, filed Feb. 24, 2023, Liu et al.
U.S. Appl. No. 16/492,548, filed Sep. 9, 2019, Maianti et al.
U.S. Appl. No. 15/784,033, filed Oct. 13, 2017, Liu et al.
U.S. Appl. No. 17/692,925, filed Mar. 11, 2022, Liu et al.
U.S. Appl. No. 16/492,553, filed Sep. 9, 2019, Liu et al.
U.S. Appl. No. 18/059,308, filed Nov. 28, 2022, Liu et al.
U.S. Appl. No. 15/934,945, filed Mar. 23, 2018, Liu et al.
U.S. Appl. No. 17/586,688, filed Jan. 27, 2022, Liu et al.
U.S. Appl. No. 18/066,878, filed Dec. 15, 2022, Liu et al.
U.S. Appl. No. 16/643,376, filed Feb. 28, 2020, Liu et al.
U.S. Appl. No. 17/700,109, filed Mar. 21, 2022, Liu et al.
U.S. Appl. No. 16/612,988, filed Nov. 12, 2019, Liu et al.
U.S. Appl. No. 16/634,405, filed Jan. 27, 2020, Liu et al.
U.S. Appl. No. 18/178,048, filed Mar. 3, 2023, Liu et al.
U.S. Appl. No. 16/976,047, filed Aug. 26, 2020, Liu et al.
U.S. Appl. No. 17/593,020, filed Sep. 3, 2021, Church et al.

Related Publications (1)

	Number	Date	Country
	20200010818 A1	Jan 2020	US

Provisional Applications (1)

	Number	Date	Country
	61510841	Jul 2011	US

Divisions (1)

	Number	Date	Country
Parent	14234031		US
Child	16441751		US

Evaluation and improvement of nuclease cleavage specificity

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

International Classifications

Disclaimer

Term Extension

Abstract